INSERT INTO `micro_posts` VALUES (6733,2,'2020-07-27 08:58:35','2020-07-27 08:58:35','Nitric oxide therapy could be critical in the world\'s struggle against SARS-CoV-2, the coronavirus which causes COVID-19, according to a review by the George Washington University (GW).\r\n\r\nNitric oxide is an antimicrobial and anti inflammatory molecule with key roles in pulmonary arterial role in the context of viral infections as well as other pulmonary diseases. In SARS-CoV-1 infection, which resulted in the outbreak of SARS (severe acute respiratory syndrome) in 2003, nitric oxide inhibited viral replication by cytotoxic reactions through intermediates like peroxynitrite.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://smhs.gwu.edu/news/nitric-oxide-may-slow-progression-covid-19\">Coronaviruses are RNA viruses that primarily infect birds or livestock, but can mutate to be very contagious and lethal in people. There\'s presently no documented therapy or vaccine for COVID-19.</a> </span>Not having a specific therapy and the high mortality rate of the virus dictate a urgent demand for therapeutics that may control the replication and rapid spread of the virus.\r\n\r\n<em>Nitric oxide plays key roles in maintaining normal vascular function and regulating inflammatory cascades that contribute to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Interventions that are protective against ALI and ARDS can play a critical role for patients and health systems during the pandemic.\"</em>Adam Friedman, MD, interim chair and professor in the Department of Dermatology at the GW School of Medicine and Health Sciences and co-senior author of the review\r\n\r\nThe team, led by first author Nagasai Adusumilli, MBA, a fourth-year medical student at the GW School of Medicine and Health Sciences, examined data from between 1993 and 2020 about the pathogenesis of coronaviruses and using nitric oxide as a treatment for respiratory disease. The authors highlight the potential for inhaled nitric oxide contributing to better clinical results and alleviating the rapidly rising strain on health care capacity because of COVID-19.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://smhs.gwu.edu/news/nitric-oxide-may-slow-progression-covid-19\">As groups continue to print additional results with their respective nitric oxide platforms, the team urges dosing and protocol variations should be analyzed in assessing the research.</a></span>\r\n\r\n\"With the development of COVID-19 because of catalyst with the ability to overwhelm the human body and our health care infrastructure, patients have a pressing need for effective agents that can slow the disease in their own bodies and in their communities,\" Friedman stated.\r\n\r\nThe authors imply that whether nitric oxide\'s effectiveness is illustrated for COVID-19, its use as a treatment could be critical in the fight against the pandemic.\r\n\r\nFriedman has been collaborating with co-senior author Joel Friedman, MD, PhD, professor of physiology and biophysics and of medicine at Albert Einstein College of Medicine, on research related to the usage of nitric oxide at a broad range of health signs for close to 2 decades, and collectively are developing nitric oxide oxide-based therapeutics for COVID-19.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://smhs.gwu.edu/news/nitric-oxide-may-slow-progression-covid-19\" target=\"_blank\" rel=\"noopener noreferrer\">George Washington University</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nAdusumilli, N.C., <em>et al.</em> (2020) Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19. <em>Nitric Oxide.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1016/j.niox.2020.07.003\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1016/j.niox.2020.07.003</a>.</span>\r\n\r\n</div>','Nitric oxide treatment can be essential in the battle against COVID-19','','publish','open','open','','nitric-oxide-treatment-can-be-essential-in-the-battle-against-covid-19','','','2020-07-27 08:58:35','2020-07-27 08:58:35','',0,'https://microbiozindia.com/?p=6733',0,'post','',0),(6734,2,'2020-07-27 08:58:35','2020-07-27 08:58:35','Nitric oxide therapy could be critical in the world\'s struggle against SARS-CoV-2, the coronavirus which causes COVID-19, according to a review by the George Washington University (GW).\r\n\r\nNitric oxide is an antimicrobial and anti inflammatory molecule with key roles in pulmonary arterial role in the context of viral infections as well as other pulmonary diseases. In SARS-CoV-1 infection, which resulted in the outbreak of SARS (severe acute respiratory syndrome) in 2003, nitric oxide inhibited viral replication by cytotoxic reactions through intermediates like peroxynitrite.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://smhs.gwu.edu/news/nitric-oxide-may-slow-progression-covid-19\">Coronaviruses are RNA viruses that primarily infect birds or livestock, but can mutate to be very contagious and lethal in people. There\'s presently no documented therapy or vaccine for COVID-19.</a> </span>Not having a specific therapy and the high mortality rate of the virus dictate a urgent demand for therapeutics that may control the replication and rapid spread of the virus.\r\n\r\n<em>Nitric oxide plays key roles in maintaining normal vascular function and regulating inflammatory cascades that contribute to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Interventions that are protective against ALI and ARDS can play a critical role for patients and health systems during the pandemic.\"</em>Adam Friedman, MD, interim chair and professor in the Department of Dermatology at the GW School of Medicine and Health Sciences and co-senior author of the review\r\n\r\nThe team, led by first author Nagasai Adusumilli, MBA, a fourth-year medical student at the GW School of Medicine and Health Sciences, examined data from between 1993 and 2020 about the pathogenesis of coronaviruses and using nitric oxide as a treatment for respiratory disease. The authors highlight the potential for inhaled nitric oxide contributing to better clinical results and alleviating the rapidly rising strain on health care capacity because of COVID-19.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://smhs.gwu.edu/news/nitric-oxide-may-slow-progression-covid-19\">As groups continue to print additional results with their respective nitric oxide platforms, the team urges dosing and protocol variations should be analyzed in assessing the research.</a></span>\r\n\r\n\"With the development of COVID-19 because of catalyst with the ability to overwhelm the human body and our health care infrastructure, patients have a pressing need for effective agents that can slow the disease in their own bodies and in their communities,\" Friedman stated.\r\n\r\nThe authors imply that whether nitric oxide\'s effectiveness is illustrated for COVID-19, its use as a treatment could be critical in the fight against the pandemic.\r\n\r\nFriedman has been collaborating with co-senior author Joel Friedman, MD, PhD, professor of physiology and biophysics and of medicine at Albert Einstein College of Medicine, on research related to the usage of nitric oxide at a broad range of health signs for close to 2 decades, and collectively are developing nitric oxide oxide-based therapeutics for COVID-19.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://smhs.gwu.edu/news/nitric-oxide-may-slow-progression-covid-19\" target=\"_blank\" rel=\"noopener noreferrer\">George Washington University</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nAdusumilli, N.C., <em>et al.</em> (2020) Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19. <em>Nitric Oxide.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1016/j.niox.2020.07.003\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1016/j.niox.2020.07.003</a>.</span>\r\n\r\n</div>','Nitric oxide treatment can be essential in the battle against COVID-19','','inherit','closed','closed','','6733-revision-v1','','','2020-07-27 08:58:35','2020-07-27 08:58:35','',6733,'https://microbiozindia.com/uncategorized/6733-revision-v1/',0,'revision','',0),(6735,2,'2020-07-27 11:18:03','2020-07-27 11:18:03','Researchers, including the ones of Indian-origin, have solved the structure of a molecule which the novel coronavirus uses to make its genetic sequence look like a part of the host\'s own, an advance which may cause the development of new antiviral drugs against COVID-19.\r\n\r\nThe researchers from the The University of Texas Health Science Center at San Antonio (UT Health San Antonio) from the US said by empowering this alteration, nsp10 protects the virus from host cell immune reaction.\r\n\r\n\"It\'s a camouflage. Because of the alterations, which fool the mobile, the consequent viral messenger RNA is currently considered as a member of the mobile\'s own code and not overseas,\" said Yogesh Gupta, a co-author of the analysis from UT Health San Antonio.\r\n\r\nAccording to the researchers, deciphering the 3D structure of nsp16 paves the way for the design of new drugs contrary to the publication coronavirus SARS-CoV-2, along with other emerging coronavirus infections.\r\n\r\nAll these medications, Gupta said can be designed to inhibit nsp16 from making the alterations, so that the host immune system could pounce to the invading virus, recognising it as foreign.\r\n\r\n\"Yogesh\'s function found the 3D structure of an essential enzyme of the COVID-19 virus needed for its replication and found a pocket inside which can be targeted to inhibit that enzyme. That is a fundamental advance in our comprehension of the virus,\" said study coauthor Robert Hromas.\r\n\r\nBased on the findings, the investigators have implied structural sites on the SARS-CoV-2 nsp10 molecule which they say can be targeted for antiviral development.','Researchers decode how coronavirus particles \'camouflage\' in have cell','','publish','open','open','','researchers-decode-how-coronavirus-particles-camouflage-in-have-cell','','','2020-07-27 11:18:03','2020-07-27 11:18:03','',0,'https://microbiozindia.com/?p=6735',0,'post','',0),(6736,2,'2020-07-27 11:18:03','2020-07-27 11:18:03','Researchers, including the ones of Indian-origin, have solved the structure of a molecule which the novel coronavirus uses to make its genetic sequence look like a part of the host\'s own, an advance which may cause the development of new antiviral drugs against COVID-19.\r\n\r\nThe researchers from the The University of Texas Health Science Center at San Antonio (UT Health San Antonio) from the US said by empowering this alteration, nsp10 protects the virus from host cell immune reaction.\r\n\r\n\"It\'s a camouflage. Because of the alterations, which fool the mobile, the consequent viral messenger RNA is currently considered as a member of the mobile\'s own code and not overseas,\" said Yogesh Gupta, a co-author of the analysis from UT Health San Antonio.\r\n\r\nAccording to the researchers, deciphering the 3D structure of nsp16 paves the way for the design of new drugs contrary to the publication coronavirus SARS-CoV-2, along with other emerging coronavirus infections.\r\n\r\nAll these medications, Gupta said can be designed to inhibit nsp16 from making the alterations, so that the host immune system could pounce to the invading virus, recognising it as foreign.\r\n\r\n\"Yogesh\'s function found the 3D structure of an essential enzyme of the COVID-19 virus needed for its replication and found a pocket inside which can be targeted to inhibit that enzyme. That is a fundamental advance in our comprehension of the virus,\" said study coauthor Robert Hromas.\r\n\r\nBased on the findings, the investigators have implied structural sites on the SARS-CoV-2 nsp10 molecule which they say can be targeted for antiviral development.','Researchers decode how coronavirus particles \'camouflage\' in have cell','','inherit','closed','closed','','6735-revision-v1','','','2020-07-27 11:18:03','2020-07-27 11:18:03','',6735,'https://microbiozindia.com/uncategorized/6735-revision-v1/',0,'revision','',0),(6737,2,'2020-07-27 12:43:36','2020-07-27 12:43:36','The new coronavirus pandemic which has infected over 16 million individuals is the worst global health emergency the World Health Organization (WHO) has confronted, its own director general Tedros Adhanom Ghebreyesus said on Monday.\r\n\r\nJust with rigorous adherence to health measures, from wearing masks to avoiding crowds, would the planet figure out how to conquer it, Tedros inserted at a digital reality briefing in Geneva.\r\n\r\n\"Where these measures are followed, instances return. Where they aren\'t, instances go up,\" he said, \'\' said Canada, China, Germany and South Korea for controlling outbreaks.\r\n\r\nResurgences of their coronavirus in a variety of regions, including where nations thought they had controlled the disease, are alarming the world, with deaths nearing 650,000.\r\n\r\nWHO disasters programme mind Mike Ryan stated a lot more important than definitions of next waves, new peaks and apocalyptic clusters, was the demand for nations around the world to keep up strict health restrictions like physical distancing.\r\n\r\n\"What\'s clear is pressure on the virus compels the numbers down. Release that strain and cases creep upward,\" he said, acknowledging, however, that it had been practically impossible for countries to continue to keep borders closed for the foreseeable future.\r\n\r\n\"We have to suppress transmission but in precisely the same time we have to recognize the vulnerable classes and rescue lives, keeping the death rates if possible to zero, if not to the very least,\" he said, \'\' said Japan and Australia in this respect.','WHO says COVID-19 by a wide margin its most noticeably terrible worldwide wellbeing crisis','','publish','open','open','','who-says-covid-19-by-a-wide-margin-its-most-noticeably-terrible-worldwide-wellbeing-crisis','','','2020-07-27 12:43:36','2020-07-27 12:43:36','',0,'https://microbiozindia.com/?p=6737',0,'post','',0),(6738,2,'2020-07-27 12:42:48','2020-07-27 12:42:48','','Tedros-Adhanom-GhebreyesusWHOworld-Health-organisation-770x433','','inherit','open','closed','','tedros-adhanom-ghebreyesuswhoworld-health-organisation-770x433','','','2020-07-27 12:42:48','2020-07-27 12:42:48','',6737,'https://microbiozindia.com/wp-content/uploads/2020/07/Tedros-Adhanom-GhebreyesusWHOworld-Health-organisation-770x433-1.jpg',0,'attachment','image/jpeg',0),(6739,2,'2020-07-27 12:43:36','2020-07-27 12:43:36','The new coronavirus pandemic which has infected over 16 million individuals is the worst global health emergency the World Health Organization (WHO) has confronted, its own director general Tedros Adhanom Ghebreyesus said on Monday.\r\n\r\nJust with rigorous adherence to health measures, from wearing masks to avoiding crowds, would the planet figure out how to conquer it, Tedros inserted at a digital reality briefing in Geneva.\r\n\r\n\"Where these measures are followed, instances return. Where they aren\'t, instances go up,\" he said, \'\' said Canada, China, Germany and South Korea for controlling outbreaks.\r\n\r\nResurgences of their coronavirus in a variety of regions, including where nations thought they had controlled the disease, are alarming the world, with deaths nearing 650,000.\r\n\r\nWHO disasters programme mind Mike Ryan stated a lot more important than definitions of next waves, new peaks and apocalyptic clusters, was the demand for nations around the world to keep up strict health restrictions like physical distancing.\r\n\r\n\"What\'s clear is pressure on the virus compels the numbers down. Release that strain and cases creep upward,\" he said, acknowledging, however, that it had been practically impossible for countries to continue to keep borders closed for the foreseeable future.\r\n\r\n\"We have to suppress transmission but in precisely the same time we have to recognize the vulnerable classes and rescue lives, keeping the death rates if possible to zero, if not to the very least,\" he said, \'\' said Japan and Australia in this respect.','WHO says COVID-19 by a wide margin its most noticeably terrible worldwide wellbeing crisis','','inherit','closed','closed','','6737-revision-v1','','','2020-07-27 12:43:36','2020-07-27 12:43:36','',6737,'https://microbiozindia.com/uncategorized/6737-revision-v1/',0,'revision','',0),(6740,2,'2020-07-27 12:46:05','2020-07-27 12:46:05','AstraZeneca in June chose Emergent to assist make 300 million doses of its possible COVID-19 vaccine vowed to the USA.\r\n\r\nAstraZeneca has signed manufacturing deals internationally to meet its goal of earning 2 billion gallons of this vaccine, for example with just two Bill Gates-backed ventures and a $1.2 billion deal with the US authorities.\r\n\r\nThe company\'s vaccine, which is co-developed from the University of Oxford, is among the very first to move into mid-stage trials. There are no approved vaccines or treatments for COVID-19, the highly infectious respiratory illness brought on by the novel coronavirus.\r\n\r\nThe latest contract follows a $87 million deal in June where Emergent signed an agreement to become the growth partner for AstraZeneca\'s COVID-19 vaccine candidate.\r\n\r\nActivities under the agreement will likely be at Emergent\'s Baltimore Bayview centre, the company said, which is a designated centre by the US Department of Health and Human Services for rapid manufacturing of large quantities of vaccines and treatments.','Emergent BioSolutions signs $174 million arrangement to make AstraZeneca\'s potential COVID-19 antibody','','publish','open','open','','emergent-biosolutions-signs-174-million-arrangement-to-make-astrazenecas-potential-covid-19-antibody','','','2020-07-27 12:46:05','2020-07-27 12:46:05','',0,'https://microbiozindia.com/?p=6740',0,'post','',0),(6741,2,'2020-07-27 12:46:05','2020-07-27 12:46:05','AstraZeneca in June chose Emergent to assist make 300 million doses of its possible COVID-19 vaccine vowed to the USA.\r\n\r\nAstraZeneca has signed manufacturing deals internationally to meet its goal of earning 2 billion gallons of this vaccine, for example with just two Bill Gates-backed ventures and a $1.2 billion deal with the US authorities.\r\n\r\nThe company\'s vaccine, which is co-developed from the University of Oxford, is among the very first to move into mid-stage trials. There are no approved vaccines or treatments for COVID-19, the highly infectious respiratory illness brought on by the novel coronavirus.\r\n\r\nThe latest contract follows a $87 million deal in June where Emergent signed an agreement to become the growth partner for AstraZeneca\'s COVID-19 vaccine candidate.\r\n\r\nActivities under the agreement will likely be at Emergent\'s Baltimore Bayview centre, the company said, which is a designated centre by the US Department of Health and Human Services for rapid manufacturing of large quantities of vaccines and treatments.','Emergent BioSolutions signs $174 million arrangement to make AstraZeneca\'s potential COVID-19 antibody','','inherit','closed','closed','','6740-revision-v1','','','2020-07-27 12:46:05','2020-07-27 12:46:05','',6740,'https://microbiozindia.com/uncategorized/6740-revision-v1/',0,'revision','',0),(6742,2,'2020-07-28 10:34:57','2020-07-28 10:34:57','The World Health Organization on Tuesday warned against complacency about new coronavirus transmission at the northern hemisphere summer, stating that this virus did not act like influenza that tended to follow seasonal trends.\r\n\r\n\"Folks are still thinking about seasons. What we all need to get our heads around is this is a new virus and. . .this one is acting otherwise,\" Margaret Harris informed a virtual briefing at Geneva, urging vigilance in applying measures to slow transmission that\'s spreading via mass parties.\r\n\r\nShe warned against believing concerning virus waves, saying:\"It is going to be one big wave. It is likely to go down and up a bit. The best thing will be to flatten it and turn it into something lapping at your toes.\"','WHO says COVID-19 pandemic is \'one major wave\', not occasional','','publish','open','open','','who-says-covid-19-pandemic-is-one-major-wave-not-occasional','','','2020-07-28 10:34:57','2020-07-28 10:34:57','',0,'https://microbiozindia.com/?p=6742',0,'post','',0),(6743,2,'2020-07-28 10:34:57','2020-07-28 10:34:57','The World Health Organization on Tuesday warned against complacency about new coronavirus transmission at the northern hemisphere summer, stating that this virus did not act like influenza that tended to follow seasonal trends.\r\n\r\n\"Folks are still thinking about seasons. What we all need to get our heads around is this is a new virus and. . .this one is acting otherwise,\" Margaret Harris informed a virtual briefing at Geneva, urging vigilance in applying measures to slow transmission that\'s spreading via mass parties.\r\n\r\nShe warned against believing concerning virus waves, saying:\"It is going to be one big wave. It is likely to go down and up a bit. The best thing will be to flatten it and turn it into something lapping at your toes.\"','WHO says COVID-19 pandemic is \'one major wave\', not occasional','','inherit','closed','closed','','6742-revision-v1','','','2020-07-28 10:34:57','2020-07-28 10:34:57','',6742,'https://microbiozindia.com/uncategorized/6742-revision-v1/',0,'revision','',0),(6744,2,'2020-07-28 11:27:21','2020-07-28 11:27:21','In a new study, researchers found that nighttime - versus day-biting species of mosquitoes have been behaviorally attracted and repelled by different colors of light at different times of day.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://som.uci.edu/news_releases/Mosquitoes-respond-differently-to-colors-of-light-time-of-day.asp\">Mosquitoes are one of important disease vectors impacting animals and humans around the globe and also the findings have important implications for applying light to restrain them.</a></span>\r\n\r\nAt the University of California, Irvine School of Medicine-led team analyzed mosquito species that bite in the day (Aedes aegypti, aka the Yellow Fever mosquito) and the ones that snack at night (Anopheles coluzzi, also a member of the Anopheles gambiae household, the significant vector for malaria).\r\n\r\nThey found distinct answers to ultraviolet light and also different colors of light between both species. Researchers also found light preference is determined by the mosquito\'s sex and species, the period of day and the color of the lighting.\r\n\r\n\"Traditional wisdom has been that insects have been non-specifically attracted to ultraviolet light, thus the widespread use of ultraviolet lighting\"bug zappers\" for insect control.\r\n\r\nWe discover that day-biting mosquitoes are attracted to a vast array of light spectra during the day, whereas night-biting mosquitoes are ardently photophobic into short-wavelength light throughout the daytime,\" said principal investigator Todd C. Holmes, PhD, a professor in the Department of Physiology and Biophysics in the UCI School of Medicine.\r\n\r\nMosquitoes pose prevalent dangers to people and other creatures as infection vectors. It\'s estimated historically that infections spread by mosquitoes have contributed to the deaths of half of all people ever to have lived.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://som.uci.edu/news_releases/Mosquitoes-respond-differently-to-colors-of-light-time-of-day.asp\">The new work demonstrates that day-biting mosquitoes, particularly females who need blood meals due to their fertilized eggs, are attracted to light during the day regardless of spectra. In contrast, night-biting mosquitoes especially avoid ultraviolet (UV) and blue light during the day.</a></span>\r\n\r\nPast work from the Holmes laboratory using fruit flies (that can be related to mosquitoes) has ascertained that the light sensors and circadian molecular mechanisms for mild mediated attraction/avoidance behaviors.\r\n\r\nAccordingly, molecular disturbance of the circadian clock severely interferes with light-evoked fascination and avoidance behaviours in mosquitoes. At the moment, light-based insect controllers do not take into account the day versus night behavioral profiles which alter with everyday light and dark cycles.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://som.uci.edu/news_releases/Mosquitoes-respond-differently-to-colors-of-light-time-of-day.asp\">\"Lighting is the principal regulator of circadian rhythms and elicits a broad assortment of time-of-day particular behaviors,\" said Holmes.</a></span>\r\n\r\n\"By getting an comprehension of how insects respond to short wavelength light at a species-specific fashion, we can develop newand environmentally friendly alternatives to controlling harmful insects more efficiently and reduce the need for environmentally harmful poisonous pesticides.\"\r\n\r\nThis research was financed in part by the National Institutes of Health, National Science Foundation along with the ARCS Foundation. This new study builds on the Holmes lab\'s previous studies in the UCI School of Medicine published over the Last Few decades at Science, Nature and Proceedings of the National Academy of Sciences.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://som.uci.edu/news_releases/Mosquitoes-respond-differently-to-colors-of-light-time-of-day.asp\" target=\"_blank\" rel=\"noopener noreferrer\">University of California - Irvine</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nBaik, L. S., <em>et al</em>. (2020) Circadian Regulation of Light-Evoked Attraction and Avoidance Behaviors in Daytime- versus NighttimeBiting Mosquitoes. <em>Current Biology</em>.<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"http://doi.org/10.1016/j.cub.2020.06.010\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1016/j.cub.2020.06.010</a></span>.\r\n\r\n</div>','Study: Mosquitoes species Have Been Drawn and repelled by light at different times Daily','','publish','open','open','','study-mosquitoes-species-have-been-drawn-and-repelled-by-light-at-different-times-daily','','','2020-07-28 11:27:21','2020-07-28 11:27:21','',0,'https://microbiozindia.com/?p=6744',0,'post','',0),(6745,2,'2020-07-28 11:27:11','2020-07-28 11:27:11','','mosquito-3743404_640','','inherit','open','closed','','mosquito-3743404_640','','','2020-07-28 11:27:11','2020-07-28 11:27:11','',6744,'https://microbiozindia.com/wp-content/uploads/2020/07/mosquito-3743404_640.jpg',0,'attachment','image/jpeg',0),(6746,2,'2020-07-28 11:27:21','2020-07-28 11:27:21','In a new study, researchers found that nighttime - versus day-biting species of mosquitoes have been behaviorally attracted and repelled by different colors of light at different times of day.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://som.uci.edu/news_releases/Mosquitoes-respond-differently-to-colors-of-light-time-of-day.asp\">Mosquitoes are one of important disease vectors impacting animals and humans around the globe and also the findings have important implications for applying light to restrain them.</a></span>\r\n\r\nAt the University of California, Irvine School of Medicine-led team analyzed mosquito species that bite in the day (Aedes aegypti, aka the Yellow Fever mosquito) and the ones that snack at night (Anopheles coluzzi, also a member of the Anopheles gambiae household, the significant vector for malaria).\r\n\r\nThey found distinct answers to ultraviolet light and also different colors of light between both species. Researchers also found light preference is determined by the mosquito\'s sex and species, the period of day and the color of the lighting.\r\n\r\n\"Traditional wisdom has been that insects have been non-specifically attracted to ultraviolet light, thus the widespread use of ultraviolet lighting\"bug zappers\" for insect control.\r\n\r\nWe discover that day-biting mosquitoes are attracted to a vast array of light spectra during the day, whereas night-biting mosquitoes are ardently photophobic into short-wavelength light throughout the daytime,\" said principal investigator Todd C. Holmes, PhD, a professor in the Department of Physiology and Biophysics in the UCI School of Medicine.\r\n\r\nMosquitoes pose prevalent dangers to people and other creatures as infection vectors. It\'s estimated historically that infections spread by mosquitoes have contributed to the deaths of half of all people ever to have lived.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://som.uci.edu/news_releases/Mosquitoes-respond-differently-to-colors-of-light-time-of-day.asp\">The new work demonstrates that day-biting mosquitoes, particularly females who need blood meals due to their fertilized eggs, are attracted to light during the day regardless of spectra. In contrast, night-biting mosquitoes especially avoid ultraviolet (UV) and blue light during the day.</a></span>\r\n\r\nPast work from the Holmes laboratory using fruit flies (that can be related to mosquitoes) has ascertained that the light sensors and circadian molecular mechanisms for mild mediated attraction/avoidance behaviors.\r\n\r\nAccordingly, molecular disturbance of the circadian clock severely interferes with light-evoked fascination and avoidance behaviours in mosquitoes. At the moment, light-based insect controllers do not take into account the day versus night behavioral profiles which alter with everyday light and dark cycles.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://som.uci.edu/news_releases/Mosquitoes-respond-differently-to-colors-of-light-time-of-day.asp\">\"Lighting is the principal regulator of circadian rhythms and elicits a broad assortment of time-of-day particular behaviors,\" said Holmes.</a></span>\r\n\r\n\"By getting an comprehension of how insects respond to short wavelength light at a species-specific fashion, we can develop newand environmentally friendly alternatives to controlling harmful insects more efficiently and reduce the need for environmentally harmful poisonous pesticides.\"\r\n\r\nThis research was financed in part by the National Institutes of Health, National Science Foundation along with the ARCS Foundation. This new study builds on the Holmes lab\'s previous studies in the UCI School of Medicine published over the Last Few decades at Science, Nature and Proceedings of the National Academy of Sciences.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://som.uci.edu/news_releases/Mosquitoes-respond-differently-to-colors-of-light-time-of-day.asp\" target=\"_blank\" rel=\"noopener noreferrer\">University of California - Irvine</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nBaik, L. S., <em>et al</em>. (2020) Circadian Regulation of Light-Evoked Attraction and Avoidance Behaviors in Daytime- versus NighttimeBiting Mosquitoes. <em>Current Biology</em>.<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"http://doi.org/10.1016/j.cub.2020.06.010\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1016/j.cub.2020.06.010</a></span>.\r\n\r\n</div>','Study: Mosquitoes species Have Been Drawn and repelled by light at different times Daily','','inherit','closed','closed','','6744-revision-v1','','','2020-07-28 11:27:21','2020-07-28 11:27:21','',6744,'https://microbiozindia.com/uncategorized/6744-revision-v1/',0,'revision','',0),(6748,2,'2020-07-28 11:50:10','2020-07-28 11:50:10','','Thermo Chemical website launche','','publish','closed','closed','','thermo-chemical-website-launche','','','2020-07-28 11:50:10','2020-07-28 11:50:10','',0,'https://microbiozindia.com/?post_type=ads&#038;p=6748',0,'ads','',0),(6749,2,'2020-07-28 11:50:42','2020-07-28 11:50:42','','Chemical website launch Thermo Fisher','','publish','closed','closed','','chemical-website-launch-thermo-fisher','','','2020-07-28 11:50:42','2020-07-28 11:50:42','',0,'https://microbiozindia.com/?post_type=ads&#038;p=6749',0,'ads','',0),(6751,2,'2020-07-28 11:51:17','2020-07-28 11:51:17','','Thermo Chemical Launch','','publish','closed','closed','','thermo-chemical-launch','','','2020-07-28 11:51:17','2020-07-28 11:51:17','',0,'https://microbiozindia.com/?post_type=ads&#038;p=6751',0,'ads','',0),(6753,2,'2020-07-28 17:47:55','2020-07-28 17:47:55','A study in the University of Pittsburgh shows the highest accuracy thus far in understanding and characterizing prostate cancer using an artificial intelligence (AI) application.1\r\n\r\n\"Humans are great at recognizing anomalies, but they have their particular biases or previous experience,\" says senior writer Rajiv Dhir, MD, MBA, chief pathologist and vice chair of pathology at University of Pittsburgh Medical Center, Shadyside and professor of biomedical informatics in Pitt. \"Machines are detached from the entire story. There\'s certainly an element of standardizing care\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.upmc.com/media/news/072720-dhir-prostate-ai-lancet\">To prepare the AI to recognize prostate cancer, Dhir and his coworkers supplied images from more than a million components of stained tissue slides taken from individual biopsies.</a></span> Each image was labeled by specialist pathologists to instruct the AI the way to discriminate between healthy and abnormal tissue. The plan was subsequently tested on a different group of 1,600 slides taken from 100 consecutive patients observed in UPMC for suspected prostate cancer.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.upmc.com/media/news/072720-dhir-prostate-ai-lancet\">In addition, this will be the first algorithm to expand beyond cancer detection, reporting high performance for tumor evaluation, sizing, along with invasion of the surrounding nerves. These all are clinically significant attributes required as part of the pathology report.</a></span>\r\n\r\nAI also flagged six slides that weren\'t noted by the expert pathologists.\r\n\r\nHowever, Dhir explained that this does not automatically mean that the system is superior to humans. By way of instance, in the course of evaluating these instances, the pathologist might have simply seen enough evidence of malignancy elsewhere in that patient\'s samples to advocate treatment. For less experienced pathologists, though, the algorithm could act as a failsafe to capture cases which may otherwise be overlooked.\r\n\r\n\"Algorithms such as this are particularly beneficial in lesions which are atypical,\" Dhir states. \"A nonspecialized individual might not be in a position to make the correct assessment. That is a major benefit of this kind of system.\"\r\n\r\nWhen these results are promising, Dhir cautions that new algorithms will have to be trained to detect different kinds of cancer. The pathology markers are not universal across all tissue forms. But he didn\'t see why that could not be done to accommodate this technology to work with breast cancer, for instance.\r\n\r\nRead more from the <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.upmc.com/media/news/072720-dhir-prostate-ai-lancet\" target=\"_blank\" rel=\"noopener noreferrer\">University of Pittsburgh</a>.</span>\r\n\r\n<strong>Reference</strong>\r\n\r\n1. Pantoanowitz L, Quiroga-Garza GM, Bien L, et al. An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study. <em>Lancet Digital Health. </em>2020;2(8):E407-E416. doi: <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thelancet.com/journals/landig/article/PIIS2589-7500(20)30159-X/fulltext\" target=\"_blank\" rel=\"noopener noreferrer\">10.1016/S2589-7500(20)30159-X.</a></span>\r\n\r\n<strong>Featured image:</strong> Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Credit: Ibex Medical Analytic.','Artificial Intelligence detects Prostate Cancer With Near-Perfect Accuracy','','publish','open','open','','artificial-intelligence-detects-prostate-cancer-with-near-perfect-accuracy','','','2020-07-28 17:47:55','2020-07-28 17:47:55','',0,'https://microbiozindia.com/?p=6753',0,'post','',0),(6754,2,'2020-07-28 17:46:37','2020-07-28 17:46:37','','Ibex-Medical-Analytics-credit_prostate-biopsy-with-cancer-probability-AI-detected_web-2-466x291','','inherit','open','closed','','ibex-medical-analytics-credit_prostate-biopsy-with-cancer-probability-ai-detected_web-2-466x291','','','2020-07-28 17:46:37','2020-07-28 17:46:37','',6753,'https://microbiozindia.com/wp-content/uploads/2020/07/Ibex-Medical-Analytics-credit_prostate-biopsy-with-cancer-probability-AI-detected_web-2-466x291-1.jpg',0,'attachment','image/jpeg',0),(6755,2,'2020-07-28 17:47:55','2020-07-28 17:47:55','A study in the University of Pittsburgh shows the highest accuracy thus far in understanding and characterizing prostate cancer using an artificial intelligence (AI) application.1\r\n\r\n\"Humans are great at recognizing anomalies, but they have their particular biases or previous experience,\" says senior writer Rajiv Dhir, MD, MBA, chief pathologist and vice chair of pathology at University of Pittsburgh Medical Center, Shadyside and professor of biomedical informatics in Pitt. \"Machines are detached from the entire story. There\'s certainly an element of standardizing care\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.upmc.com/media/news/072720-dhir-prostate-ai-lancet\">To prepare the AI to recognize prostate cancer, Dhir and his coworkers supplied images from more than a million components of stained tissue slides taken from individual biopsies.</a></span> Each image was labeled by specialist pathologists to instruct the AI the way to discriminate between healthy and abnormal tissue. The plan was subsequently tested on a different group of 1,600 slides taken from 100 consecutive patients observed in UPMC for suspected prostate cancer.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.upmc.com/media/news/072720-dhir-prostate-ai-lancet\">In addition, this will be the first algorithm to expand beyond cancer detection, reporting high performance for tumor evaluation, sizing, along with invasion of the surrounding nerves. These all are clinically significant attributes required as part of the pathology report.</a></span>\r\n\r\nAI also flagged six slides that weren\'t noted by the expert pathologists.\r\n\r\nHowever, Dhir explained that this does not automatically mean that the system is superior to humans. By way of instance, in the course of evaluating these instances, the pathologist might have simply seen enough evidence of malignancy elsewhere in that patient\'s samples to advocate treatment. For less experienced pathologists, though, the algorithm could act as a failsafe to capture cases which may otherwise be overlooked.\r\n\r\n\"Algorithms such as this are particularly beneficial in lesions which are atypical,\" Dhir states. \"A nonspecialized individual might not be in a position to make the correct assessment. That is a major benefit of this kind of system.\"\r\n\r\nWhen these results are promising, Dhir cautions that new algorithms will have to be trained to detect different kinds of cancer. The pathology markers are not universal across all tissue forms. But he didn\'t see why that could not be done to accommodate this technology to work with breast cancer, for instance.\r\n\r\nRead more from the <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.upmc.com/media/news/072720-dhir-prostate-ai-lancet\" target=\"_blank\" rel=\"noopener noreferrer\">University of Pittsburgh</a>.</span>\r\n\r\n<strong>Reference</strong>\r\n\r\n1. Pantoanowitz L, Quiroga-Garza GM, Bien L, et al. An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study. <em>Lancet Digital Health. </em>2020;2(8):E407-E416. doi: <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thelancet.com/journals/landig/article/PIIS2589-7500(20)30159-X/fulltext\" target=\"_blank\" rel=\"noopener noreferrer\">10.1016/S2589-7500(20)30159-X.</a></span>\r\n\r\n<strong>Featured image:</strong> Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Credit: Ibex Medical Analytic.','Artificial Intelligence detects Prostate Cancer With Near-Perfect Accuracy','','inherit','closed','closed','','6753-revision-v1','','','2020-07-28 17:47:55','2020-07-28 17:47:55','',6753,'https://microbiozindia.com/uncategorized/6753-revision-v1/',0,'revision','',0),(6756,2,'2020-07-28 18:03:42','2020-07-28 18:03:42','Another 6.7 million kids under the age of five round the globe might suffer from squandering this year on account of this socioeconomic effects of the COVID-19 outbreak, the UNICEF warned on Tuesday.\r\n\r\nAccording to the UNICEF, in India, there continue to be about 20 million children below five decades old that are suffering from squandering.\r\n\r\nAs stated by the International Hunger Index 2019, wasting among children in India rose from 16.5 percent in 2008-2012 to 20.8 percent in 2014-2018.\r\n\r\nWasting is a life threatening kind of malnutrition, making children too weak and thin, and sets them at greater chance of dying, inadequate growth, growth and learning.\r\n\r\nAccording to the UNICEF, before the COVID-19 pandemic, 47 million kids have been wasted in 2019.\r\n\r\nAnother 6.7 million kids below the age of five might suffer with squandering and become dangerously propounded in 2020 as a consequence of the socioeconomic effects of the COVID-19 pandemic, the UN children\'s agency said.\r\n\r\n\"Without urgent action, the worldwide number of kids suffering from squandering could reach nearly 54 million on the course of this entire year. This could bring international squandering to levels not seen that this century,\" it stated.\r\n\r\nQuoting an investigation of the Lancet, the UNICEF said 80 percent of those children are in sub-Saharan Africa and South Asia.\r\n\r\n\"More than half will be in South Asia alone,\" it stated.\r\n\r\nIt stated the Lancet evaluation finds that the incidence of wasting among children under the age of five might rise by 14.3 percent in low-income and low nations this season on account of the socio-economic effect of COVID-19.\r\n\r\n\"It has been seven weeks since the very first COVID-19 instances were reported and it\'s increasingly obvious that the consequences of this pandemic are causing greater harm to children than the disorder ,\" said UNICEF Executive Director Henrietta Foresaid\r\n\r\nCritical nutrition services and supply chains are disrupted. Food costs have jumped. Because of this, the standard of children\'s diets has gone and malnutrition rates will appear,\" she explained.','Extra 6.7 million kids under 5 could experience the ill effects of squandering due to COVID-19: UNICEF','','publish','open','open','','extra-6-7-million-kids-under-5-could-experience-the-ill-effects-of-squandering-due-to-covid-19-unicef','','','2020-07-28 18:03:42','2020-07-28 18:03:42','',0,'https://microbiozindia.com/?p=6756',0,'post','',0),(6757,2,'2020-07-28 18:03:42','2020-07-28 18:03:42','Another 6.7 million kids under the age of five round the globe might suffer from squandering this year on account of this socioeconomic effects of the COVID-19 outbreak, the UNICEF warned on Tuesday.\r\n\r\nAccording to the UNICEF, in India, there continue to be about 20 million children below five decades old that are suffering from squandering.\r\n\r\nAs stated by the International Hunger Index 2019, wasting among children in India rose from 16.5 percent in 2008-2012 to 20.8 percent in 2014-2018.\r\n\r\nWasting is a life threatening kind of malnutrition, making children too weak and thin, and sets them at greater chance of dying, inadequate growth, growth and learning.\r\n\r\nAccording to the UNICEF, before the COVID-19 pandemic, 47 million kids have been wasted in 2019.\r\n\r\nAnother 6.7 million kids below the age of five might suffer with squandering and become dangerously propounded in 2020 as a consequence of the socioeconomic effects of the COVID-19 pandemic, the UN children\'s agency said.\r\n\r\n\"Without urgent action, the worldwide number of kids suffering from squandering could reach nearly 54 million on the course of this entire year. This could bring international squandering to levels not seen that this century,\" it stated.\r\n\r\nQuoting an investigation of the Lancet, the UNICEF said 80 percent of those children are in sub-Saharan Africa and South Asia.\r\n\r\n\"More than half will be in South Asia alone,\" it stated.\r\n\r\nIt stated the Lancet evaluation finds that the incidence of wasting among children under the age of five might rise by 14.3 percent in low-income and low nations this season on account of the socio-economic effect of COVID-19.\r\n\r\n\"It has been seven weeks since the very first COVID-19 instances were reported and it\'s increasingly obvious that the consequences of this pandemic are causing greater harm to children than the disorder ,\" said UNICEF Executive Director Henrietta Foresaid\r\n\r\nCritical nutrition services and supply chains are disrupted. Food costs have jumped. Because of this, the standard of children\'s diets has gone and malnutrition rates will appear,\" she explained.','Extra 6.7 million kids under 5 could experience the ill effects of squandering due to COVID-19: UNICEF','','inherit','closed','closed','','6756-revision-v1','','','2020-07-28 18:03:42','2020-07-28 18:03:42','',6756,'https://microbiozindia.com/uncategorized/6756-revision-v1/',0,'revision','',0),(6758,2,'2020-07-29 11:57:02','2020-07-29 11:57:02','Swiss Drug maker Roche on July 29 declared that its drug Actemra (Tocilizumab), which has emerged as a widely prescribed drug for treating hosiptalised COVID-19 patients, didn\'t fulfill its primary endpoint of improved clinical standing in hospitalised adult patients with acute COVID-19 related pneumonia. In addition, the primary secondary endpoint of decreased patient mortality week , was also not fulfilled.\r\n\r\nHowever, Roche stated there was a positive trend in time to hospital discharge in patients treated with Actemra. The median time to release or\'prepared to discharge\' for Actemra had been 20 days and for placebo was 28 days.\r\n\r\nThe COVACTA study didn\'t recognize any new security signs for Actemra.\r\n\r\nAdditional Evaluation of the trial outcomes is required to fully understand the information.\r\n\r\nThe Results will be submitted for publication in a peer-reviewed journal.\r\n\r\n\"People Around the world are looking forward for further effective therapy alternatives for COVID-19 and we\'re disappointed that COVACTA did not demonstrate a benefit for patients in clinical status or mortality at week four,\" said Levi Garraway, Roche\'s Chief Medical Officer and Head of Global Product Development.\r\n\r\n\"We Will continue to generate evidence to provide a more complete comprehension of Actemra/RoActemra from COVID-19 related pneumonia,\" Garraway added.\r\n\r\nThe COVACTA Evaluated the efficacy and safety of intravenous Actemra added to standard-of-care treatment in contrast to therapy with placebo and standard of maintenance.\r\n\r\nThe Main endpoint of clinical status in hospitalised older patients having acute COVID-19 related pneumonia was quantified with a 7-category ordinal scale, and monitored patients\' clinical condition based on the need for intensive maintenance or ventilator usage, as well as supplemental oxygen requirements.\r\n\r\nThe COVACTA trial is the first global, randomised, double-blind, placebo-controlled phase III study to research Actemra in mature patients hospitalised with severe COVID-19 associated pneumonia, with\r\n\r\nResearch Places in the usa, Canada and Europe.\r\n\r\nTocilizumab Is anti-IL-6 receptor, so which works as immunomodulator, is employed in curing patients with autoimmune disorders like rheumatoid arthritis, has discovered to have a possibility to control immune system going berserk in some COVID-19 patients.\r\n\r\nIn India, the authorities protocol claims Tocilizumab could be considered in patients with moderate illness using progressively increasing oxygen demands and also in mechanically ventilated patients not improving even though use of steroids.\r\n\r\nThe drug which has to be taken in two doses, is promoted by Roche and its spouse Cipla in India.','Roche\'s Tocilizumab neglects to meet essential end focuses for COVID-19 related pneumonia','','publish','open','open','','roches-tocilizumab-neglects-to-meet-essential-end-focuses-for-covid-19-related-pneumonia','','','2020-07-29 11:57:02','2020-07-29 11:57:02','',0,'https://microbiozindia.com/?p=6758',0,'post','',0),(6759,2,'2020-07-29 11:57:02','2020-07-29 11:57:02','Swiss Drug maker Roche on July 29 declared that its drug Actemra (Tocilizumab), which has emerged as a widely prescribed drug for treating hosiptalised COVID-19 patients, didn\'t fulfill its primary endpoint of improved clinical standing in hospitalised adult patients with acute COVID-19 related pneumonia. In addition, the primary secondary endpoint of decreased patient mortality week , was also not fulfilled.\r\n\r\nHowever, Roche stated there was a positive trend in time to hospital discharge in patients treated with Actemra. The median time to release or\'prepared to discharge\' for Actemra had been 20 days and for placebo was 28 days.\r\n\r\nThe COVACTA study didn\'t recognize any new security signs for Actemra.\r\n\r\nAdditional Evaluation of the trial outcomes is required to fully understand the information.\r\n\r\nThe Results will be submitted for publication in a peer-reviewed journal.\r\n\r\n\"People Around the world are looking forward for further effective therapy alternatives for COVID-19 and we\'re disappointed that COVACTA did not demonstrate a benefit for patients in clinical status or mortality at week four,\" said Levi Garraway, Roche\'s Chief Medical Officer and Head of Global Product Development.\r\n\r\n\"We Will continue to generate evidence to provide a more complete comprehension of Actemra/RoActemra from COVID-19 related pneumonia,\" Garraway added.\r\n\r\nThe COVACTA Evaluated the efficacy and safety of intravenous Actemra added to standard-of-care treatment in contrast to therapy with placebo and standard of maintenance.\r\n\r\nThe Main endpoint of clinical status in hospitalised older patients having acute COVID-19 related pneumonia was quantified with a 7-category ordinal scale, and monitored patients\' clinical condition based on the need for intensive maintenance or ventilator usage, as well as supplemental oxygen requirements.\r\n\r\nThe COVACTA trial is the first global, randomised, double-blind, placebo-controlled phase III study to research Actemra in mature patients hospitalised with severe COVID-19 associated pneumonia, with\r\n\r\nResearch Places in the usa, Canada and Europe.\r\n\r\nTocilizumab Is anti-IL-6 receptor, so which works as immunomodulator, is employed in curing patients with autoimmune disorders like rheumatoid arthritis, has discovered to have a possibility to control immune system going berserk in some COVID-19 patients.\r\n\r\nIn India, the authorities protocol claims Tocilizumab could be considered in patients with moderate illness using progressively increasing oxygen demands and also in mechanically ventilated patients not improving even though use of steroids.\r\n\r\nThe drug which has to be taken in two doses, is promoted by Roche and its spouse Cipla in India.','Roche\'s Tocilizumab neglects to meet essential end focuses for COVID-19 related pneumonia','','inherit','closed','closed','','6758-revision-v1','','','2020-07-29 11:57:02','2020-07-29 11:57:02','',6758,'https://microbiozindia.com/uncategorized/6758-revision-v1/',0,'revision','',0),(6760,2,'2020-07-29 11:59:16','2020-07-29 11:59:16','India\'s Hetero Labs Ltd said on Wednesday it received neighborhood regulatory approval to start its own version of antiviral medication favipiravir for the treatment of COVID-19.\r\n\r\nThe drug, priced in 59 rupees (79 cents) each tablet, will probably be Available at drug stores from Wednesday, independently held Hetero explained.','India\'s Hetero Labs wins endorsement to dispatch COVID-19 medication favipiravir','','publish','open','open','','indias-hetero-labs-wins-endorsement-to-dispatch-covid-19-medication-favipiravir','','','2020-07-29 11:59:16','2020-07-29 11:59:16','',0,'https://microbiozindia.com/?p=6760',0,'post','',0),(6761,2,'2020-07-29 11:59:16','2020-07-29 11:59:16','India\'s Hetero Labs Ltd said on Wednesday it received neighborhood regulatory approval to start its own version of antiviral medication favipiravir for the treatment of COVID-19.\r\n\r\nThe drug, priced in 59 rupees (79 cents) each tablet, will probably be Available at drug stores from Wednesday, independently held Hetero explained.','India\'s Hetero Labs wins endorsement to dispatch COVID-19 medication favipiravir','','inherit','closed','closed','','6760-revision-v1','','','2020-07-29 11:59:16','2020-07-29 11:59:16','',6760,'https://microbiozindia.com/uncategorized/6760-revision-v1/',0,'revision','',0),(6762,2,'2020-07-29 12:04:49','2020-07-29 12:04:49','Sanofi And GSK said they had reached a deal with Britain to provide it with as much as 60 million doses of an expected COVID-19 vaccine, and that discussions with different authorities were ongoing.\r\n\r\nNo Vaccine has been prescribed to treat or protect against COVID-19, the respiratory disorder caused by the new coronavirus which has killed over 659,000 people and triggered economic havoc globally.\r\n\r\nFinancial Details of the arrangement weren\'t disclosed. Sanofi and GSK, that had first teamed up in April, confirmed in a statement that regulatory approval for their vaccine might be reached by the initial half 2021 if clinical data was to be positive.\r\n\r\nThe Initial clinical trials are anticipated in September.\r\n\r\nThe Vaccine will be developed by blending Sanofi\'s S-protein COVID-19 antigen along with GSK\'s pandemic adjuvant technology.\r\n\r\nAdjuvants Are efficiency boosters which play a very important role in several vaccines. An adjuvant is added to your vaccines to improve the immune reaction, and has been shown to make a more powerful and longer lasting immunity against diseases than a vaccine alone.\r\n\r\nSanofi And GSK said other talks with the European Union, Italy and France to provide their vaccine were continuing.\r\n\r\nSanofi The company wanted to secure an upfront payment for the entire inventory while the EU would rather postpone payments before the vaccine has passed substantial clinical trials.','Sanofi, GSK to gracefully up to 60 million dosages of COVID-19 antibody to UK','','publish','open','open','','sanofi-gsk-to-gracefully-up-to-60-million-dosages-of-covid-19-antibody-to-uk','','','2020-07-29 12:04:49','2020-07-29 12:04:49','',0,'https://microbiozindia.com/?p=6762',0,'post','',0),(6763,2,'2020-07-29 12:04:49','2020-07-29 12:04:49','Sanofi And GSK said they had reached a deal with Britain to provide it with as much as 60 million doses of an expected COVID-19 vaccine, and that discussions with different authorities were ongoing.\r\n\r\nNo Vaccine has been prescribed to treat or protect against COVID-19, the respiratory disorder caused by the new coronavirus which has killed over 659,000 people and triggered economic havoc globally.\r\n\r\nFinancial Details of the arrangement weren\'t disclosed. Sanofi and GSK, that had first teamed up in April, confirmed in a statement that regulatory approval for their vaccine might be reached by the initial half 2021 if clinical data was to be positive.\r\n\r\nThe Initial clinical trials are anticipated in September.\r\n\r\nThe Vaccine will be developed by blending Sanofi\'s S-protein COVID-19 antigen along with GSK\'s pandemic adjuvant technology.\r\n\r\nAdjuvants Are efficiency boosters which play a very important role in several vaccines. An adjuvant is added to your vaccines to improve the immune reaction, and has been shown to make a more powerful and longer lasting immunity against diseases than a vaccine alone.\r\n\r\nSanofi And GSK said other talks with the European Union, Italy and France to provide their vaccine were continuing.\r\n\r\nSanofi The company wanted to secure an upfront payment for the entire inventory while the EU would rather postpone payments before the vaccine has passed substantial clinical trials.','Sanofi, GSK to gracefully up to 60 million dosages of COVID-19 antibody to UK','','inherit','closed','closed','','6762-revision-v1','','','2020-07-29 12:04:49','2020-07-29 12:04:49','',6762,'https://microbiozindia.com/uncategorized/6762-revision-v1/',0,'revision','',0),(6764,2,'2020-07-29 12:06:12','2020-07-29 12:06:12','Moderna Inc will cost its coronavirus vaccine at $50 To $60 a course, at $11 more than a different drug from Pfizer Inc and also BioNTech, the Financial Times reported about July 28, citing unnamed sources.\r\n\r\nModerna\'s proposed cost for a two-dose course marketed to Governments contrasts with $39 to get 2 doses below a deal that Pfizer Inc along with German spouse BioNTech struck with the U.S. government.\r\n\r\nIndustry analysts said Pfizer and BioNTech\'s $2 billion price to Pay 50 million sufferers, which will be contingent on an approvable item, would likely pressure other manufacturers to put similar prices.\r\n\r\nModerna\'s proposed price would apply to the United States and Other high-income nations, according to the report.\r\n\r\nA Moderna spokesperson said that the firm was in talks with Governments about potential supply of the vaccine, called mRNA-1273, but did not offer any details about pricing\"granted the confidential nature of the discussions and contracts.\"\r\n\r\nThe final price for Moderna\'s COVID vaccine has yet to be Determined, a person familiar with the talks told Reuters.\r\n\r\nPfizer, Moderna and Merck &amp; Co have said they Intend to market Their vaccines in a profit, though some drugmakers, such as Johnson &amp; Johnson have declared plans to cost their fingerprints onto a non-profit foundation.\r\n\r\nAstraZeneca Plc agreed to Supply the United States 300 million Doses of its prospective vaccine in market for $1.2 billion in upfront financing, which works out to $4 per dose.\r\n\r\nThe U.S. government has supplied Moderna with almost $1 billion.\r\n\r\nGovernment to hasten the creation of an inoculation to get COVID-19, which Has so far killed around 650,000 individuals globally.','Moderna means to cost coronavirus antibody at $50-$60 per course: Report','','publish','open','open','','moderna-means-to-cost-coronavirus-antibody-at-50-60-per-course-report','','','2020-07-29 12:06:12','2020-07-29 12:06:12','',0,'https://microbiozindia.com/?p=6764',0,'post','',0),(6765,2,'2020-07-29 12:06:12','2020-07-29 12:06:12','Moderna Inc will cost its coronavirus vaccine at $50 To $60 a course, at $11 more than a different drug from Pfizer Inc and also BioNTech, the Financial Times reported about July 28, citing unnamed sources.\r\n\r\nModerna\'s proposed cost for a two-dose course marketed to Governments contrasts with $39 to get 2 doses below a deal that Pfizer Inc along with German spouse BioNTech struck with the U.S. government.\r\n\r\nIndustry analysts said Pfizer and BioNTech\'s $2 billion price to Pay 50 million sufferers, which will be contingent on an approvable item, would likely pressure other manufacturers to put similar prices.\r\n\r\nModerna\'s proposed price would apply to the United States and Other high-income nations, according to the report.\r\n\r\nA Moderna spokesperson said that the firm was in talks with Governments about potential supply of the vaccine, called mRNA-1273, but did not offer any details about pricing\"granted the confidential nature of the discussions and contracts.\"\r\n\r\nThe final price for Moderna\'s COVID vaccine has yet to be Determined, a person familiar with the talks told Reuters.\r\n\r\nPfizer, Moderna and Merck &amp; Co have said they Intend to market Their vaccines in a profit, though some drugmakers, such as Johnson &amp; Johnson have declared plans to cost their fingerprints onto a non-profit foundation.\r\n\r\nAstraZeneca Plc agreed to Supply the United States 300 million Doses of its prospective vaccine in market for $1.2 billion in upfront financing, which works out to $4 per dose.\r\n\r\nThe U.S. government has supplied Moderna with almost $1 billion.\r\n\r\nGovernment to hasten the creation of an inoculation to get COVID-19, which Has so far killed around 650,000 individuals globally.','Moderna means to cost coronavirus antibody at $50-$60 per course: Report','','inherit','closed','closed','','6764-revision-v1','','','2020-07-29 12:06:12','2020-07-29 12:06:12','',6764,'https://microbiozindia.com/uncategorized/6764-revision-v1/',0,'revision','',0),(6766,2,'2020-07-29 12:29:46','2020-07-29 12:29:46','A world-leading University of Waterloo spinoff company, that decodes blood samples for potential treatments for illnesses such as cancer and COVID-19, is expanding operations with the support of a 5-million USD investment.\r\n\r\nBin Ma, a University of Waterloo computer engineering professor who co-founded Rapid Novor at 2015, says that the company\'s technologies is the most innovative in the world in regards to deciphering the complex workings of antibody proteins, a process called sequencing.\r\n\r\n<em>The long-term goal is to profile all antibodies in human blood and ultimately provide a brand new way to diagnose disease. Compared to other protein sequencing technologies, we are faster and more accurate, allowing more complex samples. We are the only team in the world that can sequence antibody proteins from blood directly.”</em>-Bin Ma, Computer Science Professor, University of Waterloo\r\n\r\nAmong other endeavors, Ma\'s group is currently decoding the antibodies in the bloodstream of patients who are recovering from COVID-19 with the hopes that the info can be utilized to create new remedies. Even the National Research Council of Canada, through its Industrial Research Assistance Program, has also granted the Quick Novor staff a grant to encourage the human coronavirus work.\r\n\r\n<em>The team’s track record for innovation and their ambitious goal to decode immunity attracted us. Rapid Novor has built a team of world-class scientists and practitioners in proteomics and bioinformatics. Their unique technologies will have profound impact in the life sciences industry. We are thrilled to be part of this innovative team.”</em>-Eric Wen, Partner, Co-Win Venture\r\n\r\nThe recent $5-million USD financing round, led by Co-Win Venture, enables Quick Novor, which only tripled its office space at Catalyst 137 in Kitchener, Ont., to engage additional scientists.\r\n\r\nMa says his team has developed a sensitive, non-invasive blood test to monitor patients with multiple myeloma, a sort of blood cancer growing in bone marrow. The test detects a cancer relapse six months earlier than regular medical care.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://uwaterloo.ca/\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">University of Waterloo</a></span>\r\n\r\n</div>','Waterloo Technology profiles Compounds in blood of COVID-19 Sufferers','','publish','open','open','','waterloo-technology-profiles-compounds-in-blood-of-covid-19-sufferers','','','2020-07-29 12:29:46','2020-07-29 12:29:46','',0,'https://microbiozindia.com/?p=6766',0,'post','',0),(6767,2,'2020-07-29 12:28:10','2020-07-29 12:28:10','','image','','inherit','open','closed','','image-5','','','2020-07-29 12:28:10','2020-07-29 12:28:10','',6766,'https://microbiozindia.com/wp-content/uploads/2020/07/image.jpg',0,'attachment','image/jpeg',0),(6768,2,'2020-07-29 12:29:46','2020-07-29 12:29:46','A world-leading University of Waterloo spinoff company, that decodes blood samples for potential treatments for illnesses such as cancer and COVID-19, is expanding operations with the support of a 5-million USD investment.\r\n\r\nBin Ma, a University of Waterloo computer engineering professor who co-founded Rapid Novor at 2015, says that the company\'s technologies is the most innovative in the world in regards to deciphering the complex workings of antibody proteins, a process called sequencing.\r\n\r\n<em>The long-term goal is to profile all antibodies in human blood and ultimately provide a brand new way to diagnose disease. Compared to other protein sequencing technologies, we are faster and more accurate, allowing more complex samples. We are the only team in the world that can sequence antibody proteins from blood directly.”</em>-Bin Ma, Computer Science Professor, University of Waterloo\r\n\r\nAmong other endeavors, Ma\'s group is currently decoding the antibodies in the bloodstream of patients who are recovering from COVID-19 with the hopes that the info can be utilized to create new remedies. Even the National Research Council of Canada, through its Industrial Research Assistance Program, has also granted the Quick Novor staff a grant to encourage the human coronavirus work.\r\n\r\n<em>The team’s track record for innovation and their ambitious goal to decode immunity attracted us. Rapid Novor has built a team of world-class scientists and practitioners in proteomics and bioinformatics. Their unique technologies will have profound impact in the life sciences industry. We are thrilled to be part of this innovative team.”</em>-Eric Wen, Partner, Co-Win Venture\r\n\r\nThe recent $5-million USD financing round, led by Co-Win Venture, enables Quick Novor, which only tripled its office space at Catalyst 137 in Kitchener, Ont., to engage additional scientists.\r\n\r\nMa says his team has developed a sensitive, non-invasive blood test to monitor patients with multiple myeloma, a sort of blood cancer growing in bone marrow. The test detects a cancer relapse six months earlier than regular medical care.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://uwaterloo.ca/\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">University of Waterloo</a></span>\r\n\r\n</div>','Waterloo Technology profiles Compounds in blood of COVID-19 Sufferers','','inherit','closed','closed','','6766-revision-v1','','','2020-07-29 12:29:46','2020-07-29 12:29:46','',6766,'https://microbiozindia.com/uncategorized/6766-revision-v1/',0,'revision','',0),(6769,2,'2020-07-29 16:17:29','2020-07-29 16:17:29','Mumbai, India, 27th July 2020: Thermo Fisher Scientific, the world leader in serving science, continues to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments. The company is now supporting over 200 projects globally.\r\n<blockquote>“Even before the pandemic, the company was strategically increasing its manufacturing, research and development capabilities, in addition to providing critical products and solutions for treating cancer, genetic diseases and other serious health concerns. Today, these initiatives are proving to be decisive in enabling our response to COVID-19 in India. We are well-positioned to extend our end-to-end workflow solutions for COVID-19 and quickly ramp up testing infrastructure and vaccine research and manufacturing,” said <strong>Amit Chopra, managing director, India &amp; Middle East, Thermo Fisher Scientific.</strong></blockquote>\r\n<strong> </strong>Thermo Fisher is also supporting multiple vaccine programs globally that are in or entering human clinical trials, providing critical capacity and expertise that has accelerated development and readiness by months.\r\n<blockquote>“Our investments in building capacity and capabilities demonstrate our commitment to fulfill our mission to enable our customers to make the world healthier, cleaner and safer,” <strong>Amit </strong>added.</blockquote>\r\nThe company has expanded capacity for customers who are developing new and existing therapies, including promising anti-viral drugs, to meet increased demand and enable biopharma customers to significantly compress timelines for delivery to patients.\r\n\r\nIn addition to its work on COVID-19-related vaccines and therapies, the company continues to ensure that patients undergoing clinical trials continue to receive the critical medicines they need. A \"site to patient\" program, launched at the start of the pandemic, has ensured clinical trial patients have uninterrupted access to life-saving investigational drug shipments without having to visit a clinic, one of many efforts to maintain supply chain continuity during the pandemic.\r\n\r\n<strong>About Thermo Fisher Scientific </strong>\r\n\r\n<strong> </strong>Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.For more information, please visit <a href=\"http://www.thermofisher.com\">www.thermofisher.com</a>.','Thermo Fisher Scientific further strengthen its Global Response to COVID-19 to Support Development and Production of Therapeutics and Vaccines','','publish','open','open','','thermo-fisher-scientific-further-further-strengthen-its-global-response-to-covid-19-to-support-development-and-production-of-therapeutics-and-vaccines','','','2020-07-30 06:34:41','2020-07-30 06:34:41','',0,'https://microbiozindia.com/?p=6769',0,'post','',0),(6770,2,'2020-07-29 16:17:29','2020-07-29 16:17:29','Thermo Fisher Scientific, the world leader in serving science, continues to expand global capacity and capabilities throughout its top pharma services network to support customers in government, business and academia because they accelerate development and production of COVID-19 vaccines, treatments and other treatments. The business is now supporting over 200 jobs internationally.\r\n<blockquote>“Even before the pandemic, the company was strategically increasing its manufacturing, research and development capabilities, in addition to providing critical products and solutions for treating cancer, genetic diseases and other serious health concerns. Today, these initiatives are proving to be decisive in enabling our response to COVID-19 in India. We are well-positioned to extend our end-to-end workflow solutions for COVID-19 and quickly ramp up testing infrastructure and vaccine research and manufacturing,” said <strong>Amit Chopra, managing director, India &amp; Middle East, Thermo Fisher Scientific.</strong></blockquote>\r\nThermo Fisher is also encouraging Multiple vaccine programs globally that are entering or in human clinical trials, supplying critical capacity and expertise which has accelerated growth and readiness .\r\n<blockquote>“Our investments in building capacity and capabilities demonstrate our commitment to fulfill our mission to enable our customers to make the world healthier, cleaner and safer,” <strong>Amit added. </strong></blockquote>\r\nThe company has expanded capacity For clients that are developing new and present therapies, including promising anti-viral medication, to meet increased demand and enable biopharma customers to significantly compress timelines for delivery to patients.\r\n\r\nIn addition to its own work on COVID-19-related vaccines and Therapies, the company continues to ensure that patients experiencing clinical Trials continue to get the essential medicines they need. A\"website to Patient\" program, launched at the start of the pandemic, has guaranteed Clinical trial patients have uninterrupted access to life-saving Investigational drug shipments without needing to go to a clinic, among many Attempts to keep supply chain continuity during the pandemic.\r\n\r\n<strong>About Thermo Fisher Scientific</strong>\r\n\r\nThermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.For more information, please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home.html\">www.thermofisher.com.</a></span>','Thermo Fisher Scientific further fortify its Global Reaction to COVID-19 to Service Development and Production of Therapeutics and Vaccines','','inherit','closed','closed','','6769-revision-v1','','','2020-07-29 16:17:29','2020-07-29 16:17:29','',6769,'https://microbiozindia.com/uncategorized/6769-revision-v1/',0,'revision','',0),(6771,2,'2020-07-30 06:33:51','2020-07-30 06:33:51','Mumbai, India, 27th July 2020: Thermo Fisher Scientific, the world leader in serving science, continues to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments. The company is now supporting over 200 projects globally.\n<blockquote>“Even before the pandemic, the company was strategically increasing its manufacturing, research and development capabilities, in addition to providing critical products and solutions for treating cancer, genetic diseases and other serious health concerns. Today, these initiatives are proving to be decisive in enabling our response to COVID-19 in India. We are well-positioned to extend our end-to-end workflow solutions for COVID-19 and quickly ramp up testing infrastructure and vaccine research and manufacturing,” said <strong>Amit Chopra, managing director, India &amp; Middle East, Thermo Fisher Scientific.</strong></blockquote>\n<strong> </strong>Thermo Fisher is also supporting multiple vaccine programs globally that are in or entering human clinical trials, providing critical capacity and expertise that has accelerated development and readiness by months.\n<blockquote>“Our investments in building capacity and capabilities demonstrate our commitment to fulfill our mission to enable our customers to make the world healthier, cleaner and safer,” <strong>Amit </strong>added.</blockquote>\nThe company has expanded capacity for customers who are developing new and existing therapies, including promising anti-viral drugs, to meet increased demand and enable biopharma customers to significantly compress timelines for delivery to patients.\n\nIn addition to its work on COVID-19-related vaccines and therapies, the company continues to ensure that patients undergoing clinical trials continue to receive the critical medicines they need. A \"site to patient\" program, launched at the start of the pandemic, has ensured clinical trial patients have uninterrupted access to life-saving investigational drug shipments without having to visit a clinic, one of many efforts to maintain supply chain continuity during the pandemic.\n\n<strong>About Thermo Fisher Scientific </strong>\n\n<strong> </strong>Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.For more information, please visit <a href=\"http://www.thermofisher.com\">www.thermofisher.com</a>.','Thermo Fisher Scientific further strengthen its Global Response to COVID-19 to Support Development and Production of Therapeutics and Vaccines','','inherit','closed','closed','','6769-autosave-v1','','','2020-07-30 06:33:51','2020-07-30 06:33:51','',6769,'https://microbiozindia.com/uncategorized/6769-autosave-v1/',0,'revision','',0),(6772,2,'2020-07-29 16:20:25','2020-07-29 16:20:25','Thermo Fisher Scientific, the world leader in serving science, continues to expand global capacity and capabilities throughout its top pharma services network to support customers in government, business and academia because they accelerate development and production of COVID-19 vaccines, ttherapies and other treatments. The business is now supporting over 200 projects internationally.\r\n<blockquote>“Even before the pandemic, the company was strategically increasing its manufacturing, research and development capabilities, in addition to providing critical products and solutions for treating cancer, genetic diseases and other serious health concerns. Today, these initiatives are proving to be decisive in enabling our response to COVID-19 in India. We are well-positioned to extend our end-to-end workflow solutions for COVID-19 and quickly ramp up testing infrastructure and vaccine research and manufacturing,” said <strong>Amit Chopra, managing director, India &amp; Middle East, Thermo Fisher Scientific.</strong></blockquote>\r\nThermo Fisher is also encouraging Multiple vaccine programs globally that are entering or in human clinical trials, supplying critical capacity and expertise which has accelerated growth and readiness .\r\n<blockquote>“Our investments in building capacity and capabilities demonstrate our commitment to fulfill our mission to enable our customers to make the world healthier, cleaner and safer,” <strong>Amit added. </strong></blockquote>\r\nThe company has expanded capacity For clients that are developing new and present therapies, including promising anti-viral medication, to meet increased demand and enable biopharma customers to significantly compress timelines for delivery to patients.\r\n\r\nIn addition to its own work on COVID-19-related vaccines and Therapies, the company continues to ensure that patients experiencing clinical Trials continue to get the essential medicines they need. A\"website to Patient\" program, launched at the start of the pandemic, has guaranteed Clinical trial patients have uninterrupted access to life-saving Investigational drug shipments without needing to go to a clinic, among many Attempts to keep supply chain continuity during the pandemic.\r\n\r\n<strong>About Thermo Fisher Scientific</strong>\r\n\r\nThermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.For more information, please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home.html\">www.thermofisher.com.</a></span>','Thermo Fisher Scientific further fortify its Global Reaction to COVID-19 to Service Development and Production of Therapeutics and Vaccines','','inherit','closed','closed','','6769-revision-v1','','','2020-07-29 16:20:25','2020-07-29 16:20:25','',6769,'https://microbiozindia.com/uncategorized/6769-revision-v1/',0,'revision','',0),(6773,2,'2020-07-30 06:15:29','2020-07-30 06:15:29','Glassco is the biggest exporter of scientific lab ware Out of India, shipping over 600 containers of glassware every year mainly Interchangeable, Volumetric, Filtration and General lab ware made in ISO / ASTM / DIN / USP &amp; NABL Standards. Together Side glassware a lot of Allied distinct merchandise and accessories which can be used in laboratory application Such as for example Vinyl ware, Rubber ware, metalware, Liquid Handling Instruments, Hot Plate &amp; Stirrers.\r\n\r\n<strong>The Most Common:</strong>\r\n\r\n1.Your laboratory is engaged in job so vital that you absolutely should have Class A calibrated volumetric glassware, like a cylinder or flask, manufactured from the best materials in a ISO approved factory.\r\n\r\n2.This really is definitely an investment to you, and you pay attention to advice on the published certificate of calibration as well as the item.\r\n\r\n3.This certification is essential to support your production or research process and should be common for reference when required.\r\n\r\n4.The challenge is that you often wind up preserving the published certificate in a separate spot, together with the certification resting comfortably in a filing cabinet whereas the glassware is actively used on your own lab.\r\n\r\n5.When you will need the certificate of calibration, like in a typical audit scenario, you\'ve got to locate the filed certification and match it up to the cylinder or flask.\r\n\r\n6.This may go smoothly for you personally if your laboratory procedures are closely defined and always maintained. If that is not the case, it\'s rather a job to locate the certificate and match it up to the corresponding slice of glassware.\r\n\r\n<strong>The game-changer:</strong>\r\n\r\n1.Each bit of that carefully Selected Class A calibrated volumetric glassware arrives for you with a QR Code permanently screened onto it.\r\n\r\n2.A printed certificate of calibration is Also included in the package, and you are welcome to document that like you\'ve You can possibly produce a superior choice.\r\n\r\n3.The Qr-code to the product is easily scanned in your smartphone with all the Popular Neo Reader QR code app, and that scan goes instantly to the Manufacturer\'s website, where you are able to view, save and print a copy of this Same certificate of calibration which was included in this package.\r\n\r\n4.This Eliminates the requirement for you to build up a paper filing procedure for the Certification, and enables you get to the calibration information at any time, In any place.\r\n\r\n<span style=\"text-decoration: underline;\">For more information:</span>\r\n\r\ncustomercare@glasscolabs.com','Glassco QR Coded Class A Laboratory Glassware - An Easy Time-Saver For Your Research Laboratory','','publish','open','open','','glassco-qr-coded-class-a-laboratory-glassware-an-easy-time-saver-for-your-research-laboratory','','','2020-07-30 06:15:29','2020-07-30 06:15:29','',0,'https://microbiozindia.com/?p=6773',0,'post','',0),(6774,2,'2020-07-30 05:56:07','2020-07-30 05:56:07','','Microbioz Banner for Website','','inherit','open','closed','','microbioz-banner-for-website','','','2020-07-30 05:56:07','2020-07-30 05:56:07','',6773,'https://microbiozindia.com/wp-content/uploads/2020/07/Microbioz-Banner-for-Website.jpg',0,'attachment','image/jpeg',0),(6775,2,'2020-07-30 06:15:29','2020-07-30 06:15:29','Glassco is the biggest exporter of scientific lab ware Out of India, shipping over 600 containers of glassware every year mainly Interchangeable, Volumetric, Filtration and General lab ware made in ISO / ASTM / DIN / USP &amp; NABL Standards. Together Side glassware a lot of Allied distinct merchandise and accessories which can be used in laboratory application Such as for example Vinyl ware, Rubber ware, metalware, Liquid Handling Instruments, Hot Plate &amp; Stirrers.\r\n\r\n<strong>The Most Common:</strong>\r\n\r\n1.Your laboratory is engaged in job so vital that you absolutely should have Class A calibrated volumetric glassware, like a cylinder or flask, manufactured from the best materials in a ISO approved factory.\r\n\r\n2.This really is definitely an investment to you, and you pay attention to advice on the published certificate of calibration as well as the item.\r\n\r\n3.This certification is essential to support your production or research process and should be common for reference when required.\r\n\r\n4.The challenge is that you often wind up preserving the published certificate in a separate spot, together with the certification resting comfortably in a filing cabinet whereas the glassware is actively used on your own lab.\r\n\r\n5.When you will need the certificate of calibration, like in a typical audit scenario, you\'ve got to locate the filed certification and match it up to the cylinder or flask.\r\n\r\n6.This may go smoothly for you personally if your laboratory procedures are closely defined and always maintained. If that is not the case, it\'s rather a job to locate the certificate and match it up to the corresponding slice of glassware.\r\n\r\n<strong>The game-changer:</strong>\r\n\r\n1.Each bit of that carefully Selected Class A calibrated volumetric glassware arrives for you with a QR Code permanently screened onto it.\r\n\r\n2.A printed certificate of calibration is Also included in the package, and you are welcome to document that like you\'ve You can possibly produce a superior choice.\r\n\r\n3.The Qr-code to the product is easily scanned in your smartphone with all the Popular Neo Reader QR code app, and that scan goes instantly to the Manufacturer\'s website, where you are able to view, save and print a copy of this Same certificate of calibration which was included in this package.\r\n\r\n4.This Eliminates the requirement for you to build up a paper filing procedure for the Certification, and enables you get to the calibration information at any time, In any place.\r\n\r\n<span style=\"text-decoration: underline;\">For more information:</span>\r\n\r\ncustomercare@glasscolabs.com','Glassco QR Coded Class A Laboratory Glassware - An Easy Time-Saver For Your Research Laboratory','','inherit','closed','closed','','6773-revision-v1','','','2020-07-30 06:15:29','2020-07-30 06:15:29','',6773,'https://microbiozindia.com/uncategorized/6773-revision-v1/',0,'revision','',0),(6776,2,'2020-07-30 06:34:41','2020-07-30 06:34:41','Mumbai, India, 27th July 2020: Thermo Fisher Scientific, the world leader in serving science, continues to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments. The company is now supporting over 200 projects globally.\r\n<blockquote>“Even before the pandemic, the company was strategically increasing its manufacturing, research and development capabilities, in addition to providing critical products and solutions for treating cancer, genetic diseases and other serious health concerns. Today, these initiatives are proving to be decisive in enabling our response to COVID-19 in India. We are well-positioned to extend our end-to-end workflow solutions for COVID-19 and quickly ramp up testing infrastructure and vaccine research and manufacturing,” said <strong>Amit Chopra, managing director, India &amp; Middle East, Thermo Fisher Scientific.</strong></blockquote>\r\n<strong> </strong>Thermo Fisher is also supporting multiple vaccine programs globally that are in or entering human clinical trials, providing critical capacity and expertise that has accelerated development and readiness by months.\r\n<blockquote>“Our investments in building capacity and capabilities demonstrate our commitment to fulfill our mission to enable our customers to make the world healthier, cleaner and safer,” <strong>Amit </strong>added.</blockquote>\r\nThe company has expanded capacity for customers who are developing new and existing therapies, including promising anti-viral drugs, to meet increased demand and enable biopharma customers to significantly compress timelines for delivery to patients.\r\n\r\nIn addition to its work on COVID-19-related vaccines and therapies, the company continues to ensure that patients undergoing clinical trials continue to receive the critical medicines they need. A \"site to patient\" program, launched at the start of the pandemic, has ensured clinical trial patients have uninterrupted access to life-saving investigational drug shipments without having to visit a clinic, one of many efforts to maintain supply chain continuity during the pandemic.\r\n\r\n<strong>About Thermo Fisher Scientific </strong>\r\n\r\n<strong> </strong>Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.For more information, please visit <a href=\"http://www.thermofisher.com\">www.thermofisher.com</a>.','Thermo Fisher Scientific further strengthen its Global Response to COVID-19 to Support Development and Production of Therapeutics and Vaccines','','inherit','closed','closed','','6769-revision-v1','','','2020-07-30 06:34:41','2020-07-30 06:34:41','',6769,'https://microbiozindia.com/uncategorized/6769-revision-v1/',0,'revision','',0),(6777,2,'2020-07-30 09:55:44','2020-07-30 09:55:44','The Subject Expert Committee (SEC) on COVID-19 that held its meeting Tuesday deliberated about the program by SII and requested that the Pune-based company to revise its own protocol to the stage 2 and 3 clinical trials, aside from needing some extra details.\r\n\r\nOn Wednesday evening, SII filed a revised protocol for running the trials into the DCGI.\r\n\r\n\"The company on Tuesday was requested to clearly specify phase 2 and stage 3 portion of this protocol and resubmit their application for analysis from the SEC,\" an official source said.\r\n\r\nThe panel also suggested that the proposed clinical trial websites be dispersed across India, the source stated.\r\n\r\n\"In addition they haven\'t provided justification for the planned enrolment of all 1,600 subjects throughout the trial,\" the source added.\r\n\r\nAdditional Manager, Government Affairs, SII, Prakash Kumar Singh stated,\"We\'ve filed our revised protocol to DCGI office now evening for additional actions by SEC and DCGI.\"\r\n\r\nThe SII that has partnered with AstraZeneca for fabricating the Oxford vaccine candidate for COVID-19 had filed its application to the DCGI on July 24, looking for permission for running the stage 3 and 2 trials of the possible vaccine\'Covidshield\'.\r\n\r\n\"According to this program, it might run an observer-blind, randomised controlled study to ascertain the safety and immunogenicity of\'Covishield\' in healthy Indian adults. The company said that the roughly 1,600 participants of over 18 years will be registered in the study,\" a source had stated.\r\n\r\nInitial results of this initial two-phase trials of this vaccine ran in five trial sites in the united kingdom revealed it\'s an acceptable safety profile and homologous fostering increased antibody responses, the source stated.\r\n\r\nTo present the vaccine, SII, the world\'s largest vaccine manufacturer by number of doses sold and produced, has signed an agreement to fabricate the prospective vaccine produced from the Jenner Institute (Oxford University) in cooperation with British-Swedish pharma firm AstraZeneca.\r\n\r\nOn the partnership with AstraZeneca, Serum Institute of India CEO Adar Poonawalla had stated,\"Serum Institute of India has entered a production partnership with AstraZeneca to create and provide 1 billion doses of this COVID-19 vaccine being developed by Oxford University.\"\r\n\r\nThese vaccines would be for India and low and middle income nations throughout the planet (GAVI states ), he\'d stated. The company plans to initiate the stage 3 and 2 individual trials in India in August.\r\n\r\nOxford University recently had declared satisfactory progress using the vaccine, which makes it one of the primary ones among the dozens of vaccine candidates being developed across the globe.','DCGI approaches Serum Institute to update convention for stage 2, 3 preliminaries of Oxford COVID-19 vaccine','','publish','open','open','','dcgi-approaches-serum-institute-to-update-convention-for-stage-2-3-preliminaries-of-oxford-covid-19-vaccine','','','2020-07-30 09:55:44','2020-07-30 09:55:44','',0,'https://microbiozindia.com/?p=6777',0,'post','',0),(6778,2,'2020-07-30 09:55:44','2020-07-30 09:55:44','The Subject Expert Committee (SEC) on COVID-19 that held its meeting Tuesday deliberated about the program by SII and requested that the Pune-based company to revise its own protocol to the stage 2 and 3 clinical trials, aside from needing some extra details.\r\n\r\nOn Wednesday evening, SII filed a revised protocol for running the trials into the DCGI.\r\n\r\n\"The company on Tuesday was requested to clearly specify phase 2 and stage 3 portion of this protocol and resubmit their application for analysis from the SEC,\" an official source said.\r\n\r\nThe panel also suggested that the proposed clinical trial websites be dispersed across India, the source stated.\r\n\r\n\"In addition they haven\'t provided justification for the planned enrolment of all 1,600 subjects throughout the trial,\" the source added.\r\n\r\nAdditional Manager, Government Affairs, SII, Prakash Kumar Singh stated,\"We\'ve filed our revised protocol to DCGI office now evening for additional actions by SEC and DCGI.\"\r\n\r\nThe SII that has partnered with AstraZeneca for fabricating the Oxford vaccine candidate for COVID-19 had filed its application to the DCGI on July 24, looking for permission for running the stage 3 and 2 trials of the possible vaccine\'Covidshield\'.\r\n\r\n\"According to this program, it might run an observer-blind, randomised controlled study to ascertain the safety and immunogenicity of\'Covishield\' in healthy Indian adults. The company said that the roughly 1,600 participants of over 18 years will be registered in the study,\" a source had stated.\r\n\r\nInitial results of this initial two-phase trials of this vaccine ran in five trial sites in the united kingdom revealed it\'s an acceptable safety profile and homologous fostering increased antibody responses, the source stated.\r\n\r\nTo present the vaccine, SII, the world\'s largest vaccine manufacturer by number of doses sold and produced, has signed an agreement to fabricate the prospective vaccine produced from the Jenner Institute (Oxford University) in cooperation with British-Swedish pharma firm AstraZeneca.\r\n\r\nOn the partnership with AstraZeneca, Serum Institute of India CEO Adar Poonawalla had stated,\"Serum Institute of India has entered a production partnership with AstraZeneca to create and provide 1 billion doses of this COVID-19 vaccine being developed by Oxford University.\"\r\n\r\nThese vaccines would be for India and low and middle income nations throughout the planet (GAVI states ), he\'d stated. The company plans to initiate the stage 3 and 2 individual trials in India in August.\r\n\r\nOxford University recently had declared satisfactory progress using the vaccine, which makes it one of the primary ones among the dozens of vaccine candidates being developed across the globe.','DCGI approaches Serum Institute to update convention for stage 2, 3 preliminaries of Oxford COVID-19 vaccine','','inherit','closed','closed','','6777-revision-v1','','','2020-07-30 09:55:44','2020-07-30 09:55:44','',6777,'https://microbiozindia.com/uncategorized/6777-revision-v1/',0,'revision','',0),(6780,2,'2020-07-30 15:33:26','2020-07-30 15:33:26','Johnson &amp; Johnson on Thursday kicked off US human safety trials because of its COVID-19 vaccine after releasing details of a research in monkeys that showed its best-performing vaccine candidate offered strong defense in a single dose.\r\n\r\nWhen subjected to this virus, six out of six animals who obtained the vaccine candidate proved completely protected from lung disease and five from six were protected from infection as measured by the existence of virus in nasal swabs, according to the study published in the journal Nature.\r\n\r\n\"This gives us confidence that we can examine a single-shot vaccine in this outbreak and find out whether it has a synergistic effect in humans,\" Dr. Paul Stoffels, J&amp;J\'s chief scientific officer, told Reuters in a telephone interview.\r\n\r\nThe drugmaker said it had started early-stage human trials in the United States and Belgium and could test its own vaccine candidate at over 1,000 healthy adults aged 18 to 55 years, as well as adults aged 65 decades and older.\r\n\r\nEven the US government is financing J&amp;J\'s vaccine campaign with $456 million in financing as part of a spending spree directed at speeding creation of a vaccine to end the outbreak, which has infected millions and killed over 660,000 people.\r\n\r\nStoffels said earlier evaluations of this kind of vaccine in different ailments found that a second shot appreciably increases protection. But in a pandemic that a single-shot vaccine has a significant advantage, sidestepping a lot of the logistical problems involved with getting people to come back to their second dose.\r\n\r\nThe company intends to take the question up of one or two doses at its stage 1 trial.\r\n\r\nDepending on those results, J&amp;J plans to start large-scale, phase 3 testing using a single-shot regimen at the second half of September. Around precisely the identical period, the organization will begin a parallel stage 3 analysis testing a two-shot regimen of the vaccine, Stoffels stated.\r\n\r\nJ&amp;J\'s vaccine employs a standard cold virus called adenovirus type 26 or Ad26 to ferry coronavirus proteins into cells in the entire body, causing the body to mount an immune defense against the virus.\r\n\r\nIn the monkey study, scientists in J&amp;J and also Harvard\'s Beth Israel Deaconess Medical Center studied seven distinct possible vaccines in 32 creatures as compared with the results to 20 control creatures who got placebo shots.\r\n\r\nSix months later, each one the animals were subjected to this SARS-CoV-2 virus. All of 20 creatures that received the placebo developed high levels of virus in their lungs and nasal swabs.\r\n\r\nFrom the best-performing offender, which J&amp;J selected for human testing, not one of the animals had virus in their lungs and just one showed low levels of virus in nasal swabs. Laboratory tests demonstrated they all had grown antibodies capable of neutralizing the virus after one shot.\r\n\r\n\"This research indicates that even just a single immunization with the Ad26 vaccine leads to neutralizing antibody responses and robust protection of monkeys against COVID-19,\" explained Dr. Dan Barouch, a vaccine researcher at Beth Israel Deaconness who led the study in collaboration with J&amp;J.','Johnson and Johnson begins human safety preliminaries','','publish','open','open','','johnson-and-johnson-begins-human-safety-preliminaries','','','2020-07-30 15:33:26','2020-07-30 15:33:26','',0,'https://microbiozindia.com/?p=6780',0,'post','',0),(6781,2,'2020-07-30 15:33:26','2020-07-30 15:33:26','Johnson &amp; Johnson on Thursday kicked off US human safety trials because of its COVID-19 vaccine after releasing details of a research in monkeys that showed its best-performing vaccine candidate offered strong defense in a single dose.\r\n\r\nWhen subjected to this virus, six out of six animals who obtained the vaccine candidate proved completely protected from lung disease and five from six were protected from infection as measured by the existence of virus in nasal swabs, according to the study published in the journal Nature.\r\n\r\n\"This gives us confidence that we can examine a single-shot vaccine in this outbreak and find out whether it has a synergistic effect in humans,\" Dr. Paul Stoffels, J&amp;J\'s chief scientific officer, told Reuters in a telephone interview.\r\n\r\nThe drugmaker said it had started early-stage human trials in the United States and Belgium and could test its own vaccine candidate at over 1,000 healthy adults aged 18 to 55 years, as well as adults aged 65 decades and older.\r\n\r\nEven the US government is financing J&amp;J\'s vaccine campaign with $456 million in financing as part of a spending spree directed at speeding creation of a vaccine to end the outbreak, which has infected millions and killed over 660,000 people.\r\n\r\nStoffels said earlier evaluations of this kind of vaccine in different ailments found that a second shot appreciably increases protection. But in a pandemic that a single-shot vaccine has a significant advantage, sidestepping a lot of the logistical problems involved with getting people to come back to their second dose.\r\n\r\nThe company intends to take the question up of one or two doses at its stage 1 trial.\r\n\r\nDepending on those results, J&amp;J plans to start large-scale, phase 3 testing using a single-shot regimen at the second half of September. Around precisely the identical period, the organization will begin a parallel stage 3 analysis testing a two-shot regimen of the vaccine, Stoffels stated.\r\n\r\nJ&amp;J\'s vaccine employs a standard cold virus called adenovirus type 26 or Ad26 to ferry coronavirus proteins into cells in the entire body, causing the body to mount an immune defense against the virus.\r\n\r\nIn the monkey study, scientists in J&amp;J and also Harvard\'s Beth Israel Deaconess Medical Center studied seven distinct possible vaccines in 32 creatures as compared with the results to 20 control creatures who got placebo shots.\r\n\r\nSix months later, each one the animals were subjected to this SARS-CoV-2 virus. All of 20 creatures that received the placebo developed high levels of virus in their lungs and nasal swabs.\r\n\r\nFrom the best-performing offender, which J&amp;J selected for human testing, not one of the animals had virus in their lungs and just one showed low levels of virus in nasal swabs. Laboratory tests demonstrated they all had grown antibodies capable of neutralizing the virus after one shot.\r\n\r\n\"This research indicates that even just a single immunization with the Ad26 vaccine leads to neutralizing antibody responses and robust protection of monkeys against COVID-19,\" explained Dr. Dan Barouch, a vaccine researcher at Beth Israel Deaconness who led the study in collaboration with J&amp;J.','Johnson and Johnson begins human safety preliminaries','','inherit','closed','closed','','6780-revision-v1','','','2020-07-30 15:33:26','2020-07-30 15:33:26','',6780,'https://microbiozindia.com/uncategorized/6780-revision-v1/',0,'revision','',0),(6782,2,'2020-07-30 15:38:56','2020-07-30 15:38:56','CanSino Biologics Inc, one of several companies globally attempting to create a coronavirus vaccine, should run late-stage trials overseas if it\'s to remain in the race, experts say, but it has yet to declare a different country ready to help.\r\n\r\nMid-stage trials revealed that its vaccine didn\'t work also in people with immunity to a particular strain of the common cold virus and specialists say it needs to expand its pool of examining in Phase III trials to determine if this outcome, described by the firm as\"the biggest barrier\", is replicated overseas.\r\n\r\nTogether with other countries pushing ahead with their own tests and deepening worries with the United States posing a challenge to global collaboration, time is not on both sides.\r\n\r\nA Phase II trial 508 participants from Wuhan, where the coronavirus epidemic was initially identified late last season, was safe and promising, inducing an immune reaction in the majority of the volunteers that obtained one dose, the company said.\r\n\r\nHowever, the study revealed indications that individuals who had previously been subjected to a particular adenovirus in the injection had a diminished immune response.\r\n\r\nThe vaccine uses a harmless cold virus known as adenovirus type-5 (Ad5) to take genetic material by the coronavirus to the body.\r\n\r\n\"There\'s a huge fraction of people equally in the Western world and especially from the developing world that have the baseline Ad5 neutralizing antibody,\" explained Dr. Dan Barouchdirector of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston.\r\n\r\n\"And how will that impact the vaccine? It will decrease it... They (CanSino) will need to show that it\'s immunogenic from the areas of the world with the highest baseline Ad5 titers (amounts ) if they would like to make it a more global option,\" he explained.\r\n\r\nCanSino\'s co-founder said that it was in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial.\r\n\r\nChilean Science Minister Andres Couve told Reuters that the committee has meetings to examine different vaccine candidates, including CanSino\'s, for\"analysis\".\r\n\r\nCanSino did not respond to a Reuters request for comment regarding its overseas trial programs.\r\n\r\n\"The perfect solution would be to produce the Phase III trial large and multinational, therefore between as many folks as they can so that the effect of different previous exposure is sufficiently diluted,\" said Paul Griffin, a professor in the University of Queensland.\r\n\r\nResearch statistics show that people in the USA have a lesser pre-existing immunity to Ad5.\r\n\r\nBut growing political tension between Washington and Beijing has chances to its vaccine being extensively used or even tested there as the United States and other countries move forward with their particular study.\r\n\r\nU.S. President Donald Trump has expressed a willingness to work with China, but he also blames Beijing for covering up what he calls the\"China virus\" and faces widespread criticism at home for his mixed messages about the illness.\r\n\r\nAnthony Fauci, the leading U.S. specialist on infectious diseases, told Reuters this month he hoped China succeeds in finding a vaccine.\r\n\r\n\"I do not be concerned about anybody getting there ,\" he said.\r\n\r\nThe high incidence of preexisting antibodies to Ad5 has prompted some investigators to proceed to other kinds of adenovirus, Barouch stated.\r\n\r\nBoth Johnson &amp; Johnson and the University of Oxford, that is working with AstraZeneca, by way of example, use different adenoviruses, known as Ad26 and also Chimp adenovirus respectively, for their vaccine research.\r\n\r\nCanSino\'s candidate became the first in China to maneuver into individual testing in March but is running behind other potential vaccines. Two experiments created by Sinovac Biotech along with a component of China National Pharmaceutical Group (Sinopharm) have already been accepted for Phase III trials overseas. They do not utilize Ad5.\r\n\r\nCanSino\'s vaccinehas been developed by China\'s military-backed analysis unit, was accepted for use by the military.\r\n\r\nIf history is any guide, domestic use-only might be a path for China: An Ebola vaccine, also jointly developed by CanSino as well as the army research unit and according to Ad5, was approved by Beijing in 2017, but it never made it into the worldwide market.\r\n\r\nA China-only inoculation, but would be a hollow victory.','\'Greatest obstruction\': Where can CanSino test its immunization abroad?','','publish','open','open','','greatest-obstruction-where-can-cansino-test-its-immunization-abroad','','','2020-07-30 15:38:56','2020-07-30 15:38:56','',0,'https://microbiozindia.com/?p=6782',0,'post','',0),(6783,2,'2020-07-30 15:38:56','2020-07-30 15:38:56','CanSino Biologics Inc, one of several companies globally attempting to create a coronavirus vaccine, should run late-stage trials overseas if it\'s to remain in the race, experts say, but it has yet to declare a different country ready to help.\r\n\r\nMid-stage trials revealed that its vaccine didn\'t work also in people with immunity to a particular strain of the common cold virus and specialists say it needs to expand its pool of examining in Phase III trials to determine if this outcome, described by the firm as\"the biggest barrier\", is replicated overseas.\r\n\r\nTogether with other countries pushing ahead with their own tests and deepening worries with the United States posing a challenge to global collaboration, time is not on both sides.\r\n\r\nA Phase II trial 508 participants from Wuhan, where the coronavirus epidemic was initially identified late last season, was safe and promising, inducing an immune reaction in the majority of the volunteers that obtained one dose, the company said.\r\n\r\nHowever, the study revealed indications that individuals who had previously been subjected to a particular adenovirus in the injection had a diminished immune response.\r\n\r\nThe vaccine uses a harmless cold virus known as adenovirus type-5 (Ad5) to take genetic material by the coronavirus to the body.\r\n\r\n\"There\'s a huge fraction of people equally in the Western world and especially from the developing world that have the baseline Ad5 neutralizing antibody,\" explained Dr. Dan Barouchdirector of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston.\r\n\r\n\"And how will that impact the vaccine? It will decrease it... They (CanSino) will need to show that it\'s immunogenic from the areas of the world with the highest baseline Ad5 titers (amounts ) if they would like to make it a more global option,\" he explained.\r\n\r\nCanSino\'s co-founder said that it was in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial.\r\n\r\nChilean Science Minister Andres Couve told Reuters that the committee has meetings to examine different vaccine candidates, including CanSino\'s, for\"analysis\".\r\n\r\nCanSino did not respond to a Reuters request for comment regarding its overseas trial programs.\r\n\r\n\"The perfect solution would be to produce the Phase III trial large and multinational, therefore between as many folks as they can so that the effect of different previous exposure is sufficiently diluted,\" said Paul Griffin, a professor in the University of Queensland.\r\n\r\nResearch statistics show that people in the USA have a lesser pre-existing immunity to Ad5.\r\n\r\nBut growing political tension between Washington and Beijing has chances to its vaccine being extensively used or even tested there as the United States and other countries move forward with their particular study.\r\n\r\nU.S. President Donald Trump has expressed a willingness to work with China, but he also blames Beijing for covering up what he calls the\"China virus\" and faces widespread criticism at home for his mixed messages about the illness.\r\n\r\nAnthony Fauci, the leading U.S. specialist on infectious diseases, told Reuters this month he hoped China succeeds in finding a vaccine.\r\n\r\n\"I do not be concerned about anybody getting there ,\" he said.\r\n\r\nThe high incidence of preexisting antibodies to Ad5 has prompted some investigators to proceed to other kinds of adenovirus, Barouch stated.\r\n\r\nBoth Johnson &amp; Johnson and the University of Oxford, that is working with AstraZeneca, by way of example, use different adenoviruses, known as Ad26 and also Chimp adenovirus respectively, for their vaccine research.\r\n\r\nCanSino\'s candidate became the first in China to maneuver into individual testing in March but is running behind other potential vaccines. Two experiments created by Sinovac Biotech along with a component of China National Pharmaceutical Group (Sinopharm) have already been accepted for Phase III trials overseas. They do not utilize Ad5.\r\n\r\nCanSino\'s vaccinehas been developed by China\'s military-backed analysis unit, was accepted for use by the military.\r\n\r\nIf history is any guide, domestic use-only might be a path for China: An Ebola vaccine, also jointly developed by CanSino as well as the army research unit and according to Ad5, was approved by Beijing in 2017, but it never made it into the worldwide market.\r\n\r\nA China-only inoculation, but would be a hollow victory.','\'Greatest obstruction\': Where can CanSino test its immunization abroad?','','inherit','closed','closed','','6782-revision-v1','','','2020-07-30 15:38:56','2020-07-30 15:38:56','',6782,'https://microbiozindia.com/uncategorized/6782-revision-v1/',0,'revision','',0),(6785,2,'2020-07-30 16:15:07','2020-07-30 16:15:07','Roche, Basel, Switzerland, has received FDA approval for its Ventana HER2 Dual ISH DNA Probe Cocktail assay for the detection of the human epidermal growth factor receptor 2 (HER2) biomarker in breast cancer and as a companion diagnostic for Herceptin (trastuzumab) therapy. HER2 is an important biomarker sometimes found in breast cancer, and its detection and inhibition can help healthcare professionals more effectively manage this aggressive cancer.\r\n\r\n[caption id=\"attachment_6786\" align=\"alignnone\" width=\"347\"]<img class=\"wp-image-6786\" src=\"https://microbiozindia.com/wp-content/uploads/2020/07/dreamstime_l_84896320-466x310-1-300x200.jpg\" alt=\"\" width=\"347\" height=\"231\" /> 3D rendering of HER2. Amplification of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. Image © ibreakstock, courtesy Dreamstime.com (ID 84896320).[/caption]\r\n\r\nThe Ventana HER2 Double ISH DNA Probe Cocktail assay is intended to be completed within precisely the exact same day, enabling clinicians to get results back quicker than with other common procedures of confirmatory testing for HER2. Results can be read using light microscopy, eliminating the need for a specialized fluorescence microscope.\r\n<blockquote>“With this new VENTANA HER2 Dual ISH assay, Roche continues to deliver on its commitment to advance personalised healthcare,” says Thomas Schinecker, CEO of Roche Diagnostics. “Quick test results are crucial in the fight against cancer and by delivering critical information on treatment options for breast cancer patients faster, this assay will aid clinicians in their therapeutic decisions.”</blockquote>\r\nFor more information, visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.roche.com/\">Roche</a>.</span>','Roche\'s HER2 Companion Diagnostic for Breast Cancer: FDA approval','','publish','open','open','','roches-her2-companion-diagnostic-for-breast-cancer-fda-approval','','','2020-07-30 16:15:07','2020-07-30 16:15:07','',0,'https://microbiozindia.com/?p=6785',0,'post','',0),(6786,2,'2020-07-30 16:12:18','2020-07-30 16:12:18','','dreamstime_l_84896320-466x310','','inherit','open','closed','','dreamstime_l_84896320-466x310','','','2020-07-30 16:12:18','2020-07-30 16:12:18','',6785,'https://microbiozindia.com/wp-content/uploads/2020/07/dreamstime_l_84896320-466x310-1.jpg',0,'attachment','image/jpeg',0),(6787,2,'2020-07-30 16:15:07','2020-07-30 16:15:07','Roche, Basel, Switzerland, has received FDA approval for its Ventana HER2 Dual ISH DNA Probe Cocktail assay for the detection of the human epidermal growth factor receptor 2 (HER2) biomarker in breast cancer and as a companion diagnostic for Herceptin (trastuzumab) therapy. HER2 is an important biomarker sometimes found in breast cancer, and its detection and inhibition can help healthcare professionals more effectively manage this aggressive cancer.\r\n\r\n[caption id=\"attachment_6786\" align=\"alignnone\" width=\"347\"]<img class=\"wp-image-6786\" src=\"https://microbiozindia.com/wp-content/uploads/2020/07/dreamstime_l_84896320-466x310-1-300x200.jpg\" alt=\"\" width=\"347\" height=\"231\" /> 3D rendering of HER2. Amplification of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. Image © ibreakstock, courtesy Dreamstime.com (ID 84896320).[/caption]\r\n\r\nThe Ventana HER2 Double ISH DNA Probe Cocktail assay is intended to be completed within precisely the exact same day, enabling clinicians to get results back quicker than with other common procedures of confirmatory testing for HER2. Results can be read using light microscopy, eliminating the need for a specialized fluorescence microscope.\r\n<blockquote>“With this new VENTANA HER2 Dual ISH assay, Roche continues to deliver on its commitment to advance personalised healthcare,” says Thomas Schinecker, CEO of Roche Diagnostics. “Quick test results are crucial in the fight against cancer and by delivering critical information on treatment options for breast cancer patients faster, this assay will aid clinicians in their therapeutic decisions.”</blockquote>\r\nFor more information, visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.roche.com/\">Roche</a>.</span>','Roche\'s HER2 Companion Diagnostic for Breast Cancer: FDA approval','','inherit','closed','closed','','6785-revision-v1','','','2020-07-30 16:15:07','2020-07-30 16:15:07','',6785,'https://microbiozindia.com/uncategorized/6785-revision-v1/',0,'revision','',0),(6788,2,'2020-07-31 04:40:20','2020-07-31 04:40:20','Pharmaceutical company AstraZeneca replicated its promise not to profit from a COVID-19 vaccine during the pandemic as it reported it was on course with late-stage trials for the treatment. Such guarantees were boosted by strong sales across its range of remedies during lockdown.\r\n\r\nEarnings jumped by 14 percent to USD 12.6 billion in the first six months of 2020 and were aided by strong trading in new medications, in addition to respiratory and cancer medicine.\r\n\r\nDespite the fantastic earnings, CEO Pascal Soriot said he remained cautious amid the instability of the pandemic.\r\n\r\n\"If we\'ve learned one thing with this virus, then it is that it\'s unpredictable,\" he explained. \"And so we need to remain cautious.\"\r\n\r\nHe said that the company was on track to make 2 billion doses of this vaccine in a few dollars each dose. It also concluded three more deals for distribution - should the vaccine operate.\r\n\r\n\"We felt, there (is) a time in life when firms will need to step up and make a donation,\" he stated, adding that a vaccine needed to be accessible to as many people as possible.\r\n\r\n\"This is the kind of time in history when humanity, humankind is really jeopardized as a whole,\" he explained.\r\n\r\nThe cost of creating the vaccine, which was developed by Oxford University, is expected to be offset by funding from the authorities.\r\n\r\nAstraZeneca has struck a variety of deals around the world to supply the experimental COVID-19 vaccine, which has shown promise in early testing.\r\n\r\nThe deals cover 700 million doses.\r\n\r\nIt has also reached a licensing agreement with Serum Institute of India to provide low-and-middle-income nations and arrangements with R-Pharm in Russia and SK Biopharmaceuticals Co., Ltd in the Republic of Korea\"to manufacture and export for other global markets.\"','Won\'t benefit from COVID vaccine in pandemic: AstraZeneca','','publish','open','open','','wont-benefit-from-covid-vaccine-in-pandemic-astrazeneca','','','2020-07-31 04:40:20','2020-07-31 04:40:20','',0,'https://microbiozindia.com/?p=6788',0,'post','',0),(6789,2,'2020-07-31 04:40:20','2020-07-31 04:40:20','Pharmaceutical company AstraZeneca replicated its promise not to profit from a COVID-19 vaccine during the pandemic as it reported it was on course with late-stage trials for the treatment. Such guarantees were boosted by strong sales across its range of remedies during lockdown.\r\n\r\nEarnings jumped by 14 percent to USD 12.6 billion in the first six months of 2020 and were aided by strong trading in new medications, in addition to respiratory and cancer medicine.\r\n\r\nDespite the fantastic earnings, CEO Pascal Soriot said he remained cautious amid the instability of the pandemic.\r\n\r\n\"If we\'ve learned one thing with this virus, then it is that it\'s unpredictable,\" he explained. \"And so we need to remain cautious.\"\r\n\r\nHe said that the company was on track to make 2 billion doses of this vaccine in a few dollars each dose. It also concluded three more deals for distribution - should the vaccine operate.\r\n\r\n\"We felt, there (is) a time in life when firms will need to step up and make a donation,\" he stated, adding that a vaccine needed to be accessible to as many people as possible.\r\n\r\n\"This is the kind of time in history when humanity, humankind is really jeopardized as a whole,\" he explained.\r\n\r\nThe cost of creating the vaccine, which was developed by Oxford University, is expected to be offset by funding from the authorities.\r\n\r\nAstraZeneca has struck a variety of deals around the world to supply the experimental COVID-19 vaccine, which has shown promise in early testing.\r\n\r\nThe deals cover 700 million doses.\r\n\r\nIt has also reached a licensing agreement with Serum Institute of India to provide low-and-middle-income nations and arrangements with R-Pharm in Russia and SK Biopharmaceuticals Co., Ltd in the Republic of Korea\"to manufacture and export for other global markets.\"','Won\'t benefit from COVID vaccine in pandemic: AstraZeneca','','inherit','closed','closed','','6788-revision-v1','','','2020-07-31 04:40:20','2020-07-31 04:40:20','',6788,'https://microbiozindia.com/uncategorized/6788-revision-v1/',0,'revision','',0),(6790,2,'2020-07-31 06:34:26','2020-07-31 06:34:26','Washington, Jul 31 (PTI) Kids younger than five years with moderate to moderate COVID-19 have much higher levels of this novel coronavirus genetic material at the nose compared to older kids and adults, according to another study that raises concern about the reopening of schools and daycare centres across the world.\r\nThe findings, published in the journal JAMA Pediatrics, shed light on the risk that the youngest children transmit the virus just as far as other age groups.\r\n\r\nAccording to scientists, including those in Ann &amp; Robert H. Lurie Children\"s Hospital in the US, the ability of younger kids to spread COVID-19 might have been under-recognised awarded the rapid and continuing closure of schools and daycare centers during the outbreak.\r\n\r\n\"Our analyses suggest children younger than five years with mild to moderate COVID-19 have elevated amounts of the SARS-CoV-2 viral RNA in their nasopharynx in comparison with older children and adults,\" the scientists wrote in the research.\r\n\r\nAccording to the study\"s lead writer Taylor Heald-Sargent, a pediatric infectious diseases specialist at Ann &amp; Robert H. Lurie Children\"s Hospital, this may suggest increased transmission of this virus by kids than seen in adults.\r\n\r\nHe added that the findings are very similar to the transmission pattern seen with the respiratory syncytial virus, also known as RSV.\r\n\r\n\"This has important public health consequences, particularly during talks on the safety of reopening schools and daycare,\" Heald-Sargent explained.\r\n\r\nFrom the analysis, the researchers analysed 145 instances of mild to moderate COVID-19 disease within the first week of symptom onset.\r\n\r\nThey compared the amount of virus genetic material found in 3 age groups -- children younger than five decades, children five to 17 decades, and adults 18-65 yearsago\r\n\r\n\"Our study was not meant to prove that younger kids spread COVID-19 as much as adults, however, it is a potential,\" Heald-Sargent explained.\r\n\r\n\"We will need to take that into consideration in attempts to reduce transmission as we continue to learn more about this particular virus,\" he added.\r\n\r\nThe researchers cautioned that the study is restricted to detection of viral genetic material -- its own nucleic acid molecule RNA -- rather than infectious virus.\r\n\r\nBut they added that before research on pediatric cases of COVID-19 pointed to a correlation between high viral nucleic acid levels and the capability to civilization infectious virus.\r\n\r\n\"Thus, young kids can possibly be significant drivers of SARS-CoV-2 distribute in the overall population, as was demonstrated with respiratory syncytial virus, in which kids with elevated viral loads are more likely to transmit,\" the investigators explained from the research.\r\n\r\nThey said the behavioral habits of young children, as well as the quarters they occupy in school and day care settings raise concern for amplified transmission of the virus because public health constraints are eased.\r\n\r\n\"Along with public health consequences, this population will likely be important for targeting immunisation attempts as SARS-CoV-2 vaccines become available,\" the scientists concluded.PTI VIS VIS','Young children could spread COVID-19 up to older kids adults: Study','','publish','open','open','','young-children-could-spread-covid-19-up-to-older-kids-adults-study','','','2020-07-31 06:34:26','2020-07-31 06:34:26','',0,'https://microbiozindia.com/?p=6790',0,'post','',0),(6791,2,'2020-07-31 06:33:47','2020-07-31 06:33:47','','home-office-4994104_640','','inherit','open','closed','','home-office-4994104_640','','','2020-07-31 06:33:47','2020-07-31 06:33:47','',6790,'https://microbiozindia.com/wp-content/uploads/2020/07/home-office-4994104_640.jpg',0,'attachment','image/jpeg',0),(6792,2,'2020-07-31 06:34:26','2020-07-31 06:34:26','Washington, Jul 31 (PTI) Kids younger than five years with moderate to moderate COVID-19 have much higher levels of this novel coronavirus genetic material at the nose compared to older kids and adults, according to another study that raises concern about the reopening of schools and daycare centres across the world.\r\nThe findings, published in the journal JAMA Pediatrics, shed light on the risk that the youngest children transmit the virus just as far as other age groups.\r\n\r\nAccording to scientists, including those in Ann &amp; Robert H. Lurie Children\"s Hospital in the US, the ability of younger kids to spread COVID-19 might have been under-recognised awarded the rapid and continuing closure of schools and daycare centers during the outbreak.\r\n\r\n\"Our analyses suggest children younger than five years with mild to moderate COVID-19 have elevated amounts of the SARS-CoV-2 viral RNA in their nasopharynx in comparison with older children and adults,\" the scientists wrote in the research.\r\n\r\nAccording to the study\"s lead writer Taylor Heald-Sargent, a pediatric infectious diseases specialist at Ann &amp; Robert H. Lurie Children\"s Hospital, this may suggest increased transmission of this virus by kids than seen in adults.\r\n\r\nHe added that the findings are very similar to the transmission pattern seen with the respiratory syncytial virus, also known as RSV.\r\n\r\n\"This has important public health consequences, particularly during talks on the safety of reopening schools and daycare,\" Heald-Sargent explained.\r\n\r\nFrom the analysis, the researchers analysed 145 instances of mild to moderate COVID-19 disease within the first week of symptom onset.\r\n\r\nThey compared the amount of virus genetic material found in 3 age groups -- children younger than five decades, children five to 17 decades, and adults 18-65 yearsago\r\n\r\n\"Our study was not meant to prove that younger kids spread COVID-19 as much as adults, however, it is a potential,\" Heald-Sargent explained.\r\n\r\n\"We will need to take that into consideration in attempts to reduce transmission as we continue to learn more about this particular virus,\" he added.\r\n\r\nThe researchers cautioned that the study is restricted to detection of viral genetic material -- its own nucleic acid molecule RNA -- rather than infectious virus.\r\n\r\nBut they added that before research on pediatric cases of COVID-19 pointed to a correlation between high viral nucleic acid levels and the capability to civilization infectious virus.\r\n\r\n\"Thus, young kids can possibly be significant drivers of SARS-CoV-2 distribute in the overall population, as was demonstrated with respiratory syncytial virus, in which kids with elevated viral loads are more likely to transmit,\" the investigators explained from the research.\r\n\r\nThey said the behavioral habits of young children, as well as the quarters they occupy in school and day care settings raise concern for amplified transmission of the virus because public health constraints are eased.\r\n\r\n\"Along with public health consequences, this population will likely be important for targeting immunisation attempts as SARS-CoV-2 vaccines become available,\" the scientists concluded.PTI VIS VIS','Young children could spread COVID-19 up to older kids adults: Study','','inherit','closed','closed','','6790-revision-v1','','','2020-07-31 06:34:26','2020-07-31 06:34:26','',6790,'https://microbiozindia.com/uncategorized/6790-revision-v1/',0,'revision','',0),(6793,2,'2020-07-31 10:10:12','2020-07-31 10:10:12','A German shepherd,\'Buddy\', that was the first confirmed instance of this novel coronavirus infection in a pet in america has expired, according to a report.\r\n\r\nIn June, the United States Department of Agriculture\'s (USDA) National Veterinary Services Laboratories (NVSL) had declared that the pet being the first pet in America testing positive for the virus SARS-CoV-2 behind the COVID-19 pandemic.\r\n\r\nBefore the dog showing signs, among its owners, Robert Mahoney, had tested positive for COVID-19, and yet another had symptoms consistent with the virus.\r\n\r\nThe owners told National Geographic that Buddy developed breathing problems at mid-April after Mahoney had been sick with the novel coronavirus for many weeks.\r\n\r\nAccording to the report, Buddy\'s health declined steadily after he developed breathing problems and thick nasal mucus in April, and he was euthanised on July 11 after he began vomiting clotted blood.\r\n\r\nAlthough it is unknown whether the SARS-CoV-2 virus played a role in Buddy\'s death, blood tests suggested the dog may have experienced lymphoma, a cancer of the immune system.\r\n\r\nAccording to the USDA, there is currently no signs that animals play a substantial role in spreading the coronavirus.\r\n\r\nHowever, the novel coronavirus may spread from people to animals in certain situations.\r\n\r\nThe evidence for this was reported in an analysis of two dogs in Hong Kong, published in May in the journal Nature, showing signs of infection with the virus.','First coronavirus positive pet canine in US bites the dust: Report','','publish','open','open','','first-coronavirus-positive-pet-canine-in-us-bites-the-dust-report','','','2020-07-31 10:10:12','2020-07-31 10:10:12','',0,'https://microbiozindia.com/?p=6793',0,'post','',0),(6794,2,'2020-07-31 10:08:54','2020-07-31 10:08:54','','pandemic-5139204_640','','inherit','open','closed','','pandemic-5139204_640','','','2020-07-31 10:08:54','2020-07-31 10:08:54','',6793,'https://microbiozindia.com/wp-content/uploads/2020/07/pandemic-5139204_640.jpg',0,'attachment','image/jpeg',0),(6795,2,'2020-07-31 10:10:12','2020-07-31 10:10:12','A German shepherd,\'Buddy\', that was the first confirmed instance of this novel coronavirus infection in a pet in america has expired, according to a report.\r\n\r\nIn June, the United States Department of Agriculture\'s (USDA) National Veterinary Services Laboratories (NVSL) had declared that the pet being the first pet in America testing positive for the virus SARS-CoV-2 behind the COVID-19 pandemic.\r\n\r\nBefore the dog showing signs, among its owners, Robert Mahoney, had tested positive for COVID-19, and yet another had symptoms consistent with the virus.\r\n\r\nThe owners told National Geographic that Buddy developed breathing problems at mid-April after Mahoney had been sick with the novel coronavirus for many weeks.\r\n\r\nAccording to the report, Buddy\'s health declined steadily after he developed breathing problems and thick nasal mucus in April, and he was euthanised on July 11 after he began vomiting clotted blood.\r\n\r\nAlthough it is unknown whether the SARS-CoV-2 virus played a role in Buddy\'s death, blood tests suggested the dog may have experienced lymphoma, a cancer of the immune system.\r\n\r\nAccording to the USDA, there is currently no signs that animals play a substantial role in spreading the coronavirus.\r\n\r\nHowever, the novel coronavirus may spread from people to animals in certain situations.\r\n\r\nThe evidence for this was reported in an analysis of two dogs in Hong Kong, published in May in the journal Nature, showing signs of infection with the virus.','First coronavirus positive pet canine in US bites the dust: Report','','inherit','closed','closed','','6793-revision-v1','','','2020-07-31 10:10:12','2020-07-31 10:10:12','',6793,'https://microbiozindia.com/uncategorized/6793-revision-v1/',0,'revision','',0),(6796,2,'2020-07-31 11:28:07','2020-07-31 11:28:07','Pfizer Inc and BioNTech SE have consented to provide Japan with 120 million doses of their mRNA-based vaccine candidate against the novel coronavirus in the first half of 2021, the companies said on Friday.\r\n\r\nThe companies said, assuming achievement of the vaccine in clinical studies, they are on track to look for regulatory review to get the vaccine as early as October.\r\n\r\nThe companies didn\'t disclose the financial details of their arrangement.','Pfizer, BioNTech to flexibly 120 million doses of coronavirus immunization to Japan','','publish','open','open','','pfizer-biontech-to-flexibly-120-million-doses-of-coronavirus-immunization-to-japan','','','2020-07-31 11:28:07','2020-07-31 11:28:07','',0,'https://microbiozindia.com/?p=6796',0,'post','',0),(6797,2,'2020-07-31 11:28:07','2020-07-31 11:28:07','Pfizer Inc and BioNTech SE have consented to provide Japan with 120 million doses of their mRNA-based vaccine candidate against the novel coronavirus in the first half of 2021, the companies said on Friday.\r\n\r\nThe companies said, assuming achievement of the vaccine in clinical studies, they are on track to look for regulatory review to get the vaccine as early as October.\r\n\r\nThe companies didn\'t disclose the financial details of their arrangement.','Pfizer, BioNTech to flexibly 120 million doses of coronavirus immunization to Japan','','inherit','closed','closed','','6796-revision-v1','','','2020-07-31 11:28:07','2020-07-31 11:28:07','',6796,'https://microbiozindia.com/uncategorized/6796-revision-v1/',0,'revision','',0),(6799,2,'2020-07-31 15:35:58','2020-07-31 15:35:58','The US government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc to get COVID-19 vaccines to pay 50 million individuals and to underwrite the drug manufacturers\' testing and manufacturing, the companies said on Friday.\r\n\r\nThe award is the biggest yet from\'Operation Warp Speed\', the White House initiative aimed at accelerating access to treatments and vaccines to fight COVID-19, the respiratory disease caused by the publication coronavirus.\r\n\r\nThe agreement, announced by the US Department of Health and Human Services and Department of Defense, operates out in a cost of about $42 per person inoculated.\r\n\r\nThat\'s almost equal to the $40 per individual the US agreed to cover Pfizer Inc and BioNTech SE when it inked a nearly $2 billion deal to 50 million classes of that potential vaccine last week.\r\n\r\nThe Sanofi-GSK deal is for 100 million doses, at two each individual, and gives the government an choice to purchase an additional 500 million doses at an unspecified price.\r\n\r\nSanofi executive Clement Lewin said the companies had not yet agreed with the government on a specific cost for the additional doses.\r\n\r\nGSK stated in an announcement that over half the total funding will go into further development of the vaccine, such as clinical trials, with the remainder used for a production ramp-up and delivery of dosages.\r\n\r\nThe two companies\' inoculation is combination of a vaccine according to Sanofi\'s flu shots and a complementary technology from GSK known as an adjuvant, designed to enhance the vaccine\'s potency.\r\n\r\nSanofi will receive the bulk of the profits from the deal.\r\n\r\nIt marks the second contract for the Franco-British group\'s vaccine candidate once they agreed earlier this week to supply 60 million doses into the British government.\r\n\r\nReuters reported last week that Pfizer\'s deal was expected to set a pricing benchmark for future prices between drugmakers and governments.\r\n\r\nModerna Inc and Pfizer began two 30,000-subject trials of COVID-19 vaccines on Monday that may clear the way for regulatory approval and use at the end of 2020.','US to pay $2.1 billion to Sanofi, GSK in COVID-19 antibody bargain','','publish','open','open','','us-to-pay-2-1-billion-to-sanofi-gsk-in-covid-19-antibody-bargain','','','2020-07-31 15:35:58','2020-07-31 15:35:58','',0,'https://microbiozindia.com/?p=6799',0,'post','',0),(6800,2,'2020-07-31 15:35:58','2020-07-31 15:35:58','The US government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc to get COVID-19 vaccines to pay 50 million individuals and to underwrite the drug manufacturers\' testing and manufacturing, the companies said on Friday.\r\n\r\nThe award is the biggest yet from\'Operation Warp Speed\', the White House initiative aimed at accelerating access to treatments and vaccines to fight COVID-19, the respiratory disease caused by the publication coronavirus.\r\n\r\nThe agreement, announced by the US Department of Health and Human Services and Department of Defense, operates out in a cost of about $42 per person inoculated.\r\n\r\nThat\'s almost equal to the $40 per individual the US agreed to cover Pfizer Inc and BioNTech SE when it inked a nearly $2 billion deal to 50 million classes of that potential vaccine last week.\r\n\r\nThe Sanofi-GSK deal is for 100 million doses, at two each individual, and gives the government an choice to purchase an additional 500 million doses at an unspecified price.\r\n\r\nSanofi executive Clement Lewin said the companies had not yet agreed with the government on a specific cost for the additional doses.\r\n\r\nGSK stated in an announcement that over half the total funding will go into further development of the vaccine, such as clinical trials, with the remainder used for a production ramp-up and delivery of dosages.\r\n\r\nThe two companies\' inoculation is combination of a vaccine according to Sanofi\'s flu shots and a complementary technology from GSK known as an adjuvant, designed to enhance the vaccine\'s potency.\r\n\r\nSanofi will receive the bulk of the profits from the deal.\r\n\r\nIt marks the second contract for the Franco-British group\'s vaccine candidate once they agreed earlier this week to supply 60 million doses into the British government.\r\n\r\nReuters reported last week that Pfizer\'s deal was expected to set a pricing benchmark for future prices between drugmakers and governments.\r\n\r\nModerna Inc and Pfizer began two 30,000-subject trials of COVID-19 vaccines on Monday that may clear the way for regulatory approval and use at the end of 2020.','US to pay $2.1 billion to Sanofi, GSK in COVID-19 antibody bargain','','inherit','closed','closed','','6799-revision-v1','','','2020-07-31 15:35:58','2020-07-31 15:35:58','',6799,'https://microbiozindia.com/uncategorized/6799-revision-v1/',0,'revision','',0),(6801,2,'2020-08-01 07:32:43','2020-08-01 07:32:43','Sanofi SA and GlaxoSmithKline Plc on Friday said they are in advanced discussions to supply up to 300 million doses of an experimental COVID-19 vaccine to the 27-country European Union.\r\n\r\nEquipped with an emergency fund of more than 2 billion euros (Â#1.80 billion), the European Commission would like to strike deals up to six drugmakers for their offenses because of their 450 million taxpayers against the coronavirus which has murdered 674,000 people worldwide.\r\n\r\nThe Commission reported the aim of the talks with Sanofi was going to clinch an advance purchase deal.\r\n\r\n\"The envisaged contract with Sanofi would provide for an alternative for all EU Member States to purchase the vaccine,\" the Commission said in a statement.\r\n\r\n\"It is envisaged that, once a vaccine has been demonstrated to be safe and effective against COVID-19, the Commission could have a contractual framework in place for the purchase of 300 million doses, on behalf of all EU member states.\"\r\n\r\nA Commission spokesman said he couldn\'t comment on when a deal could be announced and the feasible price for your vaccine, calling it a very promising step towards the eventual agreement.\r\n\r\nSanofi is functioning on two vaccine jobs such as one in partnership with GlaxoSmithKline.\r\n\r\nThe firms said the doses could be fabricated in European countries such as France, Belgium, Germany and Italy.\r\n\r\nSanofi is leading the clinical development of the vaccine also hopes to begin a trial by the end of the season.\r\n\r\nEarlier this week, EU talks with Sanofi, Pfizer and Johnson &amp; Johnson struck an impasse over price, payment method and potential liability costs, EU officials told Reuters.\r\n\r\nOther pharmaceutical companies talking to the EU comprise France\'s Valneva, Moderna and biotech companies BioNTech and Germany\'s CureVac.','U in Discussions to Procure Sanofi Bargain for coronavirus vaccine','','publish','open','open','','u-in-discussions-to-procure-sanofi-bargain-for-coronavirus-vaccine','','','2020-08-01 07:32:43','2020-08-01 07:32:43','',0,'https://microbiozindia.com/?p=6801',0,'post','',0),(6802,2,'2020-08-01 07:32:43','2020-08-01 07:32:43','Sanofi SA and GlaxoSmithKline Plc on Friday said they are in advanced discussions to supply up to 300 million doses of an experimental COVID-19 vaccine to the 27-country European Union.\r\n\r\nEquipped with an emergency fund of more than 2 billion euros (Â#1.80 billion), the European Commission would like to strike deals up to six drugmakers for their offenses because of their 450 million taxpayers against the coronavirus which has murdered 674,000 people worldwide.\r\n\r\nThe Commission reported the aim of the talks with Sanofi was going to clinch an advance purchase deal.\r\n\r\n\"The envisaged contract with Sanofi would provide for an alternative for all EU Member States to purchase the vaccine,\" the Commission said in a statement.\r\n\r\n\"It is envisaged that, once a vaccine has been demonstrated to be safe and effective against COVID-19, the Commission could have a contractual framework in place for the purchase of 300 million doses, on behalf of all EU member states.\"\r\n\r\nA Commission spokesman said he couldn\'t comment on when a deal could be announced and the feasible price for your vaccine, calling it a very promising step towards the eventual agreement.\r\n\r\nSanofi is functioning on two vaccine jobs such as one in partnership with GlaxoSmithKline.\r\n\r\nThe firms said the doses could be fabricated in European countries such as France, Belgium, Germany and Italy.\r\n\r\nSanofi is leading the clinical development of the vaccine also hopes to begin a trial by the end of the season.\r\n\r\nEarlier this week, EU talks with Sanofi, Pfizer and Johnson &amp; Johnson struck an impasse over price, payment method and potential liability costs, EU officials told Reuters.\r\n\r\nOther pharmaceutical companies talking to the EU comprise France\'s Valneva, Moderna and biotech companies BioNTech and Germany\'s CureVac.','U in Discussions to Procure Sanofi Bargain for coronavirus vaccine','','inherit','closed','closed','','6801-revision-v1','','','2020-08-01 07:32:43','2020-08-01 07:32:43','',6801,'https://microbiozindia.com/uncategorized/6801-revision-v1/',0,'revision','',0),(6803,2,'2020-08-01 07:34:45','2020-08-01 07:34:45','Chilean police are training sniffer dogs to discover the coronavirus in people\'s sweat for an early period, after a similar trial in the UK showed encouraging results.\r\n\r\nFour dogs are chosen for the initial training, a mixture of labradors and golden retrievers who game green\"biodetector\" jackets for their task. They are being trained at the Chilean Carabineros´ pro training base in the capital Santiago.\r\n\r\nSniffer dogs are best-known for detecting drugs, explosives and individuals but have also previously been trained to find different diseases including malaria, cancer and Parkinson\'s disease.\r\n\r\nLieutenant Colonel Cristian Acevedo Yanez, director of the authorities specialty training school, said dogs had over 3 million olfactory receptors, over 50 times those of humans, so were uniquely placed to help fight the coronavirus.\r\n\r\nHe explained the canines can play a critical part as Chile attempts to gradually reopen its schools and shops and get people back to work.\r\n\r\n\"The role of police is to fortify our detection abilities in this\'new normal\',\" he explained. \"The notion is that our dogs are in busy places such as schools, bus terminals and airports, and could detect individuals at an early phase of the disease to have the ability to isolate them and perform the right PCR test, avoiding mass contagions,\" he explained.\r\n\r\n\"Fundamentally these puppies, four at first, and their guides, will do is save lives.','Try not to perspire it: Chilean canines track down coronavirus in beginning phases','','publish','open','open','','try-not-to-perspire-it-chilean-canines-track-down-coronavirus-in-beginning-phases','','','2020-08-01 07:34:45','2020-08-01 07:34:45','',0,'https://microbiozindia.com/?p=6803',0,'post','',0),(6804,2,'2020-08-01 07:33:42','2020-08-01 07:33:42','','a43d81f5-003d-4b4c-ac03-08cb809a9cef-getty-1200518974','','inherit','open','closed','','a43d81f5-003d-4b4c-ac03-08cb809a9cef-getty-1200518974','','','2020-08-01 07:33:42','2020-08-01 07:33:42','',6803,'https://microbiozindia.com/wp-content/uploads/2020/08/a43d81f5-003d-4b4c-ac03-08cb809a9cef-getty-1200518974.jpg',0,'attachment','image/jpeg',0),(6805,2,'2020-08-01 07:34:45','2020-08-01 07:34:45','Chilean police are training sniffer dogs to discover the coronavirus in people\'s sweat for an early period, after a similar trial in the UK showed encouraging results.\r\n\r\nFour dogs are chosen for the initial training, a mixture of labradors and golden retrievers who game green\"biodetector\" jackets for their task. They are being trained at the Chilean Carabineros´ pro training base in the capital Santiago.\r\n\r\nSniffer dogs are best-known for detecting drugs, explosives and individuals but have also previously been trained to find different diseases including malaria, cancer and Parkinson\'s disease.\r\n\r\nLieutenant Colonel Cristian Acevedo Yanez, director of the authorities specialty training school, said dogs had over 3 million olfactory receptors, over 50 times those of humans, so were uniquely placed to help fight the coronavirus.\r\n\r\nHe explained the canines can play a critical part as Chile attempts to gradually reopen its schools and shops and get people back to work.\r\n\r\n\"The role of police is to fortify our detection abilities in this\'new normal\',\" he explained. \"The notion is that our dogs are in busy places such as schools, bus terminals and airports, and could detect individuals at an early phase of the disease to have the ability to isolate them and perform the right PCR test, avoiding mass contagions,\" he explained.\r\n\r\n\"Fundamentally these puppies, four at first, and their guides, will do is save lives.','Try not to perspire it: Chilean canines track down coronavirus in beginning phases','','inherit','closed','closed','','6803-revision-v1','','','2020-08-01 07:34:45','2020-08-01 07:34:45','',6803,'https://microbiozindia.com/uncategorized/6803-revision-v1/',0,'revision','',0),(6806,2,'2020-08-01 11:19:47','2020-08-01 11:19:47','HBM will combine its top Harbour Mice® stage H2L2 and its expertise in global research and development of innovative molecules, with Viva Biotech\'s structure-based early phase drug discovery services. This complementary partnership will provide advanced biotech startups access to next generation technologies that create synergies to accelerate the route between ideation to merchandise. The incubated startups will operate thorough scientific research and EFS (equity for support ) model.\r\n\r\nHBM has made significant progress since its establishment in late-2016, through strategic collaborations and partnerships with major academic institutions and biotech and pharmaceutical companies across the world. The business has successfully built a robust portfolio of early and late stage assets in immune-oncology and immunology, through organic R&amp;D as well as in-licensing tactical assets that tackle high unmet medical needs throughout the world. Its internally discovered next generation ani-CTLA-4 antibody HBM4003 for solid tumors, based on its HCAb stage is already in phase 1 clinical trials.\r\n<blockquote>\"We are excited to combine our capabilities with those of Viva Biotech\'s to offer innovative startup companies\' access to our next generation technology platforms and unique R&amp;D capabilities. We are always on the lookout for innovation that can positively impact human life, and this partnership will allow us to enable the translation of such ideas to products that have global impact. Some of these innovative startups may become the next big biotech in the industry. We look forward to supporting them in multiple ways, including mentoring, alongside HBM\'s and Viva Biotech\'s management teams.\"-Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed</blockquote>\r\nViva Biotech provides world-leading structure-based drug discovery solutions to its own biotechnology and pharmaceutical clients worldwide for their pre-clinical phase innovative drug development.\r\n<blockquote>\"The strategic partnership between Viva Biotech and Harbour BioMed makes up for Viva Biotech\'s deficiency in transgenic mouse platforms for generating fully human monoclonal antibodies, and will further enhance the scalability of Viva Biotech\'s business model, thereby strengthening its ability in attracting and incubating more innovative startups.\"-Dr. Delin Ren, the president of Viva Biotech</blockquote>\r\nThe Group covers the full spectrum of the clients\' requirements for early stage drug discovery, such as biological target protein expression and structure study, drug screening, lead optimization, and clinical candidate choice. The Group also provides discovery and incubation services to biotechnology start-ups with higher potential beneath its EFS (fairness for support ) model.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.harbourbiomed.com/en/newsContent.html#181\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Harbour BioMed</a></span>\r\n\r\n</div>','Harbour BioMed and Viva Biotech declare key coordinated effort to promote biotech new startups','','publish','open','open','','harbour-biomed-and-viva-biotech-declare-key-coordinated-effort-to-promote-biotech-new-startups','','','2020-08-02 13:12:22','2020-08-02 13:12:22','',0,'https://microbiozindia.com/?p=6806',0,'post','',0),(6807,2,'2020-08-01 11:19:03','2020-08-01 11:19:03','','hand-3190204_1280','','inherit','open','closed','','hand-3190204_1280','','','2020-08-01 11:19:03','2020-08-01 11:19:03','',6806,'https://microbiozindia.com/wp-content/uploads/2020/08/hand-3190204_1280.jpg',0,'attachment','image/jpeg',0),(6808,2,'2020-08-01 11:19:47','2020-08-01 11:19:47','HBM will combine its top Harbour Mice® stage H2L2 and its expertise in global research and development of innovative molecules, with Viva Biotech\'s structure-based early phase drug discovery services. This complementary partnership will provide advanced biotech startups access to next generation technologies that create synergies to accelerate the route between ideation to merchandise. The incubated startups will operate thorough scientific research and EFS (equity for support ) model.\r\n\r\nHBM has made significant progress since its establishment in late-2016, through strategic collaborations and partnerships with major academic institutions and biotech and pharmaceutical companies across the world. The business has successfully built a robust portfolio of early and late stage assets in immune-oncology and immunology, through organic R&amp;D as well as in-licensing tactical assets that tackle high unmet medical needs throughout the world. Its internally discovered next generation ani-CTLA-4 antibody HBM4003 for solid tumors, based on its HCAb stage is already in phase 1 clinical trials.\r\n<blockquote>\"We are excited to combine our capabilities with those of Viva Biotech\'s to offer innovative startup companies\' access to our next generation technology platforms and unique R&amp;D capabilities. We are always on the lookout for innovation that can positively impact human life, and this partnership will allow us to enable the translation of such ideas to products that have global impact. Some of these innovative startups may become the next big biotech in the industry. We look forward to supporting them in multiple ways, including mentoring, alongside HBM\'s and Viva Biotech\'s management teams.\"-Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed</blockquote>\r\nViva Biotech provides world-leading structure-based drug discovery solutions to its own biotechnology and pharmaceutical clients worldwide for their pre-clinical phase innovative drug development.\r\n<blockquote>\"The strategic partnership between Viva Biotech and Harbour BioMed makes up for Viva Biotech\'s deficiency in transgenic mouse platforms for generating fully human monoclonal antibodies, and will further enhance the scalability of Viva Biotech\'s business model, thereby strengthening its ability in attracting and incubating more innovative startups.\"-Dr. Delin Ren, the president of Viva Biotech</blockquote>\r\nThe Group covers the full spectrum of the clients\' requirements for early stage drug discovery, such as biological target protein expression and structure study, drug screening, lead optimization, and clinical candidate choice. The Group also provides discovery and incubation services to biotechnology start-ups with higher potential beneath its EFS (fairness for support ) model.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.harbourbiomed.com/en/newsContent.html#181\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Harbour BioMed</a></span>\r\n\r\n</div>','Harbour BioMed and Viva Biotech declare key coordinated effort to promote biotech new startups','','inherit','closed','closed','','6806-revision-v1','','','2020-08-01 11:19:47','2020-08-01 11:19:47','',6806,'https://microbiozindia.com/uncategorized/6806-revision-v1/',0,'revision','',0),(6809,2,'2020-07-25 19:54:33','2020-07-25 19:54:33','While quality control is an important aspect for almost all industries, the level of quality control for some particular industries, such as pharmaceuticals, life sciences, and food &amp; beverages, has to be absolutely top-notch. It is quite obvious that these industries deal with crucial elements, and, if not handled properly, serious damage to human health can be caused. Take for example drugs that are used for treating diseases; any sort of impurity in the drug can put the life of a person in jeopardy. The cover story of the month titled: <strong>“Important Facts that You Should Know About the Laboratory Filtration Device market”</strong> highlighted on laboratory filtration device Market Research.','Laboratory Filtration Device : Market Research','','publish','closed','closed','','laboratory-filtration-device-market-research','','','2020-08-01 20:24:01','2020-08-01 20:24:01','',0,'https://microbiozindia.com/?post_type=magazines&#038;p=6809',0,'magazines','',0),(6810,2,'2020-08-01 20:04:29','2020-08-01 20:04:29','','MAGCVR','','inherit','open','closed','','magcvr-5','','','2020-08-01 20:04:29','2020-08-01 20:04:29','',6809,'https://microbiozindia.com/wp-content/uploads/2020/08/MAGCVR.png',0,'attachment','image/png',0),(6811,2,'2020-08-01 20:04:31','2020-08-01 20:04:31','','WEBMAG (1)','','inherit','open','closed','','webmag-1','','','2020-08-01 20:04:31','2020-08-01 20:04:31','',6809,'https://microbiozindia.com/wp-content/uploads/2020/08/WEBMAG-1.png',0,'attachment','image/png',0),(6812,2,'2020-08-01 20:04:31','2020-08-01 20:04:31','','WEBMAG (2)','','inherit','open','closed','','webmag-2','','','2020-08-01 20:04:31','2020-08-01 20:04:31','',6809,'https://microbiozindia.com/wp-content/uploads/2020/08/WEBMAG-2.png',0,'attachment','image/png',0),(6813,2,'2020-08-01 20:04:32','2020-08-01 20:04:32','','WEBMAG (3)','','inherit','open','closed','','webmag-3','','','2020-08-01 20:04:32','2020-08-01 20:04:32','',6809,'https://microbiozindia.com/wp-content/uploads/2020/08/WEBMAG-3.png',0,'attachment','image/png',0),(6814,2,'2020-08-01 20:04:33','2020-08-01 20:04:33','','WEBMAG (4)','','inherit','open','closed','','webmag-4','','','2020-08-01 20:04:33','2020-08-01 20:04:33','',6809,'https://microbiozindia.com/wp-content/uploads/2020/08/WEBMAG-4.png',0,'attachment','image/png',0),(6815,2,'2020-08-01 20:07:29','2020-08-01 20:07:29','','we','','inherit','open','closed','','we','','','2020-08-01 20:07:29','2020-08-01 20:07:29','',6543,'https://microbiozindia.com/wp-content/uploads/2020/06/we.png',0,'attachment','image/png',0),(6816,2,'2020-08-01 20:08:21','2020-08-01 20:08:21','','we','','inherit','open','closed','','we-2','','','2020-08-01 20:08:21','2020-08-01 20:08:21','',6809,'https://microbiozindia.com/wp-content/uploads/2020/08/we.png',0,'attachment','image/png',0),(6817,2,'2020-08-01 20:13:27','2020-08-01 20:13:27','While quality control is an important aspect for almost all industries, the level of quality control for some particular industries, such as pharmaceuticals, life sciences, and food &amp; beverages, has to be absolutely top-notch. It is quite obvious that these industries deal with crucial elements, and, if not handled properly, serious damage to human health can be caused. Take for example drugs that are used for treating diseases; any sort of impurity in the drug can put the life of a person in jeopardy. The cover story of the month titled: “Important Facts that You Should Know About the Laboratory Filtration Device market” highlighted on laboratory filtration device Market Research.','Laboratory Filtration Device : Market Research','','inherit','closed','closed','','6809-revision-v1','','','2020-08-01 20:13:27','2020-08-01 20:13:27','',6809,'https://microbiozindia.com/uncategorized/6809-revision-v1/',0,'revision','',0),(6818,2,'2020-08-01 20:24:01','2020-08-01 20:24:01','While quality control is an important aspect for almost all industries, the level of quality control for some particular industries, such as pharmaceuticals, life sciences, and food &amp; beverages, has to be absolutely top-notch. It is quite obvious that these industries deal with crucial elements, and, if not handled properly, serious damage to human health can be caused. Take for example drugs that are used for treating diseases; any sort of impurity in the drug can put the life of a person in jeopardy. The cover story of the month titled: <strong>“Important Facts that You Should Know About the Laboratory Filtration Device market”</strong> highlighted on laboratory filtration device Market Research.','Laboratory Filtration Device : Market Research','','inherit','closed','closed','','6809-revision-v1','','','2020-08-01 20:24:01','2020-08-01 20:24:01','',6809,'https://microbiozindia.com/uncategorized/6809-revision-v1/',0,'revision','',0),(6819,2,'2020-08-01 20:26:26','2020-08-01 20:26:26','<p style=\"text-align: center;\"><strong><span style=\"font-size: 14pt;\">Microbioz India : July 2020 e-magazine</span></strong></p>\r\n<p style=\"text-align: center;\"> <iframe style=\"width: 700px; height: 425px;\" src=\"https://online.anyflip.com/fjxiy/jfkz/index.html\" frameborder=\"0\" scrolling=\"no\" seamless=\"seamless\" allowfullscreen=\"allowfullscreen\"></iframe></p>','Microbioz India: July 2020 e-magazine','','publish','closed','closed','','microbioz-india-july-2020-e-magazine','','','2020-08-01 20:29:03','2020-08-01 20:29:03','',0,'https://microbiozindia.com/?page_id=6819',0,'page','',0),(6820,2,'2020-08-01 20:26:26','2020-08-01 20:26:26','<p style=\"text-align: center;\">Microbioz India : July 2020 e-magazine</p>\r\n <iframe style=\"width: 700px; height: 425px;\" src=\"https://online.anyflip.com/fjxiy/jfkz/index.html\" frameborder=\"0\" scrolling=\"no\" seamless=\"seamless\" allowfullscreen=\"allowfullscreen\"></iframe>','Microbioz India: July e-magazine','','inherit','closed','closed','','6819-revision-v1','','','2020-08-01 20:26:26','2020-08-01 20:26:26','',6819,'https://microbiozindia.com/uncategorized/6819-revision-v1/',0,'revision','',0),(6821,2,'2020-08-01 20:26:50','2020-08-01 20:26:50','<p style=\"text-align: center;\">Microbioz India : July 2020 e-magazine</p>\r\n <iframe style=\"width: 700px; height: 425px;\" src=\"https://online.anyflip.com/fjxiy/jfkz/index.html\" frameborder=\"0\" scrolling=\"no\" seamless=\"seamless\" allowfullscreen=\"allowfullscreen\"></iframe>','Microbioz India: July 2020 e-magazine','','inherit','closed','closed','','6819-revision-v1','','','2020-08-01 20:26:50','2020-08-01 20:26:50','',6819,'https://microbiozindia.com/uncategorized/6819-revision-v1/',0,'revision','',0),(6822,2,'2020-08-01 20:27:43','2020-08-01 20:27:43','<p style=\"text-align: center;\"><strong><span style=\"font-size: 14pt;\">Microbioz India : July 2020 e-magazine</span></strong></p>\r\n<p style=\"text-align: center;\"> <iframe style=\"width: 700px; height: 425px;\" src=\"https://online.anyflip.com/fjxiy/jfkz/index.html\" frameborder=\"0\" scrolling=\"no\" seamless=\"seamless\" allowfullscreen=\"allowfullscreen\"></iframe></p>','Microbioz India: July 2020 e-magazine','','inherit','closed','closed','','6819-revision-v1','','','2020-08-01 20:27:43','2020-08-01 20:27:43','',6819,'https://microbiozindia.com/uncategorized/6819-revision-v1/',0,'revision','',0),(6823,2,'2020-08-02 12:43:01','2020-08-02 12:43:01','In good news amid the surging novel coronavirus disease, Russia is preparing for a mass vaccination campaign against the novel coronavirus infection in October. Russia is the first state to finish the human clinical trial of a COVID-19 vaccine.\r\n\r\nBased on Russia\'s Health Minister Mikhail Murashko, the Gamaleya Institute, a state research facility in Moscow, had completed clinical trials of the vaccine and paperwork is being prepared to enroll it, reported news agency Reuters citing Interfax.\r\n\r\nThe Gamaleya Institute has been operating on an adenovirus-based vaccine,\'\' said the report.\r\n\r\nThe ministry reportedly said physicians and teachers are the very first to be vaccinated.\r\n\r\nRussia\'s first potential COVID-19 vaccine could secure local regulatory approval in August and be treated to health employees shortly afterwards, said the report citing resources.\r\n\r\nIn a bid to stop the pandemic, most countries are trying to develop the COVID-19 vaccine. Over 100 possible vaccines are being developed around the world to try and stop the contagion. Of these, at least four are in closing Phase-III human trials, such as three developed in China and another in Britain, according to the World Health Organization (WHO) data.','Russia to start mass inoculation crusade in October','','publish','open','open','','russia-to-start-mass-inoculation-crusade-in-october','','','2020-08-02 12:43:01','2020-08-02 12:43:01','',0,'https://microbiozindia.com/?p=6823',0,'post','',0),(6824,2,'2020-08-02 12:43:01','2020-08-02 12:43:01','In good news amid the surging novel coronavirus disease, Russia is preparing for a mass vaccination campaign against the novel coronavirus infection in October. Russia is the first state to finish the human clinical trial of a COVID-19 vaccine.\r\n\r\nBased on Russia\'s Health Minister Mikhail Murashko, the Gamaleya Institute, a state research facility in Moscow, had completed clinical trials of the vaccine and paperwork is being prepared to enroll it, reported news agency Reuters citing Interfax.\r\n\r\nThe Gamaleya Institute has been operating on an adenovirus-based vaccine,\'\' said the report.\r\n\r\nThe ministry reportedly said physicians and teachers are the very first to be vaccinated.\r\n\r\nRussia\'s first potential COVID-19 vaccine could secure local regulatory approval in August and be treated to health employees shortly afterwards, said the report citing resources.\r\n\r\nIn a bid to stop the pandemic, most countries are trying to develop the COVID-19 vaccine. Over 100 possible vaccines are being developed around the world to try and stop the contagion. Of these, at least four are in closing Phase-III human trials, such as three developed in China and another in Britain, according to the World Health Organization (WHO) data.','Russia to start mass inoculation crusade in October','','inherit','closed','closed','','6823-revision-v1','','','2020-08-02 12:43:01','2020-08-02 12:43:01','',6823,'https://microbiozindia.com/uncategorized/6823-revision-v1/',0,'revision','',0),(6825,2,'2020-08-02 12:43:08','2020-08-02 12:43:08','In good news amid the surging novel coronavirus disease, Russia is preparing for a mass vaccination campaign against the novel coronavirus infection in October. Russia is the first state to finish the human clinical trial of a COVID-19 vaccine.\n\nBased on Russia\'s Health Minister Mikhail Murashko, the Gamaleya Institute, a state research facility in Moscow, had completed clinical trials of the vaccine and paperwork is being prepared to enroll it, reported news agency Reuters citing Interfax.\n\nThe Gamaleya Institute has been operating on an adenovirus-based vaccine,\'\' said the report.\n\nThe ministry reportedly said physicians and teachers are the very first to be vaccinated.\n\nRussia\'s first potential COVID-19 vaccine could secure local regulatory approval in August and be treated to health employees shortly afterwards, said the report citing resources.\n\nIn a bid to stop the pandemic, most countries are trying to develop the COVID-19 vaccine. Over 100 possible vaccines are being developed around the world to try and stop the contagion. Of these, at least four are in closing Phase-III human trials, such as three developed in China and another in Britain, according to the World Health Organization (WHO) data.','Russia to start mass inoculation crusade in October','','inherit','closed','closed','','6823-autosave-v1','','','2020-08-02 12:43:08','2020-08-02 12:43:08','',6823,'https://microbiozindia.com/uncategorized/6823-autosave-v1/',0,'revision','',0),(6826,2,'2020-08-02 12:47:35','2020-08-02 12:47:35','The term of vaccine nationalism has entered our lexicon during H1N1 pandemic 2009, but has been used. But vaccine nationalism, has emerged as a real danger because of our ability to collectively finish the COVID-19 pandemic.\r\n\r\nSo what\'s vaccine nationalism?\r\n\r\nVaccine nationalism involves countries procuring doses of vaccine for its own citizens or residents through pre-purchase agreements with vaccine manufacturers and some impose restrictions on their manufacturers in order to serve their country first.\r\n\r\nThis leaves out middle and lower income countries who do not have monetary muscle or vaccine manufacturing capacities.\r\n\r\nWe watched vaccine nationalism perform a decade ago too, during the H1N1 pandemic.\r\n\r\n\"Some countries say vaccine produced within my country, are only for my citizens. There are not many countries that make the vaccine. A lot of people will be denied vaccines, and everyone will lose. As long as this virus is not under control in every single nation, it will not be under management,\" Peter Piot, renowned virologist and Manager of the London School of Hygiene &amp; Tropical Medicine, in a recent summit held by ICMR.\r\n\r\nPiot is a special adviser to Ursula von der Leyen, President of European Commission about the response to COVID-19.\r\n\r\nEuropean Commission has raised 10 billion euros ($11.2 billion) for the development and deployment of vaccines, including supporting countries worst hit by COVID-19 pandemic.\r\n\r\nPiot says COVID-19 is not only a scientific struggle or public health issue, but will probably be one of the biggest geo-political issues of our time.\r\n\r\n\"Since the states that have first access to vaccines, protect their population from this pandemic will have a major benefit, economically, politically and strategically. So that is why it\'s so important that people have the dialogue,\" Piot says.\r\n\r\nEquitable distribution\r\n\r\nVaccine nationalism is particularly dangerous at one time, World Health Organisation (WHO) that is supposed to give leadership is facing issues with questions raised over its first handling of COVID-19 pandemic and following move by the US - the largest donor to lower funding and exit the multilateral organisation.\r\n\r\nDespite these challenges, there were effort to ensure equitable distribution of vaccines.\r\n\r\nSeventy-five nations have submitted expressions of interest to secure their populations and those of other nations through joining the COVAX Facility, a mechanism designed to ensure rapid, reasonable and equitable access to COVID-19 offenses globally.\r\n\r\nCOVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO, operating in partnership with developing and developed country vaccine manufacturers.\r\n\r\nThe 75 countries, which would fund the vaccines from their own fund budgets, partner with up to 90 lower-income nations that could be supported through voluntary contributions to Gavi\'s COVAX Advance Market Commitment (AMC).\r\n\r\nCollectively, this group of up to 165 countries represents over 60% of the planet\'s population. Among the group are representatives from every continent and over half of the world\'s G20 economies.\r\n\r\nThe goal of COVAX is by the end of 2021 to provide two billion doses of safe, effective vaccines. These vaccines are sent equally to all participating countries, proportional to their populations, originally prioritising healthcare workers then expanding to pay 20% of the populace of participating nations. Further doses are then going to be made available based on state demand, vulnerability and COVID-19 hazard.\r\n\r\nThe COVAX Facility may also keep a buffer of dosages for diplomatic and emergency use, including coping with acute outbreaks before they spiral out of control.\r\n\r\nThe COVAX Center creates an integral part of the COVAX pillar (COVAX) of the Access to COVID-19 Tools (ACT) Accelerator, a international collaboration to accelerate the growth, creation, and equitable access to COVID-19 tests, therapies, and vaccines.','How antibody nationalism is hampering endeavors to end COVID-19 pandemic','','publish','open','open','','how-antibody-nationalism-is-hampering-endeavors-to-end-covid-19-pandemic','','','2020-08-02 12:47:35','2020-08-02 12:47:35','',0,'https://microbiozindia.com/?p=6826',0,'post','',0),(6827,2,'2020-08-02 12:47:35','2020-08-02 12:47:35','The term of vaccine nationalism has entered our lexicon during H1N1 pandemic 2009, but has been used. But vaccine nationalism, has emerged as a real danger because of our ability to collectively finish the COVID-19 pandemic.\r\n\r\nSo what\'s vaccine nationalism?\r\n\r\nVaccine nationalism involves countries procuring doses of vaccine for its own citizens or residents through pre-purchase agreements with vaccine manufacturers and some impose restrictions on their manufacturers in order to serve their country first.\r\n\r\nThis leaves out middle and lower income countries who do not have monetary muscle or vaccine manufacturing capacities.\r\n\r\nWe watched vaccine nationalism perform a decade ago too, during the H1N1 pandemic.\r\n\r\n\"Some countries say vaccine produced within my country, are only for my citizens. There are not many countries that make the vaccine. A lot of people will be denied vaccines, and everyone will lose. As long as this virus is not under control in every single nation, it will not be under management,\" Peter Piot, renowned virologist and Manager of the London School of Hygiene &amp; Tropical Medicine, in a recent summit held by ICMR.\r\n\r\nPiot is a special adviser to Ursula von der Leyen, President of European Commission about the response to COVID-19.\r\n\r\nEuropean Commission has raised 10 billion euros ($11.2 billion) for the development and deployment of vaccines, including supporting countries worst hit by COVID-19 pandemic.\r\n\r\nPiot says COVID-19 is not only a scientific struggle or public health issue, but will probably be one of the biggest geo-political issues of our time.\r\n\r\n\"Since the states that have first access to vaccines, protect their population from this pandemic will have a major benefit, economically, politically and strategically. So that is why it\'s so important that people have the dialogue,\" Piot says.\r\n\r\nEquitable distribution\r\n\r\nVaccine nationalism is particularly dangerous at one time, World Health Organisation (WHO) that is supposed to give leadership is facing issues with questions raised over its first handling of COVID-19 pandemic and following move by the US - the largest donor to lower funding and exit the multilateral organisation.\r\n\r\nDespite these challenges, there were effort to ensure equitable distribution of vaccines.\r\n\r\nSeventy-five nations have submitted expressions of interest to secure their populations and those of other nations through joining the COVAX Facility, a mechanism designed to ensure rapid, reasonable and equitable access to COVID-19 offenses globally.\r\n\r\nCOVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO, operating in partnership with developing and developed country vaccine manufacturers.\r\n\r\nThe 75 countries, which would fund the vaccines from their own fund budgets, partner with up to 90 lower-income nations that could be supported through voluntary contributions to Gavi\'s COVAX Advance Market Commitment (AMC).\r\n\r\nCollectively, this group of up to 165 countries represents over 60% of the planet\'s population. Among the group are representatives from every continent and over half of the world\'s G20 economies.\r\n\r\nThe goal of COVAX is by the end of 2021 to provide two billion doses of safe, effective vaccines. These vaccines are sent equally to all participating countries, proportional to their populations, originally prioritising healthcare workers then expanding to pay 20% of the populace of participating nations. Further doses are then going to be made available based on state demand, vulnerability and COVID-19 hazard.\r\n\r\nThe COVAX Facility may also keep a buffer of dosages for diplomatic and emergency use, including coping with acute outbreaks before they spiral out of control.\r\n\r\nThe COVAX Center creates an integral part of the COVAX pillar (COVAX) of the Access to COVID-19 Tools (ACT) Accelerator, a international collaboration to accelerate the growth, creation, and equitable access to COVID-19 tests, therapies, and vaccines.','How antibody nationalism is hampering endeavors to end COVID-19 pandemic','','inherit','closed','closed','','6826-revision-v1','','','2020-08-02 12:47:35','2020-08-02 12:47:35','',6826,'https://microbiozindia.com/uncategorized/6826-revision-v1/',0,'revision','',0),(6828,2,'2020-08-02 13:11:56','2020-08-02 13:11:56','Today, the U.S. Food and Drug Administration approved the initial two COVID-19 serology tests which show an estimated amount of antibodies within somebody\'s blood. Both tests from Siemens, the ADVIA Centaur COV2G and Attelica COV2G are what are known as\"semi-quantitative\" evaluations, meaning that they don\'t show an exact measurement, but estimate the number of a patient\'s radicals generated from infection with the virus that leads to COVID-19.\r\n\r\n\"Having the ability to quantify a patient\'s relative degree of antibodies in response to some preceding SARS-CoV-2 infection could be useful as we continue to learn more about the virus and what precisely the existence of antibodies may mean,\" said Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA\'s Center for Devices and Radiological Health. \"There are still many unknowns about what the presence of SARS-CoV-2 Compounds may inform us about possible immunity, but now\'s authorizations provide us additional tools to evaluate those Compounds as we continue to research and examine this virus. Patients shouldn\'t interpret results as telling them how they\'re immune, or have some amount of immunity, from the virus.\"\r\nBecause of those unknowns, the FDA warns patients against using the results from such tests, or any serology test, as an indication that they can stop taking steps to protect themselves and others, such as stopping social distancing, quitting sporting masks or returning to work. The FDA also wishes to remind patients that serology tests should not be used to diagnose an active disease, as they only detect antibodies the immune system develops in reaction to this virus - not the virus itself.','FDA authorizes initial two COVID-19 serology tests','','publish','open','open','','fda-authorizes-initial-two-covid-19-serology-tests','','','2020-08-02 13:11:56','2020-08-02 13:11:56','',0,'https://microbiozindia.com/?p=6828',0,'post','',0),(6829,2,'2020-08-02 13:11:56','2020-08-02 13:11:56','Today, the U.S. Food and Drug Administration approved the initial two COVID-19 serology tests which show an estimated amount of antibodies within somebody\'s blood. Both tests from Siemens, the ADVIA Centaur COV2G and Attelica COV2G are what are known as\"semi-quantitative\" evaluations, meaning that they don\'t show an exact measurement, but estimate the number of a patient\'s radicals generated from infection with the virus that leads to COVID-19.\r\n\r\n\"Having the ability to quantify a patient\'s relative degree of antibodies in response to some preceding SARS-CoV-2 infection could be useful as we continue to learn more about the virus and what precisely the existence of antibodies may mean,\" said Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA\'s Center for Devices and Radiological Health. \"There are still many unknowns about what the presence of SARS-CoV-2 Compounds may inform us about possible immunity, but now\'s authorizations provide us additional tools to evaluate those Compounds as we continue to research and examine this virus. Patients shouldn\'t interpret results as telling them how they\'re immune, or have some amount of immunity, from the virus.\"\r\nBecause of those unknowns, the FDA warns patients against using the results from such tests, or any serology test, as an indication that they can stop taking steps to protect themselves and others, such as stopping social distancing, quitting sporting masks or returning to work. The FDA also wishes to remind patients that serology tests should not be used to diagnose an active disease, as they only detect antibodies the immune system develops in reaction to this virus - not the virus itself.','FDA authorizes initial two COVID-19 serology tests','','inherit','closed','closed','','6828-revision-v1','','','2020-08-02 13:11:56','2020-08-02 13:11:56','',6828,'https://microbiozindia.com/uncategorized/6828-revision-v1/',0,'revision','',0),(6830,2,'2020-08-02 13:12:22','2020-08-02 13:12:22','HBM will combine its top Harbour Mice® stage H2L2 and its expertise in global research and development of innovative molecules, with Viva Biotech\'s structure-based early phase drug discovery services. This complementary partnership will provide advanced biotech startups access to next generation technologies that create synergies to accelerate the route between ideation to merchandise. The incubated startups will operate thorough scientific research and EFS (equity for support ) model.\r\n\r\nHBM has made significant progress since its establishment in late-2016, through strategic collaborations and partnerships with major academic institutions and biotech and pharmaceutical companies across the world. The business has successfully built a robust portfolio of early and late stage assets in immune-oncology and immunology, through organic R&amp;D as well as in-licensing tactical assets that tackle high unmet medical needs throughout the world. Its internally discovered next generation ani-CTLA-4 antibody HBM4003 for solid tumors, based on its HCAb stage is already in phase 1 clinical trials.\r\n<blockquote>\"We are excited to combine our capabilities with those of Viva Biotech\'s to offer innovative startup companies\' access to our next generation technology platforms and unique R&amp;D capabilities. We are always on the lookout for innovation that can positively impact human life, and this partnership will allow us to enable the translation of such ideas to products that have global impact. Some of these innovative startups may become the next big biotech in the industry. We look forward to supporting them in multiple ways, including mentoring, alongside HBM\'s and Viva Biotech\'s management teams.\"-Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed</blockquote>\r\nViva Biotech provides world-leading structure-based drug discovery solutions to its own biotechnology and pharmaceutical clients worldwide for their pre-clinical phase innovative drug development.\r\n<blockquote>\"The strategic partnership between Viva Biotech and Harbour BioMed makes up for Viva Biotech\'s deficiency in transgenic mouse platforms for generating fully human monoclonal antibodies, and will further enhance the scalability of Viva Biotech\'s business model, thereby strengthening its ability in attracting and incubating more innovative startups.\"-Dr. Delin Ren, the president of Viva Biotech</blockquote>\r\nThe Group covers the full spectrum of the clients\' requirements for early stage drug discovery, such as biological target protein expression and structure study, drug screening, lead optimization, and clinical candidate choice. The Group also provides discovery and incubation services to biotechnology start-ups with higher potential beneath its EFS (fairness for support ) model.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.harbourbiomed.com/en/newsContent.html#181\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Harbour BioMed</a></span>\r\n\r\n</div>','Harbour BioMed and Viva Biotech declare key coordinated effort to promote biotech new startups','','inherit','closed','closed','','6806-revision-v1','','','2020-08-02 13:12:22','2020-08-02 13:12:22','',6806,'https://microbiozindia.com/uncategorized/6806-revision-v1/',0,'revision','',0),(6831,2,'2020-08-02 15:45:00','2020-08-02 15:45:00','BioChromato, Fujisawa, Japan, has introduced a gamma sterilized version of its Rapid Slit Seal for scientists seeking to eliminate solvent evaporation from samples when culturing cells from 96-well microplates.\r\n\r\nRapid Slit Seal is a proprietary self-closing microplate seal which returns to its initial state even when punched having an HPLC or even LC/MS autosampler. This prevents reduction of volatile chemicals from precious samples.\r\n\r\nIn addition, with Rapid Slit Seal insertion of pipette tips and sampling needles is much simpler and can be accomplished without dragging to save time and effort when dispensing or sampling.\r\n\r\nMade to seal without having adhesive over microplate wells avoids the chance of sample contamination. In comparison to conventional sealing mats, Rapid Slit Seal also provides a way of reducing the cost of microplate sealing consumables.','Sterile 96-Well Plate Seal for Cell Culturing by BioChromato','','publish','open','open','','sterile-96-well-plate-seal-for-cell-culturing-by-biochromato','','','2020-08-02 15:45:00','2020-08-02 15:45:00','',0,'https://microbiozindia.com/?p=6831',0,'post','',0),(6832,2,'2020-08-02 15:44:53','2020-08-02 15:44:53','','BioChromato_Sterile-96-Well-Plate-Seal-for-Cell-Culturing-B_web-2-466x291','','inherit','open','closed','','biochromato_sterile-96-well-plate-seal-for-cell-culturing-b_web-2-466x291','','','2020-08-02 15:44:53','2020-08-02 15:44:53','',6831,'https://microbiozindia.com/wp-content/uploads/2020/08/BioChromato_Sterile-96-Well-Plate-Seal-for-Cell-Culturing-B_web-2-466x291-1.jpeg',0,'attachment','image/jpeg',0),(6833,2,'2020-08-02 15:45:00','2020-08-02 15:45:00','BioChromato, Fujisawa, Japan, has introduced a gamma sterilized version of its Rapid Slit Seal for scientists seeking to eliminate solvent evaporation from samples when culturing cells from 96-well microplates.\r\n\r\nRapid Slit Seal is a proprietary self-closing microplate seal which returns to its initial state even when punched having an HPLC or even LC/MS autosampler. This prevents reduction of volatile chemicals from precious samples.\r\n\r\nIn addition, with Rapid Slit Seal insertion of pipette tips and sampling needles is much simpler and can be accomplished without dragging to save time and effort when dispensing or sampling.\r\n\r\nMade to seal without having adhesive over microplate wells avoids the chance of sample contamination. In comparison to conventional sealing mats, Rapid Slit Seal also provides a way of reducing the cost of microplate sealing consumables.','Sterile 96-Well Plate Seal for Cell Culturing by BioChromato','','inherit','closed','closed','','6831-revision-v1','','','2020-08-02 15:45:00','2020-08-02 15:45:00','',6831,'https://microbiozindia.com/uncategorized/6831-revision-v1/',0,'revision','',0),(6834,2,'2020-08-03 05:55:49','2020-08-03 05:55:49','India has 18% of the global population and an increasing burden of chronic respiratory diseases<sup>1</sup>. The technique of nebulisation is commonly utilised in the treatment of such diseases including asthma, cystic fibrosis and chronic obstructive pulmonary disease (COPD)<sup>2</sup>. Recent improvements in nebuliser technologies have led to the development of vibrating mesh nebulisers (VMNs) that produce a consistent and improved aerosol generation efficiency and low residual drug volume<sup>2</sup>. The Aerogen Solo and Pro utilise VMN technology. The nebulisers are comprised of a unique dome-shaped aperture plate containing approximately 1,000 precision-formed tapered holes, surrounded by a vibrational element. When energy is applied, the aperture plate vibrates at 128,000 times per second. Each one of the 1000 cone-shaped apertures within the mesh acts as a micropump drawing liquid through the holes producing a low velocity aerosol optimised for targeted drug delivery to the lungs<sup>2,3</sup>. Each aperture creates particles of 1-5 µm in diameter, which is the optimum particle size for efficient lung deposition. Particles larger than 10–15 µm are deposited in the nose and mouth; particles that are 5–10 µm in size tend to deposit in the upper airways, while particles sized 1–5 µm have a greater probability of reaching the lower respiratory tract (i.e. from the trachea to the lung periphery)<sup>4</sup>.\r\n\r\nThe Aerogen Solo has an in-line circuit design, so the ventilator circuit does not need to be disconnected for drug delivery. It is designed so that the medication reservoir is isolated from the breathing circuit minimising the potential for nebulisation of contaminated fluids and delivers the medication dose with minimal residual remaining after nebulisation<sup>5</sup>. In addition, the Aerogen Solo is virtually silent in operation (&lt;35 dB measured at 0.3 metre distance)<sup>5</sup>. Unlike ultrasonic nebulisers (USNs), Aerogen technology does not increase the drug solution temperature as there is no heat generated during use<sup>6</sup>. During mechanical ventilation (MV) with active humidification, the nebuliser can be placed on the dry side of the humidifier or at the inspiratory limb of the breathing circuit before the patient wye. The Aerogen Solo can also be placed on the patient side of the wye and this facilitates the use of a Heat and Moisture Exchanger; however, this placement is contraindicated for neonates<sup>5</sup>. During non-invasive ventilation (NIV), the Aerogen Solo can be used in the same positions with a dual limb circuit. The Aerogen Solo may be utilised with single limb NIV circuits using non vented masks, with the nebuliser placed between the exhalation port and the patient<sup>5</sup>.\r\n\r\nSeveral studies have demonstrated optimal aerosol delivery with Aerogen VMN technology compared with jet nebulisers (JNs) and USNs in the critical care environment<sup>7–10</sup>. Ari et al. demonstrated improved inhaled dose with the Aerogen Solo compared with JN when placed before the humidifier compared to placement at the wye with both adult and paediatric MV models with bias flow<sup>9</sup>. Improved aerosol delivery with VMN technology is also associated with the minimal residual volume left in the device at the end of the treatment. Standard JNs leave up to 2 mL of the drug behind which can also be costly when using expensive drugs<sup>11,12</sup>. Dugernier et al. compared lung deposition with radiolabelled aerosol delivered via VMN in two modes of ventilation, pressure support (PSV) and volume-controlled ventilation (VCV) in a randomised controlled trial of neurosurgical patients with healthy lungs. They demonstrated 10 % and 15 % lung dose with PSV vs VCV, respectively<sup>7</sup>. Macintyre et al. previously administered radiolabelled aerosol with a JN to MV patients and they showed 2.9% lung deposition<sup>8</sup>. In comparison with the MacIntyre study, the Dugernier study demonstrated greater lung deposition with the VMN regardless of the mode of ventilation<sup>7,8</sup>.\r\n\r\n<img class=\"alignnone wp-image-6836\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/maxresdefault-300x169.jpg\" alt=\"\" width=\"431\" height=\"243\" />\r\n\r\nIn a recent review, Ari reported practical strategies for safe and effective aerosol delivery of aerosolised medications to ventilated patients with COVID-19. Delivering aerosolised medications via JN or pMDIs was deemed not to be appropriate due to the breakage of the circuits for the placement of the device on the ventilator circuit before aerosol therapy<sup>13</sup>. The benefits of VMN technology were highlighted including the fact that VMNs can stay in-line for up to 28 days as well as the reservoir design that allows addition of medication without requiring the ventilator circuit to be broken for aerosol drug delivery. Furthermore, this review article recommended to place the VMN at the dry side of the humidifier to improve the efficiency of the treatment and further reduce retrograde contamination from the patient<sup>13</sup>. Similarly, Dhand and Li outlined the suitability for use of VMN technology in the context of COVID-19. The authors reported that VMNs generate aerosols via mesh plates that separate the sealed medication reservoir from the patient interface, the aerosol derives from the fluid in the nebuliser chamber and does not carry patient-derived viral particles<sup>14</sup>. In contrast, residual drug remaining in JNs or USNs at the end of treatment could act as a breeding environment for bacteria if the nebuliser remains in the circuit between treatments<sup>14</sup>. In a letter to the editor of the <em>Journal of Critical Care</em>, Miller et al. reported safe and efficient bronchodilator administration using continuous nebulisation with the Aerogen Solo in invasively and non-invasively ventilated COVID-19 patients with COPD and asthma, and highlighted that the closed system requires minimal staff handling and no circuit opening, thereby reducing workload and increasing safety<sup>15</sup>. This is the first report of administering bronchodilators safely and efficiently to COVID-19 ventilated patients<sup>15</sup>. An expert consensus on reducing viral transmission during respiratory care for patients infected with COVID-19 has recommended to use a VMN for mechanically ventilated patients COVID-19 patients requiring inhalation therapy<sup>16</sup>. The consensus discussed how an additional filter should be placed at the expiratory port of the ventilator during nebulisation and the VMN should be positioned at the dry side of the humidifier<sup>16</sup>. In a consensus document on NIV support for adult patients with acute respiratory failure secondary to SARS-CoV-2 infection, a circuit with a VMN elbow was recommended as first choice when using inhaled therapy with NIV.\r\n\r\n<em>Note: This editorial was produced and sponsored by Aerogen and compiled by Millind Mahajan , Regional Sales Manager - West</em>\r\n\r\n<strong>PM749</strong>\r\n\r\nIf you would like to receive additional information on Aerogen or arrange for a free virtual product demonstration, please contact us below;\r\n\r\n<strong>Rajiv Julka, Country Manager</strong> – India &amp; Sub-Continent\r\n\r\n<strong>Kamal Kishore, Business Manager</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.aerogen.com/\"><strong>Aerogen Medical Devices India Pvt. Ltd.</strong></a></span>\r\n\r\n131, ABW Rectangle One Building,\r\n\r\nD-4, Saket District Centre, New Delhi,\r\n\r\nIndia - 110017\r\n\r\nOffice: +91 11 41422577\r\n\r\nEmail: <span style=\"color: #000000;\"><a style=\"color: #000000;\" href=\"mailto:India@Aerogen.com\">India@Aerogen.com</a> ; <a style=\"color: #000000;\" href=\"mailto:rjulka@aerogen.com\">rjulka@aerogen.com</a> ; <a style=\"color: #000000;\" href=\"mailto:kkishore@aerogen.com\">kkishore@aerogen.com</a></span>\r\n\r\n<strong>References</strong>\r\n\r\n1. Salvi S, Anil Kumar G, Dhaliwal RS, Paulson K, Agrawal A, Koul PA <em>et al.</em> The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990â€“2016. <em>Lancet Glob Heal</em> 2018; <strong>6</strong>: e1363–e1374.\r\n\r\n2.Ari A. Jet, Ultrasonic, and Mesh Nebulizers: An Evaluation of Nebulizers for Better Clinical Outcomes. <em>Eurasian J Pulmonol</em> 2014; <strong>16</strong>: 1–7.\r\n\r\n3 .Vecellio L. The mesh nebuliser: a recent technical innovation for aerosol delivery. <em>Breathe</em> 2006; <strong>2</strong>: 252–260.\r\n\r\n4.McNulty W, Usmani OS. Techniques of assessing small airways dysfunction. <em>Eur Clin Respir J</em> 2014; <strong>1</strong>. doi:10.3402/ECRJ.V1.25898.\r\n\r\n5 .Aerogen Solo System Instruction Manual. Aerogen Ltd. P/N 30-354, Part No. AG-AS3050. .\r\n\r\n6 .Sidler-Moix A-LL, Di Paolo ER, Dolci U, Berger-Gryllaki M, Cotting J, Pannatier A. Physicochemical aspects and efficiency of albuterol nebulization: comparison of three aerosol types in an in vitro pediatric model. <em>Respir Care</em> 2015; <strong>60</strong>: 38–46.\r\n\r\n7.Dugernier J, Reychler G, Wittebole X, Roeseler J, Depoortere V, Sottiaux T <em>et al.</em> Aerosol delivery with two ventilation modes during mechanical ventilation: a randomized study. <em>Ann Intensive Care</em> 2016; <strong>6</strong>: 73.\r\n\r\n8 .MacIntyre NR, Silver RM, Miller CW, Schuler F, Coleman RE. Aerosol delivery in intubated, mechanically ventilated patients. <em>Crit Care Med</em> 1985; <strong>13</strong>: 81–84.\r\n\r\n9.Ari A, Atalay OT, Harwood R, Sheard MM, Aljamhan EA, Fink JB. Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. <em>Respir Care</em> 2010; <strong>55</strong>: 845–851.\r\n\r\n10.Ari A, Areabi H, Fink JB, Cpft PT, Areabi H, Rrt M <em>et al.</em> Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation. <em>Respir Care</em> 2010; <strong>55</strong>: 837–844.\r\n\r\n11.Gardenshire, DS. Burnett, D. Strickland, S. Myers T. A Guide To Aerosol Delivery Devices for Respiratory Therapists. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.aarc.org/wp-content/uploads/2015/04/aerosol_guide_rt.pdf\">https://www.aarc.org/wp-content/uploads/2015/04/aerosol_guide_rt.pdf.</a> </span>2017.\r\n\r\n12.Ari A, Fink JB, Dhand R. Inhalation Therapy in Patients Receiving Mechanical Ventilation: An Update. <em>J Aerosol Med Pulm Drug Deliv</em> 2012. doi:10.1089/jamp.2011.0936.\r\n\r\n13 .Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. <em>Respir Med</em> 2020; <strong>167</strong>: 105987.\r\n\r\n14.Dhand R, Li J. Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2. <em>Am J Respir Crit Care Med</em> 2020. doi:10.1164/rccm.202004-1263PP.\r\n\r\n15.Miller A, Epstein D. Safe bronchodilator treatment in mechanically ventilated COVID-19 patients: A single center experience. J. Crit. Care. 2020; <strong>58</strong>: 56–57.\r\n\r\n16.Respiratory care committee of Chinese Thoracic Society. [Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia]. <em>Zhonghua Jie He He Hu Xi Za Zhi</em> 2020; <strong>17</strong>: E020.','Aerogen – bringing a lower risk of transmission of patient generated infectious aerosol for healthcare professionals in acute care settings compared to traditional nebulisers','','publish','open','open','','aerogen-bringing-a-lower-risk-of-transmission-of-patient-generated-infectious-aerosol-for-healthcare-professionals-in-acute-care-settings-compared-to-traditional-nebulisers','','','2020-08-03 06:00:00','2020-08-03 06:00:00','',0,'https://microbiozindia.com/?p=6834',0,'post','',0),(6835,2,'2020-08-03 05:50:05','2020-08-03 05:50:05','','Untitled design (1)','','inherit','open','closed','','untitled-design-1-10','','','2020-08-03 05:50:05','2020-08-03 05:50:05','',6834,'https://microbiozindia.com/wp-content/uploads/2020/08/Untitled-design-1.png',0,'attachment','image/png',0),(6836,2,'2020-08-03 05:50:33','2020-08-03 05:50:33','','maxresdefault','','inherit','open','closed','','maxresdefault-2','','','2020-08-03 05:50:33','2020-08-03 05:50:33','',6834,'https://microbiozindia.com/wp-content/uploads/2020/08/maxresdefault.jpg',0,'attachment','image/jpeg',0),(6837,2,'2020-08-03 05:55:49','2020-08-03 05:55:49','India has 18% of the global population and an increasing burden of chronic respiratory diseases<sup>1</sup>. The technique of nebulisation is commonly utilised in the treatment of such diseases including asthma, cystic fibrosis and chronic obstructive pulmonary disease (COPD)<sup>2</sup>. Recent improvements in nebuliser technologies have led to the development of vibrating mesh nebulisers (VMNs) that produce a consistent and improved aerosol generation efficiency and low residual drug volume<sup>2</sup>. The Aerogen Solo and Pro utilise VMN technology. The nebulisers are comprised of a unique dome-shaped aperture plate containing approximately 1,000 precision-formed tapered holes, surrounded by a vibrational element. When energy is applied, the aperture plate vibrates at 128,000 times per second. Each one of the 1000 cone-shaped apertures within the mesh acts as a micropump drawing liquid through the holes producing a low velocity aerosol optimised for targeted drug delivery to the lungs<sup>2,3</sup>. Each aperture creates particles of 1-5 µm in diameter, which is the optimum particle size for efficient lung deposition. Particles larger than 10–15 µm are deposited in the nose and mouth; particles that are 5–10 µm in size tend to deposit in the upper airways, while particles sized 1–5 µm have a greater probability of reaching the lower respiratory tract (i.e. from the trachea to the lung periphery)<sup>4</sup>.\r\n\r\nThe Aerogen Solo has an in-line circuit design, so the ventilator circuit does not need to be disconnected for drug delivery. It is designed so that the medication reservoir is isolated from the breathing circuit minimising the potential for nebulisation of contaminated fluids and delivers the medication dose with minimal residual remaining after nebulisation<sup>5</sup>. In addition, the Aerogen Solo is virtually silent in operation (&lt;35 dB measured at 0.3 metre distance)<sup>5</sup>. Unlike ultrasonic nebulisers (USNs), Aerogen technology does not increase the drug solution temperature as there is no heat generated during use<sup>6</sup>. During mechanical ventilation (MV) with active humidification, the nebuliser can be placed on the dry side of the humidifier or at the inspiratory limb of the breathing circuit before the patient wye. The Aerogen Solo can also be placed on the patient side of the wye and this facilitates the use of a Heat and Moisture Exchanger; however, this placement is contraindicated for neonates<sup>5</sup>. During non-invasive ventilation (NIV), the Aerogen Solo can be used in the same positions with a dual limb circuit. The Aerogen Solo may be utilised with single limb NIV circuits using non vented masks, with the nebuliser placed between the exhalation port and the patient<sup>5</sup>.\r\n\r\nSeveral studies have demonstrated optimal aerosol delivery with Aerogen VMN technology compared with jet nebulisers (JNs) and USNs in the critical care environment<sup>7–10</sup>. Ari et al. demonstrated improved inhaled dose with the Aerogen Solo compared with JN when placed before the humidifier compared to placement at the wye with both adult and paediatric MV models with bias flow<sup>9</sup>. Improved aerosol delivery with VMN technology is also associated with the minimal residual volume left in the device at the end of the treatment. Standard JNs leave up to 2 mL of the drug behind which can also be costly when using expensive drugs<sup>11,12</sup>. Dugernier et al. compared lung deposition with radiolabelled aerosol delivered via VMN in two modes of ventilation, pressure support (PSV) and volume-controlled ventilation (VCV) in a randomised controlled trial of neurosurgical patients with healthy lungs. They demonstrated 10 % and 15 % lung dose with PSV vs VCV, respectively<sup>7</sup>. Macintyre et al. previously administered radiolabelled aerosol with a JN to MV patients and they showed 2.9% lung deposition<sup>8</sup>. In comparison with the MacIntyre study, the Dugernier study demonstrated greater lung deposition with the VMN regardless of the mode of ventilation<sup>7,8</sup>.\r\n\r\n<img class=\"alignnone  wp-image-6836\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/maxresdefault-300x169.jpg\" alt=\"\" width=\"431\" height=\"243\" />\r\n\r\nIn a recent review, Ari reported practical strategies for safe and effective aerosol delivery of aerosolised medications to ventilated patients with COVID-19. Delivering aerosolised medications via JN or pMDIs was deemed not to be appropriate due to the breakage of the circuits for the placement of the device on the ventilator circuit before aerosol therapy<sup>13</sup>. The benefits of VMN technology were highlighted including the fact that VMNs can stay in-line for up to 28 days as well as the reservoir design that allows addition of medication without requiring the ventilator circuit to be broken for aerosol drug delivery. Furthermore, this review article recommended to place the VMN at the dry side of the humidifier to improve the efficiency of the treatment and further reduce retrograde contamination from the patient<sup>13</sup>. Similarly, Dhand and Li outlined the suitability for use of VMN technology in the context of COVID-19. The authors reported that VMNs generate aerosols via mesh plates that separate the sealed medication reservoir from the patient interface, the aerosol derives from the fluid in the nebuliser chamber and does not carry patient-derived viral particles<sup>14</sup>. In contrast, residual drug remaining in JNs or USNs at the end of treatment could act as a breeding environment for bacteria if the nebuliser remains in the circuit between treatments<sup>14</sup>. In a letter to the editor of the <em>Journal of Critical Care</em>, Miller et al. reported safe and efficient bronchodilator administration using continuous nebulisation with the Aerogen Solo in invasively and non-invasively ventilated COVID-19 patients with COPD and asthma, and highlighted that the closed system requires minimal staff handling and no circuit opening, thereby reducing workload and increasing safety<sup>15</sup>. This is the first report of administering bronchodilators safely and efficiently to COVID-19 ventilated patients<sup>15</sup>. An expert consensus on reducing viral transmission during respiratory care for patients infected with COVID-19 has recommended to use a VMN for mechanically ventilated patients COVID-19 patients requiring inhalation therapy<sup>16</sup>. The consensus discussed how an additional filter should be placed at the expiratory port of the ventilator during nebulisation and the VMN should be positioned at the dry side of the humidifier<sup>16</sup>. In a consensus document on NIV support for adult patients with acute respiratory failure secondary to SARS-CoV-2 infection, a circuit with a VMN elbow was recommended as first choice when using inhaled therapy with NIV.\r\n\r\n<em>Note: This editorial was produced and sponsored by Aerogen and compiled by Millind Mahajan , Regional Sales Manager - West</em>\r\n\r\n<strong>PM749</strong>\r\n\r\nIf you would like to receive additional information on Aerogen or arrange for a free virtual product demonstration, please contact us below;\r\n\r\n<strong>Rajiv Julka, Country Manager</strong> – India &amp; Sub-Continent\r\n\r\n<strong>Kamal Kishore, Business Manager</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.aerogen.com/\"><strong>Aerogen Medical Devices India Pvt. Ltd.</strong></a></span>\r\n\r\n131, ABW Rectangle One Building,\r\n\r\nD-4, Saket District Centre, New Delhi,\r\n\r\nIndia - 110017\r\n\r\nOffice: +91 11 41422577\r\n\r\nEmail: <a href=\"mailto:India@Aerogen.com\">India@Aerogen.com</a> ; <a href=\"mailto:rjulka@aerogen.com\">rjulka@aerogen.com</a> ; <a href=\"mailto:kkishore@aerogen.com\">kkishore@aerogen.com</a>\r\n\r\n<strong>References</strong>\r\n\r\n1           Salvi S, Anil Kumar G, Dhaliwal RS, Paulson K, Agrawal A, Koul PA <em>et al.</em> The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990â€“2016. <em>Lancet Glob Heal</em> 2018; <strong>6</strong>: e1363–e1374.\r\n\r\n2           Ari A. Jet, Ultrasonic, and Mesh Nebulizers: An Evaluation of Nebulizers for Better Clinical Outcomes. <em>Eurasian J Pulmonol</em> 2014; <strong>16</strong>: 1–7.\r\n\r\n3           Vecellio L. The mesh nebuliser: a recent technical innovation for aerosol delivery. <em>Breathe</em> 2006; <strong>2</strong>: 252–260.\r\n\r\n4           McNulty W, Usmani OS. Techniques of assessing small airways dysfunction. <em>Eur Clin Respir J</em> 2014; <strong>1</strong>. doi:10.3402/ECRJ.V1.25898.\r\n\r\n5           Aerogen Solo System Instruction Manual. Aerogen Ltd. P/N 30-354, Part No. AG-AS3050. .\r\n\r\n6           Sidler-Moix A-LL, Di Paolo ER, Dolci U, Berger-Gryllaki M, Cotting J, Pannatier A. Physicochemical aspects and efficiency of albuterol nebulization: comparison of three aerosol types in an in vitro pediatric model. <em>Respir Care</em> 2015; <strong>60</strong>: 38–46.\r\n\r\n7           Dugernier J, Reychler G, Wittebole X, Roeseler J, Depoortere V, Sottiaux T <em>et al.</em> Aerosol delivery with two ventilation modes during mechanical ventilation: a randomized study. <em>Ann Intensive Care</em> 2016; <strong>6</strong>: 73.\r\n\r\n8           MacIntyre NR, Silver RM, Miller CW, Schuler F, Coleman RE. Aerosol delivery in intubated, mechanically ventilated patients. <em>Crit Care Med</em> 1985; <strong>13</strong>: 81–84.\r\n\r\n9           Ari A, Atalay OT, Harwood R, Sheard MM, Aljamhan EA, Fink JB. Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. <em>Respir Care</em> 2010; <strong>55</strong>: 845–851.\r\n\r\n10        Ari A, Areabi H, Fink JB, Cpft PT, Areabi H, Rrt M <em>et al.</em> Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation. <em>Respir Care</em> 2010; <strong>55</strong>: 837–844.\r\n\r\n11        Gardenshire, DS. Burnett, D. Strickland, S. Myers T. A Guide To Aerosol Delivery Devices for Respiratory Therapists. https://www.aarc.org/wp-content/uploads/2015/04/aerosol_guide_rt.pdf. 2017.\r\n\r\n12        Ari A, Fink JB, Dhand R. Inhalation Therapy in Patients Receiving Mechanical Ventilation: An Update. <em>J Aerosol Med Pulm Drug Deliv</em> 2012. doi:10.1089/jamp.2011.0936.\r\n\r\n13        Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. <em>Respir Med</em> 2020; <strong>167</strong>: 105987.\r\n\r\n14        Dhand R, Li J. Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2. <em>Am J Respir Crit Care Med</em> 2020. doi:10.1164/rccm.202004-1263PP.\r\n\r\n15        Miller A, Epstein D. Safe bronchodilator treatment in mechanically ventilated COVID-19 patients: A single center experience. J. Crit. Care. 2020; <strong>58</strong>: 56–57.\r\n\r\n16        Respiratory care committee of Chinese Thoracic Society. [Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia]. <em>Zhonghua Jie He He Hu Xi Za Zhi</em> 2020; <strong>17</strong>: E020.\r\n\r\n&nbsp;','Aerogen – bringing a lower risk of transmission of patient generated infectious aerosol for healthcare professionals in acute care settings compared to traditional nebulisers','','inherit','closed','closed','','6834-revision-v1','','','2020-08-03 05:55:49','2020-08-03 05:55:49','',6834,'https://microbiozindia.com/uncategorized/6834-revision-v1/',0,'revision','',0),(6838,2,'2020-08-03 05:58:05','2020-08-03 05:58:05','India has 18% of the global population and an increasing burden of chronic respiratory diseases<sup>1</sup>. The technique of nebulisation is commonly utilised in the treatment of such diseases including asthma, cystic fibrosis and chronic obstructive pulmonary disease (COPD)<sup>2</sup>. Recent improvements in nebuliser technologies have led to the development of vibrating mesh nebulisers (VMNs) that produce a consistent and improved aerosol generation efficiency and low residual drug volume<sup>2</sup>. The Aerogen Solo and Pro utilise VMN technology. The nebulisers are comprised of a unique dome-shaped aperture plate containing approximately 1,000 precision-formed tapered holes, surrounded by a vibrational element. When energy is applied, the aperture plate vibrates at 128,000 times per second. Each one of the 1000 cone-shaped apertures within the mesh acts as a micropump drawing liquid through the holes producing a low velocity aerosol optimised for targeted drug delivery to the lungs<sup>2,3</sup>. Each aperture creates particles of 1-5 µm in diameter, which is the optimum particle size for efficient lung deposition. Particles larger than 10–15 µm are deposited in the nose and mouth; particles that are 5–10 µm in size tend to deposit in the upper airways, while particles sized 1–5 µm have a greater probability of reaching the lower respiratory tract (i.e. from the trachea to the lung periphery)<sup>4</sup>.\n\nThe Aerogen Solo has an in-line circuit design, so the ventilator circuit does not need to be disconnected for drug delivery. It is designed so that the medication reservoir is isolated from the breathing circuit minimising the potential for nebulisation of contaminated fluids and delivers the medication dose with minimal residual remaining after nebulisation<sup>5</sup>. In addition, the Aerogen Solo is virtually silent in operation (&lt;35 dB measured at 0.3 metre distance)<sup>5</sup>. Unlike ultrasonic nebulisers (USNs), Aerogen technology does not increase the drug solution temperature as there is no heat generated during use<sup>6</sup>. During mechanical ventilation (MV) with active humidification, the nebuliser can be placed on the dry side of the humidifier or at the inspiratory limb of the breathing circuit before the patient wye. The Aerogen Solo can also be placed on the patient side of the wye and this facilitates the use of a Heat and Moisture Exchanger; however, this placement is contraindicated for neonates<sup>5</sup>. During non-invasive ventilation (NIV), the Aerogen Solo can be used in the same positions with a dual limb circuit. The Aerogen Solo may be utilised with single limb NIV circuits using non vented masks, with the nebuliser placed between the exhalation port and the patient<sup>5</sup>.\n\nSeveral studies have demonstrated optimal aerosol delivery with Aerogen VMN technology compared with jet nebulisers (JNs) and USNs in the critical care environment<sup>7–10</sup>. Ari et al. demonstrated improved inhaled dose with the Aerogen Solo compared with JN when placed before the humidifier compared to placement at the wye with both adult and paediatric MV models with bias flow<sup>9</sup>. Improved aerosol delivery with VMN technology is also associated with the minimal residual volume left in the device at the end of the treatment. Standard JNs leave up to 2 mL of the drug behind which can also be costly when using expensive drugs<sup>11,12</sup>. Dugernier et al. compared lung deposition with radiolabelled aerosol delivered via VMN in two modes of ventilation, pressure support (PSV) and volume-controlled ventilation (VCV) in a randomised controlled trial of neurosurgical patients with healthy lungs. They demonstrated 10 % and 15 % lung dose with PSV vs VCV, respectively<sup>7</sup>. Macintyre et al. previously administered radiolabelled aerosol with a JN to MV patients and they showed 2.9% lung deposition<sup>8</sup>. In comparison with the MacIntyre study, the Dugernier study demonstrated greater lung deposition with the VMN regardless of the mode of ventilation<sup>7,8</sup>.\n\n<img class=\"alignnone wp-image-6836\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/maxresdefault-300x169.jpg\" alt=\"\" width=\"431\" height=\"243\" />\n\nIn a recent review, Ari reported practical strategies for safe and effective aerosol delivery of aerosolised medications to ventilated patients with COVID-19. Delivering aerosolised medications via JN or pMDIs was deemed not to be appropriate due to the breakage of the circuits for the placement of the device on the ventilator circuit before aerosol therapy<sup>13</sup>. The benefits of VMN technology were highlighted including the fact that VMNs can stay in-line for up to 28 days as well as the reservoir design that allows addition of medication without requiring the ventilator circuit to be broken for aerosol drug delivery. Furthermore, this review article recommended to place the VMN at the dry side of the humidifier to improve the efficiency of the treatment and further reduce retrograde contamination from the patient<sup>13</sup>. Similarly, Dhand and Li outlined the suitability for use of VMN technology in the context of COVID-19. The authors reported that VMNs generate aerosols via mesh plates that separate the sealed medication reservoir from the patient interface, the aerosol derives from the fluid in the nebuliser chamber and does not carry patient-derived viral particles<sup>14</sup>. In contrast, residual drug remaining in JNs or USNs at the end of treatment could act as a breeding environment for bacteria if the nebuliser remains in the circuit between treatments<sup>14</sup>. In a letter to the editor of the <em>Journal of Critical Care</em>, Miller et al. reported safe and efficient bronchodilator administration using continuous nebulisation with the Aerogen Solo in invasively and non-invasively ventilated COVID-19 patients with COPD and asthma, and highlighted that the closed system requires minimal staff handling and no circuit opening, thereby reducing workload and increasing safety<sup>15</sup>. This is the first report of administering bronchodilators safely and efficiently to COVID-19 ventilated patients<sup>15</sup>. An expert consensus on reducing viral transmission during respiratory care for patients infected with COVID-19 has recommended to use a VMN for mechanically ventilated patients COVID-19 patients requiring inhalation therapy<sup>16</sup>. The consensus discussed how an additional filter should be placed at the expiratory port of the ventilator during nebulisation and the VMN should be positioned at the dry side of the humidifier<sup>16</sup>. In a consensus document on NIV support for adult patients with acute respiratory failure secondary to SARS-CoV-2 infection, a circuit with a VMN elbow was recommended as first choice when using inhaled therapy with NIV.\n\n<em>Note: This editorial was produced and sponsored by Aerogen and compiled by Millind Mahajan , Regional Sales Manager - West</em>\n\n<strong>PM749</strong>\n\nIf you would like to receive additional information on Aerogen or arrange for a free virtual product demonstration, please contact us below;\n\n<strong>Rajiv Julka, Country Manager</strong> – India &amp; Sub-Continent\n\n<strong>Kamal Kishore, Business Manager</strong>\n\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.aerogen.com/\"><strong>Aerogen Medical Devices India Pvt. Ltd.</strong></a></span>\n\n131, ABW Rectangle One Building,\n\nD-4, Saket District Centre, New Delhi,\n\nIndia - 110017\n\nOffice: +91 11 41422577\n\nEmail: <a href=\"mailto:India@Aerogen.com\">India@Aerogen.com</a> ; <a href=\"mailto:rjulka@aerogen.com\">rjulka@aerogen.com</a> ; <a href=\"mailto:kkishore@aerogen.com\">kkishore@aerogen.com</a>\n\n<strong>References</strong>\n\n1. Salvi S, Anil Kumar G, Dhaliwal RS, Paulson K, Agrawal A, Koul PA <em>et al.</em> The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990â€“2016. <em>Lancet Glob Heal</em> 2018; <strong>6</strong>: e1363–e1374.\n\n2.Ari A. Jet, Ultrasonic, and Mesh Nebulizers: An Evaluation of Nebulizers for Better Clinical Outcomes. <em>Eurasian J Pulmonol</em> 2014; <strong>16</strong>: 1–7.\n\n3 .Vecellio L. The mesh nebuliser: a recent technical innovation for aerosol delivery. <em>Breathe</em> 2006; <strong>2</strong>: 252–260.\n\n4.McNulty W, Usmani OS. Techniques of assessing small airways dysfunction. <em>Eur Clin Respir J</em> 2014; <strong>1</strong>. doi:10.3402/ECRJ.V1.25898.\n\n5 .Aerogen Solo System Instruction Manual. Aerogen Ltd. P/N 30-354, Part No. AG-AS3050. .\n\n6 .Sidler-Moix A-LL, Di Paolo ER, Dolci U, Berger-Gryllaki M, Cotting J, Pannatier A. Physicochemical aspects and efficiency of albuterol nebulization: comparison of three aerosol types in an in vitro pediatric model. <em>Respir Care</em> 2015; <strong>60</strong>: 38–46.\n\n7.Dugernier J, Reychler G, Wittebole X, Roeseler J, Depoortere V, Sottiaux T <em>et al.</em> Aerosol delivery with two ventilation modes during mechanical ventilation: a randomized study. <em>Ann Intensive Care</em> 2016; <strong>6</strong>: 73.\n\n8 MacIntyre NR, Silver RM, Miller CW, Schuler F, Coleman RE. Aerosol delivery in intubated, mechanically ventilated patients. <em>Crit Care Med</em> 1985; <strong>13</strong>: 81–84.\n\n9           Ari A, Atalay OT, Harwood R, Sheard MM, Aljamhan EA, Fink JB. Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. <em>Respir Care</em> 2010; <strong>55</strong>: 845–851.\n\n10        Ari A, Areabi H, Fink JB, Cpft PT, Areabi H, Rrt M <em>et al.</em> Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation. <em>Respir Care</em> 2010; <strong>55</strong>: 837–844.\n\n11        Gardenshire, DS. Burnett, D. Strickland, S. Myers T. A Guide To Aerosol Delivery Devices for Respiratory Therapists. https://www.aarc.org/wp-content/uploads/2015/04/aerosol_guide_rt.pdf. 2017.\n\n12        Ari A, Fink JB, Dhand R. Inhalation Therapy in Patients Receiving Mechanical Ventilation: An Update. <em>J Aerosol Med Pulm Drug Deliv</em> 2012. doi:10.1089/jamp.2011.0936.\n\n13        Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. <em>Respir Med</em> 2020; <strong>167</strong>: 105987.\n\n14        Dhand R, Li J. Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2. <em>Am J Respir Crit Care Med</em> 2020. doi:10.1164/rccm.202004-1263PP.\n\n15        Miller A, Epstein D. Safe bronchodilator treatment in mechanically ventilated COVID-19 patients: A single center experience. J. Crit. Care. 2020; <strong>58</strong>: 56–57.\n\n16        Respiratory care committee of Chinese Thoracic Society. [Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia]. <em>Zhonghua Jie He He Hu Xi Za Zhi</em> 2020; <strong>17</strong>: E020.\n\n&nbsp;','Aerogen – bringing a lower risk of transmission of patient generated infectious aerosol for healthcare professionals in acute care settings compared to traditional nebulisers','','inherit','closed','closed','','6834-autosave-v1','','','2020-08-03 05:58:05','2020-08-03 05:58:05','',6834,'https://microbiozindia.com/uncategorized/6834-autosave-v1/',0,'revision','',0),(6839,2,'2020-08-03 06:00:00','2020-08-03 06:00:00','India has 18% of the global population and an increasing burden of chronic respiratory diseases<sup>1</sup>. The technique of nebulisation is commonly utilised in the treatment of such diseases including asthma, cystic fibrosis and chronic obstructive pulmonary disease (COPD)<sup>2</sup>. Recent improvements in nebuliser technologies have led to the development of vibrating mesh nebulisers (VMNs) that produce a consistent and improved aerosol generation efficiency and low residual drug volume<sup>2</sup>. The Aerogen Solo and Pro utilise VMN technology. The nebulisers are comprised of a unique dome-shaped aperture plate containing approximately 1,000 precision-formed tapered holes, surrounded by a vibrational element. When energy is applied, the aperture plate vibrates at 128,000 times per second. Each one of the 1000 cone-shaped apertures within the mesh acts as a micropump drawing liquid through the holes producing a low velocity aerosol optimised for targeted drug delivery to the lungs<sup>2,3</sup>. Each aperture creates particles of 1-5 µm in diameter, which is the optimum particle size for efficient lung deposition. Particles larger than 10–15 µm are deposited in the nose and mouth; particles that are 5–10 µm in size tend to deposit in the upper airways, while particles sized 1–5 µm have a greater probability of reaching the lower respiratory tract (i.e. from the trachea to the lung periphery)<sup>4</sup>.\r\n\r\nThe Aerogen Solo has an in-line circuit design, so the ventilator circuit does not need to be disconnected for drug delivery. It is designed so that the medication reservoir is isolated from the breathing circuit minimising the potential for nebulisation of contaminated fluids and delivers the medication dose with minimal residual remaining after nebulisation<sup>5</sup>. In addition, the Aerogen Solo is virtually silent in operation (&lt;35 dB measured at 0.3 metre distance)<sup>5</sup>. Unlike ultrasonic nebulisers (USNs), Aerogen technology does not increase the drug solution temperature as there is no heat generated during use<sup>6</sup>. During mechanical ventilation (MV) with active humidification, the nebuliser can be placed on the dry side of the humidifier or at the inspiratory limb of the breathing circuit before the patient wye. The Aerogen Solo can also be placed on the patient side of the wye and this facilitates the use of a Heat and Moisture Exchanger; however, this placement is contraindicated for neonates<sup>5</sup>. During non-invasive ventilation (NIV), the Aerogen Solo can be used in the same positions with a dual limb circuit. The Aerogen Solo may be utilised with single limb NIV circuits using non vented masks, with the nebuliser placed between the exhalation port and the patient<sup>5</sup>.\r\n\r\nSeveral studies have demonstrated optimal aerosol delivery with Aerogen VMN technology compared with jet nebulisers (JNs) and USNs in the critical care environment<sup>7–10</sup>. Ari et al. demonstrated improved inhaled dose with the Aerogen Solo compared with JN when placed before the humidifier compared to placement at the wye with both adult and paediatric MV models with bias flow<sup>9</sup>. Improved aerosol delivery with VMN technology is also associated with the minimal residual volume left in the device at the end of the treatment. Standard JNs leave up to 2 mL of the drug behind which can also be costly when using expensive drugs<sup>11,12</sup>. Dugernier et al. compared lung deposition with radiolabelled aerosol delivered via VMN in two modes of ventilation, pressure support (PSV) and volume-controlled ventilation (VCV) in a randomised controlled trial of neurosurgical patients with healthy lungs. They demonstrated 10 % and 15 % lung dose with PSV vs VCV, respectively<sup>7</sup>. Macintyre et al. previously administered radiolabelled aerosol with a JN to MV patients and they showed 2.9% lung deposition<sup>8</sup>. In comparison with the MacIntyre study, the Dugernier study demonstrated greater lung deposition with the VMN regardless of the mode of ventilation<sup>7,8</sup>.\r\n\r\n<img class=\"alignnone wp-image-6836\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/maxresdefault-300x169.jpg\" alt=\"\" width=\"431\" height=\"243\" />\r\n\r\nIn a recent review, Ari reported practical strategies for safe and effective aerosol delivery of aerosolised medications to ventilated patients with COVID-19. Delivering aerosolised medications via JN or pMDIs was deemed not to be appropriate due to the breakage of the circuits for the placement of the device on the ventilator circuit before aerosol therapy<sup>13</sup>. The benefits of VMN technology were highlighted including the fact that VMNs can stay in-line for up to 28 days as well as the reservoir design that allows addition of medication without requiring the ventilator circuit to be broken for aerosol drug delivery. Furthermore, this review article recommended to place the VMN at the dry side of the humidifier to improve the efficiency of the treatment and further reduce retrograde contamination from the patient<sup>13</sup>. Similarly, Dhand and Li outlined the suitability for use of VMN technology in the context of COVID-19. The authors reported that VMNs generate aerosols via mesh plates that separate the sealed medication reservoir from the patient interface, the aerosol derives from the fluid in the nebuliser chamber and does not carry patient-derived viral particles<sup>14</sup>. In contrast, residual drug remaining in JNs or USNs at the end of treatment could act as a breeding environment for bacteria if the nebuliser remains in the circuit between treatments<sup>14</sup>. In a letter to the editor of the <em>Journal of Critical Care</em>, Miller et al. reported safe and efficient bronchodilator administration using continuous nebulisation with the Aerogen Solo in invasively and non-invasively ventilated COVID-19 patients with COPD and asthma, and highlighted that the closed system requires minimal staff handling and no circuit opening, thereby reducing workload and increasing safety<sup>15</sup>. This is the first report of administering bronchodilators safely and efficiently to COVID-19 ventilated patients<sup>15</sup>. An expert consensus on reducing viral transmission during respiratory care for patients infected with COVID-19 has recommended to use a VMN for mechanically ventilated patients COVID-19 patients requiring inhalation therapy<sup>16</sup>. The consensus discussed how an additional filter should be placed at the expiratory port of the ventilator during nebulisation and the VMN should be positioned at the dry side of the humidifier<sup>16</sup>. In a consensus document on NIV support for adult patients with acute respiratory failure secondary to SARS-CoV-2 infection, a circuit with a VMN elbow was recommended as first choice when using inhaled therapy with NIV.\r\n\r\n<em>Note: This editorial was produced and sponsored by Aerogen and compiled by Millind Mahajan , Regional Sales Manager - West</em>\r\n\r\n<strong>PM749</strong>\r\n\r\nIf you would like to receive additional information on Aerogen or arrange for a free virtual product demonstration, please contact us below;\r\n\r\n<strong>Rajiv Julka, Country Manager</strong> – India &amp; Sub-Continent\r\n\r\n<strong>Kamal Kishore, Business Manager</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.aerogen.com/\"><strong>Aerogen Medical Devices India Pvt. Ltd.</strong></a></span>\r\n\r\n131, ABW Rectangle One Building,\r\n\r\nD-4, Saket District Centre, New Delhi,\r\n\r\nIndia - 110017\r\n\r\nOffice: +91 11 41422577\r\n\r\nEmail: <span style=\"color: #000000;\"><a style=\"color: #000000;\" href=\"mailto:India@Aerogen.com\">India@Aerogen.com</a> ; <a style=\"color: #000000;\" href=\"mailto:rjulka@aerogen.com\">rjulka@aerogen.com</a> ; <a style=\"color: #000000;\" href=\"mailto:kkishore@aerogen.com\">kkishore@aerogen.com</a></span>\r\n\r\n<strong>References</strong>\r\n\r\n1. Salvi S, Anil Kumar G, Dhaliwal RS, Paulson K, Agrawal A, Koul PA <em>et al.</em> The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990â€“2016. <em>Lancet Glob Heal</em> 2018; <strong>6</strong>: e1363–e1374.\r\n\r\n2.Ari A. Jet, Ultrasonic, and Mesh Nebulizers: An Evaluation of Nebulizers for Better Clinical Outcomes. <em>Eurasian J Pulmonol</em> 2014; <strong>16</strong>: 1–7.\r\n\r\n3 .Vecellio L. The mesh nebuliser: a recent technical innovation for aerosol delivery. <em>Breathe</em> 2006; <strong>2</strong>: 252–260.\r\n\r\n4.McNulty W, Usmani OS. Techniques of assessing small airways dysfunction. <em>Eur Clin Respir J</em> 2014; <strong>1</strong>. doi:10.3402/ECRJ.V1.25898.\r\n\r\n5 .Aerogen Solo System Instruction Manual. Aerogen Ltd. P/N 30-354, Part No. AG-AS3050. .\r\n\r\n6 .Sidler-Moix A-LL, Di Paolo ER, Dolci U, Berger-Gryllaki M, Cotting J, Pannatier A. Physicochemical aspects and efficiency of albuterol nebulization: comparison of three aerosol types in an in vitro pediatric model. <em>Respir Care</em> 2015; <strong>60</strong>: 38–46.\r\n\r\n7.Dugernier J, Reychler G, Wittebole X, Roeseler J, Depoortere V, Sottiaux T <em>et al.</em> Aerosol delivery with two ventilation modes during mechanical ventilation: a randomized study. <em>Ann Intensive Care</em> 2016; <strong>6</strong>: 73.\r\n\r\n8 .MacIntyre NR, Silver RM, Miller CW, Schuler F, Coleman RE. Aerosol delivery in intubated, mechanically ventilated patients. <em>Crit Care Med</em> 1985; <strong>13</strong>: 81–84.\r\n\r\n9.Ari A, Atalay OT, Harwood R, Sheard MM, Aljamhan EA, Fink JB. Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. <em>Respir Care</em> 2010; <strong>55</strong>: 845–851.\r\n\r\n10.Ari A, Areabi H, Fink JB, Cpft PT, Areabi H, Rrt M <em>et al.</em> Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation. <em>Respir Care</em> 2010; <strong>55</strong>: 837–844.\r\n\r\n11.Gardenshire, DS. Burnett, D. Strickland, S. Myers T. A Guide To Aerosol Delivery Devices for Respiratory Therapists. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.aarc.org/wp-content/uploads/2015/04/aerosol_guide_rt.pdf\">https://www.aarc.org/wp-content/uploads/2015/04/aerosol_guide_rt.pdf.</a> </span>2017.\r\n\r\n12.Ari A, Fink JB, Dhand R. Inhalation Therapy in Patients Receiving Mechanical Ventilation: An Update. <em>J Aerosol Med Pulm Drug Deliv</em> 2012. doi:10.1089/jamp.2011.0936.\r\n\r\n13 .Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. <em>Respir Med</em> 2020; <strong>167</strong>: 105987.\r\n\r\n14.Dhand R, Li J. Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2. <em>Am J Respir Crit Care Med</em> 2020. doi:10.1164/rccm.202004-1263PP.\r\n\r\n15.Miller A, Epstein D. Safe bronchodilator treatment in mechanically ventilated COVID-19 patients: A single center experience. J. Crit. Care. 2020; <strong>58</strong>: 56–57.\r\n\r\n16.Respiratory care committee of Chinese Thoracic Society. [Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia]. <em>Zhonghua Jie He He Hu Xi Za Zhi</em> 2020; <strong>17</strong>: E020.','Aerogen – bringing a lower risk of transmission of patient generated infectious aerosol for healthcare professionals in acute care settings compared to traditional nebulisers','','inherit','closed','closed','','6834-revision-v1','','','2020-08-03 06:00:00','2020-08-03 06:00:00','',6834,'https://microbiozindia.com/uncategorized/6834-revision-v1/',0,'revision','',0),(6840,2,'2020-08-03 10:08:25','2020-08-03 10:08:25','The Drugs Controller General of India (DCGI) has contributed nod to the Serum Institute of India (SII) for conducting phase 3 and 2 human clinical trials of a COVID-19 vaccine candidate, developed at the University of Oxford, in the country.\r\n\r\nGovernment officials told PTI that the approval of conducting stage 2 and 3 clinical trials by the SII was awarded by DCGI Dr VG Somani late mnight about August 2 following a thorough evaluation based on the recommendations of the Subject Expert Committee on COVID-19.\r\n\r\nAs a quick regulatory response, the expert panel at the Central Drugs Standard Control Organisation (CDSCO) on July 31, following a comprehensive deliberation and considering the data created by the vaccine candidate in stage 1 and 2 of the Oxford University trial, had advocated granting permission for stage 2 and 3 clinical trials of the potential vaccine,\'Covishield\', on healthy adults at India, the officials stated.\r\n\r\n\"As per the study design, each topic will be administered two doses four weeks apart (initial dose on day one and second dose on day 29) after that the safety and immunogenicity will be assessed in predefined periods,\" the official said.\r\n\r\nCurrently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is happening in the United Kingdom, stage 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa.\r\n\r\nThe officials stated that the SII had submitted a revised proposal on Wednesday after the expert panel on Tuesday, after deliberation over its program, had requested it to revise its own protocol for the stage 2 and 3 clinical trials apart from needing some extra details.\r\n\r\nThe panel also has recommended that the clinical trial sites that have been suggested for the study have been distributed across India.\r\n\r\nAccording to this revised proposal, 1,600 people aged above 18 years will participate in the trials across 17 selected websites, including AIIMS Delhi, B J Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital at Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore.\r\n\r\n\"According to this program, it would conduct an observer-blind, randomised controlled study to ascertain the safety and immunogenicity of\'Covishield\' on healthy Indian adults,\" the official stated.\r\n\r\nThe SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for COVID-19 had submitted its initial application to the DCGI on July 25 looking for permission for running the stage 2 and 3 trials of the potential vaccine.','Serum Institute gets DCGI gesture for stage 2 and 3 human clinical preliminaries of Oxford\'s coronavirus immunization','','publish','open','open','','serum-institute-gets-dcgi-gesture-for-stage-2-and-3-human-clinical-preliminaries-of-oxfords-coronavirus-immunization','','','2020-08-03 10:08:25','2020-08-03 10:08:25','',0,'https://microbiozindia.com/?p=6840',0,'post','',0),(6841,2,'2020-08-03 10:08:25','2020-08-03 10:08:25','The Drugs Controller General of India (DCGI) has contributed nod to the Serum Institute of India (SII) for conducting phase 3 and 2 human clinical trials of a COVID-19 vaccine candidate, developed at the University of Oxford, in the country.\r\n\r\nGovernment officials told PTI that the approval of conducting stage 2 and 3 clinical trials by the SII was awarded by DCGI Dr VG Somani late mnight about August 2 following a thorough evaluation based on the recommendations of the Subject Expert Committee on COVID-19.\r\n\r\nAs a quick regulatory response, the expert panel at the Central Drugs Standard Control Organisation (CDSCO) on July 31, following a comprehensive deliberation and considering the data created by the vaccine candidate in stage 1 and 2 of the Oxford University trial, had advocated granting permission for stage 2 and 3 clinical trials of the potential vaccine,\'Covishield\', on healthy adults at India, the officials stated.\r\n\r\n\"As per the study design, each topic will be administered two doses four weeks apart (initial dose on day one and second dose on day 29) after that the safety and immunogenicity will be assessed in predefined periods,\" the official said.\r\n\r\nCurrently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is happening in the United Kingdom, stage 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa.\r\n\r\nThe officials stated that the SII had submitted a revised proposal on Wednesday after the expert panel on Tuesday, after deliberation over its program, had requested it to revise its own protocol for the stage 2 and 3 clinical trials apart from needing some extra details.\r\n\r\nThe panel also has recommended that the clinical trial sites that have been suggested for the study have been distributed across India.\r\n\r\nAccording to this revised proposal, 1,600 people aged above 18 years will participate in the trials across 17 selected websites, including AIIMS Delhi, B J Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital at Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore.\r\n\r\n\"According to this program, it would conduct an observer-blind, randomised controlled study to ascertain the safety and immunogenicity of\'Covishield\' on healthy Indian adults,\" the official stated.\r\n\r\nThe SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for COVID-19 had submitted its initial application to the DCGI on July 25 looking for permission for running the stage 2 and 3 trials of the potential vaccine.','Serum Institute gets DCGI gesture for stage 2 and 3 human clinical preliminaries of Oxford\'s coronavirus immunization','','inherit','closed','closed','','6840-revision-v1','','','2020-08-03 10:08:25','2020-08-03 10:08:25','',6840,'https://microbiozindia.com/uncategorized/6840-revision-v1/',0,'revision','',0),(6842,2,'2020-08-03 11:12:50','2020-08-03 11:12:50','A protein produced by the human immune system may strongly inhibit corona viruses, including Sars-Cov-2, the pathogen causing Covid-19. An international team from Germany, Switzerland and the USA successfully showed the LY6E-Protein prevents coronaviruses from causing the illness.\r\n\r\n\"This finding may result in the development of new therapeutic approaches against coronaviruses,\" says Professor Stephanie Pfänder from the Department for Molecular and Medical Virology at Ruhr-Universität Bochum (RUB), lead author of the study published by the team in the journal Nature Microbiology on 23 July 2020.\r\n\r\n<strong>Strengthening flu viruses, impairing corona viruses</strong>\r\nThe LY6E protein plays a role in various diseases: US researchers Professor John Schoggins and Professor Charles Rice found that the protein enhances the infectivity of influenza viruses.\r\n\r\nFounded by a Marie Curie Individual Fellowship of the European Union, Stephanie Pfänder, who was then working in the Institute of Virology and Immunology in Switzerland, visited Charles Rice\'s lab at Rockefeller University in New York in 2017, in order to identify genes that prevent coronavirus infections.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.rub.de/english/press-releases/2020-07-28-virology-immunoprotein-impairs-sars-cov-2\">\"This led to the discovery which LY6E has the opposite effect on coronaviruses when compared with flu viruses,\" explains the researcher. Further investigations revealed that the protein exerted this inhibitory effect on all examined coronaviruses, such as the germs causing Sars and Mers and Sars-Cov-2 which causes Covid-19.</a></span>\r\n\r\nViruses not able to fuse\r\nTests with different cell cultures showed that LY6E affects the ability of the virus to fuse with the host cells.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.rub.de/english/press-releases/2020-07-28-virology-immunoprotein-impairs-sars-cov-2\">The validation in an animal model succeeded thanks to a collaboration with the lab of John Schoggins in the Southwestern Medical Center at the University of Texas.</a></span> The experiments conducted there resulted in the discovery that the mouse variant of this protein called Ly6e is vital for the protection of immune cells against infections.\r\n\r\nIn the absence of Ly6e, immune cells like dendritic cells and B-cells become more vulnerable to disease and their numbers decrease radically. Mice lacking Ly6e in immune cells are highly susceptible to some normally non-lethal mouse coronavirus and succumb to infection.\r\n\r\n<strong>Knowing basic concepts</strong>\r\nThe researchers point out that the mouse coronavirus used in the experiment differs considerably in the pathogen causing the current Covid-19 outbreak - for example, it causes hepatitis rather than respiratory disease. Regardless, it\'s widely recognized as a model for understanding the basic theories of coronavirus replication and immune reactions in a living creature.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.rub.de/english/press-releases/2020-07-28-virology-immunoprotein-impairs-sars-cov-2\">\"Our study offers new insights into just how significant these antiviral genes are for the control of viral infection and for a decent immune response against the virus,\" stated the authors.</a></span>\r\n\r\n\"Since LY6E is a naturally occurring human protein, we expect that this knowledge will aid the development of therapies that may one day be used to take care of coronavirus infections.\" A therapeutic strategy that mimics the mechanism of activity of LY6E may provide the initial line of defense against publication coronavirus infections.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.rub.de/english/press-releases/2020-07-28-virology-immunoprotein-impairs-sars-cov-2\" target=\"_blank\" rel=\"noopener noreferrer\">Ruhr-Universitaet-Bochum</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nPfaender, S., <em>et al</em>. (2020) LY6E impairs coronavirus fusion and confers immune control of viral disease. <em>Nature Microbiology. </em><span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1038/s41564-020-0769-y\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1038/s41564-020-0769-y.</a></span>\r\n\r\n</div>','Protein delivered by the human safe framework can emphatically hinder Sars-Cov-2','','publish','open','open','','protein-delivered-by-the-human-safe-framework-can-emphatically-hinder-sars-cov-2','','','2020-08-03 11:12:50','2020-08-03 11:12:50','',0,'https://microbiozindia.com/?p=6842',0,'post','',0),(6843,2,'2020-08-03 11:12:50','2020-08-03 11:12:50','A protein produced by the human immune system may strongly inhibit corona viruses, including Sars-Cov-2, the pathogen causing Covid-19. An international team from Germany, Switzerland and the USA successfully showed the LY6E-Protein prevents coronaviruses from causing the illness.\r\n\r\n\"This finding may result in the development of new therapeutic approaches against coronaviruses,\" says Professor Stephanie Pfänder from the Department for Molecular and Medical Virology at Ruhr-Universität Bochum (RUB), lead author of the study published by the team in the journal Nature Microbiology on 23 July 2020.\r\n\r\n<strong>Strengthening flu viruses, impairing corona viruses</strong>\r\nThe LY6E protein plays a role in various diseases: US researchers Professor John Schoggins and Professor Charles Rice found that the protein enhances the infectivity of influenza viruses.\r\n\r\nFounded by a Marie Curie Individual Fellowship of the European Union, Stephanie Pfänder, who was then working in the Institute of Virology and Immunology in Switzerland, visited Charles Rice\'s lab at Rockefeller University in New York in 2017, in order to identify genes that prevent coronavirus infections.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.rub.de/english/press-releases/2020-07-28-virology-immunoprotein-impairs-sars-cov-2\">\"This led to the discovery which LY6E has the opposite effect on coronaviruses when compared with flu viruses,\" explains the researcher. Further investigations revealed that the protein exerted this inhibitory effect on all examined coronaviruses, such as the germs causing Sars and Mers and Sars-Cov-2 which causes Covid-19.</a></span>\r\n\r\nViruses not able to fuse\r\nTests with different cell cultures showed that LY6E affects the ability of the virus to fuse with the host cells.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.rub.de/english/press-releases/2020-07-28-virology-immunoprotein-impairs-sars-cov-2\">The validation in an animal model succeeded thanks to a collaboration with the lab of John Schoggins in the Southwestern Medical Center at the University of Texas.</a></span> The experiments conducted there resulted in the discovery that the mouse variant of this protein called Ly6e is vital for the protection of immune cells against infections.\r\n\r\nIn the absence of Ly6e, immune cells like dendritic cells and B-cells become more vulnerable to disease and their numbers decrease radically. Mice lacking Ly6e in immune cells are highly susceptible to some normally non-lethal mouse coronavirus and succumb to infection.\r\n\r\n<strong>Knowing basic concepts</strong>\r\nThe researchers point out that the mouse coronavirus used in the experiment differs considerably in the pathogen causing the current Covid-19 outbreak - for example, it causes hepatitis rather than respiratory disease. Regardless, it\'s widely recognized as a model for understanding the basic theories of coronavirus replication and immune reactions in a living creature.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.rub.de/english/press-releases/2020-07-28-virology-immunoprotein-impairs-sars-cov-2\">\"Our study offers new insights into just how significant these antiviral genes are for the control of viral infection and for a decent immune response against the virus,\" stated the authors.</a></span>\r\n\r\n\"Since LY6E is a naturally occurring human protein, we expect that this knowledge will aid the development of therapies that may one day be used to take care of coronavirus infections.\" A therapeutic strategy that mimics the mechanism of activity of LY6E may provide the initial line of defense against publication coronavirus infections.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.rub.de/english/press-releases/2020-07-28-virology-immunoprotein-impairs-sars-cov-2\" target=\"_blank\" rel=\"noopener noreferrer\">Ruhr-Universitaet-Bochum</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nPfaender, S., <em>et al</em>. (2020) LY6E impairs coronavirus fusion and confers immune control of viral disease. <em>Nature Microbiology. </em><span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1038/s41564-020-0769-y\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1038/s41564-020-0769-y.</a></span>\r\n\r\n</div>','Protein delivered by the human safe framework can emphatically hinder Sars-Cov-2','','inherit','closed','closed','','6842-revision-v1','','','2020-08-03 11:12:50','2020-08-03 11:12:50','',6842,'https://microbiozindia.com/uncategorized/6842-revision-v1/',0,'revision','',0),(6844,2,'2020-08-03 19:08:56','2020-08-03 19:08:56','While quality control is an important aspect for almost all industries, the level of quality control for some particular industries, such as pharmaceuticals, life sciences, and food &amp; beverages, has to be absolutely top-notch. It is quite obvious that these industries deal with crucial elements, and, if not handled properly, serious damage to human health can be caused. Take for example drugs that are used for treating diseases; any sort of impurity in the drug can put the life of a person in jeopardy.\r\n\r\nIt is due to these reasons that a number of industries make use of laboratory filtration, for making sure that the end product is free of any harmful contaminant. Now, what exactly is laboratory filtration? Filtration can be described as a process where solids are separated from gases or liquids, via various mechanical, biological, and physical operations. Filtration media are utilized for removing the fluid, which can pass through the media, from solid particles, thereby providing the desired purity.\r\n\r\nDue to all these reasons, the global <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.psmarketresearch.com/market-analysis/laboratory-filtration-market\">laboratory filtration market</a></span> is predicted to generate revenue of $3.5 billion by 2023, increasing from $2.3 billion in 2017, and it is expected to progress at a 7.3% CAGR during 2018–2023.\r\n\r\n<strong>Products Used during the Process</strong>\r\n\r\nOther than the filtration media, filtration accessories and filtration assemblies are also important products that are utilized in laboratory filtration processes, among which the sales of filtration media remains highest. Different types of filtration media, namely syringeless filters, membrane filters, capsule filters, syringe filters, filtration microplates, and filter papers, are needed for different laboratory filtration processes.\r\n\r\nThe use of membrane filtration has been the widest in the past few years, which definitely couldn’t have been if the product didn’t have any merit. Membrane filters consist of microporous plastic films, along with specific pore-size ratings, which is helpful when it comes to removing minute impurities. Since other filtration media do not have such properties, membrane filters have shown the way forward in most industries.\r\n\r\n<strong>Insights into Laboratory Filtration Technologies</strong>\r\n\r\nNow that some light has been shed on the important products used in laboratory filtration processes, it’s time to talk about the different kinds of laboratory filtration technologies.\r\n<ul>\r\n 	<li><strong>Microfiltration:</strong> Under this process, a membrane filter that only enables the passing of particles smaller than 0.1 microns is used. This technology is majorly utilized for cold disinfection of beverages and pharmaceuticals, clarification of fruit juices, beers, and wines, and pretreatment, prior to the reverse osmosis (RO) purification, for removing suspended solids that can damage the RO membranes.</li>\r\n 	<li><strong>Ultrafiltration:</strong> The pore size of the membranes used in this process is generally 103–106 Daltons (Da). This pressure-driven barrier technology is utilized for suspending bacteria, endotoxins, solids, viruses, and other kinds of pathogens, and it is majorly used for producing water with a low silt density and very high purity.</li>\r\n 	<li><strong>RO:</strong> Much like ultrafiltration, this technology is utilized for removing a majority of the contaminants from water, which is done by pushing the water through a semi-permeable membrane, under pressure. The process is able to remove a large portion of the particles, dissolved salts, organics, colloids, pyrogens, and bacteria from the feed water.</li>\r\n 	<li><strong>Nanofiltration: </strong>This is one of the latest technologies when it comes to laboratory filtration. The membrane is somewhat between ultrafiltration and RO, in the basis of its ability to reject ionic or molecular species. The cut-off pore size of these membranes lies between 1,000–200 Da. Some of the features of the nanofiltration technology are a low-to-moderate rejection capability against monovalent ions, very high rejection capability against multivalent ions, and high rejection capability against organic compounds.</li>\r\n 	<li><strong>Vacuum Filtration:</strong> This is a convenient and easy way for filtering fluids, as the vacuum can be generated by a faucet aspiration system, using a pump, or in-house vacuum lines. This technology is majorly utilized in laboratory and microbiological procedures, which involve the collection of particulates containing precipitates and bacteria, from a liquid suspension.</li>\r\n</ul>\r\nOut of all these, the utilization of microfiltration has been the highest, as it is being used in a number of industries for various processes.\r\n\r\n<strong>Rising Prevalence of Chronic Diseases Making Usage of Laboratory Filtration Essential in Asia-Pacific</strong>\r\n\r\n<strong> </strong>While the adoption of this technology has been high in developed countries in the North American and European regions for quite a while, its usage is expected to rise considerably in the Asia-Pacific (APAC) region in the immediate future. Other than the increasing number of people suffering from chronic diseases in the region, the enhancing healthcare infrastructure and growing production of pharmaceutical products are also contributing significantly to the increasing need for advanced filtration technologies.\r\n\r\nThe production of pharmaceutical products is particularly high in Japan. As per the data by the International Trade Administration, on the basis of the Ministry of Health, Labor and Welfare’s annual pharmaceutical production statistics, in 2015, the production of non-prescription and prescription pharmaceuticals accounted for $88 billion in 2015 in Japan. This is the major reason for the growing use of laboratory filtration products in the region.\r\n\r\n<strong>Laboratory Filtration Technologies also Important in Food &amp; Beverage Industry</strong>\r\n\r\n<strong> </strong>It has been quite clear that the major demand for laboratory filtration products is being created from the pharmaceuticals and water treatment industries; however, the food &amp; beverage industry is also among the key users of these processes and products. The membrane filtration technique is being used increasingly in the food &amp; beverage industry, due to its effective results in terms of clarification, purification, concentration, and fractionation. Such techniques help in improving the quality of food products and various kinds of beverages as well.\r\n\r\nHence, the companies in the domain are now focusing on developing more efficient laboratory filtration products, in order to provide customers with the best solutions. The rising adoption of laboratory filtration techniques in several industries, due to the general regard for people’s health as well as the strict regulatory environment and people’s growing awareness of how their food or medicines are prepared, is driving the need for advanced products.\r\n\r\n&nbsp;','Demand for Laboratory Filtration Technologies High Due to Rising Need for Quality Control in Industries','','publish','open','open','','demand-for-laboratory-filtration-technologies-high-due-to-rising-need-for-quality-control-in-industries','','','2020-08-03 19:08:56','2020-08-03 19:08:56','',0,'https://microbiozindia.com/?p=6844',0,'post','',0),(6845,2,'2020-08-03 19:04:00','2020-08-03 19:04:00','','Untitled design (1)','','inherit','open','closed','','untitled-design-1-11','','','2020-08-03 19:04:00','2020-08-03 19:04:00','',6844,'https://microbiozindia.com/wp-content/uploads/2020/08/Untitled-design-1-1.png',0,'attachment','image/png',0),(6846,2,'2020-08-03 19:08:56','2020-08-03 19:08:56','While quality control is an important aspect for almost all industries, the level of quality control for some particular industries, such as pharmaceuticals, life sciences, and food &amp; beverages, has to be absolutely top-notch. It is quite obvious that these industries deal with crucial elements, and, if not handled properly, serious damage to human health can be caused. Take for example drugs that are used for treating diseases; any sort of impurity in the drug can put the life of a person in jeopardy.\r\n\r\nIt is due to these reasons that a number of industries make use of laboratory filtration, for making sure that the end product is free of any harmful contaminant. Now, what exactly is laboratory filtration? Filtration can be described as a process where solids are separated from gases or liquids, via various mechanical, biological, and physical operations. Filtration media are utilized for removing the fluid, which can pass through the media, from solid particles, thereby providing the desired purity.\r\n\r\nDue to all these reasons, the global <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.psmarketresearch.com/market-analysis/laboratory-filtration-market\">laboratory filtration market</a></span> is predicted to generate revenue of $3.5 billion by 2023, increasing from $2.3 billion in 2017, and it is expected to progress at a 7.3% CAGR during 2018–2023.\r\n\r\n<strong>Products Used during the Process</strong>\r\n\r\nOther than the filtration media, filtration accessories and filtration assemblies are also important products that are utilized in laboratory filtration processes, among which the sales of filtration media remains highest. Different types of filtration media, namely syringeless filters, membrane filters, capsule filters, syringe filters, filtration microplates, and filter papers, are needed for different laboratory filtration processes.\r\n\r\nThe use of membrane filtration has been the widest in the past few years, which definitely couldn’t have been if the product didn’t have any merit. Membrane filters consist of microporous plastic films, along with specific pore-size ratings, which is helpful when it comes to removing minute impurities. Since other filtration media do not have such properties, membrane filters have shown the way forward in most industries.\r\n\r\n<strong>Insights into Laboratory Filtration Technologies</strong>\r\n\r\nNow that some light has been shed on the important products used in laboratory filtration processes, it’s time to talk about the different kinds of laboratory filtration technologies.\r\n<ul>\r\n 	<li><strong>Microfiltration:</strong> Under this process, a membrane filter that only enables the passing of particles smaller than 0.1 microns is used. This technology is majorly utilized for cold disinfection of beverages and pharmaceuticals, clarification of fruit juices, beers, and wines, and pretreatment, prior to the reverse osmosis (RO) purification, for removing suspended solids that can damage the RO membranes.</li>\r\n 	<li><strong>Ultrafiltration:</strong> The pore size of the membranes used in this process is generally 103–106 Daltons (Da). This pressure-driven barrier technology is utilized for suspending bacteria, endotoxins, solids, viruses, and other kinds of pathogens, and it is majorly used for producing water with a low silt density and very high purity.</li>\r\n 	<li><strong>RO:</strong> Much like ultrafiltration, this technology is utilized for removing a majority of the contaminants from water, which is done by pushing the water through a semi-permeable membrane, under pressure. The process is able to remove a large portion of the particles, dissolved salts, organics, colloids, pyrogens, and bacteria from the feed water.</li>\r\n 	<li><strong>Nanofiltration: </strong>This is one of the latest technologies when it comes to laboratory filtration. The membrane is somewhat between ultrafiltration and RO, in the basis of its ability to reject ionic or molecular species. The cut-off pore size of these membranes lies between 1,000–200 Da. Some of the features of the nanofiltration technology are a low-to-moderate rejection capability against monovalent ions, very high rejection capability against multivalent ions, and high rejection capability against organic compounds.</li>\r\n 	<li><strong>Vacuum Filtration:</strong> This is a convenient and easy way for filtering fluids, as the vacuum can be generated by a faucet aspiration system, using a pump, or in-house vacuum lines. This technology is majorly utilized in laboratory and microbiological procedures, which involve the collection of particulates containing precipitates and bacteria, from a liquid suspension.</li>\r\n</ul>\r\nOut of all these, the utilization of microfiltration has been the highest, as it is being used in a number of industries for various processes.\r\n\r\n<strong>Rising Prevalence of Chronic Diseases Making Usage of Laboratory Filtration Essential in Asia-Pacific</strong>\r\n\r\n<strong> </strong>While the adoption of this technology has been high in developed countries in the North American and European regions for quite a while, its usage is expected to rise considerably in the Asia-Pacific (APAC) region in the immediate future. Other than the increasing number of people suffering from chronic diseases in the region, the enhancing healthcare infrastructure and growing production of pharmaceutical products are also contributing significantly to the increasing need for advanced filtration technologies.\r\n\r\nThe production of pharmaceutical products is particularly high in Japan. As per the data by the International Trade Administration, on the basis of the Ministry of Health, Labor and Welfare’s annual pharmaceutical production statistics, in 2015, the production of non-prescription and prescription pharmaceuticals accounted for $88 billion in 2015 in Japan. This is the major reason for the growing use of laboratory filtration products in the region.\r\n\r\n<strong>Laboratory Filtration Technologies also Important in Food &amp; Beverage Industry</strong>\r\n\r\n<strong> </strong>It has been quite clear that the major demand for laboratory filtration products is being created from the pharmaceuticals and water treatment industries; however, the food &amp; beverage industry is also among the key users of these processes and products. The membrane filtration technique is being used increasingly in the food &amp; beverage industry, due to its effective results in terms of clarification, purification, concentration, and fractionation. Such techniques help in improving the quality of food products and various kinds of beverages as well.\r\n\r\nHence, the companies in the domain are now focusing on developing more efficient laboratory filtration products, in order to provide customers with the best solutions. The rising adoption of laboratory filtration techniques in several industries, due to the general regard for people’s health as well as the strict regulatory environment and people’s growing awareness of how their food or medicines are prepared, is driving the need for advanced products.\r\n\r\n&nbsp;','Demand for Laboratory Filtration Technologies High Due to Rising Need for Quality Control in Industries','','inherit','closed','closed','','6844-revision-v1','','','2020-08-03 19:08:56','2020-08-03 19:08:56','',6844,'https://microbiozindia.com/uncategorized/6844-revision-v1/',0,'revision','',0),(6847,2,'2020-08-04 07:01:14','2020-08-04 07:01:14','Drug firm Wockhardt on Monday said it has entered into an agreement with the UK authorities to fill-finish COVID-19 vaccines, and will tackle manufacturing in its centre in North Wales.\r\n\r\nThe manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of the firm based in North Wales, Wockhardt said in a statement.\r\n\r\nAs per the details of the pact, the company has reserved manufacturing capacity to permit for supply of numerous vaccines to the UK government in its struggle against COVID-19, such as AZD1222, the vaccine co-invented from the University of Oxford and its spinout firm Vaccitech, and accredited by AstraZeneca, it included.\r\n\r\n\"We are proud to be collaborating with the UK authorities to create vaccines available and also the arrangement brings in a huge sense of purpose and pride, it upholds our continuing commitment to fight against such a pandemic of global human significance,\" Wockhardt Founder Chairman Habil Khorakiwala said.','Wockhardt accomplices with UK govt for COVID-19 vaccines','','publish','open','open','','wockhardt-accomplices-with-uk-govt-for-covid-19-vaccines','','','2020-08-04 07:01:14','2020-08-04 07:01:14','',0,'https://microbiozindia.com/?p=6847',0,'post','',0),(6848,2,'2020-08-04 07:01:14','2020-08-04 07:01:14','Drug firm Wockhardt on Monday said it has entered into an agreement with the UK authorities to fill-finish COVID-19 vaccines, and will tackle manufacturing in its centre in North Wales.\r\n\r\nThe manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of the firm based in North Wales, Wockhardt said in a statement.\r\n\r\nAs per the details of the pact, the company has reserved manufacturing capacity to permit for supply of numerous vaccines to the UK government in its struggle against COVID-19, such as AZD1222, the vaccine co-invented from the University of Oxford and its spinout firm Vaccitech, and accredited by AstraZeneca, it included.\r\n\r\n\"We are proud to be collaborating with the UK authorities to create vaccines available and also the arrangement brings in a huge sense of purpose and pride, it upholds our continuing commitment to fight against such a pandemic of global human significance,\" Wockhardt Founder Chairman Habil Khorakiwala said.','Wockhardt accomplices with UK govt for COVID-19 vaccines','','inherit','closed','closed','','6847-revision-v1','','','2020-08-04 07:01:14','2020-08-04 07:01:14','',6847,'https://microbiozindia.com/uncategorized/6847-revision-v1/',0,'revision','',0),(6849,2,'2020-08-04 15:16:00','2020-08-04 15:16:00','A World Health Organization team in China to research the roots of COVID-19 had\"extensive discussions\" and exchanges with scientists in Wuhan in which the outbreak was first detected, a spokesman said on Tuesday.\r\n\r\nThe talks included updates on animal health study, he said. China shut down a wildlife market in Wuhan in the start of the outbreak, a day after discovering some patients were sellers or dealers.\r\n\r\nThe WHO says the virus most likely came from bats and likely had another, intermediary animal\"host\".\r\n\r\nThe Trump government resisted the WHO of being China-centric and plans to leave the agency over its handling of this pandemic.\r\n\r\nThe three-week advance assignment comprising two experts in animal health and epidemiology was tasked with laying the groundwork for a wider team of international experts that will want to discover the way the virus which leads to COVID-19 jumped the species barrier from animals to people.\r\n\r\nLindmeier did not provide details about the time or makeup of the wider mission.\r\n\r\nTerms of reference to the broader mission have been generated together with Chinese authorities in draft form, \'\' he said, and weren\'t yet publicly available.\r\n\r\nThe team\'s composition is bound to be sensitive since any exception of US experts would be contentious. Another question will be the degree of access granted by Beijing.\r\n\r\nUS President Donald Trump and Secretary of State Mike Pompeo have stated the pathogen could have originated at a lab in Wuhan, although they\'ve presented no evidence for this and China has denied it. Researchers and US intelligence agencies have said it emerged in character.\r\n\r\nWHO emergencies chief Mike Ryan said on Monday that surprises were potential.\r\n\r\n\"The fact that that fire alarm was triggered (in Wuhan) does not necessarily indicate that is the point where the illness crossed from animals to individual,\" he explained.','WHO says China group talked with Wuhan researchers over infection sources','','publish','open','open','','who-says-china-group-talked-with-wuhan-researchers-over-infection-sources','','','2020-08-04 15:16:00','2020-08-04 15:16:00','',0,'https://microbiozindia.com/?p=6849',0,'post','',0),(6850,2,'2020-08-04 15:16:00','2020-08-04 15:16:00','A World Health Organization team in China to research the roots of COVID-19 had\"extensive discussions\" and exchanges with scientists in Wuhan in which the outbreak was first detected, a spokesman said on Tuesday.\r\n\r\nThe talks included updates on animal health study, he said. China shut down a wildlife market in Wuhan in the start of the outbreak, a day after discovering some patients were sellers or dealers.\r\n\r\nThe WHO says the virus most likely came from bats and likely had another, intermediary animal\"host\".\r\n\r\nThe Trump government resisted the WHO of being China-centric and plans to leave the agency over its handling of this pandemic.\r\n\r\nThe three-week advance assignment comprising two experts in animal health and epidemiology was tasked with laying the groundwork for a wider team of international experts that will want to discover the way the virus which leads to COVID-19 jumped the species barrier from animals to people.\r\n\r\nLindmeier did not provide details about the time or makeup of the wider mission.\r\n\r\nTerms of reference to the broader mission have been generated together with Chinese authorities in draft form, \'\' he said, and weren\'t yet publicly available.\r\n\r\nThe team\'s composition is bound to be sensitive since any exception of US experts would be contentious. Another question will be the degree of access granted by Beijing.\r\n\r\nUS President Donald Trump and Secretary of State Mike Pompeo have stated the pathogen could have originated at a lab in Wuhan, although they\'ve presented no evidence for this and China has denied it. Researchers and US intelligence agencies have said it emerged in character.\r\n\r\nWHO emergencies chief Mike Ryan said on Monday that surprises were potential.\r\n\r\n\"The fact that that fire alarm was triggered (in Wuhan) does not necessarily indicate that is the point where the illness crossed from animals to individual,\" he explained.','WHO says China group talked with Wuhan researchers over infection sources','','inherit','closed','closed','','6849-revision-v1','','','2020-08-04 15:16:00','2020-08-04 15:16:00','',6849,'https://microbiozindia.com/uncategorized/6849-revision-v1/',0,'revision','',0),(6851,2,'2020-08-04 15:16:06','2020-08-04 15:16:06','A World Health Organization team in China to research the roots of COVID-19 had\"extensive discussions\" and exchanges with scientists in Wuhan in which the outbreak was first detected, a spokesman said on Tuesday.\n\nThe talks included updates on animal health study, he said. China shut down a wildlife market in Wuhan in the start of the outbreak, a day after discovering some patients were sellers or dealers.\n\nThe WHO says the virus most likely came from bats and likely had another, intermediary animal\"host\".\n\nThe Trump government resisted the WHO of being China-centric and plans to leave the agency over its handling of this pandemic.\n\nThe three-week advance assignment comprising two experts in animal health and epidemiology was tasked with laying the groundwork for a wider team of international experts that will want to discover the way the virus which leads to COVID-19 jumped the species barrier from animals to people.\n\nLindmeier did not provide details about the time or makeup of the wider mission.\n\nTerms of reference to the broader mission have been generated together with Chinese authorities in draft form, \'\' he said, and weren\'t yet publicly available.\n\nThe team\'s composition is bound to be sensitive since any exception of US experts would be contentious. Another question will be the degree of access granted by Beijing.\n\nUS President Donald Trump and Secretary of State Mike Pompeo have stated the pathogen could have originated at a lab in Wuhan, although they\'ve presented no evidence for this and China has denied it. Researchers and US intelligence agencies have said it emerged in character.\n\nWHO emergencies chief Mike Ryan said on Monday that surprises were potential.\n\n\"The fact that that fire alarm was triggered (in Wuhan) does not necessarily indicate that is the point where the illness crossed from animals to individual,\" he explained.','WHO says China group talked with Wuhan researchers over infection sources','','inherit','closed','closed','','6849-autosave-v1','','','2020-08-04 15:16:06','2020-08-04 15:16:06','',6849,'https://microbiozindia.com/uncategorized/6849-autosave-v1/',0,'revision','',0),(6852,2,'2020-08-04 15:20:17','2020-08-04 15:20:17','Indian scientists have suggested a method to convert the plastic used in personal protective equipment (PPE) into renewable liquid fuels, an advance that could help mitigate the problem of dumped PPE, now being disposed of unprecedented levels because of this COVID-19 pandemic.\r\n\r\nAccording to the study, published in the journal Biofuels, billions of items of disposable PPE could be converted from its plastic state into biofuels using a high-temperature chemical process called pyrolysis.\r\n\r\nSapna Jain, lead author of the research in The University of Petroleum and Energy Research in Dehradun, Uttarakhand, noted in a statement that the transformation into biocrude -- a kind of artificial gas --\"does not just prevent the severe after-effects to humankind and the environment but also produce a source of energy\".\r\n\r\n\"Currently, the world is focusing to fight COVID-19, however, we could foresee the issues of economic crisis and ecological imbalance too. We have to prepare ourselves to meet the challenges that are forcefully imposed by the COVID-19 pandemic, so as to maintain sustainability,\" Jain said.\r\n\r\nShe explained that the disposal of PPE is a concern owing to its own material -- non-woven polypropylene (plastic) -- adding these are being designed for sole use followed by disposal.\r\n\r\nAccording to the researchers, when these plastic materials are discharged to the environment they end up in landfill or seas, as their natural degradation is difficult in ambient temperatures.\r\n\r\n\"They need decades to decompose. Recycling these polymers requires both physiological approaches and chemical methods,\" Jain said.\r\n\r\nShe stated the proposed strategy is a suggestive measure addressing the anticipated problem of disposal of PPE.\r\n\r\nIn the analysis, the scientists explored the current policies around the Entry of PPEs, their polypropylene content, and the feasibility of converting them into biofuel.\r\n\r\nThey focused on the structure of polypropylene, its suitability for PPE, why it poses an ecological threat, and methods of recycling the plastic material.\r\n\r\nAccording to their analysis, the scientists predict for the PPE waste to be converted to fuel using pyrolysis -- a chemical process for breaking down plastic at high temperature between 300 to 400 level Celsius for an hour without oxygen.\r\n\r\n\"Pyrolysis is the most widely used chemical method whose advantages include the ability to produce high quantities of bio-oil which is readily biodegradable,\" research co-author Bhawna Yadav Lamba said.\r\n\r\n\"There is obviously a need for other fuels or energy sources to meet our energy demands. The pyrolysis of plastics is one of the methods to mitigate our energy crisis,\" Lamba added.\r\n\r\nShe stated the challenges of PPE waste management and growing energy requirement could be addressed simultaneously by the production of liquid gas from PPE kits.\r\n\r\n\"The liquid fuel produced from plastics is fresh and contains fuel properties very similar to fossil fuels,\" Lamba said.','Disposed PPE could be transformed into biofuel, says Indian researchers','','publish','open','open','','disposed-ppe-could-be-transformed-into-biofuel-says-indian-researchers','','','2020-08-04 15:20:17','2020-08-04 15:20:17','',0,'https://microbiozindia.com/?p=6852',0,'post','',0),(6853,2,'2020-08-04 15:19:55','2020-08-04 15:19:55','','Covid-lockdown_38_20200507','','inherit','open','closed','','covid-lockdown_38_20200507','','','2020-08-04 15:19:55','2020-08-04 15:19:55','',6852,'https://microbiozindia.com/wp-content/uploads/2020/08/Covid-lockdown_38_20200507.jpg',0,'attachment','image/jpeg',0),(6854,2,'2020-08-04 15:20:17','2020-08-04 15:20:17','Indian scientists have suggested a method to convert the plastic used in personal protective equipment (PPE) into renewable liquid fuels, an advance that could help mitigate the problem of dumped PPE, now being disposed of unprecedented levels because of this COVID-19 pandemic.\r\n\r\nAccording to the study, published in the journal Biofuels, billions of items of disposable PPE could be converted from its plastic state into biofuels using a high-temperature chemical process called pyrolysis.\r\n\r\nSapna Jain, lead author of the research in The University of Petroleum and Energy Research in Dehradun, Uttarakhand, noted in a statement that the transformation into biocrude -- a kind of artificial gas --\"does not just prevent the severe after-effects to humankind and the environment but also produce a source of energy\".\r\n\r\n\"Currently, the world is focusing to fight COVID-19, however, we could foresee the issues of economic crisis and ecological imbalance too. We have to prepare ourselves to meet the challenges that are forcefully imposed by the COVID-19 pandemic, so as to maintain sustainability,\" Jain said.\r\n\r\nShe explained that the disposal of PPE is a concern owing to its own material -- non-woven polypropylene (plastic) -- adding these are being designed for sole use followed by disposal.\r\n\r\nAccording to the researchers, when these plastic materials are discharged to the environment they end up in landfill or seas, as their natural degradation is difficult in ambient temperatures.\r\n\r\n\"They need decades to decompose. Recycling these polymers requires both physiological approaches and chemical methods,\" Jain said.\r\n\r\nShe stated the proposed strategy is a suggestive measure addressing the anticipated problem of disposal of PPE.\r\n\r\nIn the analysis, the scientists explored the current policies around the Entry of PPEs, their polypropylene content, and the feasibility of converting them into biofuel.\r\n\r\nThey focused on the structure of polypropylene, its suitability for PPE, why it poses an ecological threat, and methods of recycling the plastic material.\r\n\r\nAccording to their analysis, the scientists predict for the PPE waste to be converted to fuel using pyrolysis -- a chemical process for breaking down plastic at high temperature between 300 to 400 level Celsius for an hour without oxygen.\r\n\r\n\"Pyrolysis is the most widely used chemical method whose advantages include the ability to produce high quantities of bio-oil which is readily biodegradable,\" research co-author Bhawna Yadav Lamba said.\r\n\r\n\"There is obviously a need for other fuels or energy sources to meet our energy demands. The pyrolysis of plastics is one of the methods to mitigate our energy crisis,\" Lamba added.\r\n\r\nShe stated the challenges of PPE waste management and growing energy requirement could be addressed simultaneously by the production of liquid gas from PPE kits.\r\n\r\n\"The liquid fuel produced from plastics is fresh and contains fuel properties very similar to fossil fuels,\" Lamba said.','Disposed PPE could be transformed into biofuel, says Indian researchers','','inherit','closed','closed','','6852-revision-v1','','','2020-08-04 15:20:17','2020-08-04 15:20:17','',6852,'https://microbiozindia.com/uncategorized/6852-revision-v1/',0,'revision','',0),(6855,2,'2020-08-04 15:22:48','2020-08-04 15:22:48','Researchers in the US have found a potential therapeutic treatment for SARS-CoV-2, the virus which causes COVID-19, along with other coronaviruses. Pathogenic coronaviruses are a major threat to international public health, as shown by the SARS-CoV, MERS-CoV, along with the recently emerged SARS-CoV-2.\r\n\r\nAll these coronavirus 3C-like proteases, called 3CLpro, are strong therapeutic targets because they play vital roles in coronavirus replication, \'\' the researchers stated.\r\n\r\n\"Vaccine developments and treatments are the biggest targets in COVID-19 research, and therapy is actually key,\" explained Kyeong-Ok Chang, a professor at Kansas State University in the US.\r\n\r\n\"This paper clarifies protease inhibitors targeting coronavirus 3CLpro, that can be a well-known therapeutic goal,\" Chang explained.\r\n\r\nThese findings imply that this series of chemicals should be researched further as a potential therapeutic for human coronavirus infection, they said.','US researchers discover conceivable COVID-19 treatment','','publish','open','open','','us-researchers-discover-conceivable-covid-19-treatment','','','2020-08-04 15:22:48','2020-08-04 15:22:48','',0,'https://microbiozindia.com/?p=6855',0,'post','',0),(6856,2,'2020-08-04 15:22:48','2020-08-04 15:22:48','Researchers in the US have found a potential therapeutic treatment for SARS-CoV-2, the virus which causes COVID-19, along with other coronaviruses. Pathogenic coronaviruses are a major threat to international public health, as shown by the SARS-CoV, MERS-CoV, along with the recently emerged SARS-CoV-2.\r\n\r\nAll these coronavirus 3C-like proteases, called 3CLpro, are strong therapeutic targets because they play vital roles in coronavirus replication, \'\' the researchers stated.\r\n\r\n\"Vaccine developments and treatments are the biggest targets in COVID-19 research, and therapy is actually key,\" explained Kyeong-Ok Chang, a professor at Kansas State University in the US.\r\n\r\n\"This paper clarifies protease inhibitors targeting coronavirus 3CLpro, that can be a well-known therapeutic goal,\" Chang explained.\r\n\r\nThese findings imply that this series of chemicals should be researched further as a potential therapeutic for human coronavirus infection, they said.','US researchers discover conceivable COVID-19 treatment','','inherit','closed','closed','','6855-revision-v1','','','2020-08-04 15:22:48','2020-08-04 15:22:48','',6855,'https://microbiozindia.com/uncategorized/6855-revision-v1/',0,'revision','',0),(6857,2,'2020-08-05 08:17:24','2020-08-05 08:17:24','Drug major Lupin on Wednesday announced the launch of its Favipiravir medication under the brand name\'Covihalt\' for its treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per pill in India.\r\n\r\nFavipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing.\r\n\r\nIts Covihalt dose potency has been developed keeping in mind advantage of administration, it said, adding that the drug is available as 200 mg pills in the form of a strip of 10 tablets, and priced at Rs 49 per pill.\r\n\r\nLupin President - India Region Formulations (IRF) Rajeev Sibal said the company believes that it can leverage its expertise in handling widespread community diseases like tuberculosis to proactively reach sufferers across India and ensure access to Covihalt through its strong distribution system and field force.\r\n\r\nOn August 4, Sun Pharmaceutical Industries had established Favipiravir below the brand name\"FluGuard\" for its treatment of mild to moderate cases of COVID-19, at Rs 35 per tablet in India.','Lupin dispatches COVID-19 medication Favipiravir in India at Rs 49 for each tablet','','publish','open','open','','lupin-dispatches-covid-19-medication-favipiravir-in-india-at-rs-49-for-each-tablet','','','2020-08-05 08:17:24','2020-08-05 08:17:24','',0,'https://microbiozindia.com/?p=6857',0,'post','',0),(6858,2,'2020-08-05 08:17:24','2020-08-05 08:17:24','Drug major Lupin on Wednesday announced the launch of its Favipiravir medication under the brand name\'Covihalt\' for its treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per pill in India.\r\n\r\nFavipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing.\r\n\r\nIts Covihalt dose potency has been developed keeping in mind advantage of administration, it said, adding that the drug is available as 200 mg pills in the form of a strip of 10 tablets, and priced at Rs 49 per pill.\r\n\r\nLupin President - India Region Formulations (IRF) Rajeev Sibal said the company believes that it can leverage its expertise in handling widespread community diseases like tuberculosis to proactively reach sufferers across India and ensure access to Covihalt through its strong distribution system and field force.\r\n\r\nOn August 4, Sun Pharmaceutical Industries had established Favipiravir below the brand name\"FluGuard\" for its treatment of mild to moderate cases of COVID-19, at Rs 35 per tablet in India.','Lupin dispatches COVID-19 medication Favipiravir in India at Rs 49 for each tablet','','inherit','closed','closed','','6857-revision-v1','','','2020-08-05 08:17:24','2020-08-05 08:17:24','',6857,'https://microbiozindia.com/uncategorized/6857-revision-v1/',0,'revision','',0),(6859,2,'2020-08-05 08:21:13','2020-08-05 08:21:13','The body fight it off, also identifies some parts of the novel coronavirus, according to a study whose findings might explain why some individuals have milder COVID-19 cases than others.\r\n\r\nThe research, published in the journal Science, noted that the immune system\'s memory T cells keep track of the viruses they\'ve seen previously, giving the cells a headstart in recognising and fighting repeat invaders.\r\n\r\nOn the other hand, the scientists, such as those from La Jolla Institute (LJI) in the US, cautioned it is too soon to say whether such preexisting immune cell memory impacts COVID-19 clinical outcomes.\r\n\r\n\"We have proven that, in certain people, pre-existing T cell memory against ordinary cold coronaviruses may cross-recognise SARS-CoV-2, down to the specific molecular structures,\" said Daniela Weiskopf, a co-author of this study from LJI.\r\n\r\n\"This might help explain why some people today reveal milder symptoms of disease while some get severely sick,\" Weiskopf said.\r\n\r\nAlessandro Sette, another co-author of the study from LJI, noted that the reactivity of the immune system could translate to various degrees of protection.\r\n\r\n\"Using a strong T cell response, or a much better T cell response may provide you the chance to mount a much quicker and more powerful response,\" Sette said.\r\n\r\nAn earlier study by Sette and his team had shown that 40 to 60 percent of people who were never exposed to the novel coronavirus SARS-CoV-2 had T cells that reacted to the virus.\r\n\r\nAccording to the study, the immune system in these individuals recognised fragments of the virus it\'d never seen before -- a finding that was reported among people in the Netherlands, Germany, Singapore, and the UK.\r\n\r\nIn the present research, the scientists analyzed samples collected from study participants who had never been subjected to SARS-CoV-2.\r\n\r\nThey defined the specific areas of the virus that are liable for the cross-reactive T cell response.\r\n\r\nTheir analysis showed that unexposed individuals can produce a range of memory cells that are equally reactive against SARS-CoV-2, and four types of ordinary cold coronaviruses.\r\n\r\nBased on the finding, the scientists stated battling a cold chilly coronavirus could teach the T cell compartment to recognise several parts of SARS-CoV-2 also.\r\n\r\nThey believe this method provides evidence for the hypothesis that common cold viruses can, in fact, induce cross-reactive T cell memory from SARS-CoV-2.\r\n\r\n\"We knew there was pre-existing reactivity, and this study provides quite powerful direct molecular evidence that memory T cells can\'see\' sequences which are extremely similar between common cold coronaviruses and SARS-CoV-2,\" Sette said.\r\n\r\nThe scientists found that while many cross-reactive T cells targeted at the SARS-CoV-2\'s spike protein -- the region of the virus which recognises and binds to human cells -- pre-existing immune was also directed to additional SARS-CoV-2 proteins.\r\n\r\nSette noted that the finding is applicable because most vaccine candidates target the spike protein.\r\n\r\nThe findings, according to the researchers, suggest the hypothesis that inclusion of further SARS-CoV-2 targets might enhance the capability to make the most of the cross reactivity, and could further enhance vaccine potency.','Normal cold contamination may prepare the body to perceive novel coronavirus: Study','','publish','open','open','','normal-cold-contamination-may-prepare-the-body-to-perceive-novel-coronavirus-study','','','2020-08-05 08:21:13','2020-08-05 08:21:13','',0,'https://microbiozindia.com/?p=6859',0,'post','',0),(6860,2,'2020-08-05 08:21:13','2020-08-05 08:21:13','The body fight it off, also identifies some parts of the novel coronavirus, according to a study whose findings might explain why some individuals have milder COVID-19 cases than others.\r\n\r\nThe research, published in the journal Science, noted that the immune system\'s memory T cells keep track of the viruses they\'ve seen previously, giving the cells a headstart in recognising and fighting repeat invaders.\r\n\r\nOn the other hand, the scientists, such as those from La Jolla Institute (LJI) in the US, cautioned it is too soon to say whether such preexisting immune cell memory impacts COVID-19 clinical outcomes.\r\n\r\n\"We have proven that, in certain people, pre-existing T cell memory against ordinary cold coronaviruses may cross-recognise SARS-CoV-2, down to the specific molecular structures,\" said Daniela Weiskopf, a co-author of this study from LJI.\r\n\r\n\"This might help explain why some people today reveal milder symptoms of disease while some get severely sick,\" Weiskopf said.\r\n\r\nAlessandro Sette, another co-author of the study from LJI, noted that the reactivity of the immune system could translate to various degrees of protection.\r\n\r\n\"Using a strong T cell response, or a much better T cell response may provide you the chance to mount a much quicker and more powerful response,\" Sette said.\r\n\r\nAn earlier study by Sette and his team had shown that 40 to 60 percent of people who were never exposed to the novel coronavirus SARS-CoV-2 had T cells that reacted to the virus.\r\n\r\nAccording to the study, the immune system in these individuals recognised fragments of the virus it\'d never seen before -- a finding that was reported among people in the Netherlands, Germany, Singapore, and the UK.\r\n\r\nIn the present research, the scientists analyzed samples collected from study participants who had never been subjected to SARS-CoV-2.\r\n\r\nThey defined the specific areas of the virus that are liable for the cross-reactive T cell response.\r\n\r\nTheir analysis showed that unexposed individuals can produce a range of memory cells that are equally reactive against SARS-CoV-2, and four types of ordinary cold coronaviruses.\r\n\r\nBased on the finding, the scientists stated battling a cold chilly coronavirus could teach the T cell compartment to recognise several parts of SARS-CoV-2 also.\r\n\r\nThey believe this method provides evidence for the hypothesis that common cold viruses can, in fact, induce cross-reactive T cell memory from SARS-CoV-2.\r\n\r\n\"We knew there was pre-existing reactivity, and this study provides quite powerful direct molecular evidence that memory T cells can\'see\' sequences which are extremely similar between common cold coronaviruses and SARS-CoV-2,\" Sette said.\r\n\r\nThe scientists found that while many cross-reactive T cells targeted at the SARS-CoV-2\'s spike protein -- the region of the virus which recognises and binds to human cells -- pre-existing immune was also directed to additional SARS-CoV-2 proteins.\r\n\r\nSette noted that the finding is applicable because most vaccine candidates target the spike protein.\r\n\r\nThe findings, according to the researchers, suggest the hypothesis that inclusion of further SARS-CoV-2 targets might enhance the capability to make the most of the cross reactivity, and could further enhance vaccine potency.','Normal cold contamination may prepare the body to perceive novel coronavirus: Study','','inherit','closed','closed','','6859-revision-v1','','','2020-08-05 08:21:13','2020-08-05 08:21:13','',6859,'https://microbiozindia.com/uncategorized/6859-revision-v1/',0,'revision','',0),(6861,2,'2020-08-05 08:53:34','2020-08-05 08:53:34','With over 700,000 people losing the battle to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial resistance (AMR)</a></span> every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, a<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">ntibacterial resistance (ABR)</a> </span>is currently posing serious challenges to medical science. Facets driving AMR include self-medication, access to antibiotics without prescription, and lack of knowledge to use antibiotics. Additionally, perceived patient demand, fear of losing patients, diagnostic uncertainty, a heavy patient load resulting in less time to counsel against antibiotics and lack of continuing medical education cause rise in the AMR cases.\r\n\r\n<img class=\"size-medium wp-image-6880 alignright\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/ASS-177x300.png\" alt=\"\" width=\"177\" height=\"300\" />\r\n\r\nIndia has some of the highest AMR rates among bacteria that commonly cause infections in the community and healthcare facilities like resistance to  broad-spectrum antibiotics fluoroquinolones and third-generation cephalosporin, resistance to carbapenems among various gram-negative bacteria was extremely high. With the increasing use of colistin for treatment of carbapenem-resistant gram-negative bacterial infections, colistin resistance among gram-negative bacteria has emerged in India.\r\n\r\n<strong>Tailor-made Antimicrobial Susceptibility Testing (AST) to address unique needs</strong>\r\n\r\nTo effectively combat antimicrobial resistance, there is a need for faster and more reliable <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial susceptibility testing (AST) devices.</a></span> Obtaining an accurate minimum inhibitory concentration (MIC) ensures the correct dosage of an antimicrobial or antibiotic to limit resistance, which is vital in expanding patient treatment options and improving patient outcomes.\r\n\r\nA true MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the organism is against a drug, and the exact point at which the isolate becomes resistant. However, some AST systems calculate the MIC value by extrapolating growth curves and applying dedicated algorithms.\r\n\r\nThermo Fisher Scientific, offers the widest range of testing options to combat antimicrobial resistance, reducing healthcare-associated infections. The <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">Thermo Scientific</a></span> Sensititre system generates MIC results based on the actual growth of the organism. An MIC based on direct measurement reveals whether a bacterial isolate is susceptible to a drug, evaluates the susceptibility of the organism and the exact point at which the isolate becomes resistant. With over 300 antimicrobials available in extended dilution ranges, the Sensititre System allows to consolidate susceptibility tests while meeting FDA, CLSI and EUCAST breakpoint requirements.\r\n\r\nIncreased infections caused by drug-resistant organisms result in increased mortality and prolonged duration of hospitalization, causing a significant financial burden to the affected person and healthcare systems, as well as hinder goals of sustainable development. There is a need to promote antibiotic de-escalation and antibiotic stewardship with a multidisciplinary approach to develop products that are adapted to meet the unique needs of individual lab space, budget requirements, and help microbiology labs provide results that reduce uncertainty for critical care decisions.','The need to combat antimicrobial resistance','','publish','open','open','','the-need-to-combat-antimicrobial-resistance','','','2020-08-05 09:33:13','2020-08-05 09:33:13','',0,'https://microbiozindia.com/?p=6861',0,'post','',0),(6862,2,'2020-08-05 08:36:47','2020-08-05 08:36:47','','ANTIMICROBIALRESISTANCE','','inherit','open','closed','','antimicrobialresistance','','','2020-08-05 08:36:47','2020-08-05 08:36:47','',6861,'https://microbiozindia.com/wp-content/uploads/2020/08/ANTIMICROBIALRESISTANCE.jpg',0,'attachment','image/jpeg',0),(6863,2,'2020-08-05 08:51:30','2020-08-05 08:51:30','','THERMO','','inherit','open','closed','','thermo','','','2020-08-05 08:51:30','2020-08-05 08:51:30','',6861,'https://microbiozindia.com/wp-content/uploads/2020/08/THERMO.png',0,'attachment','image/png',0),(6864,2,'2020-08-05 08:53:34','2020-08-05 08:53:34','With over 700,000 people losing the battle to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial resistance (AMR)</a></span> every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, a<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">ntibacterial resistance (ABR)</a> </span>is currently posing serious challenges to medical science. Facets driving AMR include self-medication, access to antibiotics without prescription, and lack of knowledge to use antibiotics. Additionally, perceived patient demand, fear of losing patients, diagnostic uncertainty, a heavy patient load resulting in less time to counsel against antibiotics and lack of continuing medical education cause rise in the AMR cases.\r\n\r\nIndia has some of the highest AMR rates among bacteria that commonly cause infections in the community and healthcare facilities like resistance to  broad-spectrum antibiotics fluoroquinolones and third-generation cephalosporin, resistance to carbapenems among various gram-negative bacteria was extremely high. With the increasing use of colistin for treatment of carbapenem-resistant gram-negative bacterial infections, colistin resistance among gram-negative bacteria has emerged in India.\r\n\r\n<strong>Tailor-made Antimicrobial Susceptibility Testing (AST) to address unique needs</strong>\r\n\r\n[caption id=\"attachment_6863\" align=\"alignright\" width=\"199\"]<img class=\"wp-image-6863 size-medium\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/THERMO-199x300.png\" alt=\"\" width=\"199\" height=\"300\" /> <span style=\"font-size: 8pt;\"><strong>Amit Chopra Managing</strong> <strong>Director ,</strong>India and Middle East <strong>Thermo Fisher Scientific </strong></span>[/caption]\r\n\r\nTo effectively combat antimicrobial resistance, there is a need for faster and more reliable <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial susceptibility testing (AST) devices.</a></span> Obtaining an accurate minimum inhibitory concentration (MIC) ensures the correct dosage of an antimicrobial or antibiotic to limit resistance, which is vital in expanding patient treatment options and improving patient outcomes.\r\n\r\nA true MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the organism is against a drug, and the exact point at which the isolate becomes resistant. However, some AST systems calculate the MIC value by extrapolating growth curves and applying dedicated algorithms.\r\n\r\nThermo Fisher Scientific, offers the widest range of testing options to combat antimicrobial resistance, reducing healthcare-associated infections. The <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">Thermo Scientific</a></span> Sensititre system generates MIC results based on the actual growth of the organism. An MIC based on direct measurement reveals whether a bacterial isolate is susceptible to a drug, evaluates the susceptibility of the organism and the exact point at which the isolate becomes resistant. With over 300 antimicrobials available in extended dilution ranges, the Sensititre System allows to consolidate susceptibility tests while meeting FDA, CLSI and EUCAST breakpoint requirements.\r\n\r\nIncreased infections caused by drug-resistant organisms result in increased mortality and prolonged duration of hospitalization, causing a significant financial burden to the affected person and healthcare systems, as well as hinder goals of sustainable development. There is a need to promote antibiotic de-escalation and antibiotic stewardship with a multidisciplinary approach to develop products that are adapted to meet the unique needs of individual lab space, budget requirements, and help microbiology labs provide results that reduce uncertainty for critical care decisions.','The need to combat antimicrobial resistance','','inherit','closed','closed','','6861-revision-v1','','','2020-08-05 08:53:34','2020-08-05 08:53:34','',6861,'https://microbiozindia.com/uncategorized/6861-revision-v1/',0,'revision','',0),(6865,2,'2020-08-05 08:54:35','2020-08-05 08:54:35','With over 700,000 people losing the battle to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial resistance (AMR)</a></span> every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, a<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">ntibacterial resistance (ABR)</a> </span>is currently posing serious challenges to medical science. Facets driving AMR include self-medication, access to antibiotics without prescription, and lack of knowledge to use antibiotics. Additionally, perceived patient demand, fear of losing patients, diagnostic uncertainty, a heavy patient load resulting in less time to counsel against antibiotics and lack of continuing medical education cause rise in the AMR cases.\r\n\r\nIndia has some of the highest AMR rates among bacteria that commonly cause infections in the community and healthcare facilities like resistance to  broad-spectrum antibiotics fluoroquinolones and third-generation cephalosporin, resistance to carbapenems among various gram-negative bacteria was extremely high. With the increasing use of colistin for treatment of carbapenem-resistant gram-negative bacterial infections, colistin resistance among gram-negative bacteria has emerged in India.\r\n\r\n<strong>Tailor-made Antimicrobial Susceptibility Testing (AST) to address unique needs</strong>\r\n\r\n[caption id=\"attachment_6863\" align=\"alignleft\" width=\"199\"]<img class=\"wp-image-6863 size-medium\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/THERMO-199x300.png\" alt=\"\" width=\"199\" height=\"300\" /> <span style=\"font-size: 8pt;\"><strong>Amit Chopra Managing</strong> <strong>Director ,</strong>India and Middle East <strong>Thermo Fisher Scientific </strong></span>[/caption]\r\n\r\nTo effectively combat antimicrobial resistance, there is a need for faster and more reliable <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial susceptibility testing (AST) devices.</a></span> Obtaining an accurate minimum inhibitory concentration (MIC) ensures the correct dosage of an antimicrobial or antibiotic to limit resistance, which is vital in expanding patient treatment options and improving patient outcomes.\r\n\r\nA true MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the organism is against a drug, and the exact point at which the isolate becomes resistant. However, some AST systems calculate the MIC value by extrapolating growth curves and applying dedicated algorithms.\r\n\r\nThermo Fisher Scientific, offers the widest range of testing options to combat antimicrobial resistance, reducing healthcare-associated infections. The <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">Thermo Scientific</a></span> Sensititre system generates MIC results based on the actual growth of the organism. An MIC based on direct measurement reveals whether a bacterial isolate is susceptible to a drug, evaluates the susceptibility of the organism and the exact point at which the isolate becomes resistant. With over 300 antimicrobials available in extended dilution ranges, the Sensititre System allows to consolidate susceptibility tests while meeting FDA, CLSI and EUCAST breakpoint requirements.\r\n\r\nIncreased infections caused by drug-resistant organisms result in increased mortality and prolonged duration of hospitalization, causing a significant financial burden to the affected person and healthcare systems, as well as hinder goals of sustainable development. There is a need to promote antibiotic de-escalation and antibiotic stewardship with a multidisciplinary approach to develop products that are adapted to meet the unique needs of individual lab space, budget requirements, and help microbiology labs provide results that reduce uncertainty for critical care decisions.','The need to combat antimicrobial resistance','','inherit','closed','closed','','6861-revision-v1','','','2020-08-05 08:54:35','2020-08-05 08:54:35','',6861,'https://microbiozindia.com/uncategorized/6861-revision-v1/',0,'revision','',0),(6866,2,'2020-08-05 08:55:16','2020-08-05 08:55:16','With over 700,000 people losing the battle to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial resistance (AMR)</a></span> every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, a<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">ntibacterial resistance (ABR)</a> </span>is currently posing serious challenges to medical science. Facets driving AMR include self-medication, access to antibiotics without prescription, and lack of knowledge to use antibiotics. Additionally, perceived patient demand, fear of losing patients, diagnostic uncertainty, a heavy patient load resulting in less time to counsel against antibiotics and lack of continuing medical education cause rise in the AMR cases.\r\n\r\nIndia has some of the highest AMR rates among bacteria that commonly cause infections in the community and healthcare facilities like resistance to  broad-spectrum antibiotics fluoroquinolones and third-generation cephalosporin, resistance to carbapenems among various gram-negative bacteria was extremely high. With the increasing use of colistin for treatment of carbapenem-resistant gram-negative bacterial infections, colistin resistance among gram-negative bacteria has emerged in India.\r\n\r\n<strong>Tailor-made Antimicrobial Susceptibility Testing (AST) to address unique needs</strong>\r\n\r\n[caption id=\"attachment_6863\" align=\"alignnone\" width=\"199\"]<img class=\"wp-image-6863 size-medium\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/THERMO-199x300.png\" alt=\"\" width=\"199\" height=\"300\" /> <span style=\"font-size: 8pt;\"><strong>Amit Chopra Managing</strong> <strong>Director ,</strong>India and Middle East <strong>Thermo Fisher Scientific </strong></span>[/caption]\r\n\r\nTo effectively combat antimicrobial resistance, there is a need for faster and more reliable <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial susceptibility testing (AST) devices.</a></span> Obtaining an accurate minimum inhibitory concentration (MIC) ensures the correct dosage of an antimicrobial or antibiotic to limit resistance, which is vital in expanding patient treatment options and improving patient outcomes.\r\n\r\nA true MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the organism is against a drug, and the exact point at which the isolate becomes resistant. However, some AST systems calculate the MIC value by extrapolating growth curves and applying dedicated algorithms.\r\n\r\nThermo Fisher Scientific, offers the widest range of testing options to combat antimicrobial resistance, reducing healthcare-associated infections. The <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">Thermo Scientific</a></span> Sensititre system generates MIC results based on the actual growth of the organism. An MIC based on direct measurement reveals whether a bacterial isolate is susceptible to a drug, evaluates the susceptibility of the organism and the exact point at which the isolate becomes resistant. With over 300 antimicrobials available in extended dilution ranges, the Sensititre System allows to consolidate susceptibility tests while meeting FDA, CLSI and EUCAST breakpoint requirements.\r\n\r\nIncreased infections caused by drug-resistant organisms result in increased mortality and prolonged duration of hospitalization, causing a significant financial burden to the affected person and healthcare systems, as well as hinder goals of sustainable development. There is a need to promote antibiotic de-escalation and antibiotic stewardship with a multidisciplinary approach to develop products that are adapted to meet the unique needs of individual lab space, budget requirements, and help microbiology labs provide results that reduce uncertainty for critical care decisions.','The need to combat antimicrobial resistance','','inherit','closed','closed','','6861-revision-v1','','','2020-08-05 08:55:16','2020-08-05 08:55:16','',6861,'https://microbiozindia.com/uncategorized/6861-revision-v1/',0,'revision','',0),(6867,2,'2020-08-05 09:28:13','2020-08-05 09:28:13','With over 700,000 people losing the battle to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial resistance (AMR)</a></span> every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, a<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">ntibacterial resistance (ABR)</a> </span>is currently posing serious challenges to medical science. Facets driving AMR include self-medication, access to antibiotics without prescription, and lack of knowledge to use antibiotics. Additionally, perceived patient demand, fear of losing patients, diagnostic uncertainty, a heavy patient load resulting in less time to counsel against antibiotics and lack of continuing medical education cause rise in the AMR cases.\n\n<img class=\"alignleft wp-image-6863\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/THERMO-199x300.png\" alt=\"&lt;strong&gt;Amit Chopra Managing Director&lt;/strong&gt; ,India and Middle East Thermo Fisher Scientific\" width=\"145\" height=\"219\" data-wp-editing=\"1\" />\n\nIndia has some of the highest AMR rates among bacteria that commonly cause infections in the community and healthcare facilities like resistance to  broad-spectrum antibiotics fluoroquinolones and third-generation cephalosporin, resistance to carbapenems among various gram-negative bacteria was extremely high. With the increasing use of colistin for treatment of carbapenem-resistant gram-negative bacterial infections, colistin resistance among gram-negative bacteria has emerged in India.\n\n<strong>Tailor-made Antimicrobial Susceptibility Testing (AST) to address unique needs</strong>\n\nTo effectively combat antimicrobial resistance, there is a need for faster and more reliable <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial susceptibility testing (AST) devices.</a></span> Obtaining an accurate minimum inhibitory concentration (MIC) ensures the correct dosage of an antimicrobial or antibiotic to limit resistance, which is vital in expanding patient treatment options and improving patient outcomes.\n\nA true MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the organism is against a drug, and the exact point at which the isolate becomes resistant. However, some AST systems calculate the MIC value by extrapolating growth curves and applying dedicated algorithms.\n\nThermo Fisher Scientific, offers the widest range of testing options to combat antimicrobial resistance, reducing healthcare-associated infections. The <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">Thermo Scientific</a></span> Sensititre system generates MIC results based on the actual growth of the organism. An MIC based on direct measurement reveals whether a bacterial isolate is susceptible to a drug, evaluates the susceptibility of the organism and the exact point at which the isolate becomes resistant. With over 300 antimicrobials available in extended dilution ranges, the Sensititre System allows to consolidate susceptibility tests while meeting FDA, CLSI and EUCAST breakpoint requirements.\n\nIncreased infections caused by drug-resistant organisms result in increased mortality and prolonged duration of hospitalization, causing a significant financial burden to the affected person and healthcare systems, as well as hinder goals of sustainable development. There is a need to promote antibiotic de-escalation and antibiotic stewardship with a multidisciplinary approach to develop products that are adapted to meet the unique needs of individual lab space, budget requirements, and help microbiology labs provide results that reduce uncertainty for critical care decisions.','The need to combat antimicrobial resistance','','inherit','closed','closed','','6861-autosave-v1','','','2020-08-05 09:28:13','2020-08-05 09:28:13','',6861,'https://microbiozindia.com/uncategorized/6861-autosave-v1/',0,'revision','',0),(6868,2,'2020-08-05 08:58:00','2020-08-05 08:58:00','[caption id=\"attachment_6863\" align=\"alignright\" width=\"126\"]<img class=\"wp-image-6863\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/THERMO-199x300.png\" alt=\"\" width=\"126\" height=\"190\" /> Amit Chopra Managing Director ,India and Middle East Thermo Fisher Scientific[/caption]\r\n\r\nWith over 700,000 people losing the battle to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial resistance (AMR)</a></span> every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, a<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">ntibacterial resistance (ABR)</a> </span>is currently posing serious challenges to medical science. Facets driving AMR include self-medication, access to antibiotics without prescription, and lack of knowledge to use antibiotics. Additionally, perceived patient demand, fear of losing patients, diagnostic uncertainty, a heavy patient load resulting in less time to counsel against antibiotics and lack of continuing medical education cause rise in the AMR cases.\r\n\r\nIndia has some of the highest AMR rates among bacteria that commonly cause infections in the community and healthcare facilities like resistance to  broad-spectrum antibiotics fluoroquinolones and third-generation cephalosporin, resistance to carbapenems among various gram-negative bacteria was extremely high. With the increasing use of colistin for treatment of carbapenem-resistant gram-negative bacterial infections, colistin resistance among gram-negative bacteria has emerged in India.\r\n\r\n<strong>Tailor-made Antimicrobial Susceptibility Testing (AST) to address unique needs</strong>\r\n\r\nTo effectively combat antimicrobial resistance, there is a need for faster and more reliable <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial susceptibility testing (AST) devices.</a></span> Obtaining an accurate minimum inhibitory concentration (MIC) ensures the correct dosage of an antimicrobial or antibiotic to limit resistance, which is vital in expanding patient treatment options and improving patient outcomes.\r\n\r\nA true MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the organism is against a drug, and the exact point at which the isolate becomes resistant. However, some AST systems calculate the MIC value by extrapolating growth curves and applying dedicated algorithms.\r\n\r\nThermo Fisher Scientific, offers the widest range of testing options to combat antimicrobial resistance, reducing healthcare-associated infections. The <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">Thermo Scientific</a></span> Sensititre system generates MIC results based on the actual growth of the organism. An MIC based on direct measurement reveals whether a bacterial isolate is susceptible to a drug, evaluates the susceptibility of the organism and the exact point at which the isolate becomes resistant. With over 300 antimicrobials available in extended dilution ranges, the Sensititre System allows to consolidate susceptibility tests while meeting FDA, CLSI and EUCAST breakpoint requirements.\r\n\r\nIncreased infections caused by drug-resistant organisms result in increased mortality and prolonged duration of hospitalization, causing a significant financial burden to the affected person and healthcare systems, as well as hinder goals of sustainable development. There is a need to promote antibiotic de-escalation and antibiotic stewardship with a multidisciplinary approach to develop products that are adapted to meet the unique needs of individual lab space, budget requirements, and help microbiology labs provide results that reduce uncertainty for critical care decisions.','The need to combat antimicrobial resistance','','inherit','closed','closed','','6861-revision-v1','','','2020-08-05 08:58:00','2020-08-05 08:58:00','',6861,'https://microbiozindia.com/uncategorized/6861-revision-v1/',0,'revision','',0),(6869,2,'2020-08-05 09:16:07','2020-08-05 09:16:07','With over 700,000 people losing the battle to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial resistance (AMR)</a></span> every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, a<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">ntibacterial resistance (ABR)</a> </span>is currently posing serious challenges to medical science. Facets driving AMR include self-medication, access to antibiotics without prescription, and lack of knowledge to use antibiotics. Additionally, perceived patient demand, fear of losing patients, diagnostic uncertainty, a heavy patient load resulting in less time to counsel against antibiotics and lack of continuing medical education cause rise in the AMR cases.\r\n\r\n<img class=\"alignnone size-medium wp-image-6863\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/THERMO-199x300.png\" alt=\"\" width=\"199\" height=\"300\" />India has some of the highest AMR rates among bacteria that commonly cause infections in the community and healthcare facilities like resistance to  broad-spectrum antibiotics fluoroquinolones and third-generation cephalosporin, resistance to carbapenems among various gram-negative bacteria was extremely high. With the increasing use of colistin for treatment of carbapenem-resistant gram-negative bacterial infections, colistin resistance among gram-negative bacteria has emerged in India.\r\n\r\n<strong>Tailor-made Antimicrobial Susceptibility Testing (AST) to address unique needs</strong>\r\n\r\nTo effectively combat antimicrobial resistance, there is a need for faster and more reliable <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial susceptibility testing (AST) devices.</a></span> Obtaining an accurate minimum inhibitory concentration (MIC) ensures the correct dosage of an antimicrobial or antibiotic to limit resistance, which is vital in expanding patient treatment options and improving patient outcomes.\r\n\r\nA true MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the organism is against a drug, and the exact point at which the isolate becomes resistant. However, some AST systems calculate the MIC value by extrapolating growth curves and applying dedicated algorithms.\r\n\r\nThermo Fisher Scientific, offers the widest range of testing options to combat antimicrobial resistance, reducing healthcare-associated infections. The <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">Thermo Scientific</a></span> Sensititre system generates MIC results based on the actual growth of the organism. An MIC based on direct measurement reveals whether a bacterial isolate is susceptible to a drug, evaluates the susceptibility of the organism and the exact point at which the isolate becomes resistant. With over 300 antimicrobials available in extended dilution ranges, the Sensititre System allows to consolidate susceptibility tests while meeting FDA, CLSI and EUCAST breakpoint requirements.\r\n\r\nIncreased infections caused by drug-resistant organisms result in increased mortality and prolonged duration of hospitalization, causing a significant financial burden to the affected person and healthcare systems, as well as hinder goals of sustainable development. There is a need to promote antibiotic de-escalation and antibiotic stewardship with a multidisciplinary approach to develop products that are adapted to meet the unique needs of individual lab space, budget requirements, and help microbiology labs provide results that reduce uncertainty for critical care decisions.','The need to combat antimicrobial resistance','','inherit','closed','closed','','6861-revision-v1','','','2020-08-05 09:16:07','2020-08-05 09:16:07','',6861,'https://microbiozindia.com/uncategorized/6861-revision-v1/',0,'revision','',0),(6870,2,'2020-08-05 09:16:45','2020-08-05 09:16:45','With over 700,000 people losing the battle to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial resistance (AMR)</a></span> every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, a<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">ntibacterial resistance (ABR)</a> </span>is currently posing serious challenges to medical science. Facets driving AMR include self-medication, access to antibiotics without prescription, and lack of knowledge to use antibiotics. Additionally, perceived patient demand, fear of losing patients, diagnostic uncertainty, a heavy patient load resulting in less time to counsel against antibiotics and lack of continuing medical education cause rise in the AMR cases.\r\n\r\n[caption id=\"attachment_6863\" align=\"alignright\" width=\"199\"]<img class=\"wp-image-6863 size-medium\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/THERMO-199x300.png\" alt=\"\" width=\"199\" height=\"300\" /> Amit Chopra Managing Director ,India and Middle East Thermo Fisher Scientific[/caption]\r\n\r\nIndia has some of the highest AMR rates among bacteria that commonly cause infections in the community and healthcare facilities like resistance to  broad-spectrum antibiotics fluoroquinolones and third-generation cephalosporin, resistance to carbapenems among various gram-negative bacteria was extremely high. With the increasing use of colistin for treatment of carbapenem-resistant gram-negative bacterial infections, colistin resistance among gram-negative bacteria has emerged in India.\r\n\r\n<strong>Tailor-made Antimicrobial Susceptibility Testing (AST) to address unique needs</strong>\r\n\r\nTo effectively combat antimicrobial resistance, there is a need for faster and more reliable <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial susceptibility testing (AST) devices.</a></span> Obtaining an accurate minimum inhibitory concentration (MIC) ensures the correct dosage of an antimicrobial or antibiotic to limit resistance, which is vital in expanding patient treatment options and improving patient outcomes.\r\n\r\nA true MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the organism is against a drug, and the exact point at which the isolate becomes resistant. However, some AST systems calculate the MIC value by extrapolating growth curves and applying dedicated algorithms.\r\n\r\nThermo Fisher Scientific, offers the widest range of testing options to combat antimicrobial resistance, reducing healthcare-associated infections. The <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">Thermo Scientific</a></span> Sensititre system generates MIC results based on the actual growth of the organism. An MIC based on direct measurement reveals whether a bacterial isolate is susceptible to a drug, evaluates the susceptibility of the organism and the exact point at which the isolate becomes resistant. With over 300 antimicrobials available in extended dilution ranges, the Sensititre System allows to consolidate susceptibility tests while meeting FDA, CLSI and EUCAST breakpoint requirements.\r\n\r\nIncreased infections caused by drug-resistant organisms result in increased mortality and prolonged duration of hospitalization, causing a significant financial burden to the affected person and healthcare systems, as well as hinder goals of sustainable development. There is a need to promote antibiotic de-escalation and antibiotic stewardship with a multidisciplinary approach to develop products that are adapted to meet the unique needs of individual lab space, budget requirements, and help microbiology labs provide results that reduce uncertainty for critical care decisions.','The need to combat antimicrobial resistance','','inherit','closed','closed','','6861-revision-v1','','','2020-08-05 09:16:45','2020-08-05 09:16:45','',6861,'https://microbiozindia.com/uncategorized/6861-revision-v1/',0,'revision','',0),(6871,2,'2020-08-05 09:17:30','2020-08-05 09:17:30','With over 700,000 people losing the battle to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial resistance (AMR)</a></span> every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, a<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">ntibacterial resistance (ABR)</a> </span>is currently posing serious challenges to medical science. Facets driving AMR include self-medication, access to antibiotics without prescription, and lack of knowledge to use antibiotics. Additionally, perceived patient demand, fear of losing patients, diagnostic uncertainty, a heavy patient load resulting in less time to counsel against antibiotics and lack of continuing medical education cause rise in the AMR cases.\r\n\r\n[caption id=\"attachment_6863\" align=\"alignright\" width=\"145\"]<img class=\"wp-image-6863 \" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/THERMO-199x300.png\" alt=\"\" width=\"145\" height=\"219\" /> Amit Chopra Managing Director ,India and Middle East Thermo Fisher Scientific[/caption]\r\n\r\nIndia has some of the highest AMR rates among bacteria that commonly cause infections in the community and healthcare facilities like resistance to  broad-spectrum antibiotics fluoroquinolones and third-generation cephalosporin, resistance to carbapenems among various gram-negative bacteria was extremely high. With the increasing use of colistin for treatment of carbapenem-resistant gram-negative bacterial infections, colistin resistance among gram-negative bacteria has emerged in India.\r\n\r\n<strong>Tailor-made Antimicrobial Susceptibility Testing (AST) to address unique needs</strong>\r\n\r\nTo effectively combat antimicrobial resistance, there is a need for faster and more reliable <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial susceptibility testing (AST) devices.</a></span> Obtaining an accurate minimum inhibitory concentration (MIC) ensures the correct dosage of an antimicrobial or antibiotic to limit resistance, which is vital in expanding patient treatment options and improving patient outcomes.\r\n\r\nA true MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the organism is against a drug, and the exact point at which the isolate becomes resistant. However, some AST systems calculate the MIC value by extrapolating growth curves and applying dedicated algorithms.\r\n\r\nThermo Fisher Scientific, offers the widest range of testing options to combat antimicrobial resistance, reducing healthcare-associated infections. The <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">Thermo Scientific</a></span> Sensititre system generates MIC results based on the actual growth of the organism. An MIC based on direct measurement reveals whether a bacterial isolate is susceptible to a drug, evaluates the susceptibility of the organism and the exact point at which the isolate becomes resistant. With over 300 antimicrobials available in extended dilution ranges, the Sensititre System allows to consolidate susceptibility tests while meeting FDA, CLSI and EUCAST breakpoint requirements.\r\n\r\nIncreased infections caused by drug-resistant organisms result in increased mortality and prolonged duration of hospitalization, causing a significant financial burden to the affected person and healthcare systems, as well as hinder goals of sustainable development. There is a need to promote antibiotic de-escalation and antibiotic stewardship with a multidisciplinary approach to develop products that are adapted to meet the unique needs of individual lab space, budget requirements, and help microbiology labs provide results that reduce uncertainty for critical care decisions.','The need to combat antimicrobial resistance','','inherit','closed','closed','','6861-revision-v1','','','2020-08-05 09:17:30','2020-08-05 09:17:30','',6861,'https://microbiozindia.com/uncategorized/6861-revision-v1/',0,'revision','',0),(6872,2,'2020-08-05 09:17:54','2020-08-05 09:17:54','With over 700,000 people losing the battle to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial resistance (AMR)</a></span> every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, a<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">ntibacterial resistance (ABR)</a> </span>is currently posing serious challenges to medical science. Facets driving AMR include self-medication, access to antibiotics without prescription, and lack of knowledge to use antibiotics. Additionally, perceived patient demand, fear of losing patients, diagnostic uncertainty, a heavy patient load resulting in less time to counsel against antibiotics and lack of continuing medical education cause rise in the AMR cases.\r\n\r\n[caption id=\"attachment_6863\" align=\"alignright\" width=\"145\"]<img class=\"wp-image-6863 \" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/THERMO-199x300.png\" alt=\"\" width=\"145\" height=\"219\" /> <strong>Amit Chopra Managing Director</strong> ,India and Middle East Thermo Fisher Scientific[/caption]\r\n\r\nIndia has some of the highest AMR rates among bacteria that commonly cause infections in the community and healthcare facilities like resistance to  broad-spectrum antibiotics fluoroquinolones and third-generation cephalosporin, resistance to carbapenems among various gram-negative bacteria was extremely high. With the increasing use of colistin for treatment of carbapenem-resistant gram-negative bacterial infections, colistin resistance among gram-negative bacteria has emerged in India.\r\n\r\n<strong>Tailor-made Antimicrobial Susceptibility Testing (AST) to address unique needs</strong>\r\n\r\nTo effectively combat antimicrobial resistance, there is a need for faster and more reliable <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial susceptibility testing (AST) devices.</a></span> Obtaining an accurate minimum inhibitory concentration (MIC) ensures the correct dosage of an antimicrobial or antibiotic to limit resistance, which is vital in expanding patient treatment options and improving patient outcomes.\r\n\r\nA true MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the organism is against a drug, and the exact point at which the isolate becomes resistant. However, some AST systems calculate the MIC value by extrapolating growth curves and applying dedicated algorithms.\r\n\r\nThermo Fisher Scientific, offers the widest range of testing options to combat antimicrobial resistance, reducing healthcare-associated infections. The <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">Thermo Scientific</a></span> Sensititre system generates MIC results based on the actual growth of the organism. An MIC based on direct measurement reveals whether a bacterial isolate is susceptible to a drug, evaluates the susceptibility of the organism and the exact point at which the isolate becomes resistant. With over 300 antimicrobials available in extended dilution ranges, the Sensititre System allows to consolidate susceptibility tests while meeting FDA, CLSI and EUCAST breakpoint requirements.\r\n\r\nIncreased infections caused by drug-resistant organisms result in increased mortality and prolonged duration of hospitalization, causing a significant financial burden to the affected person and healthcare systems, as well as hinder goals of sustainable development. There is a need to promote antibiotic de-escalation and antibiotic stewardship with a multidisciplinary approach to develop products that are adapted to meet the unique needs of individual lab space, budget requirements, and help microbiology labs provide results that reduce uncertainty for critical care decisions.','The need to combat antimicrobial resistance','','inherit','closed','closed','','6861-revision-v1','','','2020-08-05 09:17:54','2020-08-05 09:17:54','',6861,'https://microbiozindia.com/uncategorized/6861-revision-v1/',0,'revision','',0),(6873,2,'2020-08-05 09:24:03','2020-08-05 09:24:03','Thermo Fisher Scientific, the world leader in serving science, announced the launch of a new website for its chemicals business offerings. This website will serve as a dedicated platform towards an extensive range of Laboratory and Production chemicals. The new website will bring all major chemical brands from Thermo Fisher Scientific including Alfa Aesar, Acros Organics, Fisher Chemicals, Qualigens, Fisher Bioregaents and Maybridge under one umbrella.\r\n\r\nQualigens, the locally manufactured brand in India, will have its first online presence through this website. This will enable customers to explore the chemicals portfolio and have a consistent digital experience.\r\n\r\nThermo Fisher invites customers from various segments including educational institutions, research and development, pharmaceuticals, diagnostics, food &amp; beverage and environmental sector, to get acquainted with the capabilities that the new website will offer. The website is equipped with customized chemical search capabilities like structure search and element search and options to view availability and pricing for specific brands. The website has also been designed to cater to distinct purchase lifecycles of buyers and customers, who can also explore on-demand seminars and technical literature.\r\n<blockquote>\"At Thermo Fisher, we offer a robust portfolio of chemicals that are used from bench to production spanning across industries. I am delighted that this website is getting launched at a time when our customers need us more than ever digitally. Customers can now access our chemical brands and experience our entire portfolio offering, all in one place. With this new platform we are now one step ahead in serving our customers better.” said <strong>Amit Chopra</strong>, managing director, India and Middle East, Thermo Fisher Scientific\r\n\r\n“The global coronavirus outbreak is a powerful reminder of the importance of our mission- to enable our customers to make the world healthier, cleaner and safer. We are profoundly aware of our obligation towards our customers as essential partners and these initiatives reinforce our commitment to serve our customers”, said <strong>Amit</strong>.</blockquote>\r\nThe website is exclusive to India. Login to the new website to explore our solutions at <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.in/chemicals/en/home.html\">https://www.thermofisher.in/chemicals/en/home.html </a></span>\r\n\r\n<strong>About Thermo Fisher Scientific </strong>\r\n\r\nThermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.thermofisher.com\">www.thermofisher.com</a></span>','Thermo Fisher Scientific Launches Exclusive Website for its Chemical Business Offerings in India','','publish','open','open','','thermo-fisher-scientific-launches-exclusive-website-for-its-chemical-business-offerings-in-india','','','2020-08-05 09:24:45','2020-08-05 09:24:45','',0,'https://microbiozindia.com/?p=6873',0,'post','',0),(6874,2,'2020-08-05 09:20:20','2020-08-05 09:20:20','','Teaser 2_launched mailer','','inherit','open','closed','','teaser-2_launched-mailer','','','2020-08-05 09:20:20','2020-08-05 09:20:20','',6873,'https://microbiozindia.com/wp-content/uploads/2020/08/Teaser-2_launched-mailer.png',0,'attachment','image/png',0),(6875,2,'2020-08-05 09:24:03','2020-08-05 09:24:03','Thermo Fisher Scientific, the world leader in serving science, announced the launch of a new website for its chemicals business offerings. This website will serve as a dedicated platform towards an extensive range of Laboratory and Production chemicals. The new website will bring all major chemical brands from Thermo Fisher Scientific including Alfa Aesar, Acros Organics, Fisher Chemicals, Qualigens, Fisher Bioregaents and Maybridge under one umbrella.\r\n\r\nQualigens, the locally manufactured brand in India, will have its first online presence through this website. This will enable customers to explore the chemicals portfolio and have a consistent digital experience.\r\n\r\nThermo Fisher invites customers from various segments including educational institutions, research and development, pharmaceuticals, diagnostics, food &amp; beverage and environmental sector, to get acquainted with the capabilities that the new website will offer. The website is equipped with customized chemical search capabilities like structure search and element search and options to view availability and pricing for specific brands. The website has also been designed to cater to distinct purchase lifecycles of buyers and customers, who can also explore on-demand seminars and technical literature.\r\n<blockquote>\"At Thermo Fisher, we offer a robust portfolio of chemicals that are used from bench to production spanning across industries. I am delighted that this website is getting launched at a time when our customers need us more than ever digitally. Customers can now access our chemical brands and experience our entire portfolio offering, all in one place. With this new platform we are now one step ahead in serving our customers better.” said <strong>Amit Chopra</strong>, managing director, India and Middle East, Thermo Fisher Scientific\r\n\r\n“The global coronavirus outbreak is a powerful reminder of the importance of our mission- to enable our customers to make the world healthier, cleaner and safer. We are profoundly aware of our obligation towards our customers as essential partners and these initiatives reinforce our commitment to serve our customers”, said <strong>Amit</strong>.</blockquote>\r\nThe website is exclusive to India. Login to the new website to explore our solutions at <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.in/chemicals/en/home.html\">https://www.thermofisher.in/chemicals/en/home.html </a></span>\r\n\r\n<strong>About Thermo Fisher Scientific </strong>\r\n\r\nThermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.thermofisher.com\">www.thermofisher.com</a></span>','Thermo Fisher Scientific Launches Exclusive Website for its Chemical Business Offerings in India','','inherit','closed','closed','','6873-revision-v1','','','2020-08-05 09:24:03','2020-08-05 09:24:03','',6873,'https://microbiozindia.com/uncategorized/6873-revision-v1/',0,'revision','',0),(6876,2,'2020-08-05 09:26:13','2020-08-05 09:26:13','With over 700,000 people losing the battle to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial resistance (AMR)</a></span> every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, a<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">ntibacterial resistance (ABR)</a> </span>is currently posing serious challenges to medical science. Facets driving AMR include self-medication, access to antibiotics without prescription, and lack of knowledge to use antibiotics. Additionally, perceived patient demand, fear of losing patients, diagnostic uncertainty, a heavy patient load resulting in less time to counsel against antibiotics and lack of continuing medical education cause rise in the AMR cases.\r\n\r\n[caption id=\"attachment_6863\" align=\"alignleft\" width=\"145\"]<img class=\"wp-image-6863\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/THERMO-199x300.png\" alt=\"\" width=\"145\" height=\"219\" /> <strong>Amit Chopra Managing Director</strong> ,India and Middle East Thermo Fisher Scientific[/caption]\r\n\r\nIndia has some of the highest AMR rates among bacteria that commonly cause infections in the community and healthcare facilities like resistance to  broad-spectrum antibiotics fluoroquinolones and third-generation cephalosporin, resistance to carbapenems among various gram-negative bacteria was extremely high. With the increasing use of colistin for treatment of carbapenem-resistant gram-negative bacterial infections, colistin resistance among gram-negative bacteria has emerged in India.\r\n\r\n<strong>Tailor-made Antimicrobial Susceptibility Testing (AST) to address unique needs</strong>\r\n\r\nTo effectively combat antimicrobial resistance, there is a need for faster and more reliable <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial susceptibility testing (AST) devices.</a></span> Obtaining an accurate minimum inhibitory concentration (MIC) ensures the correct dosage of an antimicrobial or antibiotic to limit resistance, which is vital in expanding patient treatment options and improving patient outcomes.\r\n\r\nA true MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the organism is against a drug, and the exact point at which the isolate becomes resistant. However, some AST systems calculate the MIC value by extrapolating growth curves and applying dedicated algorithms.\r\n\r\nThermo Fisher Scientific, offers the widest range of testing options to combat antimicrobial resistance, reducing healthcare-associated infections. The <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">Thermo Scientific</a></span> Sensititre system generates MIC results based on the actual growth of the organism. An MIC based on direct measurement reveals whether a bacterial isolate is susceptible to a drug, evaluates the susceptibility of the organism and the exact point at which the isolate becomes resistant. With over 300 antimicrobials available in extended dilution ranges, the Sensititre System allows to consolidate susceptibility tests while meeting FDA, CLSI and EUCAST breakpoint requirements.\r\n\r\nIncreased infections caused by drug-resistant organisms result in increased mortality and prolonged duration of hospitalization, causing a significant financial burden to the affected person and healthcare systems, as well as hinder goals of sustainable development. There is a need to promote antibiotic de-escalation and antibiotic stewardship with a multidisciplinary approach to develop products that are adapted to meet the unique needs of individual lab space, budget requirements, and help microbiology labs provide results that reduce uncertainty for critical care decisions.','The need to combat antimicrobial resistance','','inherit','closed','closed','','6861-revision-v1','','','2020-08-05 09:26:13','2020-08-05 09:26:13','',6861,'https://microbiozindia.com/uncategorized/6861-revision-v1/',0,'revision','',0),(6877,2,'2020-08-05 09:27:10','2020-08-05 09:27:10','With over 700,000 people losing the battle to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial resistance (AMR)</a></span> every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, a<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">ntibacterial resistance (ABR)</a> </span>is currently posing serious challenges to medical science. Facets driving AMR include self-medication, access to antibiotics without prescription, and lack of knowledge to use antibiotics. Additionally, perceived patient demand, fear of losing patients, diagnostic uncertainty, a heavy patient load resulting in less time to counsel against antibiotics and lack of continuing medical education cause rise in the AMR cases.\r\n\r\n<img class=\"alignleft wp-image-6863\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/THERMO-199x300.png\" alt=\"&lt;strong&gt;Amit Chopra Managing Director&lt;/strong&gt; ,India and Middle East Thermo Fisher Scientific\" width=\"145\" height=\"219\" />\r\n\r\nIndia has some of the highest AMR rates among bacteria that commonly cause infections in the community and healthcare facilities like resistance to  broad-spectrum antibiotics fluoroquinolones and third-generation cephalosporin, resistance to carbapenems among various gram-negative bacteria was extremely high. With the increasing use of colistin for treatment of carbapenem-resistant gram-negative bacterial infections, colistin resistance among gram-negative bacteria has emerged in India.\r\n\r\n<strong>Tailor-made Antimicrobial Susceptibility Testing (AST) to address unique needs</strong>\r\n\r\nTo effectively combat antimicrobial resistance, there is a need for faster and more reliable <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial susceptibility testing (AST) devices.</a></span> Obtaining an accurate minimum inhibitory concentration (MIC) ensures the correct dosage of an antimicrobial or antibiotic to limit resistance, which is vital in expanding patient treatment options and improving patient outcomes.\r\n\r\nA true MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the organism is against a drug, and the exact point at which the isolate becomes resistant. However, some AST systems calculate the MIC value by extrapolating growth curves and applying dedicated algorithms.\r\n\r\nThermo Fisher Scientific, offers the widest range of testing options to combat antimicrobial resistance, reducing healthcare-associated infections. The <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">Thermo Scientific</a></span> Sensititre system generates MIC results based on the actual growth of the organism. An MIC based on direct measurement reveals whether a bacterial isolate is susceptible to a drug, evaluates the susceptibility of the organism and the exact point at which the isolate becomes resistant. With over 300 antimicrobials available in extended dilution ranges, the Sensititre System allows to consolidate susceptibility tests while meeting FDA, CLSI and EUCAST breakpoint requirements.\r\n\r\nIncreased infections caused by drug-resistant organisms result in increased mortality and prolonged duration of hospitalization, causing a significant financial burden to the affected person and healthcare systems, as well as hinder goals of sustainable development. There is a need to promote antibiotic de-escalation and antibiotic stewardship with a multidisciplinary approach to develop products that are adapted to meet the unique needs of individual lab space, budget requirements, and help microbiology labs provide results that reduce uncertainty for critical care decisions.','The need to combat antimicrobial resistance','','inherit','closed','closed','','6861-revision-v1','','','2020-08-05 09:27:10','2020-08-05 09:27:10','',6861,'https://microbiozindia.com/uncategorized/6861-revision-v1/',0,'revision','',0),(6878,2,'2020-08-05 09:29:11','2020-08-05 09:29:11','With over 700,000 people losing the battle to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial resistance (AMR)</a></span> every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, a<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">ntibacterial resistance (ABR)</a> </span>is currently posing serious challenges to medical science. Facets driving AMR include self-medication, access to antibiotics without prescription, and lack of knowledge to use antibiotics. Additionally, perceived patient demand, fear of losing patients, diagnostic uncertainty, a heavy patient load resulting in less time to counsel against antibiotics and lack of continuing medical education cause rise in the AMR cases.\r\n\r\n[caption id=\"attachment_6863\" align=\"alignnone\" width=\"145\"]<img class=\"wp-image-6863\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/THERMO-199x300.png\" alt=\"\" width=\"145\" height=\"219\" /> <strong>Amit Chopra Managing Director</strong> ,India and Middle East Thermo Fisher Scientific[/caption]\r\n\r\nIndia has some of the highest AMR rates among bacteria that commonly cause infections in the community and healthcare facilities like resistance to  broad-spectrum antibiotics fluoroquinolones and third-generation cephalosporin, resistance to carbapenems among various gram-negative bacteria was extremely high. With the increasing use of colistin for treatment of carbapenem-resistant gram-negative bacterial infections, colistin resistance among gram-negative bacteria has emerged in India.\r\n\r\n<strong>Tailor-made Antimicrobial Susceptibility Testing (AST) to address unique needs</strong>\r\n\r\nTo effectively combat antimicrobial resistance, there is a need for faster and more reliable <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial susceptibility testing (AST) devices.</a></span> Obtaining an accurate minimum inhibitory concentration (MIC) ensures the correct dosage of an antimicrobial or antibiotic to limit resistance, which is vital in expanding patient treatment options and improving patient outcomes.\r\n\r\nA true MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the organism is against a drug, and the exact point at which the isolate becomes resistant. However, some AST systems calculate the MIC value by extrapolating growth curves and applying dedicated algorithms.\r\n\r\nThermo Fisher Scientific, offers the widest range of testing options to combat antimicrobial resistance, reducing healthcare-associated infections. The <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">Thermo Scientific</a></span> Sensititre system generates MIC results based on the actual growth of the organism. An MIC based on direct measurement reveals whether a bacterial isolate is susceptible to a drug, evaluates the susceptibility of the organism and the exact point at which the isolate becomes resistant. With over 300 antimicrobials available in extended dilution ranges, the Sensititre System allows to consolidate susceptibility tests while meeting FDA, CLSI and EUCAST breakpoint requirements.\r\n\r\nIncreased infections caused by drug-resistant organisms result in increased mortality and prolonged duration of hospitalization, causing a significant financial burden to the affected person and healthcare systems, as well as hinder goals of sustainable development. There is a need to promote antibiotic de-escalation and antibiotic stewardship with a multidisciplinary approach to develop products that are adapted to meet the unique needs of individual lab space, budget requirements, and help microbiology labs provide results that reduce uncertainty for critical care decisions.','The need to combat antimicrobial resistance','','inherit','closed','closed','','6861-revision-v1','','','2020-08-05 09:29:11','2020-08-05 09:29:11','',6861,'https://microbiozindia.com/uncategorized/6861-revision-v1/',0,'revision','',0),(6879,2,'2020-08-05 09:29:37','2020-08-05 09:29:37','With over 700,000 people losing the battle to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial resistance (AMR)</a></span> every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, a<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">ntibacterial resistance (ABR)</a> </span>is currently posing serious challenges to medical science. Facets driving AMR include self-medication, access to antibiotics without prescription, and lack of knowledge to use antibiotics. Additionally, perceived patient demand, fear of losing patients, diagnostic uncertainty, a heavy patient load resulting in less time to counsel against antibiotics and lack of continuing medical education cause rise in the AMR cases.\r\n\r\n[caption id=\"attachment_6863\" align=\"alignright\" width=\"145\"]<img class=\"wp-image-6863\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/THERMO-199x300.png\" alt=\"\" width=\"145\" height=\"219\" /> <strong>Amit Chopra Managing Director</strong> ,India and Middle East Thermo Fisher Scientific[/caption]\r\n\r\nIndia has some of the highest AMR rates among bacteria that commonly cause infections in the community and healthcare facilities like resistance to  broad-spectrum antibiotics fluoroquinolones and third-generation cephalosporin, resistance to carbapenems among various gram-negative bacteria was extremely high. With the increasing use of colistin for treatment of carbapenem-resistant gram-negative bacterial infections, colistin resistance among gram-negative bacteria has emerged in India.\r\n\r\n<strong>Tailor-made Antimicrobial Susceptibility Testing (AST) to address unique needs</strong>\r\n\r\nTo effectively combat antimicrobial resistance, there is a need for faster and more reliable <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial susceptibility testing (AST) devices.</a></span> Obtaining an accurate minimum inhibitory concentration (MIC) ensures the correct dosage of an antimicrobial or antibiotic to limit resistance, which is vital in expanding patient treatment options and improving patient outcomes.\r\n\r\nA true MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the organism is against a drug, and the exact point at which the isolate becomes resistant. However, some AST systems calculate the MIC value by extrapolating growth curves and applying dedicated algorithms.\r\n\r\nThermo Fisher Scientific, offers the widest range of testing options to combat antimicrobial resistance, reducing healthcare-associated infections. The <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">Thermo Scientific</a></span> Sensititre system generates MIC results based on the actual growth of the organism. An MIC based on direct measurement reveals whether a bacterial isolate is susceptible to a drug, evaluates the susceptibility of the organism and the exact point at which the isolate becomes resistant. With over 300 antimicrobials available in extended dilution ranges, the Sensititre System allows to consolidate susceptibility tests while meeting FDA, CLSI and EUCAST breakpoint requirements.\r\n\r\nIncreased infections caused by drug-resistant organisms result in increased mortality and prolonged duration of hospitalization, causing a significant financial burden to the affected person and healthcare systems, as well as hinder goals of sustainable development. There is a need to promote antibiotic de-escalation and antibiotic stewardship with a multidisciplinary approach to develop products that are adapted to meet the unique needs of individual lab space, budget requirements, and help microbiology labs provide results that reduce uncertainty for critical care decisions.','The need to combat antimicrobial resistance','','inherit','closed','closed','','6861-revision-v1','','','2020-08-05 09:29:37','2020-08-05 09:29:37','',6861,'https://microbiozindia.com/uncategorized/6861-revision-v1/',0,'revision','',0),(6880,2,'2020-08-05 09:32:21','2020-08-05 09:32:21','','ASS','','inherit','open','closed','','ass','','','2020-08-05 09:32:21','2020-08-05 09:32:21','',6861,'https://microbiozindia.com/wp-content/uploads/2020/08/ASS.png',0,'attachment','image/png',0),(6881,2,'2020-08-05 09:32:41','2020-08-05 09:32:41','With over 700,000 people losing the battle to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial resistance (AMR)</a></span> every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, a<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">ntibacterial resistance (ABR)</a> </span>is currently posing serious challenges to medical science. Facets driving AMR include self-medication, access to antibiotics without prescription, and lack of knowledge to use antibiotics. Additionally, perceived patient demand, fear of losing patients, diagnostic uncertainty, a heavy patient load resulting in less time to counsel against antibiotics and lack of continuing medical education cause rise in the AMR cases.\r\n\r\n<img class=\"size-medium wp-image-6880 alignright\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/ASS-177x300.png\" alt=\"\" width=\"177\" height=\"300\" />India has some of the highest AMR rates among bacteria that commonly cause infections in the community and healthcare facilities like resistance to  broad-spectrum antibiotics fluoroquinolones and third-generation cephalosporin, resistance to carbapenems among various gram-negative bacteria was extremely high. With the increasing use of colistin for treatment of carbapenem-resistant gram-negative bacterial infections, colistin resistance among gram-negative bacteria has emerged in India.\r\n\r\n<strong>Tailor-made Antimicrobial Susceptibility Testing (AST) to address unique needs</strong>\r\n\r\nTo effectively combat antimicrobial resistance, there is a need for faster and more reliable <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial susceptibility testing (AST) devices.</a></span> Obtaining an accurate minimum inhibitory concentration (MIC) ensures the correct dosage of an antimicrobial or antibiotic to limit resistance, which is vital in expanding patient treatment options and improving patient outcomes.\r\n\r\nA true MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the organism is against a drug, and the exact point at which the isolate becomes resistant. However, some AST systems calculate the MIC value by extrapolating growth curves and applying dedicated algorithms.\r\n\r\nThermo Fisher Scientific, offers the widest range of testing options to combat antimicrobial resistance, reducing healthcare-associated infections. The <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">Thermo Scientific</a></span> Sensititre system generates MIC results based on the actual growth of the organism. An MIC based on direct measurement reveals whether a bacterial isolate is susceptible to a drug, evaluates the susceptibility of the organism and the exact point at which the isolate becomes resistant. With over 300 antimicrobials available in extended dilution ranges, the Sensititre System allows to consolidate susceptibility tests while meeting FDA, CLSI and EUCAST breakpoint requirements.\r\n\r\nIncreased infections caused by drug-resistant organisms result in increased mortality and prolonged duration of hospitalization, causing a significant financial burden to the affected person and healthcare systems, as well as hinder goals of sustainable development. There is a need to promote antibiotic de-escalation and antibiotic stewardship with a multidisciplinary approach to develop products that are adapted to meet the unique needs of individual lab space, budget requirements, and help microbiology labs provide results that reduce uncertainty for critical care decisions.','The need to combat antimicrobial resistance','','inherit','closed','closed','','6861-revision-v1','','','2020-08-05 09:32:41','2020-08-05 09:32:41','',6861,'https://microbiozindia.com/uncategorized/6861-revision-v1/',0,'revision','',0),(6882,2,'2020-08-05 09:33:13','2020-08-05 09:33:13','With over 700,000 people losing the battle to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial resistance (AMR)</a></span> every year and an additional 10 million projected mortality by 2050, antimicrobial resistance (AMR) is globally, one of the major causes of public health concern. Amongst the several types of AMR, a<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">ntibacterial resistance (ABR)</a> </span>is currently posing serious challenges to medical science. Facets driving AMR include self-medication, access to antibiotics without prescription, and lack of knowledge to use antibiotics. Additionally, perceived patient demand, fear of losing patients, diagnostic uncertainty, a heavy patient load resulting in less time to counsel against antibiotics and lack of continuing medical education cause rise in the AMR cases.\r\n\r\n<img class=\"size-medium wp-image-6880 alignright\" src=\"https://microbiozindia.com/wp-content/uploads/2020/08/ASS-177x300.png\" alt=\"\" width=\"177\" height=\"300\" />\r\n\r\nIndia has some of the highest AMR rates among bacteria that commonly cause infections in the community and healthcare facilities like resistance to  broad-spectrum antibiotics fluoroquinolones and third-generation cephalosporin, resistance to carbapenems among various gram-negative bacteria was extremely high. With the increasing use of colistin for treatment of carbapenem-resistant gram-negative bacterial infections, colistin resistance among gram-negative bacteria has emerged in India.\r\n\r\n<strong>Tailor-made Antimicrobial Susceptibility Testing (AST) to address unique needs</strong>\r\n\r\nTo effectively combat antimicrobial resistance, there is a need for faster and more reliable <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">antimicrobial susceptibility testing (AST) devices.</a></span> Obtaining an accurate minimum inhibitory concentration (MIC) ensures the correct dosage of an antimicrobial or antibiotic to limit resistance, which is vital in expanding patient treatment options and improving patient outcomes.\r\n\r\nA true MIC reveals the difference between whether a bacterial isolate is susceptible, how susceptible the organism is against a drug, and the exact point at which the isolate becomes resistant. However, some AST systems calculate the MIC value by extrapolating growth curves and applying dedicated algorithms.\r\n\r\nThermo Fisher Scientific, offers the widest range of testing options to combat antimicrobial resistance, reducing healthcare-associated infections. The <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.thermofisher.com/in/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html\">Thermo Scientific</a></span> Sensititre system generates MIC results based on the actual growth of the organism. An MIC based on direct measurement reveals whether a bacterial isolate is susceptible to a drug, evaluates the susceptibility of the organism and the exact point at which the isolate becomes resistant. With over 300 antimicrobials available in extended dilution ranges, the Sensititre System allows to consolidate susceptibility tests while meeting FDA, CLSI and EUCAST breakpoint requirements.\r\n\r\nIncreased infections caused by drug-resistant organisms result in increased mortality and prolonged duration of hospitalization, causing a significant financial burden to the affected person and healthcare systems, as well as hinder goals of sustainable development. There is a need to promote antibiotic de-escalation and antibiotic stewardship with a multidisciplinary approach to develop products that are adapted to meet the unique needs of individual lab space, budget requirements, and help microbiology labs provide results that reduce uncertainty for critical care decisions.','The need to combat antimicrobial resistance','','inherit','closed','closed','','6861-revision-v1','','','2020-08-05 09:33:13','2020-08-05 09:33:13','',6861,'https://microbiozindia.com/uncategorized/6861-revision-v1/',0,'revision','',0),(6883,2,'2020-08-05 11:18:32','2020-08-05 11:18:32','Medication major Cipla is working together with government agencies to come up with a treatment for COVID-19 while ramping up the production of various life saving essential drugs, according to company\'s chairman YK Hamied.\r\n\r\nSharing information with business\'s shareholders at the drug firm\'s annual report for 2019-20, Hamied said the company is at the forefront in the battle against COVID-19.\r\n\r\n\"Cipla is cooperating with the Council of Scientific &amp; Industrial Research (CSIR), Indian Institute of Chemical Technology (IICT), Indian Council of Medical Research (ICMR) and the Ministry of Public Health to develop medications for the treatment of COVID-19,\" Hamied said.\r\n\r\nMeanwhile, the business is offering drugs, which have revealed potency in treating COVID-19, in partnership with its international partners,\'\' he explained.\r\n\r\n\"Through our strategic global partnerships, we offer a wide range of drugs within our portfolio giving aid and improving treatment access. This is particularly true with all the vital life-saving drugs like remdesivir, favipiravir and tocilizumab,\" Hamied said.\r\n\r\nThe Mumbai-based medication firm can also be ramping up production of essential drugs required in the struggle against the pandemic,\'\' he added.\r\n\r\nBesides scaling up production of medicines that reveal potency against the virus -- Lopinavir + Ritonavir, Hydroxychloroquine and Azithromycin, the company is also ramping up production of medication for chronic diseases like asthma, COPD, among others, Hamied said.\r\n\r\nHe added that the pandemic has also served as a wake up call spotlighting the need for each and every state to be self-reliant.\r\n\r\nCipla\'s doctrine of self-reliance and self-sufficiency and its pledge to provide universal access to cheap medicines is becoming even more crucial now, Hamied noted.\r\n\r\nThe foundation and backbone of the pharma business is the accessibility and production of active pharmaceutical ingredients called APIs, \'\' he said.\r\n\r\n\"The Government, together with our industry, must set its priorities on availability of essential drugs and provide acceptable incentives to the business to improve development,\" Hamied said.\r\n\r\nCipla has several decades of expertise in production of bulk APIs and so it looks forward to extending its whole-hearted service to the authorities in this initiative, he added.\r\n\r\nThrough the years, the drug major has develop alternatives for various critical diseases.\r\n\r\nIn early 2001, Cipla brought from the drugs for HIV/AIDS and subsequently drugs for pandemic diseases, Hamied said, pointing out that the organization\'s prowess in developing cost effective medications for life threatening diseases.\r\n\r\nIn 2001, the business developed the world\'s first triple anti-retroviral drug combination, Triomune for HIV/AIDS patients and offered it at below $1 per day as against the then prevailing international pricing of $12,000-$15,000 per year.\r\n\r\nThe drug opened the doorway for the treatment of HIV/AIDS across third world states, especially in Sub-Saharan Africa, Hamied noted.\r\n\r\nBecause of this, millions are treated in Africa over the years, \'\' he explained.\r\n\r\nIn the end of 2019, out of 38 million people living with HIV/AIDS internationally, 25.4 million people (67% ) have had access to antiretroviral therapy (ART) and almost two-thirds of the planet\'s antiretroviral drugs are supplied from India, he added.','Working together with govt organizations to create treatment for COVID-19: Cipla','','publish','open','open','','working-together-with-govt-organizations-to-create-treatment-for-covid-19-cipla','','','2020-08-05 11:30:47','2020-08-05 11:30:47','',0,'https://microbiozindia.com/?p=6883',0,'post','',0),(6884,2,'2020-08-05 11:18:32','2020-08-05 11:18:32','Medication major Cipla is working together with government agencies to come up with a treatment for COVID-19 while ramping up the production of various life saving essential drugs, according to company\'s chairman YK Hamied.\r\n\r\nSharing information with business\'s shareholders at the drug firm\'s annual report for 2019-20, Hamied said the company is at the forefront in the battle against COVID-19.\r\n\r\n\"Cipla is cooperating with the Council of Scientific &amp; Industrial Research (CSIR), Indian Institute of Chemical Technology (IICT), Indian Council of Medical Research (ICMR) and the Ministry of Public Health to develop medications for the treatment of COVID-19,\" Hamied said.\r\n\r\nMeanwhile, the business is offering drugs, which have revealed potency in treating COVID-19, in partnership with its international partners,\'\' he explained.\r\n\r\n\"Through our strategic global partnerships, we offer a wide range of drugs within our portfolio giving aid and improving treatment access. This is particularly true with all the vital life-saving drugs like remdesivir, favipiravir and tocilizumab,\" Hamied said.\r\n\r\nThe Mumbai-based medication firm can also be ramping up production of essential drugs required in the struggle against the pandemic,\'\' he added.\r\n\r\nBesides scaling up production of medicines that reveal potency against the virus -- Lopinavir + Ritonavir, Hydroxychloroquine and Azithromycin, the company is also ramping up production of medication for chronic diseases like asthma, COPD, among others, Hamied said.\r\n\r\nHe added that the pandemic has also served as a wake up call spotlighting the need for each and every state to be self-reliant.\r\n\r\nCipla\'s doctrine of self-reliance and self-sufficiency and its pledge to provide universal access to cheap medicines is becoming even more crucial now, Hamied noted.\r\n\r\nThe foundation and backbone of the pharma business is the accessibility and production of active pharmaceutical ingredients called APIs, \'\' he said.\r\n\r\n\"The Government, together with our industry, must set its priorities on availability of essential drugs and provide acceptable incentives to the business to improve development,\" Hamied said.\r\n\r\nCipla has several decades of expertise in production of bulk APIs and so it looks forward to extending its whole-hearted service to the authorities in this initiative, he added.\r\n\r\nThrough the years, the drug major has develop alternatives for various critical diseases.\r\n\r\nIn early 2001, Cipla brought from the drugs for HIV/AIDS and subsequently drugs for pandemic diseases, Hamied said, pointing out that the organization\'s prowess in developing cost effective medications for life threatening diseases.\r\n\r\nIn 2001, the business developed the world\'s first triple anti-retroviral drug combination, Triomune for HIV/AIDS patients and offered it at below $1 per day as against the then prevailing international pricing of $12,000-$15,000 per year.\r\n\r\nThe drug opened the doorway for the treatment of HIV/AIDS across third world states, especially in Sub-Saharan Africa, Hamied noted.\r\n\r\nBecause of this, millions are treated in Africa over the years, \'\' he explained.\r\n\r\nIn the end of 2019, out of 38 million people living with HIV/AIDS internationally, 25.4 million people (67% ) have had access to antiretroviral therapy (ART) and almost two-thirds of the planet\'s antiretroviral drugs are supplied from India, he added.\r\n\r\nAnyway, the company has also in the past helped in the struggle against infectious diseases like anthrax, bird influenza and swine influenza by creating drugs, Hamied noted.\r\n\r\n\"The study is designed to encourage the regulatory approval process for the Chinese market and plans to affirm the safety and immunogenicity profile detected in participants from the German and US trials is similar to that of Chinese participants,\" BioNTech stated in a statement.','Working together with govt organizations to create treatment for COVID-19: Cipla','','inherit','closed','closed','','6883-revision-v1','','','2020-08-05 11:18:32','2020-08-05 11:18:32','',6883,'https://microbiozindia.com/uncategorized/6883-revision-v1/',0,'revision','',0),(6885,2,'2020-08-05 11:30:00','2020-08-05 11:30:00','Germany\'s BioNTech and China\'s Shanghai Fosun Pharmaceutical on Wednesday declared the start of another COVID-19 vaccine trial in China with a total of 144 participants.\r\n\r\n\"The study is designed to support the regulatory approval process for the Chinese market and plans to confirm the safety and immunogenicity profile observed in participants in the German and US trials is similar to that of Chinese participants,\" BioNTech stated in a statement.','BioNTech, Fosun Pharmaceutical dispatch another COVID-19 vaccine trial','','publish','open','open','','biontech-fosun-pharmaceutical-dispatch-another-covid-19-vaccine-trial','','','2020-08-05 11:30:00','2020-08-05 11:30:00','',0,'https://microbiozindia.com/?p=6885',0,'post','',0),(6886,2,'2020-08-05 11:30:00','2020-08-05 11:30:00','Germany\'s BioNTech and China\'s Shanghai Fosun Pharmaceutical on Wednesday declared the start of another COVID-19 vaccine trial in China with a total of 144 participants.\r\n\r\n\"The study is designed to support the regulatory approval process for the Chinese market and plans to confirm the safety and immunogenicity profile observed in participants in the German and US trials is similar to that of Chinese participants,\" BioNTech stated in a statement.','BioNTech, Fosun Pharmaceutical dispatch another COVID-19 vaccine trial','','inherit','closed','closed','','6885-revision-v1','','','2020-08-05 11:30:00','2020-08-05 11:30:00','',6885,'https://microbiozindia.com/uncategorized/6885-revision-v1/',0,'revision','',0),(6887,2,'2020-08-05 11:30:47','2020-08-05 11:30:47','Medication major Cipla is working together with government agencies to come up with a treatment for COVID-19 while ramping up the production of various life saving essential drugs, according to company\'s chairman YK Hamied.\r\n\r\nSharing information with business\'s shareholders at the drug firm\'s annual report for 2019-20, Hamied said the company is at the forefront in the battle against COVID-19.\r\n\r\n\"Cipla is cooperating with the Council of Scientific &amp; Industrial Research (CSIR), Indian Institute of Chemical Technology (IICT), Indian Council of Medical Research (ICMR) and the Ministry of Public Health to develop medications for the treatment of COVID-19,\" Hamied said.\r\n\r\nMeanwhile, the business is offering drugs, which have revealed potency in treating COVID-19, in partnership with its international partners,\'\' he explained.\r\n\r\n\"Through our strategic global partnerships, we offer a wide range of drugs within our portfolio giving aid and improving treatment access. This is particularly true with all the vital life-saving drugs like remdesivir, favipiravir and tocilizumab,\" Hamied said.\r\n\r\nThe Mumbai-based medication firm can also be ramping up production of essential drugs required in the struggle against the pandemic,\'\' he added.\r\n\r\nBesides scaling up production of medicines that reveal potency against the virus -- Lopinavir + Ritonavir, Hydroxychloroquine and Azithromycin, the company is also ramping up production of medication for chronic diseases like asthma, COPD, among others, Hamied said.\r\n\r\nHe added that the pandemic has also served as a wake up call spotlighting the need for each and every state to be self-reliant.\r\n\r\nCipla\'s doctrine of self-reliance and self-sufficiency and its pledge to provide universal access to cheap medicines is becoming even more crucial now, Hamied noted.\r\n\r\nThe foundation and backbone of the pharma business is the accessibility and production of active pharmaceutical ingredients called APIs, \'\' he said.\r\n\r\n\"The Government, together with our industry, must set its priorities on availability of essential drugs and provide acceptable incentives to the business to improve development,\" Hamied said.\r\n\r\nCipla has several decades of expertise in production of bulk APIs and so it looks forward to extending its whole-hearted service to the authorities in this initiative, he added.\r\n\r\nThrough the years, the drug major has develop alternatives for various critical diseases.\r\n\r\nIn early 2001, Cipla brought from the drugs for HIV/AIDS and subsequently drugs for pandemic diseases, Hamied said, pointing out that the organization\'s prowess in developing cost effective medications for life threatening diseases.\r\n\r\nIn 2001, the business developed the world\'s first triple anti-retroviral drug combination, Triomune for HIV/AIDS patients and offered it at below $1 per day as against the then prevailing international pricing of $12,000-$15,000 per year.\r\n\r\nThe drug opened the doorway for the treatment of HIV/AIDS across third world states, especially in Sub-Saharan Africa, Hamied noted.\r\n\r\nBecause of this, millions are treated in Africa over the years, \'\' he explained.\r\n\r\nIn the end of 2019, out of 38 million people living with HIV/AIDS internationally, 25.4 million people (67% ) have had access to antiretroviral therapy (ART) and almost two-thirds of the planet\'s antiretroviral drugs are supplied from India, he added.','Working together with govt organizations to create treatment for COVID-19: Cipla','','inherit','closed','closed','','6883-revision-v1','','','2020-08-05 11:30:47','2020-08-05 11:30:47','',6883,'https://microbiozindia.com/uncategorized/6883-revision-v1/',0,'revision','',0),(6888,2,'2020-08-05 11:32:05','2020-08-05 11:32:05','Drug firm BDR Pharmaceuticals on Wednesday said it has established its antifungal medication Favipiravir for treating COVID-19 patients in India at a cost of Rs 63 each tablet.\r\n\r\nThe business has also come up with a patient assistance programme which will allow patients and institutions who have limited resources to buy the medicine at an extremely subsidised rate, BDR Pharmaceuticals said in a statement.\r\n\r\nBDR pharma has received an endorsement from the Drugs Controller General of India (DCGI) to fabricate Favipiravir to treat mild to moderate patients using COVID-19 symptoms.\r\n\r\nThe drug has been launched under the name\'BDFAVI\', it added.\r\n\r\n\"BDR has been in the forefront of benefiting patients in this pandemic and supporting India\'s struggle against COVID-19. This launching further strengthens our commitment to the patients to provide better results for patients with mild to moderate COVID symptoms in India,\" BDR Pharmaceuticals CMD Dharmesh Shah stated.\r\n\r\nThe company has developed Favipiravir tablets in 200 mg strengths with a strip of 10 tablets, BDR Pharmaceuticals said.','BDR Pharmaceuticals dispatches Favipiravir at Rs 63 for each tablet in India','','publish','open','open','','bdr-pharmaceuticals-dispatches-favipiravir-at-rs-63-for-each-tablet-in-india','','','2020-08-05 11:32:05','2020-08-05 11:32:05','',0,'https://microbiozindia.com/?p=6888',0,'post','',0),(6889,2,'2020-08-05 11:31:57','2020-08-05 11:31:57','','Gilead1-1019x573','','inherit','open','closed','','gilead1-1019x573','','','2020-08-05 11:31:57','2020-08-05 11:31:57','',6888,'https://microbiozindia.com/wp-content/uploads/2020/08/Gilead1-1019x573-1.jpg',0,'attachment','image/jpeg',0),(6890,2,'2020-08-05 11:32:05','2020-08-05 11:32:05','Drug firm BDR Pharmaceuticals on Wednesday said it has established its antifungal medication Favipiravir for treating COVID-19 patients in India at a cost of Rs 63 each tablet.\r\n\r\nThe business has also come up with a patient assistance programme which will allow patients and institutions who have limited resources to buy the medicine at an extremely subsidised rate, BDR Pharmaceuticals said in a statement.\r\n\r\nBDR pharma has received an endorsement from the Drugs Controller General of India (DCGI) to fabricate Favipiravir to treat mild to moderate patients using COVID-19 symptoms.\r\n\r\nThe drug has been launched under the name\'BDFAVI\', it added.\r\n\r\n\"BDR has been in the forefront of benefiting patients in this pandemic and supporting India\'s struggle against COVID-19. This launching further strengthens our commitment to the patients to provide better results for patients with mild to moderate COVID symptoms in India,\" BDR Pharmaceuticals CMD Dharmesh Shah stated.\r\n\r\nThe company has developed Favipiravir tablets in 200 mg strengths with a strip of 10 tablets, BDR Pharmaceuticals said.','BDR Pharmaceuticals dispatches Favipiravir at Rs 63 for each tablet in India','','inherit','closed','closed','','6888-revision-v1','','','2020-08-05 11:32:05','2020-08-05 11:32:05','',6888,'https://microbiozindia.com/uncategorized/6888-revision-v1/',0,'revision','',0),(6891,2,'2020-08-05 18:40:35','2020-08-05 18:40:35','A team of Swiss-German researchers has developed a method of testing for neutralizing antibodies against SARS-CoV-2 that creates a result in half the time of traditional tests.\r\n\r\nA conventional neutralization test to determine immunity to SARS-CoV-2 usually takes two to three days and has to be carried out with infectious coronaviruses in a lab resorting to biosafety level 3. Now, a team from the University of Bern, in cooperation with colleagues from Ruhr-Universität Bochum (RUB), have developed a test which takes only 18 hours and does not have elevated biosafety requirements.\r\n\r\n<strong>Disguising a benign virus as SARS-CoV-2</strong>\r\n\r\nTo be able to detect antibodies against SARS-CoV-2 in serum samples from covid-19 sufferers, the researchers used another virus that does not disperse. They exchanged the envelope protein of the virus to the spike protein of this novel coronavirus, which mediates virus entry and infection. \"As a consequence, the viruses could be recognized by antibodies against Sars-Cov-2,\" explains lead author Toni-Luise Meister by Ruhr-Universität Bochum. \"The antibodies bind to the viruses which were changed in this way and neutralize them that no more can penetrate cells.\"\r\n\r\n<strong>Luminescence helps determine resistance</strong>\r\n\r\nSince the virus pseudotyped in this way can not spread in host cells, no elaborate biosafety precautions are essential for the test. To be able to find out the amount of antibodies, the researchers genetically modified the virus to ensure that green fluorescent protein and a luciferase, an enzyme from fireflies, will be generated by infected cells. \"After a single round of infection, we can then determine how many cells show green fluorescence,\" says lead author Ferdinand Zettl in the Institute of Virology and Immunology at Bern. The green fluorescence is a sign of infection with all the pseudotyped virus. The green cells the researchers are finding, the further neutralizing antibodies exist which obstructed the virus. Additionally, a luminometer may be utilized to read the luminescence signal made by the luciferase enzyme--another way of evaluating the test.\r\n\r\n<strong>Quick and reliable</strong>\r\n\r\nIn order to check the reliability and comparability with the traditional neutralization test, the researchers employed it to blood samples from covid-19 patients. \"The direct contrast revealed a fantastic correlation between the two test systems,\" explains corresponding writer Professor Stephanie Pfänder, PhD, from the Department of Molecular and Medical Virology in RUB. Compared to 56 hours to the traditional test, the new evaluation is much quicker, with only 18 hours to this test outcome. \"Another fantastic benefit is that it may be performed in virtually all medical labs, because no sophisticated security precautions are necessary,\" points outside Gert Zimmer, PhD, in the Institute of Virology and Immunology from Bern, corresponding author of the study.\r\n\r\n<strong>Reference</strong>\r\n\r\n1 Zettl F, Meister TL, Vollmer T, et al. Rapid quantification of SARS-CoV-2-neutralizing antibodies using propagation-defective vesicular stomatitis virus pseudotypes. <em>Vaccines</em>, 2020;8(3):386. doi: <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.3390/vaccines8030386\">3390/vaccines8030386</a>.</span>','Quicker Test for Covid-19 Antibodies','','publish','open','open','','quicker-test-for-covid-19-antibodies','','','2020-08-05 18:40:35','2020-08-05 18:40:35','',0,'https://microbiozindia.com/?p=6891',0,'post','',0),(6892,2,'2020-08-05 18:39:47','2020-08-05 18:39:47','','2020_07_17_km_pfander-cropped-466x273','','inherit','open','closed','','2020_07_17_km_pfander-cropped-466x273','','','2020-08-05 18:39:47','2020-08-05 18:39:47','',6891,'https://microbiozindia.com/wp-content/uploads/2020/08/2020_07_17_km_pfander-cropped-466x273-1.jpg',0,'attachment','image/jpeg',0),(6893,2,'2020-08-05 18:40:35','2020-08-05 18:40:35','A team of Swiss-German researchers has developed a method of testing for neutralizing antibodies against SARS-CoV-2 that creates a result in half the time of traditional tests.\r\n\r\nA conventional neutralization test to determine immunity to SARS-CoV-2 usually takes two to three days and has to be carried out with infectious coronaviruses in a lab resorting to biosafety level 3. Now, a team from the University of Bern, in cooperation with colleagues from Ruhr-Universität Bochum (RUB), have developed a test which takes only 18 hours and does not have elevated biosafety requirements.\r\n\r\n<strong>Disguising a benign virus as SARS-CoV-2</strong>\r\n\r\nTo be able to detect antibodies against SARS-CoV-2 in serum samples from covid-19 sufferers, the researchers used another virus that does not disperse. They exchanged the envelope protein of the virus to the spike protein of this novel coronavirus, which mediates virus entry and infection. \"As a consequence, the viruses could be recognized by antibodies against Sars-Cov-2,\" explains lead author Toni-Luise Meister by Ruhr-Universität Bochum. \"The antibodies bind to the viruses which were changed in this way and neutralize them that no more can penetrate cells.\"\r\n\r\n<strong>Luminescence helps determine resistance</strong>\r\n\r\nSince the virus pseudotyped in this way can not spread in host cells, no elaborate biosafety precautions are essential for the test. To be able to find out the amount of antibodies, the researchers genetically modified the virus to ensure that green fluorescent protein and a luciferase, an enzyme from fireflies, will be generated by infected cells. \"After a single round of infection, we can then determine how many cells show green fluorescence,\" says lead author Ferdinand Zettl in the Institute of Virology and Immunology at Bern. The green fluorescence is a sign of infection with all the pseudotyped virus. The green cells the researchers are finding, the further neutralizing antibodies exist which obstructed the virus. Additionally, a luminometer may be utilized to read the luminescence signal made by the luciferase enzyme--another way of evaluating the test.\r\n\r\n<strong>Quick and reliable</strong>\r\n\r\nIn order to check the reliability and comparability with the traditional neutralization test, the researchers employed it to blood samples from covid-19 patients. \"The direct contrast revealed a fantastic correlation between the two test systems,\" explains corresponding writer Professor Stephanie Pfänder, PhD, from the Department of Molecular and Medical Virology in RUB. Compared to 56 hours to the traditional test, the new evaluation is much quicker, with only 18 hours to this test outcome. \"Another fantastic benefit is that it may be performed in virtually all medical labs, because no sophisticated security precautions are necessary,\" points outside Gert Zimmer, PhD, in the Institute of Virology and Immunology from Bern, corresponding author of the study.\r\n\r\n<strong>Reference</strong>\r\n\r\n1 Zettl F, Meister TL, Vollmer T, et al. Rapid quantification of SARS-CoV-2-neutralizing antibodies using propagation-defective vesicular stomatitis virus pseudotypes. <em>Vaccines</em>, 2020;8(3):386. doi: <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.3390/vaccines8030386\">3390/vaccines8030386</a>.</span>','Quicker Test for Covid-19 Antibodies','','inherit','closed','closed','','6891-revision-v1','','','2020-08-05 18:40:35','2020-08-05 18:40:35','',6891,'https://microbiozindia.com/uncategorized/6891-revision-v1/',0,'revision','',0),(6895,2,'2020-08-06 09:01:56','2020-08-06 09:01:56','When the coronavirus pandemic struck, nearly everyone in the University of California, Irvine -- and colleges across the country -- had to abandon campus.\r\n\r\nThat\'s because his laboratory, which designs and constructs chemical molecules, had the ideal equipment to aid in the international push to locate remedies for COVID-19.\r\n\r\nNowick\'s group set to work in April, and now, on the preprint server bioRxiv, they characterize the growth of a ring-shaped molecule called a macrocycle that is intended to gum up the machines of this virus by blocking the action of an enzyme essential in order for it to reproduce.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.uci.edu/2020/08/05/uci-scientists-get-initial-hit-in-developing-drug-to-treat-covid-19\">But Kreutzer triumphed on his first try with the macrocycle that the team thought might work. \"It\'s a novel molecule that\'s never been produced before,\" he explained.</a></span>\r\n\r\nThe researchers then tested the macrocycle to find out whether it might block the action of this coronavirus enzyme. The macrocycle binds to a molecule molecule known as the most important protease that\'s necessary for the virus to operate.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.uci.edu/2020/08/05/uci-scientists-get-initial-hit-in-developing-drug-to-treat-covid-19\">The protease cleaves long strings of proteins the virus forces its host cell to create into different parts, which the virus then uses to maintain replicating.</a></span>\r\n\r\nThe new macrocycle, Kreutzer stated,\"stays there at the active site of the enzyme and makes it nonfunctional.\"\r\n\r\nThe research goes hand-in-hand with work in the laboratory of Rachel Martin, also a UCI professor of chemistry, who\'s determining the array of shapes that the coronavirus\'s most important protease can shoot.\r\n\r\nIdentifying these various structures is what allowed Nowick\'s laboratory to design a macrocycle that may lock onto the coronavirus.\r\n\r\nThis strategy for discontinuing the protease, Nowick mentioned, is precisely the same used in an integral category of drugs for treating human immunodeficiency virus. But since the germs are so different, the exact same inhibitors can\'t be used for either.\r\n\r\nNow that Nowick\'s laboratory has a prototype called an\"first strike,\" researchers need to make additional molecules which are more successful in preventing the protease. Then they need to work out how to actually deliver the very best molecule to infected cells.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.uci.edu/2020/08/05/uci-scientists-get-initial-hit-in-developing-drug-to-treat-covid-19\" target=\"_blank\" rel=\"noopener noreferrer\">University of California</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nKreutzer, A. G., <em>et al</em>. (2020) Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease. <em>bioRx</em><em>ⅳ.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://doi.org/10.1101/2020.08.03.234872\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1101/2020.08.03.234872</a><em>.</em></span>\r\n\r\n</div>','UCI researchers develop novel molecule for COVID-19 treatment','','publish','open','open','','uci-researchers-develop-novel-molecule-for-covid-19-treatment','','','2020-08-06 09:01:56','2020-08-06 09:01:56','',0,'https://microbiozindia.com/?p=6895',0,'post','',0),(6896,2,'2020-08-06 09:01:56','2020-08-06 09:01:56','When the coronavirus pandemic struck, nearly everyone in the University of California, Irvine -- and colleges across the country -- had to abandon campus.\r\n\r\nThat\'s because his laboratory, which designs and constructs chemical molecules, had the ideal equipment to aid in the international push to locate remedies for COVID-19.\r\n\r\nNowick\'s group set to work in April, and now, on the preprint server bioRxiv, they characterize the growth of a ring-shaped molecule called a macrocycle that is intended to gum up the machines of this virus by blocking the action of an enzyme essential in order for it to reproduce.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.uci.edu/2020/08/05/uci-scientists-get-initial-hit-in-developing-drug-to-treat-covid-19\">But Kreutzer triumphed on his first try with the macrocycle that the team thought might work. \"It\'s a novel molecule that\'s never been produced before,\" he explained.</a></span>\r\n\r\nThe researchers then tested the macrocycle to find out whether it might block the action of this coronavirus enzyme. The macrocycle binds to a molecule molecule known as the most important protease that\'s necessary for the virus to operate.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.uci.edu/2020/08/05/uci-scientists-get-initial-hit-in-developing-drug-to-treat-covid-19\">The protease cleaves long strings of proteins the virus forces its host cell to create into different parts, which the virus then uses to maintain replicating.</a></span>\r\n\r\nThe new macrocycle, Kreutzer stated,\"stays there at the active site of the enzyme and makes it nonfunctional.\"\r\n\r\nThe research goes hand-in-hand with work in the laboratory of Rachel Martin, also a UCI professor of chemistry, who\'s determining the array of shapes that the coronavirus\'s most important protease can shoot.\r\n\r\nIdentifying these various structures is what allowed Nowick\'s laboratory to design a macrocycle that may lock onto the coronavirus.\r\n\r\nThis strategy for discontinuing the protease, Nowick mentioned, is precisely the same used in an integral category of drugs for treating human immunodeficiency virus. But since the germs are so different, the exact same inhibitors can\'t be used for either.\r\n\r\nNow that Nowick\'s laboratory has a prototype called an\"first strike,\" researchers need to make additional molecules which are more successful in preventing the protease. Then they need to work out how to actually deliver the very best molecule to infected cells.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.uci.edu/2020/08/05/uci-scientists-get-initial-hit-in-developing-drug-to-treat-covid-19\" target=\"_blank\" rel=\"noopener noreferrer\">University of California</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nKreutzer, A. G., <em>et al</em>. (2020) Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease. <em>bioRx</em><em>ⅳ.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://doi.org/10.1101/2020.08.03.234872\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1101/2020.08.03.234872</a><em>.</em></span>\r\n\r\n</div>','UCI researchers develop novel molecule for COVID-19 treatment','','inherit','closed','closed','','6895-revision-v1','','','2020-08-06 09:01:56','2020-08-06 09:01:56','',6895,'https://microbiozindia.com/uncategorized/6895-revision-v1/',0,'revision','',0),(6897,2,'2020-08-06 15:56:15','2020-08-06 15:56:15','<span style=\"color: #000000;\">Cherwell Laboratories, </span>specialist suppliers of <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.cherwell-labs.co.uk/cleanroom-environmental-monitoring\">environmental monitoring</a> </span>and process validation solutions for the pharmaceutical and related industries, has launched a Redipor<sup>®</sup> prepared media distributor resource centre website. Developing this online knowledge hub supports Cherwell’s growing <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.cherwell-labs.co.uk/cherwell-redipor-distributors\">international distribution network</a> </span>within Europe and now Asia. This means that all Redipor microbiological media customers will receive quality support for their environmental monitoring, sterility testing and process validation applications, whatever their location.\r\n\r\nThe new Redipor distributor resource centre securely houses lots of useful material, including prepared media product information, safety data sheets, guides and updates which are readily accessible to the distributor at all times. This detailed information in turn enables them to help ensure the controlled environment monitoring efforts of Redipor users run as smoothly as possible. Further supporting in-house expertise, Cherwell invests time in developing a Redipor product champion at each of its distributors; training them in its processes and the complete range of Redipor culture media products, including features, benefits and applications. This is all key to ensuring customers are advised on the right solutions for their needs.\r\n<blockquote>“We are proud that the Redipor range has for many years been associated with quality products supported by an efficient, responsive and truly flexible service for small and large users alike. We therefore take great care in selecting the right partners to work closely with us to supply our products internationally,” said Andy Whittard, Managing Director, Cherwell Laboratories. “Ensuring that all our distributors can also offer quality industry expertise and product support is crucial to us. This is because maintaining cleanrooms and other aseptic areas to the most stringent regulations, plus validating sterility testing processes, not only requires high quality prepared culture media but also quality in customer care.”</blockquote>\r\nCherwell’s network of expert distributors has been growing in Europe in recent years, now it has also carefully identified partners within Asia who understand the needs of the pharmaceutical and associated industries involved in aseptic processing. Cherwell has recently appointed two new distributors in the region, these are SPD Scientific in Singapore and Trans-Enor in Taiwan. These new distributors, along with ATS Korea in South Korea, are significantly raising the profile of Cherwell’s quality Redipor prepared microbiological media products in Asia. All of Cherwell’s distribution partners can be found on its <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.cherwell-labs.co.uk/cherwell-redipor-distributors\">website</a>.</span>\r\n\r\n<a href=\"https://www.cherwell-labs.co.uk/prepared-culture-media/\"><span style=\"color: #ff6600;\">Redipor prepared culture media</span></a> products are widely used in pharmaceutical, compounding, hospital pharmacy manufacturing units and other related industries where cleanroom-based manufacturing is required. The Redipor range offers a vast selection of Contact plates and Petri dishes, plus liquid media in a variety of formats. Bespoke culture media options to meet specific needs are also available. Cherwell’s Redipor manufacturing facility is ISO 9001 registered, with all products undergoing stringent quality tests and QC certification. 100% inspection processes, gamma irradiation and special packaging further deliver absolute confidence in product quality.\r\n\r\nFor more information about Cherwell Laboratories, please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.cherwell-labs.co.uk\">www.cherwell-labs.co.uk</a></span>, follow <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://twitter.com/CherwellLabs\">@CherwellLabs on Twitter</a> </span>or follow us on<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://www.linkedin.com/company/cherwell-laboratories-ltd\">LinkedIn</a>.</span>','Cherwell launches new support hub for growing Redipor® prepared media distributor network','','publish','open','open','','cherwell-launches-new-support-hub-for-growing-redipor-prepared-media-distributor-network','','','2020-08-06 17:02:30','2020-08-06 17:02:30','',0,'https://microbiozindia.com/?p=6897',0,'post','',0),(6898,2,'2020-08-06 15:51:54','2020-08-06 15:51:54','','2005CHE - Redipor prepared media range','','inherit','open','closed','','2005che-redipor-prepared-media-range','','','2020-08-06 15:51:54','2020-08-06 15:51:54','',6897,'https://microbiozindia.com/wp-content/uploads/2020/08/2005CHE-Redipor-prepared-media-range.jpg',0,'attachment','image/jpeg',0),(6899,2,'2020-08-06 15:56:15','2020-08-06 15:56:15','Bicester, UK, 6<sup>th</sup> August 2020<span style=\"color: #ff6600;\">: <a style=\"color: #ff6600;\" href=\"https://www.cherwell-labs.co.uk/\">Cherwell Laboratories</a>,</span> specialist suppliers of <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.cherwell-labs.co.uk/cleanroom-environmental-monitoring\">environmental monitoring</a> </span>and process validation solutions for the pharmaceutical and related industries, has launched a Redipor<sup>®</sup> prepared media distributor resource centre website. Developing this online knowledge hub supports Cherwell’s growing <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.cherwell-labs.co.uk/cherwell-redipor-distributors\">international distribution network</a> </span>within Europe and now Asia. This means that all Redipor microbiological media customers will receive quality support for their environmental monitoring, sterility testing and process validation applications, whatever their location.\r\n\r\nThe new Redipor distributor resource centre securely houses lots of useful material, including prepared media product information, safety data sheets, guides and updates which are readily accessible to the distributor at all times. This detailed information in turn enables them to help ensure the controlled environment monitoring efforts of Redipor users run as smoothly as possible. Further supporting in-house expertise, Cherwell invests time in developing a Redipor product champion at each of its distributors; training them in its processes and the complete range of Redipor culture media products, including features, benefits and applications. This is all key to ensuring customers are advised on the right solutions for their needs.\r\n<blockquote>“We are proud that the Redipor range has for many years been associated with quality products supported by an efficient, responsive and truly flexible service for small and large users alike. We therefore take great care in selecting the right partners to work closely with us to supply our products internationally,” said Andy Whittard, Managing Director, Cherwell Laboratories. “Ensuring that all our distributors can also offer quality industry expertise and product support is crucial to us. This is because maintaining cleanrooms and other aseptic areas to the most stringent regulations, plus validating sterility testing processes, not only requires high quality prepared culture media but also quality in customer care.”</blockquote>\r\nCherwell’s network of expert distributors has been growing in Europe in recent years, now it has also carefully identified partners within Asia who understand the needs of the pharmaceutical and associated industries involved in aseptic processing. Cherwell has recently appointed two new distributors in the region, these are SPD Scientific in Singapore and Trans-Enor in Taiwan. These new distributors, along with ATS Korea in South Korea, are significantly raising the profile of Cherwell’s quality Redipor prepared microbiological media products in Asia. All of Cherwell’s distribution partners can be found on its <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.cherwell-labs.co.uk/cherwell-redipor-distributors\">website</a>.</span>\r\n\r\n<a href=\"https://www.cherwell-labs.co.uk/prepared-culture-media/\"><span style=\"color: #ff6600;\">Redipor prepared culture media</span></a> products are widely used in pharmaceutical, compounding, hospital pharmacy manufacturing units and other related industries where cleanroom-based manufacturing is required. The Redipor range offers a vast selection of Contact plates and Petri dishes, plus liquid media in a variety of formats. Bespoke culture media options to meet specific needs are also available. Cherwell’s Redipor manufacturing facility is ISO 9001 registered, with all products undergoing stringent quality tests and QC certification. 100% inspection processes, gamma irradiation and special packaging further deliver absolute confidence in product quality.\r\n\r\nFor more information about Cherwell Laboratories, please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.cherwell-labs.co.uk\">www.cherwell-labs.co.uk</a></span>, follow <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://twitter.com/CherwellLabs\">@CherwellLabs on Twitter</a> </span>or follow us on<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://www.linkedin.com/company/cherwell-laboratories-ltd\">LinkedIn</a>.</span>','Cherwell launches new support hub for growing Redipor® prepared media distributor network','','inherit','closed','closed','','6897-revision-v1','','','2020-08-06 15:56:15','2020-08-06 15:56:15','',6897,'https://microbiozindia.com/uncategorized/6897-revision-v1/',0,'revision','',0),(6900,2,'2020-08-06 16:02:43','2020-08-06 16:02:43','Doctors in a hospital have used a brand new drug called RLF-100, also called aviptadil, which has resulted in rapid recovery from respiratory failure in critically ill COVID-19 patients.\r\n\r\nThe drug has been approved by the FDA for emergency use at multiple clinical sites in patients that are too sick to input the FDA\'s Stage 2/3 trials.\r\n\r\nHouston Methodist Hospital has been the first to report that the rapid retrieval of patients on ventilators and people with acute medical conditions after three days of treatment.\r\n\r\nAviptadil is a formula of Vasoactive Intestinal Polypeptide (VIP), which is present in large concentrations in the lungs and also proven to block different inflammatory cytokines. NeuroRx and Relief Therapeutics have partnered to create the drug.\r\n\r\nAccording to a statement from the drug maker NeuroRX, independent scientists have reported that aviptadil blocked replication of the SARS coronavirus in cells and monocytes.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.moneycontrol.com/news/india/new-drug-rlf-100-shows-dramatic-results-for-critical-covid-19-patients-5652591.html\">According to the report, a 54-year-old guy who contracted COVID-19 while being treated for rejection of a double lung transplant came off a ventilator in four days. And, similar effects were seen in more than 15 patients.</a></span>\r\n\r\nThe drug seemed to have rapidly cleared pneumonitis findings on an X-ray, improved blood oxygen and a 50 per cent or higher average decrease in laboratory markers associated with COVID-19 inflammation, the announcement said.\r\n\r\n\"No other anti inflammatory agent has demonstrated rapid recovery from viral infection and demonstrated laboratory inhibition of viral replication,\" said Prof. Jonathan Javitt, CEO and Chairman of NeuroRx.\r\n\r\n\"We are running placebo-controlled trials to see if the observations made from the case-control and open-label studies will likely be verified for less ill patients with COVID-19-related respiratory collapse. Our independent Data Monitoring Committee will be conducting an interim evaluation of these data later this month,\" Javitt explained.','New medication RLF-100 shows sensational outcomes for basic COVID-19 patients','','publish','open','open','','new-medication-rlf-100-shows-sensational-outcomes-for-basic-covid-19-patients','','','2020-08-06 16:03:03','2020-08-06 16:03:03','',0,'https://microbiozindia.com/?p=6900',0,'post','',0),(6901,2,'2020-08-06 16:02:43','2020-08-06 16:02:43','Doctors in a hospital have used a brand new drug called RLF-100, also called aviptadil, which has resulted in rapid recovery from respiratory failure in critically ill COVID-19 patients.\r\n\r\nThe drug has been approved by the FDA for emergency use at multiple clinical sites in patients that are too sick to input the FDA\'s Stage 2/3 trials.\r\n\r\nHouston Methodist Hospital has been the first to report that the rapid retrieval of patients on ventilators and people with acute medical conditions after three days of treatment.\r\n\r\nAviptadil is a formula of Vasoactive Intestinal Polypeptide (VIP), which is present in large concentrations in the lungs and also proven to block different inflammatory cytokines. NeuroRx and Relief Therapeutics have partnered to create the drug.\r\n\r\nAccording to a statement from the drug maker NeuroRX, independent scientists have reported that aviptadil blocked replication of the SARS coronavirus in cells and monocytes.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.moneycontrol.com/news/india/new-drug-rlf-100-shows-dramatic-results-for-critical-covid-19-patients-5652591.html\">According to the report, a 54-year-old guy who contracted COVID-19 while being treated for rejection of a double lung transplant came off a ventilator in four days. And, similar effects were seen in more than 15 patients.</a></span>\r\n\r\nThe drug seemed to have rapidly cleared pneumonitis findings on an X-ray, improved blood oxygen and a 50 per cent or higher average decrease in laboratory markers associated with COVID-19 inflammation, the announcement said.\r\n\r\n\"No other anti inflammatory agent has demonstrated rapid recovery from viral infection and demonstrated laboratory inhibition of viral replication,\" said Prof. Jonathan Javitt, CEO and Chairman of NeuroRx.\r\n\r\n\"We are running placebo-controlled trials to see if the observations made from the case-control and open-label studies will likely be verified for less ill patients with COVID-19-related respiratory collapse. Our independent Data Monitoring Committee will be conducting an interim evaluation of these data later this month,\" Javitt explained.','New medication RLF-100 shows sensational outcomes for basic COVID-19 patients','','inherit','closed','closed','','6900-revision-v1','','','2020-08-06 16:02:43','2020-08-06 16:02:43','',6900,'https://microbiozindia.com/uncategorized/6900-revision-v1/',0,'revision','',0),(6902,2,'2020-08-06 16:03:03','2020-08-06 16:03:03','Doctors in a hospital have used a brand new drug called RLF-100, also called aviptadil, which has resulted in rapid recovery from respiratory failure in critically ill COVID-19 patients.\r\n\r\nThe drug has been approved by the FDA for emergency use at multiple clinical sites in patients that are too sick to input the FDA\'s Stage 2/3 trials.\r\n\r\nHouston Methodist Hospital has been the first to report that the rapid retrieval of patients on ventilators and people with acute medical conditions after three days of treatment.\r\n\r\nAviptadil is a formula of Vasoactive Intestinal Polypeptide (VIP), which is present in large concentrations in the lungs and also proven to block different inflammatory cytokines. NeuroRx and Relief Therapeutics have partnered to create the drug.\r\n\r\nAccording to a statement from the drug maker NeuroRX, independent scientists have reported that aviptadil blocked replication of the SARS coronavirus in cells and monocytes.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.moneycontrol.com/news/india/new-drug-rlf-100-shows-dramatic-results-for-critical-covid-19-patients-5652591.html\">According to the report, a 54-year-old guy who contracted COVID-19 while being treated for rejection of a double lung transplant came off a ventilator in four days. And, similar effects were seen in more than 15 patients.</a></span>\r\n\r\nThe drug seemed to have rapidly cleared pneumonitis findings on an X-ray, improved blood oxygen and a 50 per cent or higher average decrease in laboratory markers associated with COVID-19 inflammation, the announcement said.\r\n\r\n\"No other anti inflammatory agent has demonstrated rapid recovery from viral infection and demonstrated laboratory inhibition of viral replication,\" said Prof. Jonathan Javitt, CEO and Chairman of NeuroRx.\r\n\r\n\"We are running placebo-controlled trials to see if the observations made from the case-control and open-label studies will likely be verified for less ill patients with COVID-19-related respiratory collapse. Our independent Data Monitoring Committee will be conducting an interim evaluation of these data later this month,\" Javitt explained.','New medication RLF-100 shows sensational outcomes for basic COVID-19 patients','','inherit','closed','closed','','6900-revision-v1','','','2020-08-06 16:03:03','2020-08-06 16:03:03','',6900,'https://microbiozindia.com/uncategorized/6900-revision-v1/',0,'revision','',0),(6903,2,'2020-08-06 16:09:08','2020-08-06 16:09:08','American Idol, Shreveport, La, has included a covid-19 IgG/IgM rapid test to its inventory. The in vitro immunoassay, that has been allowed emergency use authorization (EUA) from the FDA, is created for the qualitative and direct discovery of anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG in human whole blood, serum, or plasma. The test is simple to administer and delivers results in about 15 minutes and has shown a high degree of accuracy.\r\n<blockquote>\"Our team has worked tirelessly during the pandemic to minimize supply chain disruptions and maintain essential products in stock while at the same time adding new items. By making the covid-19 IgG/IgM rapid evaluation available in our shop, we\'re proudly leading to the struggle against this disease and supporting efforts to solve the public health catastrophe to the best of our ability,\" American Screening says.</blockquote>\r\nThe evaluation is intended to supply qualitative detection and distinction of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood, serum, or plasma. Healthcare professionals can use it as an aid in identifying individuals with an adaptive immune response to covid-19, which might indicate a recent or past infection. Clinical evaluation has shown the test to be extremely accurate. For IgM detection, the overall confidence interval is 95 percent, while relative sensitivity, comparative specificity, and total arrangement are 93.7%, 99.1%, and 97.7%, respectively. The confidence interval is the same for IgG detection, whereas the respective amounts for relative sensitivity, relative specificity, and overall agreement are 98.8%, 98.7%, and 98.7 percent.\r\n\r\nBecause this quick and precise test doesn\'t need additional equipment, it is acceptable for application in points of maintenance. American Screening is keen to highlight that the item was created exclusively for professional usage, and its own emergency endorsement grants consent only to labs with a moderate or higher complexity license extended under the Clinical Laboratory Improvement Amendments (CLIA) regulations.','Covid-19 Antibody Rapid Serology Test by Americal Screening','','publish','open','open','','covid-19-antibody-rapid-serology-test-by-americal-screening','','','2020-08-06 16:09:08','2020-08-06 16:09:08','',0,'https://microbiozindia.com/?p=6903',0,'post','',0),(6904,2,'2020-08-06 16:08:58','2020-08-06 16:08:58','','bloodtest','','inherit','open','closed','','bloodtest','','','2020-08-06 16:08:58','2020-08-06 16:08:58','',6903,'https://microbiozindia.com/wp-content/uploads/2020/08/bloodtest.jpg',0,'attachment','image/jpeg',0),(6905,2,'2020-08-06 16:09:08','2020-08-06 16:09:08','American Idol, Shreveport, La, has included a covid-19 IgG/IgM rapid test to its inventory. The in vitro immunoassay, that has been allowed emergency use authorization (EUA) from the FDA, is created for the qualitative and direct discovery of anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG in human whole blood, serum, or plasma. The test is simple to administer and delivers results in about 15 minutes and has shown a high degree of accuracy.\r\n<blockquote>\"Our team has worked tirelessly during the pandemic to minimize supply chain disruptions and maintain essential products in stock while at the same time adding new items. By making the covid-19 IgG/IgM rapid evaluation available in our shop, we\'re proudly leading to the struggle against this disease and supporting efforts to solve the public health catastrophe to the best of our ability,\" American Screening says.</blockquote>\r\nThe evaluation is intended to supply qualitative detection and distinction of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood, serum, or plasma. Healthcare professionals can use it as an aid in identifying individuals with an adaptive immune response to covid-19, which might indicate a recent or past infection. Clinical evaluation has shown the test to be extremely accurate. For IgM detection, the overall confidence interval is 95 percent, while relative sensitivity, comparative specificity, and total arrangement are 93.7%, 99.1%, and 97.7%, respectively. The confidence interval is the same for IgG detection, whereas the respective amounts for relative sensitivity, relative specificity, and overall agreement are 98.8%, 98.7%, and 98.7 percent.\r\n\r\nBecause this quick and precise test doesn\'t need additional equipment, it is acceptable for application in points of maintenance. American Screening is keen to highlight that the item was created exclusively for professional usage, and its own emergency endorsement grants consent only to labs with a moderate or higher complexity license extended under the Clinical Laboratory Improvement Amendments (CLIA) regulations.','Covid-19 Antibody Rapid Serology Test by Americal Screening','','inherit','closed','closed','','6903-revision-v1','','','2020-08-06 16:09:08','2020-08-06 16:09:08','',6903,'https://microbiozindia.com/uncategorized/6903-revision-v1/',0,'revision','',0),(6907,2,'2020-08-06 17:01:34','2020-08-06 17:01:34','Bicester, UK, 6<sup>th</sup> August 2020<span style=\"color: #000000;\">: Cherwell Laboratories, </span>specialist suppliers of <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.cherwell-labs.co.uk/cleanroom-environmental-monitoring\">environmental monitoring</a> </span>and process validation solutions for the pharmaceutical and related industries, has launched a Redipor<sup>®</sup> prepared media distributor resource centre website. Developing this online knowledge hub supports Cherwell’s growing <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.cherwell-labs.co.uk/cherwell-redipor-distributors\">international distribution network</a> </span>within Europe and now Asia. This means that all Redipor microbiological media customers will receive quality support for their environmental monitoring, sterility testing and process validation applications, whatever their location.\r\n\r\nThe new Redipor distributor resource centre securely houses lots of useful material, including prepared media product information, safety data sheets, guides and updates which are readily accessible to the distributor at all times. This detailed information in turn enables them to help ensure the controlled environment monitoring efforts of Redipor users run as smoothly as possible. Further supporting in-house expertise, Cherwell invests time in developing a Redipor product champion at each of its distributors; training them in its processes and the complete range of Redipor culture media products, including features, benefits and applications. This is all key to ensuring customers are advised on the right solutions for their needs.\r\n<blockquote>“We are proud that the Redipor range has for many years been associated with quality products supported by an efficient, responsive and truly flexible service for small and large users alike. We therefore take great care in selecting the right partners to work closely with us to supply our products internationally,” said Andy Whittard, Managing Director, Cherwell Laboratories. “Ensuring that all our distributors can also offer quality industry expertise and product support is crucial to us. This is because maintaining cleanrooms and other aseptic areas to the most stringent regulations, plus validating sterility testing processes, not only requires high quality prepared culture media but also quality in customer care.”</blockquote>\r\nCherwell’s network of expert distributors has been growing in Europe in recent years, now it has also carefully identified partners within Asia who understand the needs of the pharmaceutical and associated industries involved in aseptic processing. Cherwell has recently appointed two new distributors in the region, these are SPD Scientific in Singapore and Trans-Enor in Taiwan. These new distributors, along with ATS Korea in South Korea, are significantly raising the profile of Cherwell’s quality Redipor prepared microbiological media products in Asia. All of Cherwell’s distribution partners can be found on its <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.cherwell-labs.co.uk/cherwell-redipor-distributors\">website</a>.</span>\r\n\r\n<a href=\"https://www.cherwell-labs.co.uk/prepared-culture-media/\"><span style=\"color: #ff6600;\">Redipor prepared culture media</span></a> products are widely used in pharmaceutical, compounding, hospital pharmacy manufacturing units and other related industries where cleanroom-based manufacturing is required. The Redipor range offers a vast selection of Contact plates and Petri dishes, plus liquid media in a variety of formats. Bespoke culture media options to meet specific needs are also available. Cherwell’s Redipor manufacturing facility is ISO 9001 registered, with all products undergoing stringent quality tests and QC certification. 100% inspection processes, gamma irradiation and special packaging further deliver absolute confidence in product quality.\r\n\r\nFor more information about Cherwell Laboratories, please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.cherwell-labs.co.uk\">www.cherwell-labs.co.uk</a></span>, follow <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://twitter.com/CherwellLabs\">@CherwellLabs on Twitter</a> </span>or follow us on<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://www.linkedin.com/company/cherwell-laboratories-ltd\">LinkedIn</a>.</span>','Cherwell launches new support hub for growing Redipor® prepared media distributor network','','inherit','closed','closed','','6897-revision-v1','','','2020-08-06 17:01:34','2020-08-06 17:01:34','',6897,'https://microbiozindia.com/uncategorized/6897-revision-v1/',0,'revision','',0),(6908,2,'2020-08-06 17:01:54','2020-08-06 17:01:54','<span style=\"color: #000000;\">Cherwell Laboratories, </span>specialist suppliers of <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.cherwell-labs.co.uk/cleanroom-environmental-monitoring\">environmental monitoring</a> </span>and process validation solutions for the pharmaceutical and related industries, has launched a Redipor<sup>®</sup> prepared media distributor resource centre website. Developing this online knowledge hub supports Cherwell’s growing <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.cherwell-labs.co.uk/cherwell-redipor-distributors\">international distribution network</a> </span>within Europe and now Asia. This means that all Redipor microbiological media customers will receive quality support for their environmental monitoring, sterility testing and process validation applications, whatever their location.\r\n\r\nThe new Redipor distributor resource centre securely houses lots of useful material, including prepared media product information, safety data sheets, guides and updates which are readily accessible to the distributor at all times. This detailed information in turn enables them to help ensure the controlled environment monitoring efforts of Redipor users run as smoothly as possible. Further supporting in-house expertise, Cherwell invests time in developing a Redipor product champion at each of its distributors; training them in its processes and the complete range of Redipor culture media products, including features, benefits and applications. This is all key to ensuring customers are advised on the right solutions for their needs.\r\n<blockquote>“We are proud that the Redipor range has for many years been associated with quality products supported by an efficient, responsive and truly flexible service for small and large users alike. We therefore take great care in selecting the right partners to work closely with us to supply our products internationally,” said Andy Whittard, Managing Director, Cherwell Laboratories. “Ensuring that all our distributors can also offer quality industry expertise and product support is crucial to us. This is because maintaining cleanrooms and other aseptic areas to the most stringent regulations, plus validating sterility testing processes, not only requires high quality prepared culture media but also quality in customer care.”</blockquote>\r\nCherwell’s network of expert distributors has been growing in Europe in recent years, now it has also carefully identified partners within Asia who understand the needs of the pharmaceutical and associated industries involved in aseptic processing. Cherwell has recently appointed two new distributors in the region, these are SPD Scientific in Singapore and Trans-Enor in Taiwan. These new distributors, along with ATS Korea in South Korea, are significantly raising the profile of Cherwell’s quality Redipor prepared microbiological media products in Asia. All of Cherwell’s distribution partners can be found on its <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.cherwell-labs.co.uk/cherwell-redipor-distributors\">website</a>.</span>\r\n\r\n<a href=\"https://www.cherwell-labs.co.uk/prepared-culture-media/\"><span style=\"color: #ff6600;\">Redipor prepared culture media</span></a> products are widely used in pharmaceutical, compounding, hospital pharmacy manufacturing units and other related industries where cleanroom-based manufacturing is required. The Redipor range offers a vast selection of Contact plates and Petri dishes, plus liquid media in a variety of formats. Bespoke culture media options to meet specific needs are also available. Cherwell’s Redipor manufacturing facility is ISO 9001 registered, with all products undergoing stringent quality tests and QC certification. 100% inspection processes, gamma irradiation and special packaging further deliver absolute confidence in product quality.\r\n\r\nFor more information about Cherwell Laboratories, please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.cherwell-labs.co.uk\">www.cherwell-labs.co.uk</a></span>, follow <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://twitter.com/CherwellLabs\">@CherwellLabs on Twitter</a> </span>or follow us on<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://www.linkedin.com/company/cherwell-laboratories-ltd\">LinkedIn</a>.</span>','Cherwell launches new support hub for growing Redipor® prepared media distributor network','','inherit','closed','closed','','6897-revision-v1','','','2020-08-06 17:01:54','2020-08-06 17:01:54','',6897,'https://microbiozindia.com/uncategorized/6897-revision-v1/',0,'revision','',0),(6909,2,'2020-08-07 06:22:55','2020-08-07 06:22:55','Biomedical engineers at Duke University have shown a way of controlling the phase separation of an emerging class of proteins to create artificial membrane-less organelles in human cells. The progress, similar to controlling how vinegar forms droplets within oil, creates chances for engineering artificial structures to modulate present cell functions or produce entirely new behaviours within cells.\r\n\r\nThe results appear online on August 3 at the journal Nature Chemistry.\r\n\r\nProteins function by folding into specific 3-D shapes which interact with different biomolecular structures. Researchers previously believed that proteins needed these mended shapes to function. But in the last two decades, a new class of intrinsically disordered proteins (IDPs) have been found that have large areas that are\"floppy\"--which is, they don\'t fold into a defined 3-D shape. It\'s currently understood these areas play an important, previously unrecognized role in controlling different cellular functions.\r\n\r\nIDPs can also be helpful for biomedical applications because they can undergo phase transitions--changing from a liquid into a gel, for example, or by a soluble to an insoluble state, and again--in response to environmental triggers, such as fluctuations in temperature. These attributes also dictate their phase behaviour in cellular environments and are commanded by adjusting attributes of the IDPs for example their molecular weight or the sequence where the amino acids have been connected together.\r\n\r\n\"Others in the field have taken a top-level strategy where they\'ll make a change to a natural IDP and determine how its behavior changes inside a cell,\" explained Michael Dzuricky, a research scientist working in the Chilkoti laboratory and first author of the study. \"We are taking the opposite approach and constructing our own artificial IDPs from straightforward thermodynamic principles. This empowers us and others to precisely tune one property--the form of the phase diagram--to better understand how this parameter affects biological behavior\"\r\n\r\n<em>Although there are many natural IDPs that show phase behavior in cells, they come in many different flavors, and it has been difficult to discern the rules that govern this behavior. This paper provides very simple engineering principles to program this behavior within a cell.\"-</em>Ashutosh Chilkoti, the Alan L. Kaganov Distinguished Professor of Biomedical Engineering at Duke\r\n\r\nThese weakly-held-together constructions allow cells to make compartments without also constructing a membrane to encapsulate it.\r\n\r\nThis simpler version enabled the researchers to make precise adjustments to the molecular weight of their IDP and amino acids of the IDPs. The researchers show that, based on just how these two factors are tweaked, the IDPs come together to form these compartments at different temperatures in a test tube. And by always trying a variety of temperatures and tweaks, the researchers obtained a good understanding of which layout parameters are most important to control the IDP\'s behaviour.\r\n\r\nAs predicted, their artificial IDPs grouped together to make a very small droplet within the cell\'s cytoplasm. And because the IDP\'s behavior was so well known, the researchers revealed they could predictably control how they coalesced using their evaluation tube principles as a guide.\r\n\"We were able to change temperatures in cells to develop a complete description of their phase behavior, which mirrored our evaluation tube predictions,\" explained Dzuricky. \"At this point, we were able to design distinct artificial IDP systems where the droplets that are formed have different material properties.\"\r\n\r\nPut the other way, since the researchers understood how to manipulate the size and composition of their IDPs to react to temperature, they can program the IDPs to form droplets or bubbles of varying densities within cells. To show this ability might be useful to biomedical engineers, the investigators subsequently used their newfound expertise, as nature frequently does, to create an organelle that performs a particular function within a cell.\r\n\r\nThe researchers showed that they might utilize the IDPs to create an enzyme to control its action level. By varying the molecular weight of the IDPs, the IDPs hold about the receptor either increased or diminished, which in turn affected how much it may interact with the remainder of the cell.\r\n\r\nTo demonstrate this ability, the researchers chose an enzyme used by E. coli to convert lactose into usable sugars. Nonetheless, in this circumstance, the investigators tracked this enzyme\'s activity with a fluorescent reporter at real time to determine the way the engineered IDP organelle was affecting enzyme action.\r\n\r\nLater on, the investigators believe they could use their new IDP organelles to restrain the activity levels of biomolecules important to illness conditions. Or to learn how normal IDPs fill similar cellular roles and understand exactly how and why they sometimes malfunction.\r\n\r\n\"That is the first time anyone was able to precisely specify the method by which the protein sequence controls phase separation behavior inside cells,\" said Dzuricky. \"We used an artificial system, but we believe the same rules apply to natural IDPs and are excited to begin testing this concept.\"\r\n\r\n\"We can also now start to program this type of phase behavior with almost any protein in a cell by alerting them to those artificial IDPs,\" said Chilkoti. \"We expect that these synthetic IDPs will offer a new tool for synthetic biology to control cell behavior.\"\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.duke.edu/\" target=\"_blank\" rel=\"noopener noreferrer\">Duke University</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nDzuricky, M., <em>et al.</em> (2020) De novo engineering of intracellular condensates using artificial disordered proteins. Nature Chemistry<em>.</em><span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://doi.org/10.1038/s41557-020-0511-7\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1038/s41557-020-0511-7</a>.</span>\r\n\r\n</div>','Biomedical scientists make counterfeit organelles to control biological function in cells','','publish','open','open','','biomedical-scientists-make-counterfeit-organelles-to-control-biological-function-in-cells','','','2020-08-07 06:22:55','2020-08-07 06:22:55','',0,'https://microbiozindia.com/?p=6909',0,'post','',0),(6910,2,'2020-08-07 06:21:53','2020-08-07 06:21:53','','20200222_STP002','','inherit','open','closed','','20200222_stp002','','','2020-08-07 06:21:53','2020-08-07 06:21:53','',6909,'https://microbiozindia.com/wp-content/uploads/2020/08/20200222_STP002.jpg',0,'attachment','image/jpeg',0),(6911,2,'2020-08-07 06:22:55','2020-08-07 06:22:55','Biomedical engineers at Duke University have shown a way of controlling the phase separation of an emerging class of proteins to create artificial membrane-less organelles in human cells. The progress, similar to controlling how vinegar forms droplets within oil, creates chances for engineering artificial structures to modulate present cell functions or produce entirely new behaviours within cells.\r\n\r\nThe results appear online on August 3 at the journal Nature Chemistry.\r\n\r\nProteins function by folding into specific 3-D shapes which interact with different biomolecular structures. Researchers previously believed that proteins needed these mended shapes to function. But in the last two decades, a new class of intrinsically disordered proteins (IDPs) have been found that have large areas that are\"floppy\"--which is, they don\'t fold into a defined 3-D shape. It\'s currently understood these areas play an important, previously unrecognized role in controlling different cellular functions.\r\n\r\nIDPs can also be helpful for biomedical applications because they can undergo phase transitions--changing from a liquid into a gel, for example, or by a soluble to an insoluble state, and again--in response to environmental triggers, such as fluctuations in temperature. These attributes also dictate their phase behaviour in cellular environments and are commanded by adjusting attributes of the IDPs for example their molecular weight or the sequence where the amino acids have been connected together.\r\n\r\n\"Others in the field have taken a top-level strategy where they\'ll make a change to a natural IDP and determine how its behavior changes inside a cell,\" explained Michael Dzuricky, a research scientist working in the Chilkoti laboratory and first author of the study. \"We are taking the opposite approach and constructing our own artificial IDPs from straightforward thermodynamic principles. This empowers us and others to precisely tune one property--the form of the phase diagram--to better understand how this parameter affects biological behavior\"\r\n\r\n<em>Although there are many natural IDPs that show phase behavior in cells, they come in many different flavors, and it has been difficult to discern the rules that govern this behavior. This paper provides very simple engineering principles to program this behavior within a cell.\"-</em>Ashutosh Chilkoti, the Alan L. Kaganov Distinguished Professor of Biomedical Engineering at Duke\r\n\r\nThese weakly-held-together constructions allow cells to make compartments without also constructing a membrane to encapsulate it.\r\n\r\nThis simpler version enabled the researchers to make precise adjustments to the molecular weight of their IDP and amino acids of the IDPs. The researchers show that, based on just how these two factors are tweaked, the IDPs come together to form these compartments at different temperatures in a test tube. And by always trying a variety of temperatures and tweaks, the researchers obtained a good understanding of which layout parameters are most important to control the IDP\'s behaviour.\r\n\r\nAs predicted, their artificial IDPs grouped together to make a very small droplet within the cell\'s cytoplasm. And because the IDP\'s behavior was so well known, the researchers revealed they could predictably control how they coalesced using their evaluation tube principles as a guide.\r\n\"We were able to change temperatures in cells to develop a complete description of their phase behavior, which mirrored our evaluation tube predictions,\" explained Dzuricky. \"At this point, we were able to design distinct artificial IDP systems where the droplets that are formed have different material properties.\"\r\n\r\nPut the other way, since the researchers understood how to manipulate the size and composition of their IDPs to react to temperature, they can program the IDPs to form droplets or bubbles of varying densities within cells. To show this ability might be useful to biomedical engineers, the investigators subsequently used their newfound expertise, as nature frequently does, to create an organelle that performs a particular function within a cell.\r\n\r\nThe researchers showed that they might utilize the IDPs to create an enzyme to control its action level. By varying the molecular weight of the IDPs, the IDPs hold about the receptor either increased or diminished, which in turn affected how much it may interact with the remainder of the cell.\r\n\r\nTo demonstrate this ability, the researchers chose an enzyme used by E. coli to convert lactose into usable sugars. Nonetheless, in this circumstance, the investigators tracked this enzyme\'s activity with a fluorescent reporter at real time to determine the way the engineered IDP organelle was affecting enzyme action.\r\n\r\nLater on, the investigators believe they could use their new IDP organelles to restrain the activity levels of biomolecules important to illness conditions. Or to learn how normal IDPs fill similar cellular roles and understand exactly how and why they sometimes malfunction.\r\n\r\n\"That is the first time anyone was able to precisely specify the method by which the protein sequence controls phase separation behavior inside cells,\" said Dzuricky. \"We used an artificial system, but we believe the same rules apply to natural IDPs and are excited to begin testing this concept.\"\r\n\r\n\"We can also now start to program this type of phase behavior with almost any protein in a cell by alerting them to those artificial IDPs,\" said Chilkoti. \"We expect that these synthetic IDPs will offer a new tool for synthetic biology to control cell behavior.\"\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.duke.edu/\" target=\"_blank\" rel=\"noopener noreferrer\">Duke University</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nDzuricky, M., <em>et al.</em> (2020) De novo engineering of intracellular condensates using artificial disordered proteins. Nature Chemistry<em>.</em><span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://doi.org/10.1038/s41557-020-0511-7\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1038/s41557-020-0511-7</a>.</span>\r\n\r\n</div>','Biomedical scientists make counterfeit organelles to control biological function in cells','','inherit','closed','closed','','6909-revision-v1','','','2020-08-07 06:22:55','2020-08-07 06:22:55','',6909,'https://microbiozindia.com/uncategorized/6909-revision-v1/',0,'revision','',0),(6912,2,'2020-08-07 09:13:47','2020-08-07 09:13:47','BD (Becton, Dickinson and Company), Franklin Lakes, NJ, received a premarket approval (PMA) supplement in the FDA for an Enlarged version of its BD Onclarity human papillomavirus (HPV) assay.\r\nThe PMA supplement comprises the expansion for genotype reporting past HPV genotypes 16, 18, and 45 to comprise types 31, 51, 52, 33/58, 35/39/68, and 56/59/66, making the BD Onclarity HPV Assay the only FDA-approved assay to individually identify and report these genotype outcomes.\r\nThe worth of elongated genotyping for cervical cancer screening and triage was reported from large clinical trials since 2015. Additionally, the need for expanded HPV genotyping for cervical screening was recognized since 2016. Oftentimes, the coverage of HPV genotypes with all the screening test result could improve risk stratification and support risk-based patient management. The April 2020 book of this ASCCP risk-based management consensus guidelines expected that extended genotyping will be introduced soon.\r\n\r\n\"BD Onclarity extended genotyping is data-driven precision medication at its best, helping us effectively and efficiently manage our patients,\" says Mark H. Stoler, MD, professor emeritus of pathology, University of Virginia Health System. \"Contemporary management of women with abnormal cervical cancer screening outcomes necessitates an evaluation of their threat of precancer. Plenty of recent science clearly demonstrates that knowing the HPV genotype of the patient offers excellent differential stratification of these risks.\"\r\n\r\n\"It is well known that different HPV genotypes carry distinct risk of cervical cancer, and with no particular understanding of the HPV genotype in a screening sample most girls will be over-treated needlessly,\" says Jesper Bonde, PhD, senior researcher and molecular pathology lab manager, Hvidovre Hospital, Denmark. \"Screening strategies that use HPV tests with simultaneous genotyping offer a easy way to improve cervical cancer screening to the benefit of the female and health care providers by enabling risk stratification on the screening sample\"\r\n\r\nThe coverage of HPV genotypes together with all the screening evaluations and surveillance tests will facilitate same-genotype persistence monitoring and risk-based management. A new systematic review by Bottari et al concluded that,\"analysis of the HPV genotype persistence may signify a legitimate option to monitor patients treated for CIN 2lesions, since relapses were detected only in patients with persistence of the exact same genotype detected at baseline.\"\r\n\r\n\"With this FDA approval, BD can now offer labs, clinicians and patients access to crucial information in screening for cervical cancer in the USA and other nations recognizing the PMA supplement or CE mark,\" states Dave Hickey, president, integrated diagnostic alternatives at BD. \"Our purpose is to continue the global fight towards eliminating diseases and associated deaths due to cervical cancer with our comprehensive diagnostic alternatives.\"\r\n\r\nFor more information, visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.bd.com/en-us\">BD</a>.</span>','BD Extended HPV Testing Gets FDA Approval','','publish','open','open','','bd-extended-hpv-testing-gets-fda-approval','','','2020-08-07 09:13:47','2020-08-07 09:13:47','',0,'https://microbiozindia.com/?p=6912',0,'post','',0),(6913,2,'2020-08-07 09:13:33','2020-08-07 09:13:33','','Onclarity_HPV_ReagentPack_HR_001-cropped','','inherit','open','closed','','onclarity_hpv_reagentpack_hr_001-cropped','','','2020-08-07 09:13:33','2020-08-07 09:13:33','',6912,'https://microbiozindia.com/wp-content/uploads/2020/08/Onclarity_HPV_ReagentPack_HR_001-cropped.jpg',0,'attachment','image/jpeg',0),(6914,2,'2020-08-07 09:13:47','2020-08-07 09:13:47','BD (Becton, Dickinson and Company), Franklin Lakes, NJ, received a premarket approval (PMA) supplement in the FDA for an Enlarged version of its BD Onclarity human papillomavirus (HPV) assay.\r\nThe PMA supplement comprises the expansion for genotype reporting past HPV genotypes 16, 18, and 45 to comprise types 31, 51, 52, 33/58, 35/39/68, and 56/59/66, making the BD Onclarity HPV Assay the only FDA-approved assay to individually identify and report these genotype outcomes.\r\nThe worth of elongated genotyping for cervical cancer screening and triage was reported from large clinical trials since 2015. Additionally, the need for expanded HPV genotyping for cervical screening was recognized since 2016. Oftentimes, the coverage of HPV genotypes with all the screening test result could improve risk stratification and support risk-based patient management. The April 2020 book of this ASCCP risk-based management consensus guidelines expected that extended genotyping will be introduced soon.\r\n\r\n\"BD Onclarity extended genotyping is data-driven precision medication at its best, helping us effectively and efficiently manage our patients,\" says Mark H. Stoler, MD, professor emeritus of pathology, University of Virginia Health System. \"Contemporary management of women with abnormal cervical cancer screening outcomes necessitates an evaluation of their threat of precancer. Plenty of recent science clearly demonstrates that knowing the HPV genotype of the patient offers excellent differential stratification of these risks.\"\r\n\r\n\"It is well known that different HPV genotypes carry distinct risk of cervical cancer, and with no particular understanding of the HPV genotype in a screening sample most girls will be over-treated needlessly,\" says Jesper Bonde, PhD, senior researcher and molecular pathology lab manager, Hvidovre Hospital, Denmark. \"Screening strategies that use HPV tests with simultaneous genotyping offer a easy way to improve cervical cancer screening to the benefit of the female and health care providers by enabling risk stratification on the screening sample\"\r\n\r\nThe coverage of HPV genotypes together with all the screening evaluations and surveillance tests will facilitate same-genotype persistence monitoring and risk-based management. A new systematic review by Bottari et al concluded that,\"analysis of the HPV genotype persistence may signify a legitimate option to monitor patients treated for CIN 2lesions, since relapses were detected only in patients with persistence of the exact same genotype detected at baseline.\"\r\n\r\n\"With this FDA approval, BD can now offer labs, clinicians and patients access to crucial information in screening for cervical cancer in the USA and other nations recognizing the PMA supplement or CE mark,\" states Dave Hickey, president, integrated diagnostic alternatives at BD. \"Our purpose is to continue the global fight towards eliminating diseases and associated deaths due to cervical cancer with our comprehensive diagnostic alternatives.\"\r\n\r\nFor more information, visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.bd.com/en-us\">BD</a>.</span>','BD Extended HPV Testing Gets FDA Approval','','inherit','closed','closed','','6912-revision-v1','','','2020-08-07 09:13:47','2020-08-07 09:13:47','',6912,'https://microbiozindia.com/uncategorized/6912-revision-v1/',0,'revision','',0),(6915,2,'2020-08-07 14:40:23','2020-08-07 14:40:23','Unlike earlier studies, scientists have found that severe COVID-19 does not solely bring about a hyperactive immune system, but instead the body\'s defense response is captured in a constant loop of activation and inhibition, an advance that may help develop superior therapeutics to combat the deadly illness.\r\n\r\nThe researchers, such as those from the Center for Neurodegenerative Diseases (DZNE), assessed blood samples by a total of 53 men and women with COVID-19 from Berlin and Bonn in Germany, whose path of disease was abbreviated as moderate or severe based on the World Health Organization (WHO) classification.\r\n\r\nIn the study, published in the journal Cell, they assessed the gene activity and the amount of proteins on the level of human immune cells circulating in the bloodstream of the patients using very large resolution single-cell OMICs technologies.\r\n\r\n\"By implementing bioinformatics methods on this exceptionally detailed data collection of this gene activity of every individual cell, we can obtain a comprehensive insight of the continuing processes in the white blood cells,\" explained Yang Li, a co-author of the study by the Centre for Individualised Infection Medicine (CiiM) in Germany.\r\n\r\n\"In combination with the observation of important proteins on the surface of immune cellswe were able to decode the changes in the immune system of patients using COVID-19,\" additional Birgit Sawitzki, yet another co-author of this study.\r\n\r\nThe scientists found that in severe cases of COVID-19 the immune cells known as neutrophils and monocytes in these patients are only partially activated and they do not function properly.\r\n\r\nHowever, these immune cells were found to be ready to defend the patient against COVID-19 in the case of mild disease classes, explained Antoine-Emmanuel Saliba, yet another co-author of the analysis.\r\n\r\n\"They can also be programmed to trigger the remaining immune system. This ultimately contributes to an effective immune response against the virus,\" Saliba said.\r\n\r\nBut in acute COVID-19 cases, the scientists noticed that there are considerably more immature neutrophils and monocytes that have a\"rather synergistic effect on the immune reaction\"\r\n\r\nThis phenomenon, according to the scientists, may also be observed in other severe ailments, even though the reason for this is uncertain.\r\n\r\n\"Many indications indicate that the immune system stands in its own way during acute courses of COVID-19,\" said research co-author Leif Erik Sander.\r\n\r\n\"This could possibly cause an inadequate immune response against the coronavirus, with a simultaneous severe inflammation in the lung tissue,\" Sander added.\r\n\r\nAccording to the researchers, the current findings could lead to new therapeutic choices.\r\n\r\n\"Our data suggest that in severe instances of COVID-19, plans should be considered go beyond the treatment of other viral diseases,\" said research co-author Anna Aschenbrenner from the University of Bonn in Germany.\r\n\r\nIn the case of viral infections, suppressing the immune system might not be beneficial, according to the scientists.\r\n\r\n\"If, but there are a lot of dysfunctional immune cells, as our study shows, then one would very much like to suppress or reprogram cells that are such \" Jacob Nattermann, another co-author of this study by the University Hospital Bonn.\r\n\r\n\"Drugs that act on the immune system might have the ability to help. However, this can be a delicate balancing act. After all, it is not an issue of shutting down the immune system completely, but only those cells which slow themselves down, so to speak,\" Nattermann explained.\r\n\r\nHe added that scientists could have a page from cancer research in attempting to understand ways to take care of these immature cells.','Researchers disentangle how safe immune system glitches in extreme COVID-19 cases','','publish','open','open','','researchers-disentangle-how-safe-immune-system-glitches-in-extreme-covid-19-cases','','','2020-08-07 14:40:23','2020-08-07 14:40:23','',0,'https://microbiozindia.com/?p=6915',0,'post','',0),(6916,2,'2020-08-07 14:40:23','2020-08-07 14:40:23','Unlike earlier studies, scientists have found that severe COVID-19 does not solely bring about a hyperactive immune system, but instead the body\'s defense response is captured in a constant loop of activation and inhibition, an advance that may help develop superior therapeutics to combat the deadly illness.\r\n\r\nThe researchers, such as those from the Center for Neurodegenerative Diseases (DZNE), assessed blood samples by a total of 53 men and women with COVID-19 from Berlin and Bonn in Germany, whose path of disease was abbreviated as moderate or severe based on the World Health Organization (WHO) classification.\r\n\r\nIn the study, published in the journal Cell, they assessed the gene activity and the amount of proteins on the level of human immune cells circulating in the bloodstream of the patients using very large resolution single-cell OMICs technologies.\r\n\r\n\"By implementing bioinformatics methods on this exceptionally detailed data collection of this gene activity of every individual cell, we can obtain a comprehensive insight of the continuing processes in the white blood cells,\" explained Yang Li, a co-author of the study by the Centre for Individualised Infection Medicine (CiiM) in Germany.\r\n\r\n\"In combination with the observation of important proteins on the surface of immune cellswe were able to decode the changes in the immune system of patients using COVID-19,\" additional Birgit Sawitzki, yet another co-author of this study.\r\n\r\nThe scientists found that in severe cases of COVID-19 the immune cells known as neutrophils and monocytes in these patients are only partially activated and they do not function properly.\r\n\r\nHowever, these immune cells were found to be ready to defend the patient against COVID-19 in the case of mild disease classes, explained Antoine-Emmanuel Saliba, yet another co-author of the analysis.\r\n\r\n\"They can also be programmed to trigger the remaining immune system. This ultimately contributes to an effective immune response against the virus,\" Saliba said.\r\n\r\nBut in acute COVID-19 cases, the scientists noticed that there are considerably more immature neutrophils and monocytes that have a\"rather synergistic effect on the immune reaction\"\r\n\r\nThis phenomenon, according to the scientists, may also be observed in other severe ailments, even though the reason for this is uncertain.\r\n\r\n\"Many indications indicate that the immune system stands in its own way during acute courses of COVID-19,\" said research co-author Leif Erik Sander.\r\n\r\n\"This could possibly cause an inadequate immune response against the coronavirus, with a simultaneous severe inflammation in the lung tissue,\" Sander added.\r\n\r\nAccording to the researchers, the current findings could lead to new therapeutic choices.\r\n\r\n\"Our data suggest that in severe instances of COVID-19, plans should be considered go beyond the treatment of other viral diseases,\" said research co-author Anna Aschenbrenner from the University of Bonn in Germany.\r\n\r\nIn the case of viral infections, suppressing the immune system might not be beneficial, according to the scientists.\r\n\r\n\"If, but there are a lot of dysfunctional immune cells, as our study shows, then one would very much like to suppress or reprogram cells that are such \" Jacob Nattermann, another co-author of this study by the University Hospital Bonn.\r\n\r\n\"Drugs that act on the immune system might have the ability to help. However, this can be a delicate balancing act. After all, it is not an issue of shutting down the immune system completely, but only those cells which slow themselves down, so to speak,\" Nattermann explained.\r\n\r\nHe added that scientists could have a page from cancer research in attempting to understand ways to take care of these immature cells.','Researchers disentangle how safe immune system glitches in extreme COVID-19 cases','','inherit','closed','closed','','6915-revision-v1','','','2020-08-07 14:40:23','2020-08-07 14:40:23','',6915,'https://microbiozindia.com/uncategorized/6915-revision-v1/',0,'revision','',0),(6917,2,'2020-08-07 14:42:28','2020-08-07 14:42:28','The US drugmaker would provide contract manufacturing services in its facility in Kansas to create the medication.\r\nPfizer Inc said on Friday it signed up a multi-year agreement with Gilead Sciences Inc to manufacture and provide the organization\'s antiviral drug remdesivir for COVID-19 patients.\r\n\r\nThe US drugmaker would provide contract manufacturing services at its center in Kansas to produce the drug.','Pfizer signs deal to produce and flexibly Gilead\'s remdesivir for COVID-19 treatment','','publish','open','open','','pfizer-signs-deal-to-produce-and-flexibly-gileads-remdesivir-for-covid-19-treatment','','','2020-08-07 14:42:28','2020-08-07 14:42:28','',0,'https://microbiozindia.com/?p=6917',0,'post','',0),(6918,2,'2020-08-07 14:42:28','2020-08-07 14:42:28','The US drugmaker would provide contract manufacturing services in its facility in Kansas to create the medication.\r\nPfizer Inc said on Friday it signed up a multi-year agreement with Gilead Sciences Inc to manufacture and provide the organization\'s antiviral drug remdesivir for COVID-19 patients.\r\n\r\nThe US drugmaker would provide contract manufacturing services at its center in Kansas to produce the drug.','Pfizer signs deal to produce and flexibly Gilead\'s remdesivir for COVID-19 treatment','','inherit','closed','closed','','6917-revision-v1','','','2020-08-07 14:42:28','2020-08-07 14:42:28','',6917,'https://microbiozindia.com/uncategorized/6917-revision-v1/',0,'revision','',0),(6919,2,'2020-08-07 14:48:39','2020-08-07 14:48:39','A test made by UCLA researchers could pinpoint which individuals with gonorrhea will react successfully to the inexpensive oral antibiotic ciprofloxacin, which had formerly been sidelined over concerns the bacterium that causes the disease was becoming resistant to it.\r\n\r\nIn study published in the peer-reviewed journal Clinical Infectious Diseases, a UCLA-led team found that of 106 subjects the evaluation identified as having a strain of gonorrhea known as wild-type gyrA serine, all were cured with a single dose of oral ciprofloxacin.\r\n\r\nThough the evaluation has been available for three years, this is actually the first time it has been systematically studied in humans.\r\n\r\n<span style=\"text-decoration: underline;\"><em>Gonorrhea is one of the most common drug-resistant infections worldwide and is becoming harder to treat. Current treatment methods require an antibiotic injection, which is expensive and painful.This new test could make it easier and safer to treat gonorrhea with different antibiotics, including one pill given by mouth.\"</em></span>Klausner, Adjunct Professor, Department of Epidemiology, University of California - Los Angeles Health Sciences\r\n\r\n\"Using a pill rather than a shooter would also make it easier and quicker to take care of sex partners of patients with gonorrhea,\" he added.\r\n\r\nThe ability of bacteria to alter over time in ways that limit or eliminate the effectiveness of drugs designed to kill them has created a global issue. Gonorrhea is particularly skilled in this regard and has developed increasing resistance to all recent antibiotics.\r\nDue to the spread of multidrug-resistant gonorrhea, public health authorities have declared it one of the top five urgent dangers to public health.\r\n\r\nScientists have been trying to determine how to identify instances for targeted usage of ciprofloxacin treatment, reducing the need to utilize the injectable antibiotic ceftriaxone and lowering the risk of resistance to that drug. Gonorrhea\'s resistance speed to ceftriaxone is now less than 1%.\r\n\r\nThe DNA test the investigators developed detects a distinct genetic mutation from the gonorrhea bacterium which makes it resistant to ciprofloxacin. Ciprofloxacin is highly effective against infections with no mutation.\r\n\r\nThe investigators note that the findings have been limited by the comparatively small number of individuals studied and the fact that participation was confined to asymptomatic individuals.\r\n\r\nAdditionally, many people who were initially diagnosed with an wild-type strain during the test were subsequently found to be infected with additional breed types.\r\n\r\n<a href=\"https://www.uclahealth.org/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"text-decoration: underline;\"><span style=\"color: #000000; text-decoration: underline;\">Source :</span></span><span style=\"color: #ff6600;\">University of California - Los Angeles Health Sciences</span></a>','New test can pinpoint which individuals with gonorrhea can be relieved with ciprofloxacin','','publish','open','open','','new-test-can-pinpoint-which-individuals-with-gonorrhea-can-be-relieved-with-ciprofloxacin','','','2020-08-07 14:48:39','2020-08-07 14:48:39','',0,'https://microbiozindia.com/?p=6919',0,'post','',0),(6920,2,'2020-08-07 14:48:28','2020-08-07 14:48:28','','ciprofloxacin','','inherit','open','closed','','ciprofloxacin','','','2020-08-07 14:48:28','2020-08-07 14:48:28','',6919,'https://microbiozindia.com/wp-content/uploads/2020/08/ciprofloxacin.jpg',0,'attachment','image/jpeg',0),(6921,2,'2020-08-07 14:48:39','2020-08-07 14:48:39','A test made by UCLA researchers could pinpoint which individuals with gonorrhea will react successfully to the inexpensive oral antibiotic ciprofloxacin, which had formerly been sidelined over concerns the bacterium that causes the disease was becoming resistant to it.\r\n\r\nIn study published in the peer-reviewed journal Clinical Infectious Diseases, a UCLA-led team found that of 106 subjects the evaluation identified as having a strain of gonorrhea known as wild-type gyrA serine, all were cured with a single dose of oral ciprofloxacin.\r\n\r\nThough the evaluation has been available for three years, this is actually the first time it has been systematically studied in humans.\r\n\r\n<span style=\"text-decoration: underline;\"><em>Gonorrhea is one of the most common drug-resistant infections worldwide and is becoming harder to treat. Current treatment methods require an antibiotic injection, which is expensive and painful.This new test could make it easier and safer to treat gonorrhea with different antibiotics, including one pill given by mouth.\"</em></span>Klausner, Adjunct Professor, Department of Epidemiology, University of California - Los Angeles Health Sciences\r\n\r\n\"Using a pill rather than a shooter would also make it easier and quicker to take care of sex partners of patients with gonorrhea,\" he added.\r\n\r\nThe ability of bacteria to alter over time in ways that limit or eliminate the effectiveness of drugs designed to kill them has created a global issue. Gonorrhea is particularly skilled in this regard and has developed increasing resistance to all recent antibiotics.\r\nDue to the spread of multidrug-resistant gonorrhea, public health authorities have declared it one of the top five urgent dangers to public health.\r\n\r\nScientists have been trying to determine how to identify instances for targeted usage of ciprofloxacin treatment, reducing the need to utilize the injectable antibiotic ceftriaxone and lowering the risk of resistance to that drug. Gonorrhea\'s resistance speed to ceftriaxone is now less than 1%.\r\n\r\nThe DNA test the investigators developed detects a distinct genetic mutation from the gonorrhea bacterium which makes it resistant to ciprofloxacin. Ciprofloxacin is highly effective against infections with no mutation.\r\n\r\nThe investigators note that the findings have been limited by the comparatively small number of individuals studied and the fact that participation was confined to asymptomatic individuals.\r\n\r\nAdditionally, many people who were initially diagnosed with an wild-type strain during the test were subsequently found to be infected with additional breed types.\r\n\r\n<a href=\"https://www.uclahealth.org/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"text-decoration: underline;\"><span style=\"color: #000000; text-decoration: underline;\">Source :</span></span><span style=\"color: #ff6600;\">University of California - Los Angeles Health Sciences</span></a>','New test can pinpoint which individuals with gonorrhea can be relieved with ciprofloxacin','','inherit','closed','closed','','6919-revision-v1','','','2020-08-07 14:48:39','2020-08-07 14:48:39','',6919,'https://microbiozindia.com/uncategorized/6919-revision-v1/',0,'revision','',0),(6922,2,'2020-08-08 16:36:02','2020-08-08 16:36:02','Drug firm Jubilant Life Sciences on Saturday said it has introduced 1,000 vials of antiviral drug Remdesivir that it sells under the brand name\'JUBI-R\' into Uttar Pradesh Chief Minister Yogi Adityanath.\r\n\r\nThe drug has been made accessible to over 1,000 hospitals supplying COVID-19 treatment in India throughout the organization\'s distribution system, Jubilant Life Sciences said in a statement.\r\n\r\n\"Remdesivir is an effective medication in the treatment of severe COVID-19 instances. In this critical situation, I am pleased that this medicine was made available by Jubilant at the brief period of 2 and a half a year,\" the firm quoted Adityanath as stating.\r\n\r\nIn May 2020,\'\' Jubilant entered into a non-exclusive licensing agreement with Gilead Sciences, Inc., which granted it the right to enroll, fabricate and promote Gilead\'s investigational drug remdesivir in 127 countries including India, the company said.','Jubilant Life Sciences presents 1,000 vials of Remdesivir to Uttar Pradesh CM Yogi Adityanath','','publish','open','open','','jubilant-life-sciences-presents-1000-vials-of-remdesivir-to-uttar-pradesh-cm-yogi-adityanath','','','2020-08-08 16:36:02','2020-08-08 16:36:02','',0,'https://microbiozindia.com/?p=6922',0,'post','',0),(6923,2,'2020-08-08 16:36:02','2020-08-08 16:36:02','Drug firm Jubilant Life Sciences on Saturday said it has introduced 1,000 vials of antiviral drug Remdesivir that it sells under the brand name\'JUBI-R\' into Uttar Pradesh Chief Minister Yogi Adityanath.\r\n\r\nThe drug has been made accessible to over 1,000 hospitals supplying COVID-19 treatment in India throughout the organization\'s distribution system, Jubilant Life Sciences said in a statement.\r\n\r\n\"Remdesivir is an effective medication in the treatment of severe COVID-19 instances. In this critical situation, I am pleased that this medicine was made available by Jubilant at the brief period of 2 and a half a year,\" the firm quoted Adityanath as stating.\r\n\r\nIn May 2020,\'\' Jubilant entered into a non-exclusive licensing agreement with Gilead Sciences, Inc., which granted it the right to enroll, fabricate and promote Gilead\'s investigational drug remdesivir in 127 countries including India, the company said.','Jubilant Life Sciences presents 1,000 vials of Remdesivir to Uttar Pradesh CM Yogi Adityanath','','inherit','closed','closed','','6922-revision-v1','','','2020-08-08 16:36:02','2020-08-08 16:36:02','',6922,'https://microbiozindia.com/uncategorized/6922-revision-v1/',0,'revision','',0),(6924,2,'2020-08-08 16:37:23','2020-08-08 16:37:23','Relief Therapeutics\' chairman said that he was optimistic that its RLF-100 (aviptadil) drug will acquire approval for treating COVID-19 patients in a matter of months.\r\n\r\nThe Swiss group owns the rights to the drug in the United States and Europe.\r\n\r\nIts US spouse NeuroRx is conducting multicentre clinical trials in patients that are severely ill due to the consequences of COVID-19, the respiratory disorder brought on by the new coronavirus.\r\n\r\n\"The active pharmaceutical ingredient of aviptadil has been utilized for a lot of years in different indications. From a security standpoint we are very optimistic,\" Raghuram Selvaraju told Swiss newspaper The Marketplace in an interview published late on Friday.\r\n\r\n\"From a performance standpoint we want more data. I\'d say the probability in the moment stands at 60 to 70 percent which we\'re going to find the drug approved,\" he added.\r\n\r\nSelvaraju said trial results could emerge within a\"couple more months\".\r\n\r\n\"When we get meaningful data, I would anticipate that the FDA (US Food and Drug Administration) would act in an expedient and collaborative method. I do not expect that we would require ten to 12 months for approval,\" he added.\r\n\r\nRelief Therapeutics states aviptadil, a synthetic vasoactive intestinal polypeptide, is the first COVID-19 therapeutic to block replication of the SARS-CoV-2 virus from human lung cells.\r\n\r\nAnticipation of advancement has driven shares in the Geneva-based firm sharply higher this season. They closed on Friday in 0.58 Swiss francs after beginning the year in 0.0010 francs.','Relief Therapeutics sees 60-70% possibility of COVID-19 medication endorsement','','publish','open','open','','relief-therapeutics-sees-60-70-possibility-of-covid-19-medication-endorsement','','','2020-08-08 16:37:23','2020-08-08 16:37:23','',0,'https://microbiozindia.com/?p=6924',0,'post','',0),(6925,2,'2020-08-08 16:37:23','2020-08-08 16:37:23','Relief Therapeutics\' chairman said that he was optimistic that its RLF-100 (aviptadil) drug will acquire approval for treating COVID-19 patients in a matter of months.\r\n\r\nThe Swiss group owns the rights to the drug in the United States and Europe.\r\n\r\nIts US spouse NeuroRx is conducting multicentre clinical trials in patients that are severely ill due to the consequences of COVID-19, the respiratory disorder brought on by the new coronavirus.\r\n\r\n\"The active pharmaceutical ingredient of aviptadil has been utilized for a lot of years in different indications. From a security standpoint we are very optimistic,\" Raghuram Selvaraju told Swiss newspaper The Marketplace in an interview published late on Friday.\r\n\r\n\"From a performance standpoint we want more data. I\'d say the probability in the moment stands at 60 to 70 percent which we\'re going to find the drug approved,\" he added.\r\n\r\nSelvaraju said trial results could emerge within a\"couple more months\".\r\n\r\n\"When we get meaningful data, I would anticipate that the FDA (US Food and Drug Administration) would act in an expedient and collaborative method. I do not expect that we would require ten to 12 months for approval,\" he added.\r\n\r\nRelief Therapeutics states aviptadil, a synthetic vasoactive intestinal polypeptide, is the first COVID-19 therapeutic to block replication of the SARS-CoV-2 virus from human lung cells.\r\n\r\nAnticipation of advancement has driven shares in the Geneva-based firm sharply higher this season. They closed on Friday in 0.58 Swiss francs after beginning the year in 0.0010 francs.','Relief Therapeutics sees 60-70% possibility of COVID-19 medication endorsement','','inherit','closed','closed','','6924-revision-v1','','','2020-08-08 16:37:23','2020-08-08 16:37:23','',6924,'https://microbiozindia.com/uncategorized/6924-revision-v1/',0,'revision','',0),(6926,2,'2020-08-08 16:39:35','2020-08-08 16:39:35','Scientists have identified a structure in host cells which the novel coronavirus likely uses to synthesise elements that will be assembled into completely infectious germs, an advance that might lead to the development of new medications against COVID-19.\r\n\r\nThe analysis, published in the journal Science Advances, uncovers a coronavirus-specific structure in cells, which might work as a goal for much-needed antiviral strategies from the family of viruses.\r\n\r\nAccording to the scientists, such as those in the Leibnitz Institute of Experimental Virology at Germany, coronaviruses replicate their big genomes in the host cell\'s cytosol -- the jelly-like material in which the components of the mobile are suspended.\r\n\r\nThey said the viruses replicate by altering host cell membranes into peculiar double-membrane vesicle (DMV) structures.\r\n\r\nIn the present study, they noted that the newly made viral genetic material, its RNA molecule, has to be exported from these DMVs into the cytoplasm to be packed into complete, infectious strains of this virus.\r\n\r\nSo far, however, they said no openings into the cytosol are detected from the DMV replication compartments.\r\n\r\nSeeking to know how viral RNA is exported from sealed DMVs, the scientists, Georg Wolff and his coworkers, used a potent microscopy technique known as electron tomography to visualise the middle phase of infection of a cell from mouse hepatitis coronavirus.\r\n\r\nThey said this virus has been used instead of the novel coronavirus SARS-CoV-2 due to biosafety constraints for such electron microscopy studies.\r\n\r\nThe scientists also discovered a coronavirus-specific crown-shaped structure -- a molecular pore spanning both DMV membranes -- that likely plays a part during RNA release in the compartment.\r\n\r\nThen using pre-fixed samples of SARS-CoV-2-infected cells, they showed that the arrangement can also be found in SARS-CoV-2-induced DMVs.\r\n\r\nAccording to the researchers, this structure might be a generic complicated with a pivotal role in the coronavirus replication cycle, facilitating the export of newly synthesised viral RNA from the DMVs to the cytosol.\r\n\r\n\"Although the exact mode of function of this molecular pore remains to be elucidated, it may provide a general coronavirus-specific drug target,\" the scientists noted.','Researchers distinguish cell structure that may assume basic job in coronavirus replication','','publish','open','open','','researchers-distinguish-cell-structure-that-may-assume-basic-job-in-coronavirus-replication','','','2020-08-08 16:39:35','2020-08-08 16:39:35','',0,'https://microbiozindia.com/?p=6926',0,'post','',0),(6927,2,'2020-08-08 16:39:35','2020-08-08 16:39:35','Scientists have identified a structure in host cells which the novel coronavirus likely uses to synthesise elements that will be assembled into completely infectious germs, an advance that might lead to the development of new medications against COVID-19.\r\n\r\nThe analysis, published in the journal Science Advances, uncovers a coronavirus-specific structure in cells, which might work as a goal for much-needed antiviral strategies from the family of viruses.\r\n\r\nAccording to the scientists, such as those in the Leibnitz Institute of Experimental Virology at Germany, coronaviruses replicate their big genomes in the host cell\'s cytosol -- the jelly-like material in which the components of the mobile are suspended.\r\n\r\nThey said the viruses replicate by altering host cell membranes into peculiar double-membrane vesicle (DMV) structures.\r\n\r\nIn the present study, they noted that the newly made viral genetic material, its RNA molecule, has to be exported from these DMVs into the cytoplasm to be packed into complete, infectious strains of this virus.\r\n\r\nSo far, however, they said no openings into the cytosol are detected from the DMV replication compartments.\r\n\r\nSeeking to know how viral RNA is exported from sealed DMVs, the scientists, Georg Wolff and his coworkers, used a potent microscopy technique known as electron tomography to visualise the middle phase of infection of a cell from mouse hepatitis coronavirus.\r\n\r\nThey said this virus has been used instead of the novel coronavirus SARS-CoV-2 due to biosafety constraints for such electron microscopy studies.\r\n\r\nThe scientists also discovered a coronavirus-specific crown-shaped structure -- a molecular pore spanning both DMV membranes -- that likely plays a part during RNA release in the compartment.\r\n\r\nThen using pre-fixed samples of SARS-CoV-2-infected cells, they showed that the arrangement can also be found in SARS-CoV-2-induced DMVs.\r\n\r\nAccording to the researchers, this structure might be a generic complicated with a pivotal role in the coronavirus replication cycle, facilitating the export of newly synthesised viral RNA from the DMVs to the cytosol.\r\n\r\n\"Although the exact mode of function of this molecular pore remains to be elucidated, it may provide a general coronavirus-specific drug target,\" the scientists noted.','Researchers distinguish cell structure that may assume basic job in coronavirus replication','','inherit','closed','closed','','6926-revision-v1','','','2020-08-08 16:39:35','2020-08-08 16:39:35','',6926,'https://microbiozindia.com/uncategorized/6926-revision-v1/',0,'revision','',0),(6928,2,'2020-08-08 16:49:28','2020-08-08 16:49:28','India’s leading manufacturer of Sterile Injectables company to soon enter the EU markets with various range of injectables and expand gradually.\r\n\r\nSwiss Parenterals Limited, one of the India’s leading sterile injectable manufacturer has received the European Union (EU) GMP for its two state of the art manufacturing facilities located at Bavla in Gujarat. The certification will allow the company to market its product in all the 27 member countries of EU and also give access to European Economic Area (EEA) countries.\r\n\r\nThe company plans to enter in the EU and EEA with its super specialty niche molecules in sterile injectables segment.\r\n\r\nThe inspection was carried out in the end February 2020 and first week of March 2020 for both of its site situated in Bavla, Ahmedabad. The final approval received on 31st of July 2020.\r\n\r\nThe company is currently engaged in manufacturing sterile injectables in both liquid and powder forms and covers a special segment of niche injectables in various dosage like ampoules, vials, lyophilization, pre filled syringe, cartridges, sterile eye drops and expanding soon into liquid inhalation anesthesia, sterile ointment and suppositories. Above this the company is also engaged in contract manufacturing of oral solid dosage including tablets, capsules and other forms from its various vendors.\r\n\r\nMr. Vikram Shah, Managing Director, Swiss Parenterals Limited said. “We are very delighted to receive the EU GMP accreditation for our sterile manufacturing plants and this is an outcome of our great team work, I am thankful to the members of the company who are maintaining the GMP standards”\r\n\r\nMrs Sindhu Marar, Director International Business, said “This approval is very important to us and the stepping stone to increase our international foot print. The company had previously approval of EU GMP on its one of the manufacturing sites along with PIC/s and TGA Australia approval, post which this year company decided to go for EU GMP approval for its both injectables site in Ahmedabad.\r\n\r\nMr Naishadh Shah and Mr Piyush Pandya, Directors who are responsible for the operations said “EU GMP approval is the result of stringent quality and compliance norms followed at Swiss Parenterals across all department and especially in Microbiology and Quality assurance including data compliance.\r\n\r\nWith the EU GMP approval the company will focus to cater to the niche segment and growing needs of injectables around the world. The company plans to enter along with the EU and EEA now through the Mutual Recognition Agreements (MRA) to various other stringent regulated markets including Brazil, Colombia, Mexico, Australia, New Zealand and South Africa in the first phase.\r\n\r\nThe company has been operational only in exports and this key approval will help to get a boost in sales worldwide. The company is focusing to develop new molecules year on year basis through its formulation development. Since competition in the injectables domain is less the company also is maintaining a high net profit ratio.\r\n\r\nSwiss Parenterals Limited is a third generation, unlisted family run business. The company has strong portfolio in injectables. Company is currently present in 47 countries and this approval will bring a minimum boost of 90 plus countries. Current presence of the company is across Arica, Latin America, South east Asia and Middle east.\r\n\r\nThe company believes in maintaining a high level of GMP and manufacturing more profitable products at lower production utilization and thus is not currently looking forward to enter domestic markets, and focus on export-oriented growth.','Swiss Parenterals Limited received European Union (EU) GMP approval','','publish','open','open','','swiss-parenterals-limited-received-european-union-eu-gmp-approval','','','2020-08-08 16:49:28','2020-08-08 16:49:28','',0,'https://microbiozindia.com/?p=6928',0,'post','',0),(6929,2,'2020-08-08 16:49:28','2020-08-08 16:49:28','India’s leading manufacturer of Sterile Injectables company to soon enter the EU markets with various range of injectables and expand gradually.\r\n\r\nSwiss Parenterals Limited, one of the India’s leading sterile injectable manufacturer has received the European Union (EU) GMP for its two state of the art manufacturing facilities located at Bavla in Gujarat. The certification will allow the company to market its product in all the 27 member countries of EU and also give access to European Economic Area (EEA) countries.\r\n\r\nThe company plans to enter in the EU and EEA with its super specialty niche molecules in sterile injectables segment.\r\n\r\nThe inspection was carried out in the end February 2020 and first week of March 2020 for both of its site situated in Bavla, Ahmedabad. The final approval received on 31st of July 2020.\r\n\r\nThe company is currently engaged in manufacturing sterile injectables in both liquid and powder forms and covers a special segment of niche injectables in various dosage like ampoules, vials, lyophilization, pre filled syringe, cartridges, sterile eye drops and expanding soon into liquid inhalation anesthesia, sterile ointment and suppositories. Above this the company is also engaged in contract manufacturing of oral solid dosage including tablets, capsules and other forms from its various vendors.\r\n\r\nMr. Vikram Shah, Managing Director, Swiss Parenterals Limited said. “We are very delighted to receive the EU GMP accreditation for our sterile manufacturing plants and this is an outcome of our great team work, I am thankful to the members of the company who are maintaining the GMP standards”\r\n\r\nMrs Sindhu Marar, Director International Business, said “This approval is very important to us and the stepping stone to increase our international foot print. The company had previously approval of EU GMP on its one of the manufacturing sites along with PIC/s and TGA Australia approval, post which this year company decided to go for EU GMP approval for its both injectables site in Ahmedabad.\r\n\r\nMr Naishadh Shah and Mr Piyush Pandya, Directors who are responsible for the operations said “EU GMP approval is the result of stringent quality and compliance norms followed at Swiss Parenterals across all department and especially in Microbiology and Quality assurance including data compliance.\r\n\r\nWith the EU GMP approval the company will focus to cater to the niche segment and growing needs of injectables around the world. The company plans to enter along with the EU and EEA now through the Mutual Recognition Agreements (MRA) to various other stringent regulated markets including Brazil, Colombia, Mexico, Australia, New Zealand and South Africa in the first phase.\r\n\r\nThe company has been operational only in exports and this key approval will help to get a boost in sales worldwide. The company is focusing to develop new molecules year on year basis through its formulation development. Since competition in the injectables domain is less the company also is maintaining a high net profit ratio.\r\n\r\nSwiss Parenterals Limited is a third generation, unlisted family run business. The company has strong portfolio in injectables. Company is currently present in 47 countries and this approval will bring a minimum boost of 90 plus countries. Current presence of the company is across Arica, Latin America, South east Asia and Middle east.\r\n\r\nThe company believes in maintaining a high level of GMP and manufacturing more profitable products at lower production utilization and thus is not currently looking forward to enter domestic markets, and focus on export-oriented growth.','Swiss Parenterals Limited received European Union (EU) GMP approval','','inherit','closed','closed','','6928-revision-v1','','','2020-08-08 16:49:28','2020-08-08 16:49:28','',6928,'https://microbiozindia.com/uncategorized/6928-revision-v1/',0,'revision','',0),(6930,2,'2020-08-08 16:57:43','2020-08-08 16:57:43','Engineers in the UCLA Samueli School of Engineering and their colleagues at Stanford School of Medicine have demonstrated that drug levels inside the body is able to be tracked in real time using a custom smartwatch which assesses the compounds found in sweat. This wearable technology can be incorporated into a more personalized approach to drugs -- where an perfect drug and doses could be tailored to a person.\r\n\r\nIn general, medications are prescribed using a\'one-size-fits-all\' strategy -- drugs are designed and prescribed based on statistical averages of the efficacy. You will find guidelines for variables such as individuals\' age and weight. However, along with these fundamental differentiators, our body chemistry continuously changes -- depending on what we consume and how much we\'ve exercised. And on top of these dynamic factors, every individual\'s genetic makeup is unique and consequently answers to drugs can fluctuate. This affects how fast drugs are absorbed, take effect and become eliminated from an individual.\r\n\r\nAccording to the researchers, present efforts to personalize the drug dosage rely heavily on repeated blood draws in the hospital. The samples are then sent out to be examined in central labs. These alternatives are somewhat inconvenient, time-consuming, invasive and costly. That\'s why they are only performed on a tiny subset of individuals and on rare events.\r\n\r\n<em>We wanted to create a wearable technology that can track the profile of medication inside the body continuously and non-invasively. This way, we can tailor the optimal dosage and timing of the intake for each individual. And using this personalization approach, we can improve <a class=\"linked-term\" href=\"https://www.news-medical.net/health/What-Does-Efficacy-Mean.aspx\">the efficacy of</a> the therapeutic treatments.\"-</em>Sam Emaminejad, study leader, assistant professor of electrical and computer engineering at UCLA\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://samueli.ucla.edu/smartwatch-tracks-medication-levels-to-personalize-treatments\">Due to their small molecular dimensions, many distinct kinds of drugs end up in sweat, where their concentrations closely reflect the medication\' circulating levels. That is why the researchers produced a smartwatch, equipped with a detector that assesses the sampled tiny droplets of sweat.</a></span>\r\n\r\nThe team\'s experiment tracked the effect of acetaminophen, a typical over-the-counter pain medication, on individuals within the period of a few hours. First, the researchers stimulated sweat glands on the wrist by employing a small electric currentthe same method that Emaminejad\'s research group shown in previous wearable technologies.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://samueli.ucla.edu/smartwatch-tracks-medication-levels-to-personalize-treatments\">This allowed the researchers to detect changes in body chemistry, without even needing issues to develop a sweat by exercising. As different drugs each have their own distinct electrochemical signature, the detector can be designed to look for the degree of a specific medication at any given time.</a></span>\r\n\r\n\"Emerging pharmacogenomic options, which allow us to pick drugs based on the genetic makeup of people, have already shown to be useful in enhancing the effectiveness of remedies. So, in combination with our wearable remedy, which helps us to optimize the drug dosages for every person, we can now truly personalize our approaches to pharmacotherapy.\"\r\n\r\nWhat makes this study significant is the ability to accurately discover a drug\'s unique electrochemical signal, against the backdrop of signals from many other molecules which may be circulating in the human body and in greater concentrations than the drug, \'\' said the study\'s lead author Shuyu Lin, a UCLA doctoral student and associate of Emaminejad\'s Interconnected and Integrated Bioelectronics Lab (I²BL). Emaminejad added that the technology can be adapted to monitor medication adherence and drug abuse.\r\n\r\n\"This may be particularly important for individuals with mental health issues, where physicians prescribe them protracted pharmacotherapy treatments,\" he said.\" The patients may gain from these easy-to-use, noninvasive monitoring tools, while doctors could observe how the medication is performing in the individual.\"\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://samueli.ucla.edu/smartwatch-tracks-medication-levels-to-personalize-treatments\" target=\"_blank\" rel=\"noopener noreferrer\">University of California - Los Angeles</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nLin, S., <em>et al.</em> (2020) Noninvasive wearable electroactive pharmaceutical monitoring for personalized therapeutics. <em>PNAS.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1073/pnas.2009979117\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1073/pnas.2009979117</a>.</span>\r\n\r\n</div>','Custom smartwatch tracks sedate levels inside the body continuously','','publish','open','open','','custom-smartwatch-tracks-sedate-levels-inside-the-body-continuously','','','2020-08-08 16:57:43','2020-08-08 16:57:43','',0,'https://microbiozindia.com/?p=6930',0,'post','',0),(6931,2,'2020-08-08 16:56:40','2020-08-08 16:56:40','','This-smartwatch-could-track-drug-levels-in-real-time','','inherit','open','closed','','this-smartwatch-could-track-drug-levels-in-real-time','','','2020-08-08 16:56:40','2020-08-08 16:56:40','',6930,'https://microbiozindia.com/wp-content/uploads/2020/08/This-smartwatch-could-track-drug-levels-in-real-time.jpg',0,'attachment','image/jpeg',0),(6932,2,'2020-08-08 16:57:43','2020-08-08 16:57:43','Engineers in the UCLA Samueli School of Engineering and their colleagues at Stanford School of Medicine have demonstrated that drug levels inside the body is able to be tracked in real time using a custom smartwatch which assesses the compounds found in sweat. This wearable technology can be incorporated into a more personalized approach to drugs -- where an perfect drug and doses could be tailored to a person.\r\n\r\nIn general, medications are prescribed using a\'one-size-fits-all\' strategy -- drugs are designed and prescribed based on statistical averages of the efficacy. You will find guidelines for variables such as individuals\' age and weight. However, along with these fundamental differentiators, our body chemistry continuously changes -- depending on what we consume and how much we\'ve exercised. And on top of these dynamic factors, every individual\'s genetic makeup is unique and consequently answers to drugs can fluctuate. This affects how fast drugs are absorbed, take effect and become eliminated from an individual.\r\n\r\nAccording to the researchers, present efforts to personalize the drug dosage rely heavily on repeated blood draws in the hospital. The samples are then sent out to be examined in central labs. These alternatives are somewhat inconvenient, time-consuming, invasive and costly. That\'s why they are only performed on a tiny subset of individuals and on rare events.\r\n\r\n<em>We wanted to create a wearable technology that can track the profile of medication inside the body continuously and non-invasively. This way, we can tailor the optimal dosage and timing of the intake for each individual. And using this personalization approach, we can improve <a class=\"linked-term\" href=\"https://www.news-medical.net/health/What-Does-Efficacy-Mean.aspx\">the efficacy of</a> the therapeutic treatments.\"-</em>Sam Emaminejad, study leader, assistant professor of electrical and computer engineering at UCLA\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://samueli.ucla.edu/smartwatch-tracks-medication-levels-to-personalize-treatments\">Due to their small molecular dimensions, many distinct kinds of drugs end up in sweat, where their concentrations closely reflect the medication\' circulating levels. That is why the researchers produced a smartwatch, equipped with a detector that assesses the sampled tiny droplets of sweat.</a></span>\r\n\r\nThe team\'s experiment tracked the effect of acetaminophen, a typical over-the-counter pain medication, on individuals within the period of a few hours. First, the researchers stimulated sweat glands on the wrist by employing a small electric currentthe same method that Emaminejad\'s research group shown in previous wearable technologies.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://samueli.ucla.edu/smartwatch-tracks-medication-levels-to-personalize-treatments\">This allowed the researchers to detect changes in body chemistry, without even needing issues to develop a sweat by exercising. As different drugs each have their own distinct electrochemical signature, the detector can be designed to look for the degree of a specific medication at any given time.</a></span>\r\n\r\n\"Emerging pharmacogenomic options, which allow us to pick drugs based on the genetic makeup of people, have already shown to be useful in enhancing the effectiveness of remedies. So, in combination with our wearable remedy, which helps us to optimize the drug dosages for every person, we can now truly personalize our approaches to pharmacotherapy.\"\r\n\r\nWhat makes this study significant is the ability to accurately discover a drug\'s unique electrochemical signal, against the backdrop of signals from many other molecules which may be circulating in the human body and in greater concentrations than the drug, \'\' said the study\'s lead author Shuyu Lin, a UCLA doctoral student and associate of Emaminejad\'s Interconnected and Integrated Bioelectronics Lab (I²BL). Emaminejad added that the technology can be adapted to monitor medication adherence and drug abuse.\r\n\r\n\"This may be particularly important for individuals with mental health issues, where physicians prescribe them protracted pharmacotherapy treatments,\" he said.\" The patients may gain from these easy-to-use, noninvasive monitoring tools, while doctors could observe how the medication is performing in the individual.\"\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://samueli.ucla.edu/smartwatch-tracks-medication-levels-to-personalize-treatments\" target=\"_blank\" rel=\"noopener noreferrer\">University of California - Los Angeles</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nLin, S., <em>et al.</em> (2020) Noninvasive wearable electroactive pharmaceutical monitoring for personalized therapeutics. <em>PNAS.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1073/pnas.2009979117\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1073/pnas.2009979117</a>.</span>\r\n\r\n</div>','Custom smartwatch tracks sedate levels inside the body continuously','','inherit','closed','closed','','6930-revision-v1','','','2020-08-08 16:57:43','2020-08-08 16:57:43','',6930,'https://microbiozindia.com/uncategorized/6930-revision-v1/',0,'revision','',0),(6933,2,'2020-08-08 16:57:48','2020-08-08 16:57:48','Engineers in the UCLA Samueli School of Engineering and their colleagues at Stanford School of Medicine have demonstrated that drug levels inside the body is able to be tracked in real time using a custom smartwatch which assesses the compounds found in sweat. This wearable technology can be incorporated into a more personalized approach to drugs -- where an perfect drug and doses could be tailored to a person.\n\nIn general, medications are prescribed using a\'one-size-fits-all\' strategy -- drugs are designed and prescribed based on statistical averages of the efficacy. You will find guidelines for variables such as individuals\' age and weight. However, along with these fundamental differentiators, our body chemistry continuously changes -- depending on what we consume and how much we\'ve exercised. And on top of these dynamic factors, every individual\'s genetic makeup is unique and consequently answers to drugs can fluctuate. This affects how fast drugs are absorbed, take effect and become eliminated from an individual.\n\nAccording to the researchers, present efforts to personalize the drug dosage rely heavily on repeated blood draws in the hospital. The samples are then sent out to be examined in central labs. These alternatives are somewhat inconvenient, time-consuming, invasive and costly. That\'s why they are only performed on a tiny subset of individuals and on rare events.\n\n<em>We wanted to create a wearable technology that can track the profile of medication inside the body continuously and non-invasively. This way, we can tailor the optimal dosage and timing of the intake for each individual. And using this personalization approach, we can improve <a class=\"linked-term\" href=\"https://www.news-medical.net/health/What-Does-Efficacy-Mean.aspx\">the efficacy of</a> the therapeutic treatments.\"-</em>Sam Emaminejad, study leader, assistant professor of electrical and computer engineering at UCLA\n\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://samueli.ucla.edu/smartwatch-tracks-medication-levels-to-personalize-treatments\">Due to their small molecular dimensions, many distinct kinds of drugs end up in sweat, where their concentrations closely reflect the medication\' circulating levels. That is why the researchers produced a smartwatch, equipped with a detector that assesses the sampled tiny droplets of sweat.</a></span>\n\nThe team\'s experiment tracked the effect of acetaminophen, a typical over-the-counter pain medication, on individuals within the period of a few hours. First, the researchers stimulated sweat glands on the wrist by employing a small electric currentthe same method that Emaminejad\'s research group shown in previous wearable technologies.\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://samueli.ucla.edu/smartwatch-tracks-medication-levels-to-personalize-treatments\">This allowed the researchers to detect changes in body chemistry, without even needing issues to develop a sweat by exercising. As different drugs each have their own distinct electrochemical signature, the detector can be designed to look for the degree of a specific medication at any given time.</a></span>\n\n\"Emerging pharmacogenomic options, which allow us to pick drugs based on the genetic makeup of people, have already shown to be useful in enhancing the effectiveness of remedies. So, in combination with our wearable remedy, which helps us to optimize the drug dosages for every person, we can now truly personalize our approaches to pharmacotherapy.\"\n\nWhat makes this study significant is the ability to accurately discover a drug\'s unique electrochemical signal, against the backdrop of signals from many other molecules which may be circulating in the human body and in greater concentrations than the drug, \'\' said the study\'s lead author Shuyu Lin, a UCLA doctoral student and associate of Emaminejad\'s Interconnected and Integrated Bioelectronics Lab (I²BL). Emaminejad added that the technology can be adapted to monitor medication adherence and drug abuse.\n\n\"This may be particularly important for individuals with mental health issues, where physicians prescribe them protracted pharmacotherapy treatments,\" he said.\" The patients may gain from these easy-to-use, noninvasive monitoring tools, while doctors could observe how the medication is performing in the individual.\"\n<div class=\"content-src-label\"><strong>Source:</strong></div>\n<div class=\"content-src-value\">\n\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://samueli.ucla.edu/smartwatch-tracks-medication-levels-to-personalize-treatments\" target=\"_blank\" rel=\"noopener noreferrer\">University of California - Los Angeles</a></span>\n\n</div>\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\n<div class=\"content-src-value\">\n\nLin, S., <em>et al.</em> (2020) Noninvasive wearable electroactive pharmaceutical monitoring for personalized therapeutics. <em>PNAS.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1073/pnas.2009979117\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1073/pnas.2009979117</a>.</span>\n\n</div>','Custom smartwatch tracks sedate levels inside the body continuously','','inherit','closed','closed','','6930-autosave-v1','','','2020-08-08 16:57:48','2020-08-08 16:57:48','',6930,'https://microbiozindia.com/uncategorized/6930-autosave-v1/',0,'revision','',0),